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COVID-19 has been threatening the world for almost two years now. Fortunately, the care 
of many researchers has allowed the development of precise combat weapons in the form of 
vaccines in record time. But this pandemic will leave us many absences, and many 
consequences, such as those derived from the temporary eclipse of the greatest health challenge: 
the antimicrobial resistances (AMR). The increase of multidrug-resistant (MDR) bacteria to 
last-resorts antibiotics (i.e. to colistin, carbapenems, cephalosporins) is one of the most serious 
public health problems worldwide due to the lack of options for an adequate treatment, the 
increase of mortality rates and health costs. According to the European Centre for Disease 
Prevention and Control (ECDC), more than 670.000 bacterial infections can be attributed to 
MDR bacteria, which causes 33.000 deaths annually in Europe. 
 
Considering the risk associated with the antimicrobial use in animals and potential impact 
on humans, the European Medicines Agency (EMA) has recently proposed a new 
categorization, including in Category A (“Avoid”) those antibiotics not currently authorized in 
veterinary medicine in the EU, such as fosfomycin or monobactams; and Category B 
(“Restrict”) for those antimicrobials that should be restricted in animals to mitigate the risk to 
public health, namely, quinolones, 3rd- and 4th-generation cephalosporins and polymyxins. 
Therefore, this is a critical moment when the reduction of antibiotic pressure by different 
approaches, makes necessary to track bacterial evolution in order to design new strategies.  
 
Escherichia coli is part of the commensal microbiota of the digestive system in warm-
blood vertebrates that can play diverse roles depending on its virulence profile. While intestinal 
pathogenic E. coli (InPEC) are accurately distinguished from the commensal gut microbiota 
based on certain virulence factors, this is not as simple with the extraintestinal pathogenic E. 
coli (ExPEC) since they behave as opportunistic pathogens that can colonize the intestinal 
environment without causing harm to the host. Thus, no set of genes can unequivocally define 
ExPEC strains or the different categories. So far, they have been categorized due to their 
isolation from infections located outside of the digestive system, and / or based on the presence 
of genes statistically associated with the extraintestinal pathogenic potential of the strains, 
which can be used predictively. Besides, certain extraintestinal lineages of E. coli, such as the 
pandemic ST131, have been worldwide recognized by their implication in human infections, 
and also, by their role in the spreading of antibiotic resistances. The hypothesis that food, 
particularly poultry products, can act as a reservoir for human extraintestinal pathogens like E. 
coli and other Enterobacteriaceae in humans is based on scientific evidence. Certain strains that 
cause avian pathology (avian pathogenic E. coli, APEC) show a high genetic similarity to those 
that cause extraintestinal pathology in humans, so several studies report that some human 
ExPEC strains have evolved from or are common to APEC strains. The evidence suggesting 
this hypothesis are, among others: A) The geographical and temporal grouping of ExPEC 
strains isolated from patients with extraintestinal infections, suggesting the appearance of an 
outbreak or a common source of exposure. B) The global distribution of lineages of identical 
ExPEC strains, which indicate the global spread of contamination carried through food. C) The 
detection of identical genotypes of ExPEC isolated from human infections, as well as from food 
products when strains from the same geographic area were analyzed. D) The disproportionate 
representation of pandemic or international ExPEC lineages among the hundreds of ST causing 
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extraintestinal infections in all regions of the world, indicating a greater biological or fitness 
advantage in different reservoirs, production animals or non-production animals (birds wild). 
E) The relatively recent appearance of the ST69, ST131 and ST393 genotypes as ExPEC, 
suggesting the recent introduction of these genotypes into the human intestinal niche from 
external sources. 
 
Due to the high plasticity of the E. coli genome hybrid pathotypes are frequent and 
unpredictably emerging due to the important role played by different mobile genetic elements 
(MGEs) such as plasmids, bacteriophages, pathogenicity islands, transposons and insertion 
sequence elements, in the evolution of the bacteria. Furthermore, strains with complex hybrid 
pathotypes with combinations of two different groups of intestinal pathogenic E. coli (InPEC) 
(Shiga toxin-producing E. coli; STEC + enteroaggregative E. coli; EAEC) or InPEC and 
ExPEC (for example, atypical enteropathogenic E. coli; aEPEC + ExPEC and STEC + APEC) 
are increasingly reported in human clinical cases. Since 2011, when a novel Shiga-toxin-
producing E. coli belonging to serotype O104:H4, with virulence features common to the EAEC 
and CTX-M-15 producer was identified as the one involved in the large German outbreak the 
concept of pathotype has been questioned and currently, classical and new approaches (WGS), 
are being used to enhance the understanding of the evolution of this highly adaptable species. 
 
The use of antibiotic therapy in food production animals has been accepted as the main 
cause of the AMR increase, including resistance to colistin. A rapid spread of extended-
spectrum β-lactamases (ESBL) has occurred in the last decades, mainly due to their presence 
in plasmids and expansion through successful clonal groups, such as the pandemic ST131 of E. 
coli. Presently, there is great concern about the in vivo acquisition of mcr- and blaESBL-bearing 
plasmids by human E. coli isolates following treatment with colistin, or via animal transmission 
through direct contact or the food chain. ST131 is the main pandemic clone responsible for the 
global spread of ESBLs. First identified in 2008, ST131 strains belong to phylogroup B2 and 
mainly to the serotypes O25b:H4 or, less frequently, O16:H5. Three years after its first 
isolation, it was already spread, being the bacterial agent involved in more than 50% of cases 
of UTIs caused by ESBL-producing strains in numerous hospitals in different countries. The 
prevalence of resistance to first-line oral antibiotics such as trimethoprim-sulfamethoxazole, 
amoxicillin, and amoxicillin-clavulanate has been steadily increasing during these years, 
making the treatment of infections very difficult and endangering the lives of patients. Although 
it is associated with ExPEC infections such as UTI, septicemia, surgical wound infections and 
meningitis, this clone is also frequently isolated from the digestive tract of healthy humans. 
That is why, the human intestinal tract was though the main reservoir of ST131. However, the 
growing scientific community interest towards this ST, found it within diverse sources such as 
companion, food-production and wild animals, rivers, sewage, even in the Antarctic region. 
The clades A and C of ST131 are mainly associated with human pathology, while the clade B 
is determined in strains isolated from different niches such as poultry and pigs, along with 
humans. An important challenge is to know which determinants make certain clones adapt to a 
specific host meanwhile others can be transmitted between different species, with jumps as 
important as between mammals and birds. In the case of ST131, this relationship between the 
different clades and their presence in different hosts has not be completed understood yet.  
 
The present doctoral thesis comprises three studies, “Chicken and turkey meat: Consumer 
exposure to multidrug-resistant Enterobacteriaceae including mcr-carriers, uropathogenic E. 




assessment of turkey and chicken meat for consumer: Significant differences regarding 
multidrug resistance, mcr or presence of hybrid aEPEC/ExPEC pathotypes of E. coli” (Díaz-
Jiménez et al., 2021) and “Genomic Characterization of Escherichia coli Isolates Belonging to 
a New Hybrid aEPEC/ExPEC Pathotype O153:H10-A-ST10 eae-beta1 Occurred in Meat, 
Poultry, Wildlife and Human Diarrheagenic Samples” (Díaz-Jiménez et al., 2020b).  
 
The aim of the present doctoral thesis, developed in the frame of two national projects (PN 
AGL2016-79343-R and PID2019-104439RB-C21/AEI/10.13039/501100011033), were to 
analyse the zoonotic potential of Enterobacteriaceae isolated from poultry, with the 
characterization of antibiotic resistances and definition of clonal groups pathogenic for humans. 
Thus, we evaluated the consumer exposure to Enterobacteriaceae with capacity to develop 
problematic extraintestinal infections, either by their virulence and / or resistance traits, via 
chicken and turkey meat. The hypothesis of the present thesis was that poultry meat would act 
as a reservoir, and potentially transmitter, of pathogenic strains that might be implicated in 
human UTI. To demonstrate this hypothesis, the strategy was to analyze retail poultry meat 
directly acquired at points of sale with the idea that the final product provides data on what is 
happening on the farm, at the slaughterhouse, and what goes into the consumer's kitchen. The 
second strategy was to identify potential uropathogenic clonal groups of E. coli based on 
specific genetic markers. Finally, we considered “high-risk” strain that with the capacity to 
develop a serious extraintestinal infection in humans, due to either its virulence potential and / 
or its antibiotic resistance. 
 
The specific goals of the present doctoral thesis were first to design an efficient protocol 
for the recovery of food-borne E. coli and other pathogenic and / or antimicrobial-resistant 
Enterobacteriaceae. The second objective was to acquire knowledge on the current situation 
regarding AMR in poultry farming, paying special attention to antimicrobial categories A and 
B of EMA. We also aimed to assess the consumer exposure, via poultry meat, to high-risk E. 
coli and other Enterobacteriaceae isolates with potential to develop severe infections by either 
bacterial virulence and / or antibiotic resistance traits. Finally, we aimed to explore the food 
transmission route of specific E. coli clones of human and animal origin through comparative 
genetic and genomic analysis.  
 
We randomly sampled 100 retail fresh meat products (50 of chicken and 50 of turkey) in 
six Spanish supermarket chains and local butcher located in Lugo (northwest Spain). By 
conventional culture, 358 different Enterobacteriaceae isolates were recovered (170 isolates 
recovered from chicken samples and 188 isolates recovered from turkey samples) using 
MacConkey Lactose, MacConkey Sorbitol with tellurite and cefixime, CHROMID® ESBL and 
CHROMID®CARBA SMART. Bacterial identification revealed that 323 out of 358 isolates 
were E. coli, 28 K. pneumoniae, six Serratia fonticola and one Enterobacter cloacae. This 
collection was fully characterized including: phylogroup, serotype, ST and clonal complex, 
clonotype, virulence and resistance profile.   
 
A second collection was obtained during the period of 2005 to 2015 from different 
surveillance studies performed at LREC, in Lugo, Spain, which aimed the detection of ESBL-
producing E. coli. These studies included samples from chicken, beef and pork meat, as well as 
poultry farm environment and wildlife. Those isolates conforming the aEPEC pathotype of 
serotype O153 were further characterized.  
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In our first study we evaluated the consumer exposure via poultry meat to 
Enterobacteriaceae with capacity to develop severe extraintestinal infections by either bacterial 
virulence and / or antibiotic resistance traits. The characterization of 256 isolates (84 
representative E. coli isolates, 137 ESBL-producing E. coli isolates, 28 ESBL-producing 
Klebsiella pneumoniae isolates, six ESBL-producing Serratia fonticola isolates and one ESBL-
producing Enterobacter cloacae isolate) and the assessment of five parameters showed that 96 
out of 100 poultry meat samples acquired in supermarkets of the northwest of Spain posed ≥ 
one potential risk. Specifically, i) 96% of the samples carried Enterobacteriaceae resistant to 
antimicrobials of categories A (64% with resistance to monobactams) or B (95% with resistance 
to cephalosporins of 3rd- and 4rd- generation, quinolones and / or polymyxins) of the new 
categorization of EMA. ii) More than one ESBL-producing Enterobacteriaceae species were 
recovered from 29% of samples, mostly E. coli and K. pneumoniae. iii) Characterization of E. 
coli isolates showed that extraintestinal and / or uropathogenic high-risk clonal groups (ST10, 
ST23, ST38, ST48, ST58, ST69, ST88, ST93, ST95, ST101, ST115, ST117, ST131, ST141, 
ST167, ST350, ST345, ST354, ST359, ST410, ST602, ST617, ST641, ST906, ST1485) were 
present in 62% samples. iv) E. coli isolates recovered from 25% samples conformed the ExPEC 
status v) E. coli isolates recovered from 17% samples conformed UPEC status. Regarding K. 
pneumoniae, at least eight of the 11 STs identified in our collection have been reported within 
human clinic isolates; specifically: ST15, ST45, ST111, ST147, ST307, ST627, ST966 and 
ST1086 (22 of the 28 K. pneumoniae belonged to these eight STs). The plasmid-mediated 
colistin resistance mcr-1 gene was determined in 13 E. coli isolates from seven meat samples, 
however, the eleven K. pneumoniae phenotypically resistant to colistin were negative by PCR 
for the presence of mcr-1 to mcr-8 genes, probably indicating chromosomic-encoding 
resistance. 
 
In our second study, we assessed the risk for consumers attending only to E. coli isolates, 
we proposed a laboratory workflow based on six virulence and / or antimicrobial resistance 
traits and included the development of a duplex PCR for the screening of ExPEC isolates. We 
characterized 323 isolates recovered from 100 poultry meat samples. This characterization 
revealed that poultry meat is a rich phylogenetic source of E. coli phylogroups (A to G) and 
Escherichia clade I. Non-susceptible E. coli isolates to monobactams, 3rd-generation 
cephalosporins and / or fluoroquinolones, were present in 71% of the samples. Besides, 47% 
carried ≥2 different E. coli positive for ESBL, pAmpC or mcr genes. Isolates from 78% of the 
poultry meat exhibited ExPEC status, and 53% were carriers of isolates positive for the UPEC 
status. The STs identified in 86% of the samples belonged to the so-called ExPEC high-risk 
lineages, being 73% carriers of clonal groups identified in human infections of the same Health 
Area. Moreover, different human-associated clones co-occurred in same meat sample: ST131-
B2 (CH40-22), ST648-F (CH4-58), ST93-A (CH11-neg) or ST95-B2 (CH38-27), ST354-F 
(CH88-58), ST155-B1 (CH4-neg). Globally, 84% of the meat samples posed ≥ 3 risks factors, 
including resistance genes, successful clones and virulence traits. Turkey meat showed 
significant higher rates concerning mcr-carriage or MDR; while the ExPEC status rate, or the 
presence of hybrid pathotypes such as the aEPEC/ExPEC O153:H10-A-ST10 (CH11-54), were 
associated with chicken origin (P < 0.05).  
 
In our third study we took as start point the different surveillance studies (2005–2015) in 
northwest Spain that revealed the presence of eae-positive isolates of E. coli O153:H10 in meat 
for human consumption, poultry farm, wildlife and human diarrheagenic samples. The aim of 




isolates, as well as the mechanism of its persistence. We also wanted to know whether it was a 
geographically restricted lineage, or whether it was also reported elsewhere. Conventional 
typing showed that 32 isolates were O153:H10-A-ST10 fimH54, fimAvMT78, traT and eae-
beta1. Amongst these, 21 were CTX-M-32 or SHV-12 producers. The PFGE XbaI - 
macrorestriction comparison showed high similarity (>85%) between the isolates of the 
collection. The plasmidome analysis revealed a stable combination of IncF (F2:A-:B-), IncI1 
(ST unknown) and IncX1 plasmid types, together with non-conjugative Col-like plasmids. The 
core genome investigation based on the core genome multilocus sequence typing (cgMLST) 
scheme from EnteroBase proved close relatedness between isolates of human and animal origin.  
 
From our results we concluded that poultry meat microbiota is a source of genetically 
diverse Enterobacteriaceae, resistant to relevant antimicrobials (categories A and B of EMA) 
and potentially pathogenic for humans, including hybrid pathotypes of E. coli, high-risk clonal 
groups of E. coli associated with human extraintestinal and / or uropathogenic pathologies, as 
well as K. pneumoniae clonal groups of clinical interest. Our results would indicate that the 
industrial production system for turkey meat seems to exert greater selection pressure of 
antibiotic resistant strains compared to chicken, which is reflected in significant higher rates of 
mcr-positive E. coli and MDR isolates, including ESBL-producing K. pneumoniae, in turkey 
meat. 
 
With regard to the methods here investigated, we found that protocols I and II, based on 
MacConkey Lactose and MacConkey Sorbitol with telurite and cefixime agar incubated at 37 
ºC, are the most effective for the recovery of isolates satisfying the ExPEC and UPEC status, 
as well as the rbfO25b-positive isolates associated with the clonal group STl31. The protocol 
V (CHROMID® ESBL agar plates 37 ºC) is key for the recovery of ESBL or pAmpC-
producing Enterobacteriaceae. The duplex PCR based on iutA and KpsM II genes on 
MacConkey Lactose and MacConkey Sorbitol with telurite and cefixime agar is essential for 
the accurate screening of the isolates conforming ExPEC status, as well as for the recovery of 
those with UPEC status. Finally, we concluded that the microbiological method proposed here 
(pre-enrichment, enrichment in MacConkey Lactose broth, and inoculation onto MacConkey 
Lactose agar/ MacConkey Sorbitol with telurite and cefixime agar/CHROMID® ESBL), 
followed by the screening of six virulence/AMR traits (ExPEC status, UPEC status, 
ESBL/pAmpC producer, mcr-1 carrier, MDR, rfbO25b), would help to elucidate the role of 
ExPEC as new extraintestinal food-borne pathogens. 
 
Our results prove that a hybrid MDR aEPEC/ExPEC belonging to the clonal group 
O153:H10-A-ST10 (CH11-54) eae-beta1 is circulating in our region within different hosts, 
including wildlife. It seems implicated in human diarrhea via food (meat) transmission, and in 
the spreading of ESBL genes (mainly of CTX-M-32 type). The concomitant presence of IncF 
(F2:A-:B-), IncI1 and IncX1, together with non-conjugative Col156-like plasmids might be 
implicated in the successful persistence of this hybrid pathotype. 
 
Keywords: Enterobacteriaceae, Escherichia coli, Klebsiella pneumoniae, ExPEC, ST131, 
mcr, hybrid pathotype, antibioresistance, ESBL, EnteroBase, risk assessment, poultry meat, 
One Health, from farm to fork.






La COVID-19 lleva amenazando al mundo durante ya más de dos años. Por suerte, el 
trabajo de muchos investigadores ha permitido el desarrollo en un tiempo récord de 
herramientas para combatir esta pandemia de forma precisa en forma de vacunas. Pero esta 
pandemia nos está dejando muchas ausencias y consecuencias, como las derivadas del eclipse 
temporal del mayor desafío de salud en la actualidad: las resistencias a los antibióticos (ABR). 
El aumento en el número de bacterias multirresistentes (MDR) a antibióticos de último recurso 
(como por ejemplo a la colistina, los carbapenémicos o las cefalosporinas) es uno de los 
problemas de salud pública más graves a nivel mundial debido a la falta de opciones 
terapéuticas alternativas adecuado, al aumento de las tasas de mortalidad y a los costes de salud 
derivados de los tratamientos no efectivos. Según el Centro Europeo para la Prevención y el 
Control de Enfermedades (ECDC), más de 670.000 infecciones bacterianas pueden atribuir a 
las bacterias MDR, siendo responsables de más de 33.000 muertes al año solo en Europa.  
 
Debido al riesgo asociado al uso terapéutico de antibióticos en animales de producción y a 
su potencial impacto para el ser humano, la Agencia Europea de Medicamentos (EMA) ha 
propuesto recientemente una nueva categorización, en la cual incluye en la Categoría A 
(“Evitar”) aquellos antibióticos no autorizados actualmente para su uso en medicina veterinaria 
en la Unión Europea (UE), como son la fosfomicina o los monobáctamicos; y en la Categoría 
B (“Restringir”) se incluyen aquellos antimicrobianos en los que debe restringirse su uso en 
animales para así mitigar el riesgo para la salud pública, a saber, las quinolonas, las 
cefalosporinas de tercera y cuarta generación y las polimixinas. Por lo tanto, este es un momento 
crítico en el que la reducción de la presión de los antibióticos a través de diferentes enfoques 
hace necesario rastrear la evolución bacteriana para comprobar la evolución de las medidas 
tomadas y así diseñar nuevas estrategias. 
 
La bacteria Escherichia coli forma parte de la microbiota comensal natural del sistema 
digestivo en vertebrados de sangre caliente y pueden desempeñar diversas funciones 
dependiendo de sus características y su perfil de virulencia. Si bien las cepas de E. coli 
patógenas intestinales (InPEC) se distinguen con precisión de la microbiota intestinal comensal 
debido a la presencia de factores de virulencia asociados a los diferentes patotipos, esto no es 
tan simple con las bacterias de E. coli patógenas extraintestinales (ExPEC), ya que se comportan 
como patógenos oportunistas pudiendo colonizar de forma indefinida el sistema digestivo sin 
causar daño al anfitrión. Por ahora no ha sido determinados ningún conjunto de genes pueda 
definir inequívocamente las cepas ExPEC o sus diferentes categorías. Actualmente se están 
categorizando en fusión de su aislamiento en infecciones localizadas fuera del sistema digestivo 
y / o en función de la presencia de genes asociados estadísticamente con el potencial patogénico 
extraintestinal de estas cepas, los cuales pueden usarse de manera predictiva. Además, ciertos 
linajes de E. coli extraintestinales, como el clon pandémico ST131, han sido reconocidos 
mundialmente por su implicación en infecciones humanas, así como por su papel en la 
propagación de resistencias a antibióticos de uso habitual. La hipótesis de que los alimentos, en 
particular los productos avícolas, pueden actuar como reservorio de patógenos extraintestinales 
humanos como E. coli y otras Enterobacteriaceae se basa en la evidencia científica. Cepas 




genética con las que causan patología extraintestinal en humanos, por lo que la hipótesis que ha 
surgido en varios estudios es que algunas cepas humanas ExPEC pueden haber evolucionado a 
partir de cepas APEC o ser iguales a ellas. Las evidencias que apuntan a esta hipótesis son, 
entre otras, las siguientes: A) La existencia de una agrupación geográfica y temporal de las 
cepas ExPEC aisladas de pacientes con infecciones extraintestinales que sugiere la aparición de 
un brote o una fuente común de exposición. B) La distribución global de linajes de cepas ExPEC 
idénticas, que indican la propagación global de la contaminación transmitida a través de los 
alimentos. C) La detección de genotipos idénticos de ExPEC aislados de infecciones humanas, 
así como de productos alimenticios detectados y analizados en una misma área geográfica. D) 
La representación desproporcionada de ciertos linajes pandémicos de ExPEC entre cientos de 
ST diferentes que causan infecciones extraintestinales en todas las regiones del mundo, lo que 
sugiere una ventaja biológica o de aptitud para diferentes reservorios de estos linajes 
pandémicos, como pueden ser los animales de producción u otros animales como las aves 
silvestres. E) La aparición relativamente reciente de los clones ST69, ST131 y ST393 como 
cepas ExPEC, sugiriendo la reciente introducción de estos genotipos en el nicho intestinal 
humano a partir de fuentes externas. 
 
Debido a la alta plasticidad del genoma de E. coli, los patotipos híbridos están siendo cada 
vez más frecuentes e impredecibles debido al importante papel que juegan los elementos 
genéticos móviles (EGM) como los plásmidos, los bacteriófagos, las islas de patogenicidad, los 
transposones y las secuencias de inserción en la evolución de las bacterias. Además, las cepas 
con patotipos híbridos complejos con combinaciones de dos grupos diferentes de cepas 
patógenas intestinales de E. coli (InPEC) (E. coli productores de toxinas Shiga; STEC + E. coli 
enteroagregativos; EAEC) o InPEC y ExPEC (por ejemplo, E. coli enteropatógeno atípica; 
aEPEC + ExPEC y STEC + APEC) se notifican cada vez más en casos clínicos humanos. Desde 
2011, cuando se identificó una nueva cepa de E. coli productora de toxinas Shiga perteneciente 
al serotipo O104: H4, con características de virulencia comunes a la EAEC y productora del 
gen de resistencia CTX-M-15, como involucrada en el gran brote alemán, el concepto de 
patotipo ha sido cuestionado y actualmente se están utilizando enfoques clásicos y actuales 
como la secuenciación genómica completa (WGS) para mejorar la comprensión de la evolución 
de esta especie altamente adaptable. 
 
Actualmente está aceptada la premisa de que el uso de terapia con antibióticos en animales 
destinados a la producción de alimentos para consumo humano es la principal causa del 
aumento de la ABR, incluida la resistencia a la colistina. En las últimas décadas se ha producido 
una rápida diseminación de cepas portadoras de betalactamasas de espectro extendido (BLEE), 
principalmente debido a su presencia en plásmidos y su expansión a través de grupos clonales 
exitosos, como el clon pandémico ST131 de E. coli. Hoy en día existe una gran preocupación 
ante la posibilidad de adquisición in vivo de plásmidos portadores del gen mcr de resistencia a 
colistina, así como de genes blaBLEE por parte de cepas de E. coli causantes de patología humana 
después de tratamientos clínicos o por transmisión animal a través del contacto directo o la 
cadena alimentaria entre cepas portadoras y cepas de la microbiota humana. ST131 es 
considerado el principal clon pandémico responsable de la propagación global de genes BLEE. 
Identificado por primera vez en 2008, el grupo clonal ST131 pertenece al filogrupo B2 y 
principalmente a los serotipos O25b:H4 o, con menor frecuencia, al serotipo O16: H5. Tres 
años después de su primer aislamiento, ya se encontraba diseminado a nivel global, siendo el 
agente bacteriano involucrado en más del 50% de los casos de UTIs por cepas productoras de 
BLEE en numerosos hospitales de diferentes países. La prevalencia de resistencias a 
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antibióticos orales de primera línea como trimetoprim-sulfametoxazol, amoxicilina y 
amoxicilina-clavulánico ha ido aumentando constantemente durante estos años, dificultando 
cada vez más el tratamiento de infecciones y poniendo en peligro la vida de los pacientes. 
Aunque está asociado con infecciones ExPEC como UTIs, septicemias, infecciones de heridas 
quirúrgicas y meningitis, este clon también se encuentra con frecuencia en el sistema digestivo 
de humanos sanos. Por eso, se sospecha que el tracto intestinal humano conforma un posible 
nicho para el clon ST131. Sin embargo, el creciente interés de la comunidad científica hacia 
este clon ha hecho que haya sido detectado fuentes tan diversas como animales de compañía, 
animales de producción de alimentos y salvajes; o en el propio medio ambiente, como en ríos, 
playas o en el alcantarillado; incluso en la región antártica. Los clados A y C están asociados 
principalmente a patología humana, mientras que el clado B agrupa a cepas aisladas de 
diferentes nichos como aves y cerdos, junto con humanos. Un desafío importante es saber qué 
determinantes hacen que ciertos clones se adapten mejor a un huésped específico mientras que 
otros pueden transmitirse entre diferentes especies, con saltos tan importantes como entre 
mamíferos y aves. En el caso de ST131, esta relación entre los diferentes clados y su presencia 
en diferentes hospedadores aún no se ha entendido completamente. 
 
La presente tesis doctoral incluye tres estudios, "Chicken and turkey meat: Consumer 
exposure to multidrug-resistant Enterobacteriaceae including mcr-carriers, uropathogenic E. 
coli and high-risk lineages such as ST131” (Díaz-Jiménez et al., 2020a), “Microbiological risk 
assessment of turkey and chicken meat for consumer: Significant differences regarding 
multidrug resistance, mcr or presence of hybrid aEPEC/ExPEC pathotypes of E. coli” (Díaz-
Jiménez et al., 2021) y “Genomic Characterization of Escherichia coli Isolates Belonging to a 
New Hybrid aEPEC/ExPEC Pathotype O153:H10-A-ST10 eae-beta1 Occurred in Meat, 
Poultry, Wildlife and Human Diarrheagenic Samples” (Díaz-Jiménez et al., 2020b). El objetivo 
de la presente tesis doctoral, desarrollada en el marco de dos proyectos nacionales (PN 
AGL2016-79343-R y PID2019-104439RB-C21 / AEI / 10.13039 / 501100011033), fue 
analizar el potencial zoonótico de cepas de la familia Enterobacteriaceae aisladas de ave de 
corral para consumo humano, con caracterización de resistencias a antibióticos y definición de 
grupos clonales patógenos para el ser humano. De este modo, evaluamos la exposición del 
consumidor a cepas de la familia Enterobacteriaceae con capacidad para desarrollar infecciones 
extraintestinales de riesgo, ya sea por la virulencia de las cepas o por su patrón de resistencias 
a antibióticos adquiridos a través de la carne de pollo y pavo. 
 
La hipótesis de la presente tesis plantea que la carne de ave de corral destinada a consumo 
humano estaría actuando como reservorio y potenciales agentes transmisores de cepas 
patógenas que podrían estar implicadas en infecciones extraintestinales humanas. Para 
demostrar esta hipótesis, la estrategia fue analizar carne de ave a la venta al por menor adquirida 
directamente en los puntos de venta con el objetivo de que el producto final nos proporcione 
datos sobre lo que sucede en la granja, en el matadero, así como la calidad del producto que 
entra en la cocina del consumidor. La segunda estrategia sería la identificación de grupos 
clonales potencialmente uropatógenos de E. coli basados en marcadores genéticos específicos. 
Y, por último, consideramos como cepa de “alto riesgo” aquella con capacidad de desarrollar 
una infección extraintestinal grave en el ser humano, ya sea por su potencial de virulencia y / o 
por su resistencia a los antibióticos. 
 
Los objetivos específicos de la presente tesis doctoral fueron en primer lugar, el diseño de 




Enterobacteriaceae con potencial patógeno y / o resistentes a los antimicrobianos. Un segundo 
objetivo fue conocer la situación actual de las ABR en la producción avícola, prestando especial 
atención a las categorías de antimicrobianos A y B de la clasificación EMA. Como tercer 
objetivo presentamos la evaluación de la exposición del consumidor, a través de la carne de ave 
a cepas de E. coli de alto riesgo y otras Enterobacteriaceae con potencial para desarrollar 
infecciones graves debido a su perfil de virulencia y / o a su perfil de resistencia a antibióticos. 
Nuestro último objetivo fue explorar la ruta de transmisión alimentaria de clones específicos de 
E. coli de origen humano y animal mediante análisis comparativo de genomas. 
 
Se tomaron al azar muestras de 100 productos cárnicos de origen aviar (50 muestras de 
pollo y 50 muestras de pavo) en seis cadenas de supermercados españolas y carnicerías locales 
ubicadas en Lugo (noroeste de España). Mediante un protocolo de cultivo convencional se 
recuperaron 358 cepas diferentes de especies pertenecientes a la familia Enterobacteriaceae 
(170 aislamientos recuperados de muestras de pollo y 188 aislamientos recuperados de muestras 
de pavo) utilizando los medios agar MacConkey Lactosa, agar MacConkey Sorbitol con telurito 
y cefixima, CHROMID® ESBL y CHROMID®CARBA SMART. La identificación bacteriana 
reveló que 323 de 358 aislamientos eran E. coli, 28 de K. pneumoniae, seis de Serratia fonticola 
y uno de Enterobacter cloacae. Esta colección se caracterizó por completo incluyendo: 
filogrupo, serotipo, ST y complejo clonal, clonotipo, perfil de virulencia y de resistencia. 
 
Una segunda colección fue obtenida durante el período entre 2005 y 2015 a partir de 
diferentes estudios de vigilancia realizados en el LREC, Lugo, España, que tenían como 
objetivo la detección de cepas de E. coli productoras de BLEE. Estos estudios incluyeron 
muestras de carne de ave, vacuno y porcino, así como del ambiente de granjas de producción 
avícola y animales salvajes, y se seleccionaron y caracterizaron los aislamientos que 
presentaban un patotipo aEPEC y el serotipo O153. 
 
El primer estudio evalúa la exposición del consumidor a través de la carne de ave a cepas 
de la familia Enterobacteriaceae con capacidad para provocar infecciones extraintestinales 
severas debido a sus características de virulencia y / o rasgos de resistencia a antibióticos. La 
caracterización de 256 cepas (84 aislamientos representativos de E. coli, 137 aislamientos de 
cepas de E. coli productores de BLEE, 28 aislamientos de cepas de Klebsiella pneumoniae 
productoras de BLEE, seis aislamientos de cepas de Serratia fonticola productoras de BLEE y 
un aislado de Enterobacter cloacae productor de BLEE) y la evaluación de cinco parámetros 
mostró que 96 de cada 100 muestras de carne de ave de corral adquiridas en supermercados del 
noroeste de España presentaban más de un factor de riesgo potencial. En concreto, i) el 96% de 
las muestras eran portadoras de cepas de Enterobacteriaceae resistentes a antimicrobianos de 
las categorías A (64% con resistencia a monobactamicos) o B (95% con resistencia a 
cefalosporinas de 3a y 4a generación, quinolonas y / o polimixinas) de la nueva categorización 
de EMA. ii) Se recuperó más de una especie de Enterobacteriaceae productoras de BLEE del 
29% de las muestras, principalmente cepas de E. coli y K. pneumoniae. iii) La caracterización 
de los aislados de E. coli mostró que los grupos clonales extraintestinales de alto riesgo y / o 
potencialmente uropatógenos (ST10, ST23, ST38, ST48, ST58, ST69, ST88, ST93, ST95, 
ST101, ST115, ST117, ST131, ST141, ST167, ST350, ST345, ST354, ST359, ST410, ST602, 
ST617, ST641, ST906, ST1485) estaban presentes en el 62% de las muestras. iv) De las cepas 
recuperadas de E. coli el 25% satisficieron los criterios para ser denominadas según el criterio 
como ExPEC y v) el 25% satisficieron los criterios para ser denominadas según el criterio como 
UPEC. Con respecto a las cepas de K. pneumoniae, al menos ocho de las 11 ST identificadas 
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en nuestra colección han sido reportadas como aislamientos de cepas clínicas humanas; 
específicamente: ST15, ST45, ST111, ST147, ST307, ST627, ST966 y ST1086 (22 de las 28 
K. pneumoniae pertenecían a alguno de estos ocho ST). El gen mcr-1 de resistencia a la colistina 
mediado por un plásmido se identificó en 13 aislamientos de E. coli de siete muestras de carne 
diferentes, sin embargo, las once K. pneumoniae que presentaron resistencia fenotípica la 
colistina fueron negativas por PCR para la presencia de genes mcr-1 a mcr-8, probablemente 
indicando una resistencia de tipo cromosómica a la colistina. 
 
En nuestro segundo estudio, se evaluó el riesgo al que se exponían los consumidores de 
carne de ave atendiendo únicamente a las cepas aisladas de E. coli. Se propuso un flujo de 
trabajo de laboratorio basado en seis rasgos de virulencia y / o resistencia a los antimicrobianos 
e incluimos el desarrollo de una PCR doble para el cribado de cepas con genes asociados al 
criterio ExPEC. Caracterizamos 323 cepas recuperadas de 100 muestras de carne de ave de 
corral para consumo humano. Esta caracterización reveló que la carne de aves es una fuente de 
cepas con diversidad filogenética rica en filogrupos de E. coli (A a G) y Escherichia clado I. 
Además, el 47% de las muestras era portadora de 2 o más E. coli diferentes positivos para genes 
BLEE, pAmpC o mcr. Las cepas aisladas del 78% de las muestras carne de ave cumplieron los 
requerimientos del criterio del estatus ExPEC y el 53% fueron portadores de cepas positivas 
para el estatus UPEC. Las STs identificadas en el 86% de las muestras pertenecían a los 
llamados linajes ExPEC de alto riesgo, siendo el 73% portadores de grupos clonales 
identificados en infecciones humanas de la misma área de salud. Además, diferentes clones 
asociados con patología humana aparecieron en la misma muestra de carne: ST131-B2 (CH40-
22), ST648-F (CH4-58), ST93-A (CH11-neg) o ST95-B2 (CH38-27), ST354-F (CH88-58), 
ST155-B1 (CH4-neg). De forma general, el 84% de las muestras de carne presentaban tres o 
más factores de riesgo, incluidos genes de resistencia, clones exitosos de riesgo y rasgos de 
virulencia. La carne de pavo mostró una presencia significativamente más alta de genes mcr o 
resistencia a múltiples fármacos; mientras que la tasa de cepas con estatus ExPEC, o la 
presencia de patotipos híbridos como el aEPEC / ExPEC O153: H10-A-ST10 (CH11-54), se 
asociaron con el origen del pollo (P < 0.05). 
 
En nuestro tercer estudio tomamos como punto de partida los diferentes estudios de 
vigilancia (2005-2015) realizados en el noroeste de España. Estos revelaron la presencia de 
aislamientos eae-positivos de cepas de E. coli del serotipo O153: H10 en muestras de carne 
para consumo humano, granjas avícolas, fauna silvestre y casos de diarrea humana. El objetivo 
de este estudio fue explorar la relación genética entre los aislados humanos y animales / 
cárnicos, así como su mecanismo de persistencia. También era objetivo saber si se trataba de 
un linaje geográficamente restringido o si había sido reportado en otro lugar. La caracterización 
convencional mostró que 32 aislamientos eran O153: H10-A-ST10 fimH54, fimAvMT78, traT 
y eae-beta1. Entre ellas, 21 eran productoras de CTX-M-32 o SHV-12. La comparación 
empleando la técnica de PFGE XbaI - macrorrestricción mostró una alta similitud (> 85%) entre 
los aislamientos de diferentes orígenes de la colección. El análisis del plasmidoma reveló una 
combinación estable de los tipos de plásmidos IncF (F2: A-: B-), IncI1 (ST desconocido) e 
IncX1, junto con plásmidos de tipo Col no conjugativos. La investigación del core genome 
basada en el esquema de tipado de secuencias multilocus del core genoma (cgMLST) de 
EnteroBase demostró una estrecha relación entre los aislamientos de origen humano y animal. 
 
A partir de nuestros resultados, llegamos a la conclusión de que la microbiota presenten en  




antimicrobianos relevantes (categorías A y B de EMA) y potencialmente patógenas para los 
seres humanos, incluyendo patotipos híbridos de E. coli, grupos clonales de E. coli de alto 
riesgo asociados a patologías humanas extraintestinales y / o cepas uropatógenas, así como  
grupos clonales de K. pneumoniae de interés clínico. Nuestros resultados indicarían también 
que  el sistema de producción industrial de carne de pavo da como resultado una mayor presión 
de selección para cepas resistentes a los antibióticos en comparación con el sistema de 
producción de pollo, lo que se refleja en tasas significativamente más altas de cepas de E. coli 
MDR positivas para el gen mcr, y cepas de K. pneumoniae productora de BLEE, en carne de 
pavo. 
 
Con respecto a los métodos aquí propuestos, encontramos que los protocolos I y II, basados 
en los medios MacConkey Lactosa y MacConkey Sorbitol con telurito y cefixima incubados a 
37 ºC, son los más efectivos para la recuperación de cepas que cumplen el estatus ExPEC y 
UPEC, así como las cepas positivas al gen rbfO25b, asociado con el grupo clonal STl31. El 
protocolo V (placas de agar CHROMID® ESBL incubadas a 37 ºC) es clave para la 
recuperación de Enterobacteriaceae productoras de BLEE o pAmpC. La PCR dúplex basada en 
la detección de genes iutA y KpsM II en MacConkey Lactosa y MacConkey sorbitol con telurito 
y cefixima es esencial para el cribado preciso de cepas que cumplen el estatus ExPEC, así como 
para la recuperación de aquellos con estatus UPEC. Finalmente, concluimos que el método 
microbiológico propuesto aquí (pre-enriquecimiento, enriquecimiento en caldo ML e 
inoculación en MacConkey Lactosa / MacConkey sorbitol con telurito y cefixima / 
CHROMID® ESBL), seguido de la selección de seis rasgos de virulencia / ABR (estatus 
ExPEC, estatus UPEC, BLEE / productor de pAmpC, portador de mcr-1, MDR, rfbO25b), 
ayudaría a dilucidar el papel de ExPEC como nuevos patógenos extraintestinales transmitidos 
por los alimentos. 
 
Nuestros resultados demuestran que un híbrido MDR aEPEC / ExPEC perteneciente al 
grupo clonal O153: H10-A-ST10 (CH11-54) eae-beta1 está circulando en nuestra región dentro 
de diferentes hospedadores, incluida la fauna silvestre. Parece estar implicado en la diarrea 
humana a través de transmisión alimentaria (carne) y en la propagación de genes BLEE 
(principalmente del tipo CTX-M-32). La presencia concomitante de IncF (F2: A-: B-), IncI1 e 
IncX1, junto con plásmidos de tipo Col156 no conjugativos podría estar implicada en la 
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A COVID-19 leva ameazando ó mundo durante máis de dous anos. Por sorte, o traballo de 
moitos investigadores permitiu o desenvolvemento nun tempo récord de ferramentas para 
combater esta pandemia de forma precisa en forma de vacinas. Pero esta pandemia está a 
deixarnos moitas ausencias e consecuencias, como as derivadas da eclipse temporal do maior 
desafío de saúde na actualidade: as resistencias aos antibióticos (ABR). O aumento no número 
de bacterias multirresistentes (MDR) a antibióticos de último recurso (por exemplo á colistina, 
os carbapenémicos ou as cefalosporinas) é un dos problemas de saúde pública máis graves a 
nivel mundial debido á falta de opcións terapéuticas alternativas adecuadas, ó aumento das taxas 
de mortalidade e aos custos de saúde derivados dos tratamentos non efectivos. Segundo o 
Centro Europeo para a Prevención e o Control de Enfermidades (ECDC), máis de 670.000 
infeccións bacterianas podense atribuír ás bacterias MDR, sendo responsables de máis de 
33.000 mortes ó ano só en Europa.  
 
Debido ó risco asociado ó uso terapéutico de antibióticos en animais de produción e ó seu 
potencial impacto para o ser humano, a Axencia Europea de Medicamentos ( EMA) propuxo 
recentemente unha nova  categorización, na cal inclúe na Categoría A (“Evitar”) aqueles 
antibióticos non autorizados actualmente para o seu uso en medicina veterinaria na Unión 
Europea (UE), como son a fosfomicina ou os monobáctamicos; e na Categoría  B (“Restrinxir”) 
inclúense aqueles antimicrobianos nos que debe restrinxirse o seu uso en animais para así 
mitigar o risco para a saúde pública, a saber, as quinolonas, as cefalosporinas de terceira e cuarta 
xeración e as polimixinas. Polo tanto, leste é un momento crítico no que a redución da presión 
dos antibióticos a través de diferentes enfoques fai necesario rastrexar a evolución bacteriana 
para comprobar a evolución das medidas tomadas e así deseñar novas estratexias. 
 
A bacteria Escherichia coli forma parte da microbiota comensal natural do sistema 
dixestivo en vertebrados de sangue quente e poden desempeñar diversas funcións dependendo 
das súas características e o seu perfil de virulencia. Aínda que as cepas de E. coli patóxenas 
intestinais (InPEC) distínguense con precisión da microbiota intestinal comensal debido á 
presenza de factores de virulencia asociados aos diferentes patotipos, isto non é tan simple coas 
bacterias de E. coli patóxenas extraintestinais (ExPEC), xa que se comportan como patógenos 
oportunistas podendo colonizar de forma indefinida o sistema dixestivo sen causar dano ó 
anfitrión. Polo de agora non foi determinados ningún conxunto de xenes poida definir 
inequivocamente as cepas ExPEC ou as súas diferentes categorías. Na actualidade estanse 
categorizando en fusión do seu illamento en infeccións localizadas fóra do sistema dixestivo e 
/ ou en función da presenza de xenes asociados estatisticamente co potencial patoxénico 
extraintestinal destas cepas, os cales poden usarse de maneira preditiva. Ademais, certas liñaxes 
de E. coli extraintestinais, como o clon pandémico ST131, foron recoñecidos mundialmente 
pola súa implicación en infeccións humanas así como polo seu papel na propagación de 
resistencias a antibióticos de uso habitual. A hipótese de que os alimentos, en particular os 
produtos avícolas, poden actuar como reservorio de patóxenos extraintestinais humanos como 
E. coli e outras Enterobacteriaceae, baséase na evidencia científica. Cepas causantes de 
patoloxía aviaria (APEC) mostran unha alta similitude xenética coas que causan patoloxía 




cepas humanas ExPEC poden evolucionar a partir de cepas APEC ou ser iguais a elas. As 
evidencias que apuntan a esta hipótese son, entre outras: A) A existencia dunha agrupación 
xeográfica e temporal das cepas ExPEC illadas de pacientes con infeccións extraintestinas que 
suxire a aparición dun brote ou unha fonte común de exposición. B) A distribución global de 
liñaxes de cepas ExPEC idénticas, que indican a propagación global da contaminación 
transmitida a través dos alimentos. C) A detección de xenotipos idénticos de ExPEC illados de 
infeccións humanas, así coma de produtos alimenticios detectados e analizados nunha mesma 
área xeográfica. D) A representación desproporcionada de certas liñaxes pandémicas de ExPEC 
entre centos de ST diferentes que causan infeccións extraintestinais en todas as rexións do 
mundo, o que suxire unha vantaxe biolóxica ou de aptitude para diferentes reservorios destas 
liñaxes pandémicas, como poden ser os animais de produción ou outros animais como as aves 
silvestres. E) A aparición relativamente recente dos clons ST69, ST131 e ST393 como cepas 
ExPEC, suxerindo a recente introdución destes xenotipos no nicho intestinal humano a partir 
de fontes externas. 
 
Debido á alta plasticidade do xenoma de E. coli, os patotipos híbridos están a ser cada vez 
máis frecuentes e impredicibles debido ó importante papel que xogan os elementos xenéticos 
móbiles (EXM) como os plásmidos, os bacteriófagos, as illas de patoxenicidade, os transposons 
e as secuencias de inserción na evolución das bacterias. Ademais, as cepas con patotipos 
híbridos complexos con combinacións de dous grupos diferentes de cepas InPEC (E. coli 
produtores de toxinas Shiga; STEC + E. coli enteroagregativos; EAEC) ou InPEC e ExPEC 
(por exemplo, E. coli enteropatóxeno atípico; aEPEC + ExPEC e STEC + APEC) notifícanse 
cada vez máis en casos clínicos humanos. Desde 2011, cando se identificou unha nova cepa de 
E. coli produtora de toxinas Shiga pertencente ó serotipo O104:H4, con características de 
virulencia comúns á EAEC e produtora do xene de resistencia CTX- M-15, como involucrada 
no gran brote alemán, o concepto de patotipo foi cuestionado e actualmente estanse utilizando 
enfoques clásicos e actuais como a secuenciación xenómica completa (WGS) para mellorar a 
comprensión da evolución desta especie altamente adaptable. 
 
Actualmente está aceptada a premisa de que o uso de terapia con antibióticos en animais 
destinados á produción de alimentos para consumo humano é a principal causa do aumento das 
ABR, incluída a resistencia á colistina. Nas últimas décadas produciuse unha rápida 
diseminación de cepas portadoras de betalactamasas de espectro estendido (BLEE), 
principalmente debido á súa presenza en plásmidos e a súa expansión a través de grupos clonais 
exitosos, como o clon pandemico ST131 de E. coli. Hoxe en día existe unha gran preocupación 
ante a posibilidade de adquisición in vivo de plásmidos portadores do xene mcr de resistencia a 
colistina, así como de xenes blaBLEE por parte de cepas de E. coli causantes de patoloxía humana 
despois de tratamentos clínicos ou por transmisión animal a través do contacto directo ou a 
cadea alimentaria entre cepas portadoras e cepas da microbiota humana. ST131 é considerado 
o principal clon pandémico responsable da propagación global de xenes ESBL. Identificado por 
primeira vez en 2008, o grupo clonal ST131 pertence ó filogrupo B2 e principalmente aos 
serotipos O25b:H4 ou, con menor frecuencia, ó serotipo O16:H5. Tres anos despois do seu 
primeiro illamento, xa se atopaba diseminado a nivel global, sendo o axente bacteriano 
involucrado en máis do 50% dos casos de UTIs por cepas produtoras de BLEE en numerosos 
hospitais de diferentes países. A prevalencia de resistencias a antibióticos orais de primeira liña 
como trimetoprim-sulfametoxazol, amoxicilina e amoxicilina-clavulánico foi aumentando 
constantemente durante estes anos, dificultando cada vez máis o tratamento de infeccións e 
poñendo en perigo a vida dos pacientes. Aínda que está asociado con infeccións ExPEC como 
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UTIs, septicemias, infeccións de feridas cirúrxicas e meninxites, este clon tamén se atopa con 
frecuencia no sistema dixestivo de humanos sans. Por iso, sospéitase que o tracto intestinal 
humano conforma un posible nicho para o clon ST131. Con todo, o crecente interese da 
comunidade científica cara a este clon fixo que fose detectado en fontes tan diversas como 
animais de compañía, animais de produción de alimentos e salvaxes; ou no propio medio 
ambiente, como en ríos, praias ou na rede de sumidoiros; mesmo na rexión antártica. Cos datos 
actuais, apréciase o feito de que os clados A e C están asociados principalmente a patoloxía 
humana, mentres que o clado B agrupa a cepas illadas de diferentes nichos como aves e porcos, 
xunto con humanos. Un desafío importante é saber que determinantes fan que certos clons se 
adapten mellor a un hóspede específico mentres que outros poden transmitirse entre diferentes 
especies, con saltos tan importantes como entre mamíferos e aves. No caso de ST131, esta 
relación entre os diferente clados e a súa presenza en diferentes hospedadores aínda non se 
entendeu completamente. 
 
A presente tese doutoral inclúe tres estudos, "Chicken and turkey meat: Consumer exposure 
to multidrug-resistant Enterobacteriaceae including mcr-carriers, uropathogenic E. coli and 
high-risk lineages such as ST131” (Díaz-Jiménez et al., 2020a), “Microbiological risk 
assessment of turkey and chicken meat for consumer: Significant differences regarding 
multidrug resistance, mcr or presence of hybrid aEPEC/ExPEC pathotypes of E. coli” (Díaz-
Jiménez et al., 2021) e “Genomic Characterization of Escherichia coli Isolates Belonging to a 
New Hybrid aEPEC/ExPEC Pathotype O153:H10-A-ST10 eae-beta1 Occurred in Meat, 
Poultry, Wildlife and Human Diarrheagenic Samples” (Díaz-Jiménez et al., 2020b). O 
obxectivo da presente tese doutoral, desenvolta no marco de dous proxectos nacionais (PN 
AGL2016-79343- R e PID2019-104439 RB- C21 / AEI / 10.13039 / 501100011033), foi 
analizar o potencial zoonótico de cepas da familia Enterobacteriaceae illadas de ave de curral 
para consumo humano, con caracterización de resistencias a antibióticos e definición de grupos 
clonais patógenos para o ser humano. Deste xeito, avaliamos a exposición do consumidor a 
cepas da familia Enterobacteriaceae con capacidade para desenvolver infeccións 
extraintestinais de risco, xa sexa pola virulencia das cepas ou polo seu patrón de resistencias a 
antibióticos adquiridos a través da carne de polo e pavo. 
 
A hipótese da presente tese expón que a carne de ave de curral destinadas a consumo 
humano estarían a actuar como reservorio e potenciais axentes transmisores de cepas patóxenas 
que poderían estar implicadas en infeccións extraintestinais humanas. Para demostrar esta 
hipótese, a estratexia foi analizar carne de ave á venda polo miúdo adquirida directamente nos 
puntos de venda co obxectivo de que o produto final nos proporcione datos sobre o que sucede 
na granxa, no matadoiro, así como a calidade do produto que entra na cociña do consumidor. A 
segunda estratexia foi identificar os grupos clonais potencialmente uropatóxenos de E. coli 
baseados en marcadores xenéticos específicos. E finalmente, considerar como cepa de “risco” 
aquela con capacidade de desenvolver unha infección extraintestinal grave no ser humano, xa 
sexa polo seu potencial de virulencia e / ou pola súa resistencia aos antibióticos. 
 
Os obxectivos específicos da presente tesis doutoral foron o deseño dun protocolo eficaz 
para a recuperación de E. coli transmitido polos alimentos e outras Enterobacteriaceae con 
potencial patógeno e / ou resistentes aos antimicrobianos. Un segundo obxetivo foi coñecer a 
situación actual das ABR na produción avícola, prestando especial atención ás categorías de 
antimicrobianos A e B da clasificación EMA. Tamén realizamos a avaliación da exposición do 




con potencial para desenvolver infeccións graves debido ó seu perfil de virulencia e / ou ó seu 
perfil de resistencia a antibióticos. Por derradeiro, quixemos explorar o roteiro de transmisión 
alimentaria de clons específicos de E. coli de orixe humana e animal mediante análise 
comparativa de xenomas. 
 
Tomáronse ó azar mostras de 100 produtos cárnicos de orixe aviaria (50 mostras de polo e 
50 mostras de pavo) en seis cadeas de supermercados españolas e carnicerías locais situadas en 
Lugo (noroeste de España). Mediante un protocolo de cultivo convencional recuperáronse 358 
cepas diferentes de especies pertencentes á familia Enterobacteriaceae (170 illamentos 
recuperados de mostras de polo e 188 illamentos recuperados de mostras de pavo) utilizando 
os medios agar MacConkey Lactosa agar MacConkey Sorbitol con telurito e cefixima, 
CHROMID® ESBL e CHROMID® CARBA SMART. A identificación bacteriana revelou que 
323 de 358 illamentos eran E. coli, 28 de K. pneumoniae, seis de Serratia fonticola e un de 
Enterobacter cloacae. Esta colección caracterizouse por completo incluíndo: filogrupo, 
serotipo, ST e complexo clonal, clonotipo, perfil de virulencia e de resistencia. 
 
Unha segunda colección foi obtida durante o período entre 2005 e 2015 a partir de 
diferentes estudos de vixilancia realizados no LREC, Lugo, España, que tiñan como obxectivo 
a detección de cepas de E. coli produtoras de BLEE en diferentes fontes na nosa rexión. Estes 
estudos incluíron mostras de carne de ave, vacún e porcino, así como do ambiente de granxas 
de produción avícola e animais salvaxes, e caracterizaronse os illamentos que presentaban un 
patotipo aEPEC e o serotipo O153. 
 
O primeiro estudo evalua a exposición do consumidor a través da carne de ave a cepas da 
famila Enterobacteriaceae con capacidade para provocar infeccións extraintestinais severas 
debido ás súas características de virulencia e / ou trazos de resistencia a antibióticos. A 
caracterización de 256 cepas (84 illamentos representativos de E. coli, 137 illamentos de cepas 
de E. coli produtores de  BLEE, 28 illamentos de cepas de Klebsiella pneumoniae produtoras 
de  BLEE, seis illamentos de cepas de Serratia fonticola produtoras de BLEE e un illado de 
Enterobacter cloacae produtor de BLEE) e a avaliación de cinco parámetros mostrou que 96 
de cada 100 mostras de carne de ave de curral adquiridas en supermercados do noroeste de 
España presentaban máis dun factor de risco potencial. En concreto, i) o 96% das mostras eran 
portadoras de cepas de Enterobacteriaceae resistentes a antimicrobianos das categorías A (64% 
con resistencia a monobactamicos) ou B (95% con resistencia a cefalosporinas de 3a e 4a 
xeración, quinolonas e / ou polimixinas) da nova categorización de EMA. ii) Recuperouse máis 
dunha especie de Enterobacteriaceae produtoras de BLEE do 29% das mostras, principalmente 
cepas de E. coli e K. pneumoniae. iii) A caracterización dos illados de E. coli mostrou que os 
grupos clonais extraintestinais de alto risco e / ou potencialmente uropatóxenos (ST10, ST23, 
ST38, ST48, ST58, ST69, ST88, ST93, ST95, ST101, ST115, ST117, ST131, ST141, ST167, 
ST350, ST345, ST354, ST359, ST410, ST602, ST617, ST641, ST906, ST1485) estaban 
presentes no 62% das mostras. iv) Das cepas recuperadas de E. coli o 25% satisfixeron os 
criterios para ser denominadas segundo o criterio como ExPEC e v) o 17% satisfixeron os 
criterios para ser denominadas segundo o criterio como UPEC. Con respecto ás cepas de K. 
pneumoniae, polo menos oito das 11 ST identificadas na nosa colección foron reportadas como 
illamentos de cepas clínicas humanas; especificamente: ST15, ST45, ST111, ST147, ST307, 
ST627, ST966 e ST1086 (22 das 28 K. pneumoniae pertencían a algún destes oito ST). O xene 
mcr-1 de resistencia á colistina mediado por un plásmido identificouse en 13 illamentos de E. 
coli de sete mostras de carne diferentes, con todo, as once K. pneumoniae que presentaron 
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resistencia fenotípica a colistina foron negativas por PCR para a presenza de xenes mcr-1 a 
mcr-8, probablemente indicando unha resistencia de tipo cromosómica á colistina. 
 
No noso segundo estudo, avaliouse o risco ó que se expoñían os consumidores de carne de 
ave atendendo unicamente ás cepas illadas de E. coli. Propúxose un fluxo de traballo de 
laboratorio baseado en seis trazos de virulencia e / ou resistencia aos antimicrobianos e 
incluímos o desenvolvemento dunha PCR dobre para o cribado de cepas con xenes asociados ó 
criterio ExPEC. Caracterizamos 323 cepas recuperadas de 100 mostras de carne de ave de curral 
para consumo humano. Esta caracterización revelou que a carne de aves é unha fonte de cepas 
con diversidade filogenética rica en filogrupos de E. coli (Á - G) e Escherichia clado I. 
Ademais, o 47% das mostras eran portadoras de 2 ou máis E. coli diferentes positivos para 
xenes BLEE, pAmpC ou mcr. As cepas illadas do 78% de mostras de carne de ave cumpriron 
os requirimentos do criterio do status ExPEC e o 53% foron portadores de cepas positivas para 
o status UPEC. As STs identificadas no 86% das mostras pertencían ás chamadas liñaxes 
ExPEC de alto risco, sendo os 73% portadores de grupos clonais identificados en infeccións 
humanas da mesma área de saúde. Ademais, diferentes clons asociados con patoloxía humana 
apareceron na mesma mostra de carne:  ST131-B2 (CH40-22), ST648-F (CH4-58), ST93-A 
(CH11-neg) ou ST95-B2 (CH38-27), ST354-F (CH88-58), ST155-B1 (CH4- neg). De forma 
xeral, o 84% das mostras de carne presentaban tres ou máis factores de risco, incluídos xenes 
de resistencia, clons exitosos de risco e trazos de virulencia. A carne de pavo mostrou unha 
presenza significativamente máis alta de xenes mcr ou resistencia a múltiples fármacos; mentres 
que a taxa de cepas con estatus ExPEC, ou a presenza de patotipos híbridos como o aEPEC / 
ExPEC O153:H10-A-ST10 (CH11-54), asociáronse coa orixe do polo (P < 0.05). 
 
No noso terceiro estudo tomamos como punto de partida os diferentes estudos de vixilancia 
(2005-2015) realizados no noroeste de España. Estes revelaron a presenza de illamentos eae-
positivos de cepas de Escherichia coli do serotipo O153:H10 en mostras de carne para consumo 
humano, granxas avícolas, fauna silvestre e casos de diarrea humana. O obxectivo deste estudo 
foi explorar a relación xenética entre os illados humanos e animais / cárnicos, así como o seu 
mecanismo de persistencia. Tamén era obxectivo saber se se trataba dunha liñaxe 
xeograficamente restrinxida ou se fora reportado noutro lugar. A caracterización convencional 
mostrou que 32 illamentos eran O153:H10-A- ST10 fimH54, fimAvMT78, traT e eae- beta1. 
Entre elas, 21 eran produtoras de CTX- M-32 ou SHV-12. A comparación empregando a técnica 
de PFGE XbaI - macrorrestricción mostrou unha alta similitude (> 85%) entre os illamentos de 
diferentes orixes da colección. A análise do plasmidoma revelou unha combinación estable dos 
tipos de plásmidos IncF (F2:A-:B-), IncI1 (ST descoñecido) e IncX1, xunto con  plásmidos de 
tipo Col non conxugativos. A investigación do core genome baseada no esquema do tipado das 
secuencias multilocus do core genoma (cgMLST) de EnteroBase demostrou unha estreita 
relación entre os illamentos de orixe humana e animal. 
 
A partir dos nosos resultados, chegamos á conclusión de que a microbiota presente na carne 
de ave de curral é unha fonte de enterobacterias xeneticamente diversas, resistentes a 
antimicrobianos relevantes (categorías A e B de EMA) e potencialmente patóxenas para os 
seres humanos, incluíndo patotipos híbridos de E. coli, grupos clonais de E. coli de alto risco 
asociados a patoloxías humanas extraintestinales e / ou cepas uropatógenas, así como grupos 
clonais de K. pneumoniae de interese clínico. Os nosos resultados indicarían tamén que o 
sistema de produción industrial de carne de pavo dá como resultado unha maior presión de 




polo, o que se reflicte en taxas significativamente máis altas de cepas de E. coli MDR positivas 
para o xene mcr, e cepas de K. pneumoniae produtoras de BLEE en carne de pavo.  
 
Con respecto aos métodos aquí propostos, atopamos que os protocolos I e II, baseados nos 
medios ML e MLST incubados a 37 º C, son os máis efectivos para a recuperación de cepas 
que cumpren o estatus ExPEC e UPEC, así como as cepas positivas ó xene rbfO25b, asociado 
co grupo clonal STl31. O protocolo V (placas de agar CHROMID® ESBL incubadas a 37 º C) 
é clave para a recuperación de Enterobacteriaceae produtoras de BLEE ou pAmpC. A PCR 
dúplex baseada na detección de xenes iutA e KpsM II en MacConkey Lactosa e MacConkey 
sorbitol con telurio e cefixima é esencial para o cribado preciso de cepas que cumpren o estatus 
ExPEC, así como para a recuperación daqueles con status UPEC. Finalmente, concluímos que 
o método microbiológico proposto aquí (pre-enriquecemento, enriquecemento en caldo 
MacConkey inoculación en MacConkey Lactosa / MacConkey sorbitol con telurio e cefixima 
/ CHROMID® ESBL), seguido da selección de seis trazos de virulencia / ABR (estatus ExPEC, 
estatus UPEC, BLEE / produtor de pAmpC, portador de mcr-1, MDR, rfbO25b), axudaría a 
dilucidar o papel dos ExPEC como novos patógenos extraintestinales transmitidos polos 
alimentos. 
 
Os nosos resultados demostran que un híbrido MDR aEPEC / ExPEC pertencente ó grupo 
clonal O153:H10-A- ST10 (CH11-54) eae- beta1 está a circular na nosa rexión dentro de 
diferentes hospedadores, incluída a fauna silvestre. Parece estar implicado na diarrea humana a 
través de transmisión alimentaria (carne) e na propagación de xenes BLEE (principalmente do 
tipo CTX- M-32). A presenza concomitante de IncF (F2:A-:B-), IncI1 e IncX1, xunto con 
plásmidos de tipo Col156 non conxugativos podería estar implicada na persistencia satisfactoria 
deste patotipo híbrido. 
 
 
Palabras chave:  Enterobacteriaceae, Escherichia coli, Klebsiella pneumoniae, ExPEC, 
ST131, mcr, patotipo híbrido, antibiorresistencia, BLEE, EnteroBase, evaluación do risco, 
carne de ave, Unha Soa Saúde, da granxa á mesa. 
 
 



























ABR: From Spanish “Cepas resistentes a antibióticos” 
adk: Adenylate Kinase gene 
aEPEC: Atypical enteropathogenic E. coli 
AIEC: Disease-associated adherent-invasive E. coli  
AMC: Amoxicillin-clavulanic acid  
AMEG: Antimicrobial Advice Ad Hoc Expert Group 
AMK: Amikacin  
AMP: Ampicillin  
AMR: Antimicrobial resistance  
APEC: Avian pathogenic E. coli  
AST: Antibiotic susceptibility testing 
ATB: Antibiotic 
ATM: Aztreonam   
 
BFP: Bundle-forming pilus 
BLAST: Basic Local Alignment Search Tool 
BLEE: From Spanish “betalactamasas de espectro extendido” 
bp: Base pairs 
BPW: Buffered peptone water  
 
CAZ: Ceftazidime   
cba: Colicin B gene  
CC: Clonal complex  
celb: Endonuclease colicin E2 gene 
CFA: Colonization factor antigens 
CF3rd: Cephalosporine of 3rd generation  
cfu: Colony forming units  
CGE: Center for Genomic Epidemiology  
cgMLST: Core genome Multilocus Sequence Typing  
Ch: Chicken  
CH: Clonotype 
CHL: Chloramphenicol   
CIP: Ciprofloxacin  
CLSI: Clinical & Laboratory Standards Institute   
cma: Colicin M gene 
cnf: Cytotoxin necrotizing factor gene 
CST: Colistin  
CTX: Cefotaxime  
CTX-M: Cefotaximases 
 
DAEC: Diffusely adherent E. coli 
DEC: Diarrheagenic E. coli 
DNA: Desoxyribonucleic acid  
DOX: Doxycycline  
DPMT: Degenerate Prime MOB Typing 
 




E. coli: Escherichia coli  
eae: Intimin gene 
EAE: Attaching and effacing protein 
EAEC: Enteroaggregative E. coli  
EAST1: Heat-stable EAEC toxin 
ECDC: European Centre for Disease Prevention and Control 
EEA: European Economic Area 
EIEC: Enteroinvasive E. coli 
EMA: European Medicines Agency  
EPEC: Enteropathogenic E. coli 
ESBL: Extended Spectrum β-lactamases 
ETEC: Enterotoxigenic E. coli 
ExPEC: Extraintestinal pathogenic E. coli 
 
fimH: Type 1 fimbrial adhesine gene 
FQ: Fluoroquinolone  
FOF: Fosfomycin  
FOX: Cefoxitin 
fumC: Type 1 fimbrial adhesin gene  
 FWD-Net: European Food and Waterborne Diseases and Zoonoses Network 
 
GEN: Gentamicin   
gyrB: DNA gyrase gene 
 
HC: Hemorrhagic colitis  
HierCC: Hierarchical Clustering 
hly: Hemolysin gene 
HNM: H non-motile isolate 
HULA: Hospital Universitario Lucus Augusti  
HUS: Hemolytic uremic syndrome  
 
icd: Isocitrate/isopropylmalate dehydrogenase gene 
IMP: Imipenem  
Inc.: Incompatibility groups 
InPEC: Intestinal pathogenic E. coli  
iroN: Enterobactin siderophore receptor protein  
IS: Insertion sequences 
iss: Increased serum survival 
 
LREC: From Spanish “Laboratorio de Referencia de Escherichia coli” 
LT: Heat-labile toxin 
 
MALDI-TOF: Matrix-Assisted Laser Desorption/Ionization – Time of fly 
MB: Monobactam 
mchF: ABC transporter protein MchF gene 
MCPs: Multicopy plasmids  
mcr: Mobile colistin resistance gene 





MDR: Multidrug-resistant  
MEGA: Molecular Evolutionary Genetics Analysis  
MGE: Mobile genetic element 
MIC: Minimum inhibitory concentration  
ML: MacConkey Lactose agar   
MLEE: Multilocus Enzyme Electrophoresis  
MLST: Multilocus Sequence Typing  
MOB: Relaxase protein 
Mpb: Mega Base Pairs 
MSTC: MacConkey Sorbitol with Telurite and Cefixime  
 
NAL: Nalidixic acid   
NCBI: National Center for Biotechnology Information 
NIT: Nitrofurantoin  
NJ: Neighbor-Joining 
NMEC: Neonatal meningitis-associated E. coli 
nt: Non typable  
NR: Not realized  
 
ONT: O non-typeable isolate 
ori: Replication initiator  
 
PAI: Pathogenicity Island  
PCR: Polymerase chain reaction 
PDR: Pandrug resistance  
PFGE: Pulsed field gel electrophoresis  
PG: Phylogroup  
pMLST: PCR-based replicon subtyping 
PRAN: From Spanish “Plan Nacional Resistencia Antibióticos” 
purA: Adenylosuccinate dehydrogenase gene 
 
Q: Quinolone  
 
R: Representative isolate 
recA: ATP/GTP binding motif gene 
Rep: Replication initiator  
 
ShET2: Enteroinvasive toxin 
SNP: Single Nucleotide Polymorphism  
spp.: Species 
ST: Sequence type  
STa/STb: Heat-stable toxin 
STEC: Shiga toxin-producing E. coli  
Stx1/Stx2: Shiga toxins genes 
SXT: Sulfamethoxazole-trimethoprim  
 
 
T: Turkey  




tEPEC: Typical enteropathogenic E. coli  
TGC: Tigecycline  
Tn: Transposons  
tnp: Transposase genes 
TOB: Tobramycin 
Tra: Conjugative systems 
TSA: Tryptone soy agar 
TSB: Tryptone soy broth 
tsh: Temperature-sensitive hemagglutinin gene 
 
UPEC: Uropathogenic E. coli 
UPGMA: Unweighted pair group method with arithmetic mean 
UTI: Urinary tract infection 
USC: Universidad de Santiago de Compostela  
 
VF: Virulence factors 
 
WGS: Whole genome sequencing  
WHO: World Health Organization  
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1.1. ESCHERICHIA COLI  
 
1.1.1. General characteristics of E. coli and clinical relevance 
 
This bacterium was first described by the German pediatrician Theodor Von Escherich in 
1885 after isolating it from the feces of a healthy child. Initially was named Bacterium coli 
(Escherich, 1885). 
 
Escherichia coli is a member of the family Enterobacteriaceae, which includes Gram-
negative facultatively anaerobic rod-shaped bacteria (possessing both a fermentative and 
respiratory metabolism) and which do not produce the enzyme oxidase. E. coli cells are 
typically 1.1–1.5 μm wide, 2–6 μm long and occur as single straight rods. They can be either 
motile or nonmotile, and when motile produce lateral, rather than polar, flagella. In addition to 
flagella, many strains produce other appendages such as fimbriae or pili, which play a role in 
the attachment to other cells or host tissues. E. coli carry strain-specific O lipopolysaccharide 
antigens on their cell wall (at least 181 O antigens are currently recognized) and flagella or H 
antigens if present (53 H types are recognized). There are also 80 different capsular 
polysaccharide (K) antigens. E. coli are serotyped based on the combination of O, H, and K 
antigens, although generally only the O and H types are listed (Kaper et al., 2004; 
Desmarchelier and Fegan, 2011).  
 
E. coli  is part of the commensal microbiota of the digestive system in warm-blood 
vertebrates (Hartl and Dykhuizen, 1984). This bacterium fulfills physiological functions such 
as the acquisition of nutrients for the intestinal epithelium, plays a role in the vitamin K 
synthesis, processes waste, constantly stimulates the immune system response of the host 
organism or avoids the colonization of the intestine by other non-desired enteropathogens 
through competitive inhibition (Kruis, 2004). Due to its intestinal origin, the presence of E. coli 
in environment, food or water samples is used as an indicator of recent fecal contamination or 
unsanitary practices in food processing plants (Alonso et al., 2007; Odonkor and Ampofo, 
2013).  
 
Although most E. coli strains play a beneficial or harmless role for their hosts, there are 
also pathogenic members within this species. These have been classified into two main groups: 
intestinal pathogenic E. coli (InPEC), causing enteric pathologies, and extraintestinal 
pathogenic E. coli (ExPEC), causing pathology outside the digestive system (urinary tract 
infections, sepsis, meningitis, lung or wound infections, among others). ExPEC strains are the 
main agent responsible of urinary tract infections in humans (UTI) worldwide, accounting for 
between 75 and 85% of cases (Foxman, 2010). Pathogenic strains show specific virulence 
factors (VF) that provides the ability to produce a wide variety of infections in both humans 
and animals (Russo and Johnson, 2000; Kaper et al., 2004). Traditionally only enteric infections 
caused by InPEC have been accepted as food-borne pathogens. Within InPEC, seven main 
subgroups recognized on the basis of specific virulence mechanisms: Shiga toxin-producing or 
enterohaemorrhagic E. coli  (STEC / EHEC), enteropathogenic E. coli  (EPEC), enterotoxigenic 
E. coli  (ETEC), enteroinvasive E. coli  (EIEC), enteroaggregative E. coli  (EAEC), diffusely 
adherent E. coli  (DAEC), and disease-associated adherent-invasive E. coli  (AIEC) (Nataro 
and Kaper, 1998; Kaper et al., 2004; Denamur et al., 2021). On the other hand, the ExPEC 
group includes uropathogenic E. coli  (UPEC), avian pathogenic E. coli  (APEC) and neonatal 





While InPEC are accurately distinguished from the commensal gut microbiota based on 
certain VF, this is not as simple with ExPEC since they behave as opportunistic pathogens that 
can colonize the intestinal environment without causing harm to the host (Riley, 2020). Thus, 
no set of genes can unequivocally define ExPEC strains or the different categories. So far, they 
are being categorized due to their isolation from infections located outside of the digestive 
system, and / or based on the presence of genes statistically associated with the extraintestinal 
pathogenic potential of the strains, which can be used predictively (Johnson et al., 2003c; 
Spurbeck et al., 2012). Besides, certain extraintestinal lineages of E. coli, such as the pandemic 
ST131, have been worldwide recognized by their implication in human infections, and also, by 
their role in the spreading of antibiotic resistances  (Riley, 2014; Manges et al., 2019). 
 
In industrial farming, colibacillosis is a highly frequent pathology affecting newborn 
animals. This syndrome causes significant economic losses due to mortality, weight loss and 
handling (Gyles and Fairbrother, 2010; Kazibwe et al., 2020). Its control and treatment have 
been largely based on antimicrobials. Currently, it is assumed that antibiotic used and misused 
in food producing animal has been playing an important role in the dissemination of multidrug-
resistant (MDR) bacteria, which can reach human population through food chain (Mora et al., 
2010; Hindermann et al., 2017; García-Meniño et al., 2021b). In fact, there is a great concern 
that extended-spectrum β-lactamase (ESBL) / AmpC- and carbapenemase-producing 
Enterobacteriaceae occurring in animals constitutes a public-health issue (EFSA, 2021). 
ESBL/AmpC genes are mostly located on mobile genetic elements (MGEs) such as plasmids, 
some of which are regarded as epidemic, and the size of the commensal ESBL/AmpC reservoir 
in non-human sources is dramatically rising (Viso, 2017). Even the companion animals are 
described as potential sources of acquisition (Abreu-Salinas et al., 2020). 
 
1.1.2. Population structure of E. coli    
 
E. coli presents great plasticity, genetic diversity and its population structure and evolution 
has been studied in depth over time, being the most extensively characterized prokaryotic model 
(Tenaillon et al., 2010). The genus Escherichia includes three species, E. albertii, E. fergusonii, 
and E. coli, and five clades named I to V. The clades are indistinguishable from E. coli at the 
phenotypic level, but divergent at various levels within the nucleotide profile. It has been proved 
that between the strains that belong to clade I and the ones that belong to E. coli there is an 
exchange of genes of the core genome that does not occur between them and the rest of the 
genus Escherichia. For that reason, it has been suggested that the strains of clade I change their 
name to E. coli sensu lato and those classically known as E. coli, to E. coli sensu stricto 
(Denamur et al., 2021).  
 
E. coli sensu stricto has a very well defined and preserved phylogenetic structure, which 
includes eight phylogenetic groups, divided into two main clusters. The first cluster includes 
phylogroups B2, D, G, and F, usually associated with ExPEC strains, carriers of a higher 
number of virulence genes compared to other phylogroups. The second cluster groups the 
phylogroups A, B1, C and E, mainly including commensal strains and those that cause digestive 
pathology and. Phylogroup H, associated with phylogroup D, has been recently described 
(Clermont et al., 2019; Denamur et al., 2021). E. coli shows a clonal population structure within 
which, diversity is generated mainly by mutation events (vertical diversity). Although the 
species also experiments a very high number of small fragment recombination events, the 
vertical structure of the population is not affected. The recombination ratio is not the same all 
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through the chromosome, hence there are regions known as “bastions of polymorphism” where 
this ratio is higher (Tourret and Denamur, 2016). 
 
The first studies on the E. coli population structure were based on the analysis of the 
serotypes and their global distribution, followed by Multilocus Enzyme Electrophoresis 
(MLEE), although the latter was quickly discarded because of its low phylogenetic resolution. 
With the implementation of new molecular typing tools such as Multilocus Sequence Typing 
(MLST) (Dale and Woodford, 2015), a better visualization of these relationships was achieved. 
The Achtman seven-gene MLST scheme (adk, fumC, gyrA, icd, mdh, purA and recA) has been 
adopted all over the world (Wirth et al., 2006). Currently, this scheme is implemented in 
EnteroBase, which is an integrated software environment that supports the identification of 
global population structures within several bacterial genera including E. coli. With the use of 
massive sequencing tools (Whole Genome Sequencing, WGS) and their availability at an 
affordable price, much more is known about the population structure of the species. The E. coli 
genome is generally formed by 3,900 - 5,800 genes, corresponding to 4,2 – 6,0 Mpb. All the 
strains of the species share a group of approximately 2,000 genes, known as the core genome, 
while the total number of genes found in the different strains of this species increases as more 
of them are sequenced, showing a continuously expanding pangenome. In one study, with the 
sequencing of 20 genomes, 15,000 genes were described, however, with the sequencing of 
1,500 strains, the pangenome increased to 75,000 genes. It is estimated that for each new isolate 
sequenced, 26 new genes are identified (Denamur et al., 2021). EnteroBase assembles from 
Illumina short reads and genotypes those assemblies by core genome multilocus sequence 
typing (cgMLST). Hierarchical clustering of cgMLST sequence types allows mapping a new 
bacterial strain to predefined population structures at multiple levels. EnteroBase also supports 
single nucleotide polymorphism (SNP) calls and can also provide a global overview of the 
genomic diversity within an entire genus (Zhou et al., 2020). Presently, there are recognized 
more than 10.700 sequences type profiles (ST) and more than 56 clonal complexes (CC) for E. 
coli (last access: 18/05/2021). It is remarkable that the STs most frequently identified within 
ExPEC strains represent 0.001% of the total STs (ST10, ST12, ST69, ST73, ST95, ST117, 
ST127, ST131, ST405), but the total number of strains associated with these STs exceeds 19% 
of the total, making it clear that there are successful linages of E. coli (Riley, 2020; Zhou et al., 
2020). Within the E. coli  species, the definition of a clone has been established as an organism 
descended from a common precursor strain, with similar phenotypic or genotypic traits, being 
grouped in the same ST (Riley, 2014). Similarly, according to the 2007 modification of the 
MLST database, CCs are defined as groups of, at least, three STs that share six alleles in a pair-
wise comparisons (Wirth et al., 2006).  
 
WGS allows the in silico prediction of the classical bacterial typing through computer 
simulation. For this, there are online tools available to researchers such as those integrated in 
the Center for Genomic Epidemiology (CGE). Examples of this can be SeroTypeFinder for 
typing the O and H antigens (Joensen et al., 2015), the MLST tool to determine the ST and CC 
(Larsen et al., 2012), or the FimTyper used for typing the fimH gene (Louise Roer et al., 2017). 
The typing carried out by these tools is based on the comparison of the problem sequence with 
the template sequences stored in databases, which present minor variations among themselves. 
In silico analysis tools also allow for a much deeper and powerful analysis such as the 
construction of phylogenetic trees based on the single nucleotide polymorphism (SNP) of the 
core genome, which gives us a more accurate information on the historical evolution of the 





With this tool we can also see the divergence of the core genome between strains of the same 
ST and of different STs. An example of this would be the ST131 strains, which show great 
divergence between each other, being distributed in three clades (A, B, C) and in more than ten 
subclades. Therefore, even strains that share the same ST can differ substantially in their genetic 
repertoire (Denamur et al., 2021).  
 
1.1.3. The emergence of virulence in E. coli  
 
Virulence is the sum of different factors happening as variable combinations. The evolution 
of virulence in E. coli has exhibited three important mechanisms: 
 
- The acquisition of genes and / or functions through horizontal transfer by MGEs such 
as plasmids, phages or conjugative and integrative elements. All these acquired 
elements have in common the presence of a modular mosaic structure, a compendium 
of various genes of different origins that can generate multiple combinations, potentially 
developing new phenotypes. The islands of pathogenicity seem to have their origin in 
the integration of some of these mobile elements in the chromosome. Virulence factors 
transmitted by mobile elements can be classified into 5 main groups: adhesins, toxins, 
iron acquisition systems, protectin-invasins and others (Table 1) (Dale and Woodford, 
2015; Denamur et al., 2021).  
- The inactivation of genes whose expression is incompatible with virulence 
(antivirulence genes). These genes are useful in a non-pathogenic context since it is an 
energy saving method, however it is limiting when the bacterium needs to express 
pathogenicity. Normally this phenomenon is seen in metabolic pathways (Bliven and 
Maurelli, 2012). 
- Point mutations that cause changes in function. These patho-adaptive mutations are 
particularly well described in the type 1 fimbrial adhesive subunit (fimH). In some cases, 
a variation in amino acids can cause a change in their ability to adhere to different cells, 
for example, enhancing adherence into the urinary tract, in consequence increasing their 
urovirulence, while decreasing their intestinal colonization capacity (Sokurenko, 2016). 
 
 
Table 1. Virulence factors in ExPEC (Dale and Woodford, 2015) 
 
Adhesins Gene (s) 
Adhesion siderophore iha 
Dr binding adhesins afa/draBC 
E. coli common pilus ecpA 
F1C fimbriae foc gene cluster 
Heat-resistant haemagglutinin hra 
M fimbriae bmaE 
N-acetyl D-glucosamina-specific fimbriae gaf 
P fimbriae papACEFG 
S fimbriae sfa/sfaD 
Temperature sensitive haemagglutinin ths 
Type 1 fimbriae fimH 
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Iron acquisition systems Gene (s) 
Aerobactin receptor iutA 
Peri-plasmic iron binding protein sitA 
Salmochelin receptor iroN 
Siderophore receptor ireA 
Yersiniabactin receptor fyuA 
Protectins and invasins Gene (s) 
Colicin V cva 
Conjugal transfer surface exclusion 
protein traT 
Group 3 capsule kpsMT II 
Increased serum survival iss 
Invasion of brain endothelium ibeA 
K1/K2/K5 grupo 2 capsule variants K1/K2/K5 genes 
KpsM II group 2 capsule kpsM II 
Outer membrane protease T ompT 
Toxins Gene (s) 
Α-haemolysin hlyID 
Cytolethal distending toxin cdtB 
Cytotoxic necrotising factor cnf1 
Enteroaggregative E. coli toxin astA 
α-Haemolysin hlyA 
Secreted autotransporter toxin sat 
Serine protease pic 
Vacuolating toxin vat 
Others Gene (s) 
Colibactin synthesis clb & clbB 
Uropathogenic-specific protein ups 
Pathogenicity island maker malX 
D-serine deaminase dsdA 
 
 
According to Denamur et al. (Denamur et al., 2021), two characteristics of the genetic 
history of the strains explains the emergence of these virulence mechanisms. First, the 
emergence of the same virulence mechanism is repeated several times throughout the 
evolutionary history of the bacterium until it is fixed, which is why it is considered that this 
convergent evolution is a strong sign of selection regarding certain characteristics. Secondly, 
the phylogeny of the strain plays an important role since strains of the phylogroups B2, D, F 
and G carry numerous virulence genes and are usually isolated in extraintestinal infections, 
while strains belonging to phylogroups A, B1, C and E are less virulent (Sannes et al., 2004; 
Clermont et al., 2019). Therefore, these mechanisms have a higher incidence in certain strains 






Virulence is also the result of the additive effect of different virulence factors present within 
the bacteria. For example, studies on the virulence of wild type strains, in which a specific 
pathogenicity island (PAI) was eliminated, the same level of virulence was observed when 
assayed in a murine model. Even knocking out islands known as "highly pathogenic" (PAI 
IV536 carrying the yersinabactin gene), strains did not show a decrease in the virulence of the 
modified strain. However, when several islands were knocked out, a decrease in virulence was 
observed, being able to conclude that the pathogenicity islands have an additive effect. This 
fact evidences the great genetic complexity of virulence in these strains (Tourret and Denamur, 
2016). However, the number of virulence factors correlates with the intrinsic virulence of the 
strains. Those with a high content of virulence factors killed more than 80% of the mice in a 
murine septicemia model, while strains with a lower content of virulence factors caused less 
than 10% of casualties (Tourret and Denamur, 2016).  
 
When the clinical relevance of virulence is considered, we cannot forget that infections are 
the result of the interaction between the pathogen and the host. Considering the hierarchy 
described by Tourret and Denamur (Tourret and Denamur, 2016) about the importance of the 
factors involved in extraintestinal clinical infections, we would first have to consider the factors 
related to the host such as the species, gender, age, previous and / or underlying pathologies, as 
well as the state of the immune system. The microbiota is also an important not fully 
understood. These factors condition the phylogenetic group of the strains responsible of the 
infection. Thus, in immunocompromised patients, the isolation of strains of phylogroups A and 
B1 is more frequent. On the other hand, in patients without predisposing factors who present 
pyelonephritis or urosepsis, strains of the phylogroup B2 with numerous virulence factors are 
the most frequently isolated. The most important risk factors for a patient decease in cases of 
E. coli septicemia are related with the patient, his/her age, possible cirrhosis, previous 
hospitalizations, immunosuppression or the cutaneous origin of the septicemia. Only one 
bacterial factor, the capsule, has been recognized as promoting the translocation of bacteria 
from the urinary tract to the bloodstream. When septicemias originate from the urinary tract, 
they seem to be associated with more virulent strains, frequently from the B2 phylogroup, 
although these have a better prognosis than infections caused by strains from the phylogroups 
A and B1, which usually have their origin mainly in the digestive tract (Lefort et al., 2011).  
Regarding antibiotic resistance, it is of note that the strains of phylogroup B2, although they 
tend to be more virulent, they are usually sensitive to antibiotics, except in some cases such as 
the high-risk pandemic clonal group ST131. In contrast, the strains of phylogroups A and B1 
present a lower number of virulence factors and yet a higher resistance rate (Jauréguy et al., 
2007; Krieger et al., 2011). 
 
1.1.4. Intestinal E. coli pathotypes (InPEC) 
 
As mentioned in section “1.1.1. General characteristics of Escherichia coli and clinical 
relevance”, three large groups can be differentiated according to their ability to cause pathology. 
First, the commensal strains, which do not normally cause harm on the host. On the other hand, 
InPEC strains that cause digestive or intestinal pathology present a set of virulence factors 
clearly defined and associated with each pathotype. And finally, the strains that cause 
extraintestinal pathology (ExPEC), which do not have specific virulence factors that allows 
their clear categorization, but are defined according to their pathogenicity mechanisms, the 
infections or syndromes that they cause or the point of isolation of the strains (Blanco et al., 
2002). In the last decade, the increasing emergence of clones that fulfil the criteria of different 
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pathotypes has been reported, defining the new concept of hybrid pathotype. This situation is 
caused by the great plasticity of the genome of this bacterium. An example of it would be the 
outbreak that took place in Germany in 2011 where an E. coli  strain with virulence factors of 
the enteroaggregative pathotype and producer of Shiga toxins caused an outbreak associated 
with the consumption of fenugreek seeds (Mora et al., 2011b).  
 
Unlike commensal and ExPEC strains, InPEC strains rarely appear in the feces of healthy 
hosts and their presence is associated with digestive pathology if they are ingested in sufficient 
quantity (Russo and Johnson, 2000). Diarrheagenic pathologies are one of the major causes of 
mortality and morbidity among children under five years, with an annual death count of 718,000 
and 1,731 million cases, the incidence of diarrheal processes in children was 2,7 episodes per 
year in 2011 (Walker et al., 2013). InPECs are classified into seven categories based on their 
clinical and epidemiological characteristics and virulence factors: STEC and / or EHEC, EPEC, 
ETEC, EIEC, EAEC, DAEC and AIEC (Table 2). 
 
Shiga toxin-producing and / or enterohemorrhagic E. coli (STEC and / or EHEC): 
The group is characterized by the production of Shiga toxins (Stx1 and / or Stx2) (also called 
verotoxins, VT1 and / or VT2) transmitted by prophages, but only strains that also contain the 
pathogenicity island LEE "locus of enterocyte effacement" are considered EHEC (Kaper et al., 
2004). The strains of this group were first described in 1977 by Konowalchuk et al. 
(Konowalchuk et al., 1977), and are the main cause of hemorrhagic colitis (HC) and hemolytic 
uremic syndrome (HUS). Since its first description, its clinical importance has been increasing, 
and currently it is still among the main infectious agents responsible for gastroenteritis (CDC, 
2019b). Verotoxins are produced in the colon and can travel through the bloodstream to the 
kidneys where they damage the endothelial cells and occlude the microvasculature through the 
combination of direct cytokine toxicity and the production of chemokines, which cause kidney 
inflammation. This damage is what triggers HUS, although the most common clinical 
presentation is HC, with a common combination of symptoms as abdominal pain and bloody 
diarrhea without fever. Only in approximately 10% of cases HC ends up developing HUS. This 
causes hemolytic anemia, thrombocytopenia and acute kidney failure, in some cases requiring 
dialysis or even transplantation. Its mortality rate is between 5 and 10% (Friedrich et al., 2002; 
Kaper et al., 2004).  
 
This pathotype is characterized by the production of two important toxins that are cytotoxic 
to Vero cells and that is the reason they are known as verotoxins (VT1 and VT2), and as they 
are similar to toxins produced by Shigella spp. they are also known as Shiga toxins (Stx1 and 
Stx2). There are several subtypes, being the Stx2a variety the most powerful toxin, followed by 
Stx2d and Stx2c, commonly associated with HUS (Friedrich et al., 2002; Feng et al., 2011). 
These toxins are encoded in the genome of prophages integrated in the bacterial chromosome 
and are formed by two subunits, an enzyme subunit A of 33,000 d of molecular weight and 5 
or 6 subunits B 7,500 d that bind the toxin to cellular receptors composed of glycolipids and 
inhibit cell protein synthesis by catalytically inactivating the 60S ribosomal subunit (Muniesa 
et al., 2003; Allison, 2007).  
 
Most outbreaks have been associated with strains of the O157:H7 serotype. According to 
European Food Safety Authority / European Centre for Disease Prevention and Control (EFSA 
/ ECDC) data from 2020, 38.4% of HUS cases, 60.4% of hospitalizations and 71.6% of bloody 





second serotype in order of clinical importance (9.8%) is O26:H11. Regarding sporadic cases, 
the prevalence between O157 and non-O157 ECVT is very similar, even being the predominant 
non-O157 (Koutsoumanis et al., 2020). Due to the prominent presence of serogroup O157 and 
its association with severe cases of HC and HUS, STEC are usually classified in O157 and non-
O157 strains. It is clearly demonstrated that cattle act as the main reservoir of STEC. However, 
small ruminants, sheep and goats are also important carriers. Even wild ruminants can act as 
reservoir. During carcass processing operations in slaughterhouses, and especially during 
skinning and evisceration, strains of E. coli from the animal's intestinal microbiota reach the 
surfaces of the carcasses. The same occurs during milking, in which there is a risk of 
contamination of the milk with intestinal bacteria. The only way to avoid food poisoning is to 
heat the meat or pasteurize the milk to ensure bacterial inactivation. Especially dangerous are 
minced meat and derived products such as hamburgers, since microorganisms are found 
throughout their mass, it is not enough to heat the surface part. In fact, most of the outbreaks 
have been due to the consumption of hamburgers and therefore HC is known in Anglo-Saxon 
countries as “the disease of hamburgers”. In addition, animal feces can contaminate the 
environment, especially irrigation water, which in turn contaminates vegetables and fruits  
(López Capón and Capon López, 2018) 
 
Enteropathogenic E. coli  (EPEC): This was first described in England in 1945, 
associated to large outbreaks of infant diarrhea (Kaper et al., 2004). EPEC is still a cause of 
infant mortality in developing countries. This pathotype is typically carrier of the eae gene as 
part of the pathogenicity island LEE, which encodes a protein called intimin. Intimin is 
responsible for the intimate adherence of the bacteria to the enterocyte membrane, and the 
attaching and effacing lesion (AE) of the borders of the intestinal microvilli (Caron et al., 2006). 
The protein encoded by the eae sequence has a C-terminal variable ending that defines more 
than 30 types and subtypes of intimins associated with tissue tropism (Blanco et al., 2004; Mora 
et al., 2009a). EPEC strains are classified as typical (tEPEC) when they carry a plasmid called 
pEAF (EPEC adherence factor) that encodes a type IV pilus, BFP (bundle-forming pilus) 
responsible for mediating distant adherence between bacteria and epithelial cells. Atypical 
strains (aEPEC) are those that produce the AE lesion but do not carry the bfpA gene and 
therefore do not express the adhesin BFP (Hernandes et al., 2009; Mora et al., 2009a). Some 
epidemiological and experimental studies support the hypothesis that some aEPEC could have 
evolved from STEC / ECVT that had lost their stx genes (Afset et al., 2008; Scaletsky et al., 
2009; Horcajo et al., 2012).  
 
Currently, aEPEC strains are one of the emerging enteropathogens detected worldwide in 
different niches (animal species, environment and food samples), meanwhile the main reservoir 
of tEPEC strains are humans (Otero et al., 2013; Alonso et al., 2017). tEPEC is clearly related 
to diarrhea in children under one year and they are the main cause of endemic diarrhea in 
developing countries (Regina et al., 1983; Gomes et al., 1991; Trabulsi et al., 2002). However, 
there are controversial reports regarding the epidemiologic association of aEPEC with diarrhea 
since they are also frequently isolated from healthy individuals. In Spain, aEPEC is routinely 
isolated in stool cultures of patients with diarrhea and other gastrointestinal disorders. In a 
LREC study carried out between the years 1996 and 1999, aEPEC strains accounted for 5.2% 
of the patients with diarrhea or digestive disorders, while tEPEC strains for 0.2% (Blanco et al., 
2006). In a second study carried out in the period 2005-2013, a significant increase in infections 
caused by EPEC was detected (0.6% tEPEC and 11.5% aEPEC), supporting the hypothesis of  
the latter as an emerging cause of diarrhea in developed countries (Blanco et al., 2006).  
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Enterotoxigenic E. coli (ETEC): This pathotype was first reported in diarrhea associated 
with colibacillosis in neonatal and recently weaned pigs (Melkebeek et al., 2013). In 1971 
DuPont et al. demonstrated that ETEC strains could cause diarrhea in humans by infecting adult 
human volunteers (DuPont et al., 1971). ETEC, together with EPEC and rotaviruses, are the 
pathogens most frequently reported as cause of childhood digestive disease and traveler's 
diarrhea in developing countries (World Health Organization (WHO), 2005; Denamur et al., 
2021)(Denamur et al., 2021). ETEC strains colonize the mucosa of the small intestine by means 
of the fimbrial adhesins known as colonization factor antigens (CFA), and release two 
enterotoxins: heat-labile toxin (LT) and / or heat-stable toxin (STa/STb). The heat-labile toxin 
is related to the choleric enterotoxin expressed by the bacterium Vibrio cholerae (Sixma et al., 
1993). There are two types of heat-stable toxins with different structure and mechanisms of 
action. One would be the STa toxin associated with human, porcine and ruminant strains and 
STb toxin associated with mainly pig strains. The ETEC strains that cause infections in humans 
possess intestinal colonization antigens (CFA / I, CFA / II, CFA / III, CFA / IV) different from 
those present in the ETEC strains that cause colibacillosis in pigs (K88, K99, F41, P987, F18) 
and in ruminants (K99, F41). 
 
Enteroinvasive E. coli (EIEC): This pathotype is very similar to the members of the genus 
Shigella from the biochemical and genetic point of view and due to their pathogenicity 
mechanisms. Molecular evolution studies suggest that the different Shigella species arose from 
the acquisition of different virulence plasmids by E. coli strains (Yang et al., 2007). These 
strains invade the cells of the intestinal epithelium where they produce an enterotoxin (ShET2) 
encoded in a plasmid gene, sen. The pathogenicity mechanism follows several steps, firstly the 
bacterium penetrates the interior of the cells of the colon mucosa by endocytosis, then it 
produces the lysis of the enterocytic vacuole, to multiply intracellularly and moving through 
the interior of the cell cytoplasm until produce lateral spread to adjacent cells (Kaper et al., 
2004). The symptoms of this type of infection include watery diarrhea, dysentery in some cases 
manifested with blood, mucus, leukocytes in the stool and fever. Ulcers can appear in severe 
cases (Nataro and Kaper, 1998). 
 
Enteroaggregative E. coli (EAEC): The EAEC pathotype has been defined by its 
aggregative pattern of adherence to tissue culture cells. In developing countries, EAEC strains 
are associated with persistent childhood diarrhea, lasting up to 14 days. These strains present 
fimbriae that allow aggregative adherence to HEp-2 cells and the intestinal epithelium. They 
induce an increase in mucus secretion that leads to the formation of a biofilm where bacteria 
are trapped, allowing a more persistent colonization of the area and a worse absorption of 
nutrients at the intestinal level. EAEC strains produce a heat-stable enterotoxin known as 
EAST1 and a cytotoxin that is suspected of being responsible for diarrhea and characteristic 
histopathological lesions with shortening of the microvilli (Nataro and Kaper, 1998; Okeke and 
Nataro, 2001).  The pCVD432 (pAA) gene associated with the enteroaggregative adherence 
pattern is usually targeted to investigate presence of EAEC (Nataro and Kaper, 1998; Piva et 
al., 2003; Blanco et al., 2005). 
 
Diffuse adherent E. coli (DAEC): DAEC strains are defined based on the presence of a 
diffuse adherence pattern (DA) on HeLa and HEp-2 epithelial cells. In the DA pattern, bacteria 
uniformly cover the cell surface  (Scaletsky et al., 2002). According to the adhesin expression, 
two groups of DAEC strains have been identified, Afa/Dr DAEC and AIDA-I DAEC. Afa/Dr 





older, with persistent diarrhea. The Afa/Dr family includes fimbrial and afimbrial adhesins:  
Afa-I, Afa-II, Afa-III, Afa-V, Afa-VII, Afa-VIII (afimbrial); plus Dr-2 as well as Dr and F1845 
(fimbrial). Many of these adhesins have been identified in E. coli strains isolated from human 
UTIs or diarrhoea, except Afa-VII, which was only found in E. coli isolated from bovine faeces. 
F1845 adhesin was first identified in an E. coli strain (C1845) isolated from a child with chronic 
diarrhoea. DAEC could play an important role in the induction of inflammatory bowel disease 
(Lalioui et al., 1999; Kaper et al., 2004; Lozer et al., 2013; Servin, 2014; Denamur et al., 2021). 
 
Adherent-invasive E. coli (AIEC): The main characteristics of AIEC are the ability to 
adhere to and invade intestinal epithelial cells, and the ability to survive and replicate 
expansively within macrophages without triggering host cell death and inducing the release of 
tumor necrosis factor alpha. AIEC strains, which are associated with Crohn's disease, share 
many genetic and phenotypic features with extraintestinal pathogenic E. coli (ExPEC) 
strains.  However, the majority of ExPEC strains did not behave like AIEC strains, confirming 
that the AIEC pathovar possesses virulence-specific features that, to date, are detectable only 
phenotypically (Darfeuille-Michaud et al., 2004; Martinez-Medina et al., 2009; Denamur et al., 
2021). 
Table 2. Main characteristics of InPEC bacteria (Denamur et al., 2021).  
 






isolates   
Human, cattle, 
sheep 
stx, eae, ehxA B1 and E 
EPEC 
Attaching and effacing 












Coding genes for LT and STa 
enterotoxins and colonization 
factors  
A, B1, C and E 
EIEC 




ipa, isc, vir. Inactivación de 
nadA, nadB y cadA 








fimbriae (aaf/agg) and 
transcriptional genes (aggR) 
A, B1, B2 and D 
DAEC 
Diffuse adhesion on 
enterocytes  
Humans  
Genes encoding adhesins (afa 
and dra)  
All phylogroups 
AIEC 
Adhesion and invasion 
of intestinal epithelial 
cells 
Humans  Unknown 
All phylogroups 
with a majority of 
B2 
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1.1.5. Extraintestinal pathogenic E. coli (ExPEC) 
 
E. coli is one of the predominant microorganisms in extraintestinal infections in both 
humans and animals, causing many types of infections. As mention previously, a great diversity 
of virulence genes associated with ExPEC strains that encode adhesins, toxins, siderophores, 
protectins, capsular antigens, invasins, etc. have been described (Table 1) (Kaper et al., 2004; 
Riley, 2014). ExPEC strains have been alternatively defined by the number and constellation 
of virulence genes they possess (“special pathogenicity” definition) and by their identification 
as predominant lineages in the gut prior to causing extraintestinal infections by mass action 
(“prevalence” definition) (Johnson et al., 2001). Johnson et al. (2003) determined 5 predictive 
virulence markers of the ExPEC status: papA and / or papC (encode P fimbria), sfa / foc (F1C 
and S fimbriae), afa / dra (Afa / Dr adhesins), iutA (aerobactin) and kspMII (group II capsule). 
E. coli strains conform the ExPEC status if carry two or more of these five markers (Johnson et 
al., 2003b).  But despite the overrepresentation of classic ExPEC virulence genes in main 
lineages causing infection, there is still uncertainty about what defines or differentiates 
commensal E. coli and facultative ExPEC pathogens. Thus, Manges et al. (Manges et al., 2019) 
reviewed and meta-analyzed 217 studies (1995 to 2018) that performed multilocus sequence 
typing or whole-genome sequencing to genotype E. coli recovered from extraintestinal 
infections or the gut. As a conclusion, the authors found that a discrete set of ExPEC lineages 
contributes to the enormous burden of human extraintestinal infections. Twenty major ExPEC 
sequence types (STs) accounted for 85% of E. coli isolates from the included studies, including 
(by decreasing study positivity): ST131, ST69, ST10, ST405, ST38, ST95, ST648, ST73, 
ST410, ST393, ST354, ST12, ST127, ST167, ST58, ST617, ST88, ST23, ST117, and ST1193. 
ST131 was detected in over 90% of studies, however, it is important to take into consideration 
that emphasis on MDR ExPEC ST131 has unfortunately created a gap in our knowledge about 
other important ExPEC lineages, such as ST73 and ST95.  
 
Most of the global ExPEC lineages are frequently determined in isolates from animal 
sources (farming, companion an also wildlife) (Mora et al., 2009b, 2010, 2013; Cortés et al., 
2010; Jørgensen et al., 2019; Abreu-Salinas et al., 2020) . Such is the case of the recent study 
on three pinniped species (Leptonychotes weddellii, Mirounga leonina and Arctocephalus 
gazella) from the west coast of the Antarctic Peninsula, which were analyzed for the presence 
of Escherichia spp. As a result, 62 of the 158 E. coli isolates (39.2%) exhibited the ExPEC 
status and 27 (17.1%) belonged to top STs frequently occurring among urinary/bacteremia 
ExPEC clones: ST12, ST73, ST95, ST131 and ST141 (Mora et al., 2018)). There is a division 
in opinion regarding the idea of transmission of ExPEC strains between animals and humans. 
Most authors support this idea due to the genetic similarity that can be appreciated between 
animal strains, mainly those of avian origin, with strains that cause extraintestinal infections in 
humans (Johnson and Russo, 2005; Moulin-Schouleur et al., 2006; Jørgensen et al., 2019), 
however other authors have doubts about the clarity of these indications and argue that the most 
important transmission route is human-human and that strains of zoonotic origin would be 
minor (Schwarz et al., 2017). What it is becoming increasingly clear is that we cannot continue 
to work at the level of a single species anymore. A recent reformulation of the classic One 
Health approach emphasizes the role of interconnected (and hence geographically close) 
ecosystems in the emergence and dissemination of traits that influence local human, animal, 
plant, and integrated environmental health, such as antibiotic resistance. The increasing 





niches and bacterial individuals, with the potential emergence of highly transmissible 
multispecialists (Baquero et al., 2019, 2021). 
 
As stated in 1.1.1., the classical classification of the ExPEC group includes UPEC, NMEC 
and APEC, and they exhibit a considerable genomic diversity and a wide range of virulence-
associated factors which do not allow a clear categorization. Nevertheless, these subgroups are 
defined according to their pathogenicity mechanisms, the infections or syndromes that they 
cause or the point of isolation of the strains: 
 
Uropathogenic E. coli  (UPEC): E. coli  is recognized as the main cause of UTIs in 
humans and is commonly caused by autoinfections from the host itself  (Yamamoto et al., 1997; 
Nataro and Kaper, 1998). The pathogenesis of a UTI involves several steps, first the periurethral 
and vaginal colonization for UPEC isolates, followed by the ascension into the bladder lumen 
and growth in the urine. The bacteria interact and adheres to the surface of the bladder 
epithelium and forms biofilm. At this point, the bacteria grow forming communities who will 
stay in the underlying urothelium. From here is where the UPEC isolates can colonize the 
kidney, cause tissue damage and generate great risk of septicemia (Terlizzi et al., 2017).  
 
It has been accepted that the main source of these isolates is the human gut microbiota, 
nevertheless, external reservoirs and host to host infections need to be studied. An important 
part of the prevention of the spread of these pathotype is to be able to identity the reservoirs in 
order to reduce the risk of disease transmission. Spurbeck et al. (Spurbeck et al., 2012) 
described for it a set of four genes (yfcV, vat, fyuA and chuA) that present a statistical association 
with the strains causing urinary pathology and consider that the strains that possess at least three 
of these virulence genes as UPEC. Whit this knowledge the aim is to identify the carriers and, 
to investigate why some individuals are more susceptible to the colonization and recolonization 
of UPEC isolates than others.  
 
Some authors pointed out the similarity between virulence profiles from both UPEC and 
APEC isolates, highlighting the potential of the latter to cause a zoonotic infection mainly when 
associated with plasmids and pathogenicity islands of UPEC, also pointing out the possibility 
of the APEC isolates to act as possible reservoirs of urovirulence genes for humans.  
Nevertheless, there are still some significant differences in the prevalence of virulence traits 
between the two groups that suggest that not all APEC would be potentially involved in human 
infections (Mora et al., 2009b; Jørgensen et al., 2019).  
 
Avian pathogenic E. coli (APEC): These isolates are responsible for avian colibacillosis 
in wild birds as well as domesticated ones. The clinical presentation of the infection usually 
starts with respiratory symptomatology but also is associated with non-specific signs as 
weakness, depression, reduced appetite, poor growth that could evolve to a systemic infection 
that affects internal organs, presenting with fibrinous lesions as airsacculitis, pericarditis or 
perihepatitis, usually associated with septicemia (Solà-Ginés et al., 2015; Kazibwe et al., 2020). 
 
There is no unique virulence profile for this pathotype, nevertheless is frequently associated 
with virulence genes that allow their extraintestinal survival and colonization. This genes are 
usually harbored by plasmids and by its acquisition, an avian commensal strain can enhance its 
abilities to kill chicken embryos, grow in human urine and colonize the murine kidney on in 
vivo assays (Skyberg et al., 2006; Mora et al., 2013).  
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As mentioned before, this pathotype has been hypothesized numerous times with the 
possibility that they constitute a zoonotic risk, since this strains even though they show a higher 
virulence in poultry, are able to cause infections in mammals. Jorgensen et al. demonstrated the 
existence of multiple lineages belonging to the ExPEC lineage ST95, where the majority may 
cause infection in humans, only a part of the ST95 cluster was able to cause avian infection, 
supporting the zoonotic hypothesis (Ron, 2006; Skyberg et al., 2006; Mora et al., 2013; Maluta 
et al., 2014; Jørgensen et al., 2019).  
  
Neonatal meningitis-causing E. coli (NMEC): These isolates can cause bacterial 
meningitis in newborns (NMEC) in different hosts. The mortality rate of these infections is 
found between 15 and 40%, leaving neurological sequelae in 50% of cases. (Nataro and Kaper, 
1998; Wang and Kim, 2013). As well as the previous ExPEC subgroups, these isolates can be 
found in meat-source samples and are proved to have overlapping traits shared between them 
(Mellata et al., 2018). In order to cause meningitis, the bacteria have to invade the blood-brain 
barrier and penetrate into the brain, and so as to it the cytotoxin necrotizing factor 1 (CNF1) 
has been described as an associated virulence factor to this subgroup of ExPEC.  
 
1.1.6. ST131 and other high-risk clones  
 
As stated above, the rapid dissemination of ESBLs seems to be largely associated with the 
so-called successful ExPEC lineages such as the ST131, ST38, ST69, ST405, ST648 or ST1193 
(Shaik et al., 2017; Yamaji et al., 2018a; Manges et al., 2019). For a clone to be considered 
high-risk, it must meet the next six criteria (Mathers et al., 2015; Pitout and Finn, 2020):   
 
- To exhibit global distribution. 
- To be associated with multiple determinants of resistance. 
- To have the ability to colonize and persist in a host for at least six months. 
- To be able to effectively spread between different hosts. 
- To have an improved pathogenicity and aptitude compared to other clones. 
- To have the ability to cause severe or recurrent infections. 
 
ST131 is the main pandemic clone responsible for the global spread of ESBLs. First 
identified in 2008, ST131 strains belong to phylogroup B2 and mainly to the serotypes O25b:H4 
or, less frequently, O16:H5 (Coque et al., 2008; Nicolas-Chanoine et al., 2008). Three years 
after its first isolation, it was already spread, being the bacterial agent involved in more than 
50% of cases of UTIs caused by ESBL-producing strains in numerous hospitals in different 
countries. Normally, phylogroup B2 strains are characterized by being associated with a 
significant load of virulence genes, however, in addition in the case of this clone, its association 
with genes of resistance to both ESBL and fluoroquinolones is remarkable. The prevalence of 
resistance to first-line oral antibiotics such as trimethoprim-sulfamethoxazole, amoxicillin, and 
amoxicillin-clavulanate has been steadily increasing during these years, making the treatment 
of infections very difficult and endangering the lives of patients (Mora et al., 2011a, 2014; 
Dahbi et al., 2013, 2014; Nicolas-Chanoine et al., 2014, 2017; Ghizlane Dahbi Zbiti, 2015; 
Mamani et al., 2019). 
 
Although it is associated with ExPEC infections such as UTI, septicemia, surgical wound 
infections and meningitis, this clone is also frequently found in the digestive system of healthy 





et al., 2017)That is why, it was thought that human intestinal tract was ST131 only niche. 
However, the growing scientific community interest towards this ST, detected it in all diverse 
sources such as companion, food-production and wild animals; or the environment itself in 
rivers, beaches or sewage; even in the Antarctic region (Coelho et al., 2011; Colomer-Lluch et 
al., 2013; García-Meniño et al., 2018; Mora et al., 2018; Pitout and Finn, 2020).  
 
WGS analysis had revealed that ST131 consists of three different clades (A, B, and C) 
characterized by different alleles of the fimH gene that is implicated in the colonization abilities, 
i.e., fimH41, fimH22, and fimH30, respectively (Petty et al., 2014; Ben Zakour et al., 2016). 
The first expansion of clone ST131 was described in the United States and the predominant 
subclade was H30. This clone is defined by the presence of fimbrial adhesin fimH, allele 30 
(H30). Within this, new subclades emerged as H30R, which includes point mutations in the 
gyrA and parC genes that confers them resistance to fluoroquinolones. Other subclade emerged 
from H30 is H30Rx, where in addition to point mutations in gyrA and parC, it is associated 
with the presence of the blaCTX-M-15 gene (Stoesser et al., 2016).  
 
Clade A, associated with the fimH41 allele and the O16:H5 serotype, arose in Southeast 
Asia around 1880 and this is usually an antibiotic-sensitive clade. This clade is located on the 
longest branch of the ST131 phylogeny and because of it, this clade has been the one with more 
evolutionary changes accumulated. When compared with clade B/C a different plasmid and 
phage collection can be seen between them, and the hypothesis for it is that rarely these clades 
share ecological niches at the same time, making them have differentiated accessory genome 
elements (McNally et al., 2019; Pitout and Finn, 2020). Clade B, associated with strains 
predominantly carriers of the fimH22 allele and of serotype O25b:H4, is suspected of having 
its origin in the 1900s in North America. Like clade A, this is typically an antibiotic-sensitive 
clade. This fact means that due to the bias of most studies designed to detect ESBL-producing 
strains, it could be underrepresented within the entire ST131 population. The studies by Zakout 
et al. and Flament-Simon et al. describe subclades within B between B0 and B9 (Ben Zakour 
et al., 2016; Flament-Simon et al., 2020c). Dean and Downing suggest that the subclade B0 was 
the one that led the evolution towards clade C (Decano and Downing, 2019). Clade C shows 
three clearly defined subclades. Clade C0, associated with fimH30 and O25b:H4, evolved in 
the 1980s from strains from clade B in North America. After seven years, this clade separated, 
giving rise to the subclades C0, C1 and C2. The biggest difference between the original clade 
C0 and its derivatives C1 and C2 is in the susceptibility to fluoroquinolones, since C0 arose 
before they began to be used regularly in both human and veterinary clinical practice, therefore, 
is sensitive to this antibiotic. Clades C1 and C2 are considered successful globally due to their 
rapid and widespread. Both are resistant to fluoroquinolones due to two-point mutations in the 
gyrA and parC gene that, once introduced via recombination, were vertically transmitted, 
getting integrated into the clade. The main difference between clade C1 and C2 is that C2 (also 
known as subclone H30Rx) is also strongly associated with the production of extended 
spectrum β-lactamases (ESBL), normally blaCTX-M-15, and seems to be the most expanded and 
successful ST131 so far (Banerjee et al., 2013; Price et al., 2013; Dahbi et al., 2014; Peirano et 
al., 2014; Sauget et al., 2016; Pitout and Finn, 2020). However, cluster C1-M27 of subclade 
C1, which produces CTX-M-27, has recently expanded, first in Japan (Matsumura et al., 2016, 
2017), then in other countries (Thailand, Australia, Canada, USA, France, Italy, Germany, The 
Netherlands and Spain) (Blanc et al., 2014; Birgy et al., 2016; Bevan et al., 2017; Merino et al., 
2018; Peirano and Pitout, 2019).  
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In 2013, Blanco et al. (Blanco et al., 2013) described for the first time a classification of 
the strains of the clone ST131 in four clusters regarding their virulence genes. This clusters 
where named virotypes, were found internationally distributed and that corresponded with 
pulsed-field electrophoresis profiles (PFGE). Later on, on their study Dahbi et al. (Dahbi et al., 
2014) analyzed a total of 154 E. coli isolates from ST131 recovered between 2005 and 2012 
from 5 different Spanish hospitals and studied the presence and absence of 32 genes coding for 
virulence factors typically associated with extraintestinal pathology as well as their PFGE 
profile.  From the results, 12 virotypes and subtypes were described, A, B, C1, C2, C3, D1, D2, 
D3, D4, D5, E and F. The association between each virotype and virulence profile can be found 
in Table 3. 
 
Table 3. Virulence-gene scheme for defining ST131 E. coli virotypes (Dahbi et al., 2014) 
 




iroN sat ibeA papG II 
papG 







A + + - +/- a - - - - - - - + - 
B - - + +/- a - +/- - - - - - - +/- 
C1 - - - + - - - - - - - + - 
C2 - - - + - - - - - - - - + 
C3 - - - + - - - - - - - - - 
D1 - - +/- - + - - - - + - - + 
D2 - - +/- - + - + - - + - - + 
D3 +/- b +/- b +/- +/- b + - - - - - - - + 
D4 - - +/- - + - - - - - + - - 
D5 - - +/- - + - + + + - - - + 
E - - - + - + - + + - - - + 
F - - - + - + - - - - - - + 
a Most strains of virotypes A (97%) and B (75%) are positive for the sat gene b Virotype D3 strains carry the sat 
and afa/draBC genes, or at least one of them. Furthermore, some afa/draBC positive strains are also positive 
for afa operon FM955459 
 
An important challenge is to know which determinants make certain clones adapt to a 
specific host meanwhile others can be transmitted between different species, with jumps as 
important as between mammals and birds. In the case of ST131, this relationship between the 
different clades and their presence in different hosts has yet to be completed understood. With 
the current data, is noticeable that clades A and C are mainly associated with human pathology, 
while clade B groups strains isolated from different niches such as poultry and pigs, along with 
humans (Flament-Simon et al., 2020). In fact, we recently proved the genomic identity of 
porcine (meat and animal origin) and clinical human ST131-H22 isolates belonging to the new 
subclades B6 and B7 (Flament-Simon et al., 2020c).  With a different approach, Liu et al. (Liu 
et al., 2018) combined detection of poultry-associated ColV plasmids with high-resolution 
phylogenetics to quantify the proportion of human extraintestinal infections. From their results, 
the authors stated that sub lineage ST131-H22 has become established in poultry populations 
around the world and that meat may serve as a vehicle for human exposure and infection. 
According to the authors, ST131-H22 would be just one of many E. coli lineages that may be 





APEC strains as an external reservoir for human ExPEC strains, including UPEC (Jørgensen et 
al., 2019). The results of the study conducted by Jørgensen et al. (Jørgensen et al., 2019) 
demonstrate, via data collected through WGS that there are multiple ST95 lineages, most of 
which cause infection in humans while only a part of them cause avian pathology. Within these 
branches, there is overlap between strains of both origins. This overlap can be understood as 
evidence of a zoonotic capacity of a group of strains from this ST. Regarding the association 
between genes and the origin of isolation of the strain, only the iss, papC, vat and sitA genes 
seem to be associated with the APEC strains, while cgsA and fimH appear to have a strong 
association with the human ExPEC strains.  
 
In recent years, an emerging high-risk lineage belonging to phylogroup F, ST648, has been 
described. A particular characteristic of this clonal complex CC648 is the absence of the uidA 
(β-glucuronidase) gene, which has made this CC to be underrepresented in all the samplings in 
which the techniques for the detection of E. coli  were based on the β-glucuronidase detection 
(Johnson et al., 2017a). ST648 together with ST131 represented 44% of the ESBL strains 
isolated in a water treatment plants, a very high percentage of the total of strains recovered. 
Through faeces, since humans are a known reservoir of ExPEC strains, and urine of patients 
with UTIs caused by UPEC strains, the presence of bacteria in the wastewater of populations 
has increased significantly and the water processing plants and the environment have begun to 
be considered an adequate sampling point to be representative of the presence of these bacteria 
in a population  (Paulshus et al., 2019). The presence of the high-risk clonal groups ST131 and 
ST648, both carriers of resistance, has been described in aquatic environments in different 
countries such as Brazil (Furlan et al., 2020), or in water purification systems in Norway 
(Paulshus et al., 2019) it makes clear the importance of the dissemination of these resistances 
worldwide through environmental niches. Wastewater, wastewater treatment plants and 
canalization systems are considered reservoirs for bacteria that potentially carry resistance 
genes, which can benefit from this scenario to carry out the horizontal transfer of resistance 
genes to both antibiotics and metals or disinfectants. All stated above, makes the One Health 
approach a priority. 
 
1.1.7. Hybrid clones of E. coli 
 
Hybrid pathotypes of E. coli are frequent and unpredictably emerging due to the important 
role played by MGEs such as plasmids, bacteriophages, pathogenicity islands, transposons and 
insertion sequence elements in the evolution of the bacteria (Stokes and Gillings, 2011; Robins-
Browne et al., 2016). Furthermore, strains with complex hybrid pathotypes with combinations 
of two different groups of InPEC (STEC + EAEC) or InPEC and ExPEC (for example aEPEC 
+ ExPEC and STEC + APEC) are increasingly reported in human clinical cases (Denamur et 
al., 2021) 
Since 2011, when a novel Shiga-toxin-producing E. coli (STEC) belonging to serotype 
O104:H4, with virulence features common to the EAEC and CTX-M-15 producer was 
identified as the one involved in the large German outbreak (Mora et al., 2011b), the concept 
of pathotype has been questioned. More recently, Lindstedt et al. (Lindstedt et al., 2018) 
reported that a high frequency (> 93%) of routinely submitted faecal E. coli strains from 
Norwegian hospitals, previously characterized as IPEC, also harbored ExPEC virulence 
factors. It is of note the EPEC/STEC O80:H2-ST301 clone, which emerged in France and 
spread within Europe. This emerging hybrid, associated with severe cases of CH and HUS, 
combines intestinal VFs (stx2d, eae-xi and ehxA genes) and extraintestinal genes characteristic 
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of the plasmid pS88. It is to highlight the location of MDR and pS88 genes in the same plasmid, 
as well as the presence of two additional plasmids (a carrier of ehxA gene and a cryptic one) 
(Cointe et al., 2018, 2020). Gati et al. (Gati et al., 2019) hypothesized that specific E. coli 
lineages, such as ST141, would serve as a melting pot for pathogroup conversion between IPEC 
and ExPEC, contrasting the classical theory of pathogen emergence from nonpathogens. 
Currently, classical and new approaches (WGS), are being used to enhance the understanding 
of the evolution of this highly adaptable species (Scheutz, 2014; Robins-Browne et al., 2016).  
 
1.1.8. Mobile Genetic Elements (MGEs) 
 
Mobile Genetic Elements (MGEs) is a term that refers to the elements that promote DNA 
mobility. The movement of the DNA can happen within the bacteria, as in the case of genes 
from the chromosome that integrates into a plasmid or parts shared from one plasmid to another, 
and is described as intracellular mobility, but also can take place between different bacteria, 
known in this case as intercellular mobility (Partridge et al., 2018).  
 
This genetic movement contribute to the inter and intra species variations, makes possible 
to for the bacteria to achieve evolutionary genetic advantages against other bacteria as virulence 
or resistance genes, often associated with MGEs (Hacker and Kaper, 2000; Dobrindt, 2005).  
 
1.1.8.1. Intracellular mobility  
Insertion sequences (IS) and transposons (Tn) are discrete segments of DNA that are able 
to move by themselves and also associated resistance genes in a nonspecific way withing a 
single cell, meanwhile integrons use site-specific recombination to move resistance genes 
between defined sites (Partridge et al., 2018). 
  
Insertion sequences are arguably the smallest and most numerous autonomous 
transportable elements, usually they carry little more than one, or sometimes two, transposase 
(tnp) genes (Partridge et al., 2018). There are classified into different families using a variety 
of mechanisms as the length and sequence of the short imperfect terminal inverted repeat 
sequences, the length and sequence of the short flanking direct target DNA repeats often 
generated on insertions, the organization of their open reading frames or the target sequences 
into which their insert. Nevertheless, the principal characteristic used for its classification is the 
similarity, at the primary sequence level, of the enzymes which catalyze their movement, the 
transposases (Siguier et al., 2014).  
The replicative events can occur by copy-and-paste mechanisms, where the IS is preserved 
in the donor as well as in the recipient, and by copy-and-paste-in, where the IS integrates into 
the recipient  (Partridge et al., 2018).  
 
Transposons, like IS, are transposable elements with nonspecific movement and are 
usually integrated into the chromosome. They are distinguished from IS because they carry 
passenger or cargo genes not involved in catalyzing or regulating their movement, and therefore 
they are usually larger than ISs. These passenger genes may encode antibiotic resistance as in 
the case of the Tn3 family transposons or the superfamily Tn7-like transposons (Dobrindt, 






Gene cassettes are small mobile elements consisting in a single gene, or sporadically, two, 
that can exist in a free circular form as non-replicative, but usually they are found inserted into 
an. integron. The structure of an integron comprises a site-specific integrase (intI), an integron-
associated attachment site (attI), an integron-carrier promoter (Pc) and a gene cassette as 
described previously, with a downstream attachment site (attC). These elements are ancient, 
diverse and widely spread. They possess mechanisms for creating genetic diversity and trigger 
adaptive responses in the bacteria due to their facility for the acquisition of antibiotic resistance 
genes and uses site-specific recombination mechanisms (Gillings, 2014; Partridge et al., 2018). 
 
1.1.8.2. Intercellular mobility  
In this case, the MGEs move from a doner cell to a recipient cell through different exchange 
mechanisms. Intercellular mechanisms of genetic exchange include conjugation or 
mobilization, mediated by plasmids and integrative conjugative elements, transduction, 
mediated by bacteriophages and transformation, when occurs the uptake of extracellular DNA.  
 
As mentioned earlier, plasmids play an important role in the dissemination of antibiotic 
resistance since they promote their horizontal transfer through conjugation or mobilization 
processes. These processes involve the transfer of genetic material from a donor cell to a 
recipient cell. Plasmids are extrachromosomal elements that contain their own replication 
initiation (ori), genes encoding specific replication initiators (Rep) and internal systems to 
control de number of copies of the plasmid inside the cell to not affect their stability. They can 
be classified as conjugative plasmids when containing a conjugative system (Tra) and the 
coding genes for the functions necessary for this transfer to occur to the new host via 
conjugation, or as mobilizable plasmids if they must use those functions from other plasmids 
to be transferred, helper plasmids (Carattoli, 2011).  
 
In many cases, resistance and /or virulence genes are encoded in plasmids and provide the 
host bacteria with a selective advantage against non-carriers. Strains with traits that confer these 
advantages will disperse more successfully in the environment, producing a positive selection. 
The transmission of plasmids can occur even between bacteria that are not related, making 
possible to find indistinguishable plasmids in different bacterial species in very distant and 
diverse places. In this fact lies the importance of mobile elements, since they have the capability 
to perform conjugative event, the worldwide spread of genes associated with antibiotic 
resistance of high virulence profiles put at risk clinical treatments of patients infected with these 
strains and in consequence, the health of the whole population (Carattoli, 2011; Alvarado et al., 
2012). 
 
In 2013, the NCBI database had catalogued 580 complete circular DNA sequences from 
plasmids identified in different genera of the Enterobacteriaceae family and 60 from strains of 
Acinetobacter spp. In 2017, this number increased to 9,351 plasmid sequences in the same 
database (Carattoli, 2013; Roosaare et al., 2018).  
 
The first typing schemes for these mobile elements emerged in 1971 designed by Datta and 
Hedges (Datta and Hedges, 1971) and was based on the stability of the plasmids throughout 
conjugation. This phenomenon, known as plasmid incompatibility (Inc), is defined as the 
situation whereby two plasmids from the same incompatibility group cannot stably propagate 
in the same cell. With WGS tools, 28 different replicons are presently described (Carattoli et 
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al., 2014; Rozwandowicz et al., 2018). Another typing scheme developed by Alvarado et al. 
(Alvarado et al., 2012) is based on the classification of the relaxases or MOBs, the only common 
component among all transmissible plasmids (both conjugative and mobilizable). This 
classification includes 6 families and for its classification the Degenerate Prime MOB Typing 
(DPMT) technique is applied. 
 
The classification of the relaxases or MOBs shows a high correlation with the 
incompatibility scheme, which means that the plasmids of each type of Inc have relaxases from 
a single subfamily of MOB (Table 4) (Rozwandowicz et al., 2018).  
 
Table 4. Correlation between relaxase classification (MOB) and the incompatibility scheme (Inc) 
(Rozwandowicz et al., 2018). 
 
Replicon type Relaxase type Size (kb) Copy number Tranferability Host range 
IncF MOBF 45-200 Low Conjugative Enterobacteriaceae 
IncI MOBP 50-250 Low Conjugative Narrow 
IncK, InckB/O, IncZ MOBP 80-150 Low Conjugative Narrow 
IncA/C MOBH 18-230 Low Conjugative Narrow 
IncH MOBH 75-400 Low Conjugative Wide host rage 
IncP MOBP 70-275 Low Conjugative Broad 
IncL/M MOBP 50-80 Low Conjugative Broad 
IncN MOBF 30-70 Low Conjugative Broad 
Col MOBP 6-40 1-20 Mobilizable  
IncX MOBP 30-50   Narrow 
IncR Not included 40-160  Mobilizable Broad 
IncW MOBF Up to 40 Low Conjugative Broad 
IncQ MOBQ 8-14 Medium (4-12) Mobilizable Broad 
IncT MOBH ~217 Low Conjugative Narrow 
IncU MOBP 29-60 Low Conjugative Broad 
 
The low copy number conjugative type plasmids IncF or MOBF are the most frequently 
described in humans and animals, mainly associated with E. coli  (Rozwandowicz et al., 2018). 
This type of plasmid is prevalent within clone ST131 and is usually associated with ESBL 
resistance, especially with the production of the β-lactamase enzyme CTX-M, though it can 
undergo frequent recombination resulting in new genetic repertoires. In the plasmidome of this 
group we not only find antibiotic resistance, but also virulence factors and little-studied 
functions such as metabolic genes, colicins and other cryptic functions, all of which result in 
frequent and rapid adaptations to the environment that guarantee their survival and global 
expansion (Carattoli, 2013; Lanza et al., 2014; Rozwandowicz et al., 2018). 
 
The integrative conjugative elements (ICE), also called conjugative transposons, do not 
contain an origin of replication, so it is necessary that they be integrated into a replicon to be 
able to maintain themselves in the host cell, this trait gives them an adaptive advantage over 
plasmids because the genetic load they require is lower. These elements are highly 






Another type of transmission that can occur are transduction processes, where 
bacteriophages, instead of the own phage DNA, carry bacterial DNA with genes of interest, 
which is injected into a recipient bacterium. There are two types of transduction, the 
generalized, where any segment of DNA can be encapsulated in the phage, or specialized, 
where only a set of genes restricted to the points adjacent to the insertion point of the prophage 
in the chromosome is packaged. These elements play a central role in moderating bacterial 
populations as well as mediating horizontal gene transfer as mention previously (Chiang et al., 
2019). And finally, transformation processes, which take place when the DNA is free in the 
environment and a competent bacterium captures it from there. In this process, the naked DNA 
is incorporated into the recipient's genome through homologous recombination or 
rearrangement (Van Hoek et al., 2011).   
 
All the described MGEs can be identified in the same bacterial cell, so at this point, 
interactions between them have been studied. Rodríguez-Rubio et al. (Rodríguez-Rubio et al., 
2020) performed a comprehensive study regarding the relevance of the multicopy plasmids 
carriers of antimicrobial resistance (AMR) genes and their relationship with phage particles, 
due to the fact that recently fragments of phages had been identified in small multicopy 
plasmids (MCPs) from Enterobacteriaceae. The fact of finding these fragments is what made 
them hypothesize about the possibility of this MCPs being transferred between bacteria using 
phage transduction. They suggest that this transduction phenomenon could be an extremely 
efficient mean of AMR genes mobilization. They propose a model where MCPs transduction 
is a major powerful route for AMR gene disseminations in nature because these genes, borne 
on small MCPs are encapsidated up to 1000 times more efficiently than when borne on large 
low-copy plasmids and have the possibility to be disseminated over distance to transduce 
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1.2. THE SILENT PANDEMIC: ANTIBIOTIC RESISTANCES 
 
The World Health Organization (WHO) currently identifies the spread of multiresistance, 
together with the decrease in the available antimicrobial treatments, as a main threat to the 
global health. WHO, together with ECDC and Center for Disease Control and Prevention 
(CDC), urge to implement a One Health approach, involving human and veterinary medicine 
(World Health Organization (WHO), 2019). The magnitude of the problem is now accepted, 
and the estimation is that by 2050, 10 million lives a year and a cumulative 100 trillion USD of 
economic output are at risk due to the rise of drug-resistant infections if we do not find proactive 
solutions to slow down the rise of drug resistance. Even today, 700,000 people die of resistant 
infections every year. Antibiotics are a special category of antimicrobial drugs that underpin 
modern medicine as we know it (O’Neill, 2016). 
 
Overusing of antibiotics in the human and veterinary medicine has led to the development 
of multidrug-resistant (MDR; at least one antimicrobial agent in three or more antibiotic 
classes), extensively drug-resistant (XDR; species are only susceptible to two antimicrobial 
drug classes), and pandrug-resistant (PDR; resistant to almost all commercially available 
antimicrobials Gram-negative bacteria (Magiorakos et al., 2012). Rising AMR causes difficult-
to-treat infections, longer hospital stays, therapeutic complications, and increased mortality. 
Especially, extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, such as E. 
coli, as well as carbapenem-resistant Enterobacteriaceae, particularly Klebsiella spp., have been 
increasingly associated with high morbidity rates due to limited treatment options (ECDC, 
2019). 
 
According to the ECDC, more than 670.000 bacterial infections can be attributed to MDR 
bacteria, which causes 33.000 death annually in Europe (ECDC, 2019). As a result, it is 
estimated that MDR infections and complications cost the healthcare system 1.1 billion 
annually in Europe. The enormous lack of novel antimicrobials active against these MDR 
Gram-negative bacteria, particularly those producing carbapenemases, requires the growing use 
of last-resort antibiotics, such as polymyxins (Grundmann et al., 2017).On the other hand, 
polymyxins have been continuously used in Europe in livestock for prophylactic, therapeutic, 
and, until 2006, growth promotion purposes (Regulation (EC) No 1831/2003). The frequent 
application of antibiotics in food-producing animals is associated with selection of resistant 
zoonotic strains with the risk of transmission, directly from animal to human, or indirectly via 
the food chain, and eventually causing difficult-to-treat illnesses in humans (Marshall and Levy, 
2011). Nowadays, the One Health approach aims to address the urgent problem of AMR by 
reducing the use of antimicrobials in food-producing animals, since human health and animal 
health are interconnected (Min et al., 2013). 
 
Specifically, the family of Enterobacteriaceae is among the most significant public health 
problems worldwide due to the high resistance to antibiotics. In early 2017, WHO published a 
pathogen priority list, which included carbapenem-resistant Enterobacteriaceae as “critical” 
antibiotic-resistant bacteria that represent an enormous threat to public health (De Freitas, 
2013). Members of the Enterobacteriaceae account for about 80% of Gram-negative isolates 
with a variety of diseases in humans including UTIs, pneumonia, diarrhea, meningitis, sepsis, 
endotoxic shock, and others. Escherichia, Klebsiella, Salmonella, Shigella, Enterobacter, 





intestinal commensals, Escherichia and Salmonella spp. have also the potential to become 
pathogens causing infections such as diarrhea and colibacillosis, among others.  
 
The SARS-CoV-2 pandemic has exacerbated the existing global crisis of AMR due to 
secondary infections by MDR bacteria along with the increased use of disinfectants. Altogether, 
is anticipated to lead to novel resistances in the coming years (García-Meniño et al., 2021a; 
Gonzalez-Zorn, 2021; Mahoney et al., 2021).  
 
1.2.1. Main antibiotic families and resistance mechanisms 
 
With the discovery of antibiotics as an effective therapeutic tool for infections in 1929, a 
new horizon was established in clinical medicine since fatal infections were now manageable. 
From the moment of their discovery, were used both as a therapeutic tool and as a production 
tool in the livestock sector. A high number of natural antibiotic families were discovered and 
soon after, synthetic and semi-synthetic derivative modifications were developed (Van Hoek et 
al., 2011).  
 
Nevertheless, as a response to it the bacteria population started developing numerous and 
varied mechanisms of resistance against them to ensure their survival. Some of the more studied 
ones are: 
 
- Intracellular reduction of antibiotic presence due to permeability changes in the bacterial 
cell wall or active efflux of the antibiotic from the interior of microbial cell.  
- The enzymatic modification or degradation of the antibiotic, that makes it lose their 
antibiotic properties. 
- The acquisition of alternative metabolic pathways to the ones inhibited by the antibiotic.  
- The modification of the antibiotic targets of the cell. 
- The overproduction of the target enzyme.  
 
The acquisition of these resistance responses is mainly due to horizontal transfer of MGE 
but there is also the possibility of mutation events that can be transmitted vertically, 
nevertheless they have a low frequency of appearance (1/107 to 1/109) (Van Hoek et al., 2011; 
Schwarz et al., 2017).  
 
The antibiotic resistance mechanisms previously mentioned have become one of the most 
important health problems of society and a global priority recognized by the WHO and the 
European Union (WHO, 2017). Some of the antibiotic families discovered years ago are now a 
days still working as first line of defense against infections and are used daily in clinical 
medicine. Some of the most used are the following:  
 
Aminoglycosides: First discovered in 1940s, this groups was led by streptomycin, first 
recovered from Streptomyces griseus (Schatz and Waksman, 1944). Later neomycin and 
kanamycin were found and recovered from other spp. of Streptomycies, and in the 1960s, 
gentamicin was recovered from the actinomycete Micromonospora purpurea. The first 
semisynthetic antibiotic, amikacin, was synthesized in the 1970s from kanamycin (Begg and 
Barclay, 1995). The action mechanism of this antibiotic family is the inhibition of protein 
synthesis and / or the alteration of the integrity of cell membranes. It has a wide spectrum of 
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action among Gram negative and positive bacterial species and often acts in synergy with other 
antibiotics, giving them greater antibacterial capacity (Vakulenko and Mobashery, 2003).  
 
There are several types of resistance mechanisms known acting against this family of 
antibiotics, as for example, active expulsion, decreased permeability, alteration of ribosomes 
and inactivation of antibiotics by modifying enzymes. The main mechanisms of resistance are 
the target modification and the enzymatic inactivation. The modification of the target site can 
be achieved by methylation of residues of the site A of the 16S RNA, resulting in high level or 
resistance to amikacin, tobramycin, gentamicin and netilcmicin.16S RNA methylases include 
ArmA, RmtA/B/C/D/E/F/G/H and NmpA, being armA the first coding gene for methylases 
found in a plasmid. The enzymatic inactivation of aminoglycosides is achieved by the 
modification of the molecules do they are unable to get to the target point. The three enzymes 
known to this day are classified into acetyltransferases (AAC(3)-II/IV and AAC(6)Ib being the 
most frequently found in E. coli), nucleotidyltransferases (ANT(2”) and ANT(3”) the most 
commonly found in Gram negative) and phosphotransferases (APH(6)-Ia and APH(6)-Ib being 
the most common in E. coli) (Galimand et al., 2003; Poirel et al., 2018).  
 
β-lactams: Penicillin was first antibiotic described, discovered in 1929 by scientist 
Alexander Flemming when he notice the presence of a substance with antimicrobial properties 
produced by the Penicillium notatum mold (Flemming, 1929) and also was the first member of 
the family of β-lactams . In the last 30 years, many new antibiotics of this family have been 
synthesized, most of them sharing a β-lactamase nucleus in their molecular structure. It includes 
penicillin, cephalosporins, carbapenems, monobactams, and β-lactamase inhibitors. They are 
grouped into first, second, third and fourth generation cephalosporins based on the spectrum of 
activity and the time of introduction of the agent.  
 
First-generation cephalosporins are mainly effective against Gram positive, with minimal 
coverage against Gram negative, examples of this group are cefazolin or cephalothin.  
 
Second-generation cephalosporins have less activity against Gram positive bacteria 
compared to first generation but a better antibiotic effect against Gram-negative bacilli. This 
group can be divided in two groups, the second generation (cefuroxime or cefprozil) and 
cephamycin subgroup (cefoxitin or cefmetazole).  
 
In the third-generation group we can find cefotaxime, ceftazidime, ceftriaxone, cefixime 
and others as main representers of it. This generation has an extended spectrum against Gram 
negative bacteria, and importantly, against bacteria that are resistant to antibiotics from the first 
and second generation. When administrated intravenous can penetrate the blood-brain barrier 
and act against bacteria located in the spinal fluid, important in cases of meningitis.  
 
Fourth-generation cephalosporin includes cefepime, a broad-spectrum antibiotic that can, 
as well as third-generation, penetrate the cerebral spinal fluid, but in addition, its composition 
allows them to penetrate the outer membrane of Gram negative more easily and is effective 
against β-lactamase-producing isolates (Bui and Preuss, 2021).  
 
Carbapenems are also β-lactams that can easily diffuse into bacteria, which is why they are 
considered broad spectrum, examples of this subgroup are imipenem and ertapenem. In the case 





being the most used of them the aztreonam. Inhibitors of β-lactamases, such as clavulanic acid, 
contain the ring within their structure but exhibit a very low antimicrobial power, therefore they 
are used in combination with other β-lactams to increase their efficacy against β-lactamase 
producing bacteria (Van Hoek et al., 2011).   
 
Its mechanism of action is based on the inhibition of cell wall synthesis, acting as a false 
structural component of it, the penicillin-binding proteins (PBP). As consequence, the wall is 
weakened, resulting in cytolysis or death due to poor regulation of osmotic pressure (Kotra and 
Mobashery, 1998; Bush, 2018).  
 
The first enzyme described that had activity against penicillin was AmpC and it was found 
in E. coli  in the 1940s, since then bacterial resistance to this antibiotic family has increased at 
a significant rate (Abrahan and Chain, 1940). There are diverse mechanisms of resistance 
against β-lactams, modification of the PBPs target, porin modifications that affect the 
permeability of the membrane or efflux pumps. Nevertheless, the most common mechanism of 
resistance is the production of β-lactamase enzymes such as ESBL or enzymes associated with 
AmpC-type plasmids or carbapenem hydrolyzing β-lactamases. These are versatile enzymes 
with a limited range of molecular structures that are found in a wide range of bacterial species 
due to their horizontal dissemination mainly associated with plasmid acquisition (Van Hoek et 
al., 2011; Bush, 2018).  
 
There are currently two classification systems for these enzymes, one proposed by Ambler 
in 1980 where they are grouped into four classes based on their nucleotide and amino acid 
sequence (Ambler, 1980), and one proposed by Bush, Jacoby and Medeiros in 1995 and updated 
in 2010 based on structural and functional biochemical characteristics (Bush et al., 1995; Bush 
and Jacoby, 2010). The following table (Table 5) shows the correlation between both 
classifications.  
 










by AC a o 
TZB b 
Inhibited 
by  EDTA c Defining characteristic(s) 
Representative 
enzyme(s) 
1 C Cephalosporins  No No 




E. coli AmpC, P99, 
ACT-1, CMY-2, 
FOX-1, MIR-1 
1e C Cephalosporins No No 
Increased hydrolysis of 
ceftazidime and often other 
oxyimino-β- lactams * 
GC1, CMY-37 
2a A Penicillins Yes No 




2b A Penicillins, early cephalosporins Yes No 














2br A Penicillins  No No Resistance to clavulanic acid, sulbactam, and tazobactam TEM-30, SHV-10 
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Increased hydrolysis of 
oxyimino-β-lactams * + 
Resistance to clavulanic acid, 
sulbactam, and tazobactam 
TEM-50 
2c A Carbenicillin (carboxypenicillin) Yes No 
Increased hydrolysis of 
carbenicillin PSE-1, CARB-3 
2ce A Carbenicillin, cefepime Yes No 
Increased hydrolysis of 
carbenicillin, cefepime and 
cefpirome 
RTG-4 

















Inhibited by clavulanic acid but 
not aztreonam 
CepA 
2f A Carbapenems  Variable No 





3a B(B1) Carbapenems  No Yes 
Broad-spectrum hydrolysis 




  B(B3)         L1, CAU-1, GOB-1, FEZ-1 
3b B(B2) Carbapenems No  Yes Preferential hydrolysis of carbapenems CphA, Sfh-1 
a Clavulanic acid; b Tazobactam; c Ethylenediaminetetraacetic acid * Cefotaxime, ceftazidime, ceftriaxone, cefepime, 
aztreonam.  
 
Now a days, resistance to β-lactams through the production of ESBL enzymes represents 
an important problem worldwide, with high-risk pandemic clones such as ST131, to which the 
CTX-M-15 enzyme is associated.  
 
ESBL enzymes can hydrolyze monobactams, first, second, third and fourth generation 
cephalosporins but they are unable to inactivate cephamycins and carbapenems. These enzymes 
are inhibited by class A β-lactamase inhibitors such as clavulanic acid, sulbactam and 
tazobactam (Gurrero and Sanchez, 2017) .  
 
The main ESBL enzymes produced by E. coli are TEM, SHV and CTX-M. TEM-1, TEM-
2 and SHV-1 are considered classic plasmidic β-lactamases from which new and with higher 
hydrolytic power enzymes are generated (Juan J et al., 2000; Cantón and Coque, 2006). The 
TEM family has more than 200 allelic variants described and some of them are characterized 
by an incremented hydrolysis of oxyimino β-lactams, meanwhile SHV family has been 
associated with 190 allelic variants which can be divided into three subgroups, subgroup 2b 
(can hydrolyze penicillin, first generation cephalosporins and is inhibited by clavulanic acid 
and tazobactam), subgroup 2br (with action against extended spectrum β-lactams and resistant 
to clavulanic acid) and subgroup 2be (can hydrolyze one or more oxyimino β-lactams) 






In the 90s, the antibiotic resistant enzymes scene was dominated by TEM and SHV 
enzymes worldwide but after the description of the CTX-M family this had been the one that 
arise as dominant, with the most rapid and dramatic expansion (Cantón and Coque, 2006; 
Cantón et al., 2012). Soon after its discovery was already observed not only in nosocomial 
environment but also in the community settings associated to MGEs. This expansion can be 
divided into three stages, first, the dissemination of diverse CTX-M enzymes in distant 
geographic areas until mid-90s, second, the rise of new CTX enzymes as CTX-M-3, CTX-M-
9, CTX-M-14, and CTX-M-15 between 1994 and 2000 and the third event that took part from 
the 2000 when CTX-M-14, and CTX-M-15 become the most predominant ESBL worldwide 
mainly due to their association with the pandemic clonal group ST131 (Mora et al., 2010; 
Cantón et al., 2012; Poirel et al., 2018).  
 
ESBL-producing E. coli have adaptative advantages against isolates that does not carry 
resistance genes, making certain STs more frequently found in both animals and humans, being 
examples of this ST10, ST23, ST38, ST88, ST131, ST167, ST410 and ST648. These clonal 
groups are found worldwide and located in varied ecosystems, which enables the spreading. of 
these resistances between niches, making the ESBL dissemination an important world health 
problem (Poirel et al., 2018).  
 
Chloramphenicol: It was first described in 1947 produced by a Strepotmyces venezuelae 
(Ehrlich et al., 1947). This compound has a simple structure, which makes it very difficult to 
synthesize new compounds from it, since it easily loses its antibiotic characteristics. 
Chloramphenicol is a potent and specific inhibitor of protein synthesis through the affinity to 
peptidyltransferases of the 50S ribosomal subunit of 70S ribosomes. This antibiotic has a broad 
spectrum since it acts on Gram positive and negative bacteria, both aerobic and anaerobic 
(Schwarz et al., 2004).   
The resistance to this antibiotic in E. coli is mediated by three main mechanisms, the most 
frequently encountered mechanism is the enzyme inactivation by acetylation of the antibiotic 
through the action of different types of acetyltransferases encoded by cat genes. Two types have 
been defined, the classic catA and the new or xenobiotic ones known as catB. Another resistance 
mechanism is the active efflux of nonfluorinated phenicols coded by the genes cmlA or by floR 
genes when dealing with fluorinated and nonfluorinated phenicols. The last major mechanism 
is the methylation of the target site by an rRNA methylase encoded by the multiresistance gene 
cfr (Schwarz et al., 2004; Poirel et al., 2018).  
 
Quinolones and fluoroquinolones: In 1962, during the synthesis and purification of the 
chloroquine, used as an antimalarial agent, nalidixic acid was discovered and shown 
bactericidal capacities against Gram negative bacteria (Lesher et al., 1962). These capacities 
were increased with the addition of a fluorine atom, becoming known as fluoroquinolones, or 
second-generation quinolones (Wolfson and Hooper, 1989). In the 1980s, new 
fluoroquinolones such as ciprofloxacin, norfloxacin or ofloxacin were synthesized, in which 
the spectrum of action came to include Gram-positive ones. The main binding point for the 
quinolones are the DNA-gyrase and topoisomerase IV, essential enzymes for DNA replication. 
The DNA-gyrase is formed by 4 subunits, 2 GyrA and 2 GyrB, as well as topoisomerase IV 
with 2 A and 2 B subunits encoded by genes parC and parE respectively, and them are the 
targets for the point mutations that confer resistance to the bacterial organism (Van Hoek et al., 
2011).  
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At first it was assumed that mechanisms of resistance towards these antibiotics were only 
encoded in the chromosome. The main mechanism of resistance arouse spontaneously due to 
point mutations that results in amino acid substitutions within the topoisomerase and gyrase 
subunits triggering the decreasing expression of outer membrane porins or overexpressing the 
multidrug efflux pumps (Hopkins et al., 2005). Mutations occur at specific points known as 
"quinolone resistance determining regions" in the two genes coding for the subunits of gyrase 
(gyrA and gyrB) and the two subunits of topoisomerase IV (parC and parE). Individual 
mutations in the gyrA gene can confer resistance to quinolones, but fluoroquinolone resistance 
requires mutations in both gyrA and parC (Poirel et al., 2018).  An example of the global 
importance of these mutations is their presence in the pandemic clonal group ST131, where the 
H30R and H30Rx subclades are characterized by carrying these mutations (Stoesser et al., 
2016).  
In the 1990s, a quinolone resistance gene of plasmid origin was described for the first time, 
the qnr gene that encodes a protein that protects DNA gyrase and topoisomerase IV from 
inhibition by quinolones. A second type of plasmid resistance to quinolones are the cr variants 
of the aac(6 ')-Ib, aac(60)-Ib-cr gene responsible for low-level resistance to ciprofloxacin. And, 
finally, a third mechanism, the hydrophilic fluoroquinolone ejection pumps, mediated by the 
qepA plasmid gene (Van Hoek et al., 2011). 
 
Sulfonamides: First synthesized in 1932, they have evolved to the present day, with 
sulfamethoxazole as their most widely used representative (Domagk, 1935). In 1968 its use was 
associated with trimethoprim, developing co-trimoxazole, widely used due to its synergistic 
action, the reduction of resistance and its costs. Sulfonamide has a structure analogous to the p-
aminobenzoic acid, which is involved in the metabolic pathway of folic acid, therefore, its 
interference in this path causes problems in the growth of bacterial cells. 
 
Resistance to this group of antibiotics arose shortly after the start of its clinical use. They 
were developed at the chromosome level by mutation of the folP gene that encodes the enzyme 
dihydropteroase synthase (DHPS) that participates in the metabolic pathway of folic acid 
synthesis. The first plasmid-type resistances appeared in the eighties, encoded in the sul1 and 
sul2 genes, although the sul3 gene has now also been described. sul1 gene is spread worldwide 
because is a part of the 3’-conserved segment of Class 1 integrons, who are present in E. coli 
isolated from healthy and diseased food producing animals, companion animals and wildlife 
(Roberts, 2002; Poirel et al., 2018). 
 
Trimethoprim: This antibiotic available since 1962 is considered the last new antibiotic 
introduced in the clinical therapeutic arsenal, since all those that have subsequently emerged 
have been variations of those already described (Roth et al., 1962). It is totally synthetic and 
belongs to the group of diaminopyrimidine compounds. It inhibits the enzyme dihydrofolate 
reductase (DHFR) by competitive binding on its target. What this enzyme does is to catalyze 
the NAHPH reductions dependent on dihydrofolate acid to the active coenzyme 
tetrahydrofolate, therefore, trimethoprim acts as an antifolate, a structural analog of folic acid, 
interfering in its metabolic pathway. 
 
In the same way as sulfonamides, being synthetic antimicrobials, it was assumed that the 
appearance of natural enzymes that would degrade or modify them was unlikely. However, a 
low resistance could be seen through variations in the chromosomal folA gene that codes for 






plasmid DHFR replaces the chromosomal DHFR target of the antibiotic (Sköld, 2001). Plasmid 
DHFRs are grouped into two major groups, dfrA and dfrB based on their sizes and structures. 
dfrA genes have been identified in E. coli from dogs, cats, horses, pigs, cattle, chicken and giant 
pandas in contrast with dfrB genes that have rarely been detected in animals (Poirel et al., 2018).  
 
Tetracyclines: The first tetracycline was characterized in 1948, chlortetracycline, 
produced by Streptomyces aureofaciens (Chopra, 1994). Since then, more natural tetracyclines 
have been found, such as oxytetracycline, and also semi-synthetic products, such as 
doxycycline, have begun to be obtained. This was the first family in which the term "broad-
spectrum" was used, which together with the fact of their relative safety and low cost made 
them the second most used antibiotics after penicillin. Two different mechanisms of action have 
been described in this family. First, typical tetracyclines prevent bacterial growth by inhibiting 
protein synthesis by interacting with the ribosomes, and second, some tetracyclines with little 
affinity for ribosomes act on the bacterial membrane (Chopra, 1994; Van Hoek et al., 2011). 
 
The first resistance did was not described until the 1950s but since these antibiotics were 
widely used in veterinary medicine, the selective pressure made appear large number of 
tetracycline resistances. The resistance mechanisms could be grouped in three categories: nine 
genes for energy-dependent ejection pumps (tet(A, B, C, D, E, G, J, L, Y)), two genes coding 
for ribosomal protection proteins (RPPs) (tet(M, W)) and one gene coding for an oxidoreductase 
that produces enzymatic inactivation (tet(X)) (Poirel et al., 2018).  
 
Polymyxins: This family of antibiotics was described in the 1940s as fermentation products 
of the bacterium Bacillus polymyxa. It comprises five antimicrobial compounds (polymyxin A, 
B, C, D, and E). Due to their reduced renal toxicity compared to the other polymyxins, only 
polymyxin B and E (colistin) are used as last-resort defense against severe infections with 
carbapenem-resistant Enterobacteriaceae in clinical sector (Li, 2019). The polymyxins share a 
similar structure and are pentacationic polypeptides consisting of a cyclic heptapeptide linked 
to a linear tripeptide, whose N-terminus is acylated with a fatty acid moiety. Colistin is a 
secondary metabolite peptide produced by the soil bacterium Paenibacillus polymyxa (formerly 
named Bacillus polymyxa). The polymyxins have bactericidal activity against most members 
of the Enterobacteriaceae family including E. coli, Klebsiella, Salmonella, Shigella, and 
Enterobacter, as well as other clinically relevant Gram-negative pathogens such as 
Acinetobacter baumannii and Pseudomonas aeruginosa. However, the polymyxins 
demonstrated no activity towards Gram-negative and Gram-positive cocci and Gram-positive 
bacilli. Besides, polymyxins lack activity against intrinsically resistant species, such as Serratia 
or Proteus spp. (Muyembe et al., 1973; Storm et al., 1977; Pogue et al., 2011).  
 
Since its introduction in the 1950s, colistin has been used continuously in the veterinary 
medicine to treat and prevent animal infectious caused by Gram-negative bacteria. In human 
medicine, colistin was gradually abandoned in the early 1980s due to concerns about 
neurotoxicity and nephrotoxicity (Brown et al., 1970) Thereafter, colistin was re-introduced for 
systemic treatment due to MDR Gram-negative bacteria (Conway et al., 1997). 
 
Initially, resistance mechanisms were caused by mutations in a small number of 
chromosomal encoded genes. Particularly in E. coli, it can be due to mutations in the two-
component systems PmrAB and PhoPQ, or in the MgrB regulator. Thus, Quesada et al. 
(Quesada et al., 2015) detected two colistin-resistant E. coli recovered in 2011 and 2013 from 
DAFNE DÍAZ JIMÉNEZ 
30 
 
the stools of two pigs, which showed mutations in PmrB V161G and PmrA S39I, reporting the 
finding as a rare event. Subsequently, other authors have reported not only different mutations 
in the amino acid sequences of the MgrB, PhoP, PhoQ, and PmrB proteins, but also the co-
occurrence of transmissible colistin resistance genes (García-Meniño et al., 2019).  
 
Since the mcr-1 (mobile colistin resistance gene 1) plasmid gene was first described (Liu 
et al., 2016), it has been identified in members of the Enterobacteriaceae family encoded in 
different plasmid types, including IncI2, IncX4, IncHI1, IncHI2, IncFI, IncFII, IncP, IncK (Sun 
et al., 2018). The encoding enzyme is responsible for the transfer of pEtN to lipid A thereby 
mediating colistin resistance. Further investigation showed that the mcr-1 gene was present in 
E. coli since 2011 and it has spread in isolates from livestock, raw meat products and even 
humans (El Garch et al., 2017), and WGS analysis showed that the mcr-1 gene was present in 
continents (Ling et al., 2020). In Europe, the mcr-1 gene seems to be present since 2004, when 
it was found in E. coli from diseased cattle (El Garch et al., 2017). To date, ten different mcr-
genes (mcr-2 (Xavier et al., 2016), mcr-3 (Yin et al., 2017), mcr-4 (Carattoli et al., 2017), mcr-
5 (Borowiak et al., 2017), mcr-6 (AbuOun et al., 2018), mcr-7 (Yang et al., 2018), mcr-8 (Yang 
et al., 2018), mcr-9 (Carroll et al., 2019), mcr-10 (Wang et al., 2020)) have been characterized 
in a wide number of plasmid reservoirs. Several variants have been described for mcr-1 to mcr-
9, of which mcr-1 and mcr-3 genes comprise the largest groups.  
 
1.2.2. Standardized definitions of MDR, XDR and PDR 
 
In 2012 Magiorakos et al. (Magiorakos et al., 2012) together with a group of international 
experts and through the initiative of the ECDC and the Center for Disease Control and 
Prevention (CDC) established an internationally standardized terminology to describe the 
resistance profiles of different bacteria associated with human clinical infections and 
predisposed to multidrug-resistance. 
 
Different classifications were considered for different bacteria, so the definitions vary 
according to the family, in the case of Enterobacteriaceae, multidrug-resistant strains or MDR 
are defined as those that are resistant to one or more agents of three or more categories. Strains 
known as extensively drug-resistant or XDR are those that are resistant to one or more agents 
of all except for two or fewer antimicrobial categories. And finally, pandrug-resistant strains or 
PDR are considered to be those resistant to agents of all categories (Table 6). 
 
Table 6. Categories and antimicrobial agents used to define MRD, XDR and PDR in Enterobacteriaceae. 
Adapted from Magiorakos et al. (Magiorakos et al., 2012)  
 
Antimicrobial category  Antimicrobial agent 
Aminoglycosides Gentamicin, Tobramycin, Amikacin, Netilmicin  
Anti-MRSA Cephalosporins  Ceftaroline (approved only for E. coli, Klebsiella pneumoniae, Klebsiella oxytoca) 




Carbapenems  Ertapenem, imipenem, meropenem, doripenem 
1st and 2nd generation cephalosporins, 
not extended spectrum  Cefazolin, cefuroxime 
3rd and 4th generation cephalosporins, 
extended spectrum  
Cefotaxime or ceftriaxone, ceftazidime, 
cefepime 





Antimicrobial category  Antimicrobial agent 
Fluoroquinolones Ciprofloxacin 
Inhibitors of the folate pathway  Trimethoprim-sulfamethoxazole 
Glycylglycines Tigecycline 
Monobactams  Aztreonam  
Penicillins  Ampicillin  
Penicillins + β-lactamase inhibitors Amoxicillin – clavulanic acid, ampicillin-sulbactam 
Phenicols Chloramphenicol  
Phosphonic acids  Fosfomycin 
Polymyxins  Colistin 
Tetracyclines Tetracycline, doxycycline, minocycline  
 
1.3. THE ROLE OF FOOD IN MICROORGANISM’S TRANSMISSION 
 
Microorganisms can access the human body through diverse ways, being one of them 
within contaminated food. This contact can develop a wide variety of situations in the host 
organism. Microorganisms can act as a beneficial health element with the stimulation of host 
antibodies, the release of chemicals to stimulate the health of the overall system, by the 
inhibition of pathogen development, as well as shapers of the diversity of the human microbiota. 
Some of them can cause minimal changes within the equilibrium of the host microbial 
community being able to balance itself again to the optimal situation, but these food-borne 
microorganisms can also act as a pathogenic element. When this happens and the consumption 
of food or water is associated with a pathogenic organism and a disease is caused, they are 
considered as food-borne infections (European Food Safety Authority, 2019). These infections 
are the most frequently reported pathology in the United States according to the CDC with an 
estimated annual number of food-borne illness of 9.4 million cases associated with 31 known 
food-borne pathogenic agents, usually concomitant with gastrointestinal symptoms (Scallan et 
al., 2011; CDC, 2018). However, these symptoms are not routinely reported unless they come 
from an outbreak situation or a programmed sampling. So, the actual number of cases is known 
to be much higher. The same situations happens when the data from the EU is analyzed, in this 
case only 13 zoonotic elements were considered and the final report only accounted for 350,000 
confirmed human cases, nevertheless the real incidence is suspected to be higher (EFSA/ECDC, 
2020).   
 
For a food-borne disease event to occur, three situations have to overlap: presence of a 
contaminated food item, a susceptible host and a bacterial pathogen able to survive and multiply 
in the new environment niche. The pathogen usually is able to cause a food-borne disease by 
three different mechanisms, first, by the ingestion of a toxin produced by the bacteria and 
present on the food, second, by the production of the toxin within the gastrointestinal tract after 
the pathogen has been ingested, or third, by the invasion of the intestinal epithelial cells 
(Antunes et al., 2020). 
 
To have full picture of the transmission of hazardous microorganisms from food to the 
human population, we need to take into account the three following related items. First, the 
bacterial pathogen itself, the food chain and lastly, the human host (Antunes et al., 2020). The 
bacterial pathogens need to be able to survive the stress situations suffered during the 
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transmission from reservoir to host and keep their capability to multiply in order to colonize the 
new environment.  For this adaptation, the bacteria use their genetic plasticity to acquire genetic 
elements through horizontal transfer, genetic recombination, mutations or modifications of their 
metabolic pathways. Antibiotic resistance and / or virulence genes are some of the adaptations 
usually give the bacteria the best adaptations for its survival. Another related item is the food 
chain itself, from the production systems to the global distribution of the food. With the new 
global situation, the demand and manufacture of food has created the necessity of industrial 
scale production systems for animal production as well as for agriculture. This intensive 
livestock practices with high density animal densities makes it easy for the bacteria to 
disseminate and persist on the facilities, as well as to take as reservoir the production animals 
and spread themselves through the food chain, at slaughterhouses and during the distribution of 
the products. Also, the fact that products or animals can travel from countries with lower food 
safety standards or safety practices to countries with higher standards can make possible de 
dissemination of diverse microorganisms. This is the case of poultry products imported from 
Brazil, one of the most important exporters, that has been linked to the dissemination of 
epidemic clones of MDR Salmonella enterica into European countries (Campos et al., 2018). 
Moreover, is needed to take into account the paper of the final host. In the last decades the 
consumption habits of the populations have change drastically, ready-to-eat and / or ready-to-
cook products, consumption of uncooked or undercooked food from animal origin and a more 
frequent habit of eating in food service establishments prone the population to be more expose 
to possible hazardous situations, as for example, inadequate time - temperature control of the 
products, cross contamination, insufficient cleaning or personal hygiene of the handler are some 
of the possibilities for an outbreak to develop. Also, is important to notice that the own 
characteristics of the host will make an important difference in how the infection develops. The 
elderly and immunocompromised, as well as the infants are more susceptible to the infections. 
Is frequent the assessment of cases of listeriosis among elderly population (Buyck et al., 2018), 
as well as STEC severe outbreaks among children younger than five years old.  
 
Cross contamination can happen at any step of the food chain and affects the final 
microbiological quality of the product. EFSA defines cross contamination as the process by 
which microbes or substances are involuntarily transferred from one object to another, with 
harmful effects. 
 
EFSA carries out food risk assessment programs which provide data on cross 
contamination for the quantitative assessment of microbiological risks. According to the 
European Union Zoonosis Report issued in 2018, it is estimated that 40.5% of the outbreaks of 
bacterial infections have occurred at the domestic level, with 15.6% being cases of outbreaks 
in which a contaminated food was the cause. In these reports there is clear evidence that cross 
contamination in these cases is one of the determining factors producing the outbreaks (EFSA, 
2019). This cross contamination or bacterial transfer can occur at various points in the food 
preparation process, but frequently the starting point of it is contaminated meat as a source of 
microorganisms. The handling of the meat during its preparation usually has several critical 
points to consider, from its cut and the utensils used for it, such as boards or knives, to the hands 
of the person who is handling it. The main determinant of risk in these cases is the fact that the 
food that receives the cross contamination will be served uncooked and without heat treatments 
as is the case with salads. On the contrary, when the food will be consumed after a heat process, 
bacteria usually die. The recommendations issued by the EFSA include good hand hygiene, 





product to another, as well as establishing a correct order of actions when working with food 
(EFSA/ECDC, 2020; Iulietto and Evers, 2020). 
  
However, this cross contamination does not only occur at the domestic level. There are 
numerous studies on cross-contamination of microorganisms that originate in slaughterhouses, 
both in cattle (Mather et al., 2008), pigs (Botteldoorn et al., 2003) and poultry, chicken and 
turkey (Olsen et al., 2003; Nde et al., 2007). Most studies are biased towards the detection of 
zoonotic organisms described as classic food-borne pathogens, usually associated with 
digestive pathologies as well as ESBL-producing isolates. In fact, the most common causes of 
food-borne disease according to the EFSA and CDC are Campylobacter spp., Salmonella spp., 
Yersinia spp., E. coli, Listeria spp., Clostridium perfringens. In relation to viral agents, 
norovirus is the most frequently reported (EFSA/ECDC, 2020). Yet, this criterion does not 
include microorganisms that are currently describe as food-borne pathologies, more often 
associated with extraintestinal pathologies, such as ExPEC or Klebsiella spp. For this reason, 
some authors (Smith et al., 2007; Davis et al., 2015; Hartantyo et al., 2020; Riley, 2020; Hu et 
al., 2021) highlight in their reviews the importance of these new recognized food-borne 
pathogens and the need of conducting studies and include them in the actual monitoring systems 
in order to have a more deep knowledge about them.  
 
Due to the importance of these diseases and their association with increasingly frequent 
outbreaks and antibiotic resistance spread, in recent decades it has become necessary to develop 
surveillance systems and make preventive decisions to try to reduce the risk of exposure for 
consumer. As mentioned before, factors as changes in the eating and consumption habits of the 
population, increase in international travel, changes in the production processes and food 
distribution, the adaptation of pathogens to new environments, the acquisition of virulence and 
resistance factors by microorganisms, the improvement of the detection methods, poor hygiene 
and vector control, inadequate health services or even a deficient information to the consumer 
(Schirone et al., 2019) make necessary a continuous surveillance system in order to assess the 
possible outbreaks as soon as possible and be able to trace its route of spread and stop it as soon 
as possible. Also, a comprehensive evaluation of antibiotic resistances in the food chain and in 
production animals is essential to understand the magnitude of the problem and be able to act 
accordingly to reduce its burden on humans. However, food surveillance is considered a 
sensitive issue, therefore, the information derived is, in some cases, incomplete or difficult to 
access or understand by society (Tacconelli et al., 2018). Some of the most recent data are 
summarized below. 
 
In the EU in 2019 the number of reported cases of human campylobacteriosis was 220,682. 
From them, 58,074 were related with meat and meat products meanwhile 2,760 were related 
with milk and milk products. The number of cases has decreased 6.9% regarding the data 
reported in 2018. Using new approaches in methodology, such as the WGS, it is possible to 
trace the origin of the infection. This is the case of a Campylobacter fetus outbreak in the 
Netherlands due to the consumption of unpasteurized sheep milk processed into unripened 
cheese (Koppenaal et al., 2017). The presence of Campylobacter spp. at a farm level as well as 
in the transport and slaughtering houses for broilers is a matter of discussion. In 2018 a process 
hygiene criterion (Regulation (EU) 2017/1495) with a critical limit of < 1000 cfu/g neck skin 
has been implemented in the EU countries, but an intervention method is needed at slaughter 
level in order to have a better control of the situation(Rasschaert et al., 2020).  
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In 2019, Salmonella was the second most commonly reported gastrointestinal infection in 
humans and an important cause of food-borne outbreaks. Thus, 87,923 confirmed cases were 
reported in humans, which meant the same level of incidence as in 2018. In total, 926 outbreaks 
were reported, 17.9% of the total amount of food-borne outbreaks of 2019. The vehicles of the 
infections were mainly, eggs and egg products followed by bakery products and pig meat. 
Within the EU, the national control programs carried out in poultry found a significant increase 
of the prevalence of Salmonella in breeding flocks, laying hens and fattening turkey flocks over 
the last 4 to 6 years (EFSA/ECDC, 2020). As with campylobacteriosis, WGS was not only 
useful to determinate the profile of Salmonella enteritidis from an outbreak linked to eggs from 
Poland with international impact, but also to identify the source and the movement of the 
bacteria (Pijnacker et al., 2019).  
 
Regarding other bacteria, Listeria spp. was reported from 2,621 cases in 2019, with the 
same level of incidence as in 2018. Usually, these infections are reported within the group of 
age over 64 years old, which presented a fatality rate of 17.6% (higher in comparison to 
previous years). From the 2,621 cases, 1,803 were considered as domestic cases, acquired at 
home. One of the biggest Listeria outbreaks of last years occurred in Spain in 2017, where 222 
confirmed cases were reported, with three deaths, six miscarriages and one travel-related case 
in France. The infected food associated with the outbreak was ready-to-eat pulled pork meat. 
After it, studies to determinate the diversity as well as the virulence potential of isolates 
recovered from pigs were carried out in the same region, pointing out the presence of virulent 
strains among the samples recovered from farm pigs, highlighting the importance of the 
veterinary medicine regarding the food safety (Gómez-Laguna et al., 2020; EFSA, 2021).  
 
In 2019, the report on STEC infections accounted for 8,313 cases of infection, these 
infections were the third most commonly stated to the European Food and Waterborne Diseases 
and Zoonoses Network (FWD-Net) after campylobacteriosis and salmonellosis being all of 
them associated with digestive symptoms. After six years of stable trend, in 2017 a large 
increase of the cases was observed probably due to the change in the detection methodology 
used, now with a higher presence of PCR replacing culture diagnostic methods.  Ruminants are 
known to be the main natural reservoir of STEC and because of this, undercooked ground beef 
or other meats are found to be a significant risk factor for food-borne infections associated with 
STEC isolates. In 2019 these infections involved 273 human cases in 42 known outbreaks in 
11 different countries of the EU, which accounted for 0.8% of all food and waterborne 
outbreaks and 5.6% of the reported domestic STEC cases at the EU level (Ecdc, 2021).  
 
Antibiotic resistance is a major priority in food safety as well as a global public health issue 
for humans and animals referred by a high number of entities as the European Commission, 
WHO or the Food and Agriculture Organization of the United Nations. The European Union, 
in order to protect the consumer and the environment and with the wide assumption that the 
misuse of antibiotic drugs in the animal production played an important role in the spread of 
ESBL and resistant E. coli strains through the food chain to humans, on January 1st 2006 banned 
the use of antibiotics as prophylaxis tool or as growth promoter in veterinary medicine 
(Hindermann et al., 2017; Mora et al., 2010). And since then, the European Medicines Agency 
(EMA) has been following the veterinary antimicrobial consumption of the EU updating yearly 
the trends of the antimicrobial sales and use in animals. Also has been developing successive 
One Health action plans against AMR that have been successively reviewed until the last 





In order to control the impact on public and animal health of the use of antibiotics allowed 
to be applied in production animals, the EMA in 2020 established a new categorization in the 
veterinary handling of these drugs to help clarify the guidelines for its use in order to prevent 
and control derived resistances (EMA, 2019, 2020). In the categorization process, defined 
criteria, based on evidence and experts’ considerations, have been applied to provide a rationale 
for the ranking. The updated criteria on which the categorization is based are as follows:  
 
- If the (sub)class or group is authorized for use as a veterinary medicine in the EU. 
- The importance of the (sub)class or group to human medicine according to the WHO 
ranking and considering the EU situation. 
- The knowledge of factors influencing the likelihood and possible consequences of AMR 
transfer from animals to humans, considering mechanisms where a single gene confers 
multiresistance (or resistance to several classes).  
- The availability of alternative antibiotic (sub)classes in veterinary medicine with lower 
AMR risk to animal and public health.  
 
Based on this criteria, four categories have been established, from A to D, with an 
associated keyword to facilitate its use (Table 7). They would be the following: 
 
- Category A or "Avoid": includes antibiotics not authorized for use in veterinary 
medicine but authorized in human medicine in the EU. They can be used exceptionally 
in animals not intended for consumption whenever their treatment with an antibiotic of 
a lower category is not possible. 
- Category B or "Restrict": These are substances that fall within the category of high 
priority for the WHO except for macrolides and those that are already included in 
category A. In these antibiotics, the risk to public health derived from its use in 
veterinary medicine must be mitigated by its control. 
- Category C or "Caution": It is an intermediate category for those substances that there 
are in general alternatives in human medicine in the EU but there are few alternatives 
in veterinary medicine for certain indications.  
- Category D or “Prudence”: It is the category in which there is the least risk to public 
health. It is known that the use of these antibiotics does not have a negative impact on 
the development and spread of antibiotic resistance, due to co-selection. 
 




categories Antimicrobial class, subclasses and substances Example of antimicrobial 
Category A 
("Avoid") 
Amdinopenicillins Mecilinam, pivmecilinam 
Carbapenems Meropenem, doripenem 
Other cephalosporins and penems, including 

















Penicillin: carboxypenicillins and ureidopenicillins, 
including combinations with β-lactamase inhibitors Piperacillin-tazobactam 
Phosphonic acid derivates Fosfomycin 
Pseudomonic acids Mupirocin 
Rifamycins (except rifaximin) Rifampicin 
Riminofenazines Clofazimine 
Streptogramins Pristinamycin, virginiamycin 
Sulfones Dapsone 




Substances newly authorized in human medicine 
following publication of the AMEG categorization. To be determined 
Category B 
("Restrict") 
Cephalosporins: 3rd- and 4th-generation, except 
combinations with β-lactamase inhibitors 
Ceftiofur, cefovecin, 
cefquinome 
Polymyxins Colistin, polymyxin B 
Quinolones: fluoroquinolones and other quinolones Enrofloxacin, ciprofloxacin, ofloxacin, oxolinic acid 
Category C 
("Caution") 
Aminoglycosides (except spectinomycin) Etreptomycin, gentamicin 
Aminopenicillins in combination with β-lactamase 
inhibitors Amoxicillin-clavulanic acid 
Amphenicols Florfenicol, thiamphenicol 
Cephalosporins: 1st- and 2nd-generation, and 
cephamycins Cefalexin, cefapirin 
Macrolides (not including ketolides) Tylosin, tulathomycin 
Lincosamides Clindamycin, lincomycin 
Pleuromutilins Tiamulin, valnemulin 
Rifamycins: rifaximin only Rifaximin 
Category D 
("Prudence") 
Aminopenicillins, without β-lactamase inhibitors Amoxicillin, ampicillin 
Cyclic polypeptides Bacitracin 
Nitrofuran derivatives Furazoldone 
Nitroimidazoles Metronidazole 
Penicillins: Anti-staphylococcal penicillins (β-
lactamase-resistant penicillins) Cloxacillin 




Aminoglycosides: spectinomycin only Spectinomycin 
Steroid antibacterial Fusidic acid 
Sulfonamides, dihydrofolate reductase inhibitors 
and combinations 
Sulfadiazine, trimethoprim 





The EU carried out a monitoring program for antibiotic resistant bacteria, both zoonotic 
and indicators of bacterial quality in for humans, animals and food in all the states members. 
The annual monitoring of resistance in animals and food set its target in 2017 on pigs and cattle 
less than one year old, as well as their carcasses and meat. Similarly, in 2018 the target was 
birds and their derived products, carcasses and meat. The data collected these years included 
information from Salmonella spp., Campylobacter spp. and E. coli  as indicator, as well as data 
obtained directly from the monitoring of ESBL / AmpC / carbapenemases producing E. coli  
strains (EMA, 2019).  
 
According to the Regulation (EC) No 2073/2005 since 2017 the monitoring of AMR 
Salmonella spp. at slaughter was mandatory in isolates recovered from carcass swabs of 
fattening pigs and calves under one year of age and in 2018 become mandatory as well for 
isolates recovered from carcass swabs of broilers and fattening turkeys. Also, data from human 
cases were reported. In 2018, high proportions of human Salmonella isolates were resistant to 
sulfonamides (30.5%), tetracyclines (28.8%) and ampicillin (25.9%) and 0.8% of the isolates 
were presumptive ESBL-producing, meanwhile AmpC resistance was less frequent, only 
identified in 0.2% of tested isolates. MDR was high in this species with overall in the EU with 
a 28.5%.  
 
Regarding Campylobacter jejuni, AMR monitoring was mandatory in slaughter in 2018 
for caecal samples of broilers and fattening turkeys, and voluntary for caecal samples of 
fattening pigs and calves under 1 year. In 2018 a very high to extremely high resistance levels 
to ciprofloxacin were reported in almost all EU countries, but on the other hand low proportions 
of Campylobacter isolates were resistant to gentamicin and amoxicillin-clavulanic acid, except 
in Luxembourg, Malta and Spain with between 20 and 27.3% of C. coli resistant to clavulanic 
acid-amoxicillin, this differences are probably associated with the differences in the use of 
antimicrobials (EMA, 2019).  
 
Each year, 30 EU and European Economic Area (EEA) countries report antibiotic 
susceptibility testing (AST) results collected from medical microbiology laboratories to EARS-
Net for eight bacterial species under surveillance (E. coli, K. pneumoniae, P. aeruginosa, 
Acinetobacter species, S. pneumoniae, S. aureus, E. faecalis and E. faecium). In 2019, more 
than half of the E. coli isolates reported to EARS-Net and more than a third of the K. 
pneumoniae isolates were resistant to at least one antimicrobial group under surveillance, and 
combined resistance to several antimicrobial groups was frequent. Resistance percentages were 
generally higher in K. pneumoniae than in E. coli. While carbapenem resistance remained rare 
in E. coli, several countries reported carbapenem resistance percentages above 10% in K. 
pneumoniae. Carbapenem resistance was also common in P. aeruginosa and Acinetobacter 
species, and at higher percentages than in K. pneumoniae (ECDC, 2020). Recent studies have 
suggested that E. coli and Klebsiella pneumoniae, both associated with extraintestinal infections 
as well as with the widespread of antibiotic resistances, may be considered food-borne 
pathogens. The epidemiologic observations of the key lineages of these organisms suggested a 
common point-source exposure, such as contaminated food. Since contaminated food is the 
main source for microorganisms causing gastrointestinal infections, is easy to assume that this 
should be as well the entrance of microorganisms that are able to cause extraintestinal diseases.  
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1.3.1. The role of food-borne E. coli 
 
The role of Escherichia coli as a pathogen is difficult to adequate into just a single type of 
pathology, as well as a single type of transmission or end host. It presents a complexity and 
extension as a species that makes it necessary to group it accordingly to its characteristics and 
taking into account its form of transmission which is also heterogeneous. InPEC strains with 
their pathotypes, their own characteristics and differences with the commensal strains, already 
described previously, shows a clear and indisputable transmission from food to the host. In fact, 
the pathotypes of E. coli most commonly detected in food and water destinated to human 
consumption are STEC isolates, usually associated with diarrhea, HC, HUS and end-stage renal 
disease with the highest rate of confirmed cases observed in children from zero to four years 
old. Some countries have surveillance networks in order to detect possible outbreaks (Yun et 
al., 2021) and collect epidemiologic data of the isolates in order to support decision-making at 
national level. In EU, the ECDC publishes yearly an epidemiological report with data recovered 
from the different countries (EFSA, 2019). The characterization of the food STEC isolates is 
pivotal for the assessment of the risk for consumers posed by food, usually serotyping was an 
important part of this process nevertheless, a recent pathogenicity assessment (Koutsoumanis 
et al., 2020) affirms that this feature is not an indicator of pathogenicity, but they admit that has 
some importance as an epidemiological marker, useful to observe the circulation of the different 
STEC types in food and human cases. Regarding the major food-borne outbreaks caused by E. 
coli in the last two decades we find a wide diversity of sources and pathotypes (Yang et al., 
2017). Below, the most recent events and pathotypes are cited. 
 
Two different aEPEC serotypes, O157:H45 and O127a:K63 caused two different outbreaks 
in China and South Korea in 2010 and 2013, respectively. The Chinese outbreak affected 112 
students, from 18 to 23 years old. They developed digestive symptoms after eating in the same 
dining room, nevertheless, in this case, the researchers were not able to identify the origin of 
the infection, but associated its high virulence to the presence of the eae intimin alongside with 
resistance to quinolone and extended spectrum cephalosporin, mediated by five mutations, two 
in gyrA, two in parC, one in parE and the resistance genes aac(6’)-Ib-cr and blaCTX-M-15 (Hao 
et al., 2012) In the Korean outbreak, the authors analyzed samples from stool, environment as 
well as preserved food items, to finally determinate the tuna bibimbap, a typical Korean soup 
breakfast, to be de vehicle for the aEPEC that infected 33 people  (Park et al., 2014). In 
developed countries is uncommon to find food-borne outbreaks associated with EIEC, 
nevertheless, an outbreak with a total of 109 cases of EIEC O96:H19 happened in 2012 in Italy. 
It was associated with the consumption of vegetables and affected the canteen of the Milan Fire 
Brigade (Escher et al., 2014).  
 
In Europe, in 2006 and 2013, two different outbreaks associated with EAEC isolates were 
registered, one in a food festival in England and another associated with cheese from 
unsterilized raw milk (Scavia et al., 2008). In the food festival, different serotypes were 
involved, including O131:H27, O104:H4, O20:H19 among the 592 registered cases. The EAEC 
O104:H4 strains found in this outbreak had a close phylogenetic relationship with the one from 
the large outbreak of HUS in Germany in 2011 (Dallman et al., 2014). The causing agent of the 
latter was a hybrid pathotype of STEC and EAEC, carrier of several virulence factors of the 
ExPEC group, and a wide range of antibiotic resistances. The outbreak accounted for 3,816 
cases in humans, with 845 of them developing HUS and 36 dying from it and 2,971 cases of 





were: serotype O104:H4, virulence factors associated with STEC (stx2a) and with 
enteroaggregative pathotype, as well as the blaCTX-M-15  gene (Mora et al., 2011b; Blanco, 2012). 
In May 31th of 2011, the Robert Koch Institute reported that the suspected origin of the outbreak 
were cucumbers from Spain, nevertheless in June 23rd fenugreek seeds imported from Egypt 
was determined as the real vehicle for the hybrid pathotype (EFSA, 2011).  
 
However, the dominant pathotype / serotype in food-borne outbreaks is still by far the 
STEC/EHEC O157:H7, with cases reported all over the world associated mainly with meat and 
vegetables (Jay et al., 2007; Wendel et al., 2009; CDC, 2014, 2015, 2019a, 2020b; Watahiki et 
al., 2014). Comparing the incidence of O157 and non O157 STEC outbreaks, we can appreciate 
that those associated with non O157 are less frequently linked to meat, water or vegetables, but 
more prone to be linked to person-to-person infection. While outbreaks caused by O157 strains 
are more frequently produced by meat as well as contaminated water and vegetables watered 
with it (Doyle et al., 2008).  
 
 On the other hand, in ExPEC strains, the transmission through food, especially animal-
derived products, has been proposed on multiple occasions but due to the lack of knowledge of 
the time period between the colonization of the intestinal tract and the development of the 
infection, it is difficult to detect the reservoirs through which these strains are transmitted 
(Manges and Johnson, 2012).  
 
In a recent review, Riley (Riley, 2020), stated that the problem arises from not being able 
asses with full certainty the reservoir from where these strains came, since knowing it could 
give valuable information about the flow of movement that they follow to cause infection. The 
problem that arises with ExPEC stains is the dichotomy of its nature. On one hand, if the ExPEC 
strains are simply commensals that are able to cross the hematological barrier and cause disease, 
the reservoir should be the human digestive tract, but, on the other hand, if we consider that the 
ExPEC strains are pathogenic strains, their natural habitat must lie outside the human intestine, 
where they must reach and colonize to cause disease. So, if we consider the ExPEC strains as 
pathogens, then their transmission must come from external sources such as food or water 
(Riley, 2020). This whole process is also hampered by the fact that the colonization time of 
these strains until the moment of causing infection remains unknown (Manges and Johnson, 
2012).  
 
The hypothesis that food, particularly avian products, can act as a reservoir for 
extraintestinal pathogenic Enterobacteriaceae is based on scientific evidence obtained from 
different approaches (Mora et al., 2009b, 2013; Jakobsen et al., 2010; Davis et al., 2015; 
Hindermann et al., 2017; Mellata et al., 2018; Jørgensen et al., 2019; Riley, 2020). In fact, 
certain strains that cause avian pathology, APEC isolates, show a high genetic similarity to 
those that cause extraintestinal pathology in humans. The hypothesis emerged from several 
studies is that some human ExPEC strains might have evolved from APEC lineages (Manges 
and Johnson, 2012; Jørgensen et al., 2019). The evidence that suggests this hypothesis are, 
among others: 
 
- The geographical and temporal grouping of ExPEC strains isolated from patients with 
extraintestinal infections, suggesting the appearance of an outbreak and / or a common 
source of exposure (Yamaji et al., 2018a). 
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- The global distribution of lineages of identical ExPEC strains, which would indicate the 
global spread of contamination carried through food (Liu et al., 2018).  
- The detection of identical genotypes of ExPEC isolated from human infections, as well 
as from food products (Yamaji et al., 2018a).  
- The disproportionate representation of pandemic ExPEC lineages among the hundreds 
of STs causing extraintestinal infections worldwide, indicating a high biological or 
fitness advantage within different reservoirs (Mora et al., 2018).  
- The relatively recent occurrence of the ST69, ST131 and ST393 genotypes as ExPEC, 
suggesting the recent emergence of these genotypes into the human intestinal niche from 
external sources (Manges and Johnson, 2012).  
 
Riley's review analyzes the most frequently reported STs identified in two or more regions 
within isolates of clinical (human) and animal origin. The following table summarizes the nine 
dominant lineages (Table 8). 
 
Table 8. The nine prevalent STs of E. coli identified in human extraintestinal infections (Riley, 2020) 
 
ST Number of EnteroBase entries Food and food-animal sources Other sources 
ST10 6432 Poultry, bovine, swine, dairy (raw-milk cheese), goat, sheep, fish 
Dog, horse, rabbit, sea lion, camel, 
pigeon, gazelle 
ST12 598 Swine, bovine, fish Dog, cat, horse, mink, raccoon, rat 
ST69 1529 Poultry, bovine, sheep, dairy (raw-milk cheese)  
Dog, horse, dolphin, mink, bald eagle, 
seagull 
ST73 1984 Poultry, swine, bovine 
Cat, donkey, duck, horse, giraffe, 
orangutan, elephant, gorilla, rhesus 
monkey, ferret, mouse 
ST95 1590 Poultry, bovine, lettuce Dog, ostrich, swan, rat, gecko, poultry feed 
ST117 925 Poultry, bovine, calf, swine Dog, cat, mink, rabbit, rat, animal feed 
ST127 525 Turkey, bovine, celery Dog, gazelle, rat, horse 
ST131 6574 Poultry, bovine, pork Dog, cat, rook, horse, seagull, rodent 
ST405 646 Bovine, whale Dog, crow, marmoset 
 
Yamaji et al. (Yamaji et al., 2018a) analyzed cases of UTIs and meat samples of different 
origins recovered in the same. The study shows an overlap between the STs of the E. coli 
recovered from patients with UTIs and those found, mainly, in poultry meat samples. Thus, 
21% of the STs determined in isolates of human origin were also found in poultry meat (ST10, 
ST38, ST69, ST101, ST117, ST131, ST569 and ST1844 in chicken meat and ST10, ST69, 
ST80, ST88, ST117 and ST1844 in turkey meat). The authors concluded that poultry meat may 
be acting as a reservoir for ExPEC isolates responsible of UTIs. 
 
But E. coli is not only important to be consider as a pathogen, as mentioned previously, it 
is considered a carrier and spreading agent of antibacterial resistances. According to the study 
carried out by the European Union between 2017 and 2018, where commensal E. coli from 
healthy production animals were analyzed at slaughterhouses, these could be acting as a 
reservoir for resistant strains that could potentially spread among animals, as well as from 
animals to humans through the food chain. The rates of resistance detected to ampicillin, 
sulfamethoxazole, trimethoprim and tetracyclines in the strains were classified in most of the 





2018. Furthermore, particularly in poultry, resistance to ciprofloxacin and nalidixic acid was 
also common and was given a level of very high or extremely high resistance, both for chickens 
and turkeys (EMA, 2019). 
 
In the same study, when they compared the four different species studied regarding MDR, 
the higher levels were clearly found in chickens (49.4%) and turkeys (52.4%) compared to pigs 
(31.1%) and calves (28.4%) (EMA, 2019). A possible explanation for these large differences 
may corelate with the method of administration of the antibiotic treatments during the 
production stage, since in poultry farms, the whole group is treated through water or food, 
meanwhile in the case of pigs and cattle, the treatments are mainly individual. The importance 
of these data, as we said before, lies in the possibility that these antibiotic resistances spread 
worldwide to commensal strains and pathogenic strains, therefore complicating antibiotic 
treatments for common pathologies such as UTIs. An improvement of the situation is beginning 
to be appreciated thanks to the implementation of programs such as the National Plan against 
Antibiotic Resistance (PRAN) 2014-2018 and 2019-2021 and international measures like the 
legislation on the use of antibiotics, although it must be mentioned that each member country 
starts from different conditions and levels of resistance, which will determinate its evolution. 
 
Due to the methodology applied, data obtained from the majority of studies regarding 
ExPEC isolates is generally biased towards the recovery of ESBL-producing isolates or strains 
causing clinical pathology in humans, missing all the possible pathways that ExPEC isolates 
may colonize the human gut (Singer, 2015; Liu et al., 2018). Currently, there are many studies 
oriented to the detection of AMR ExPEC, or specific clades of the clonal group ST131 
associated with human pathology (Ghodousi et al., 2015; Johnson et al., 2017b; Park et al., 
2019; Vounba et al., 2019; Nagaoka et al., 2020; Taati Moghadam et al., 2021), nevertheless, 
this trend is slowly changing since many authors point out the importance of analyzing the 
diversity of ExPEC isolates involved in the dissemination of virulence genes through the 
environment and the different reservoirs.  The same approach based on surveys for STEC 
should be applied for ExPEC isolates to assess the risk exposure for the costumer (Smith et al., 
2007; Johnson and Manges, 2015; Riley, 2020).  
 
1.3.2. Klebsiella spp. as food-borne pathogen 
 
The members of Klebsiella spp. have been commonly described as commensals located in 
a wide diversity of niches such as the gastrointestinal tract of humans. Before the 90s, when 
certain lineages associated with epidemic outbreaks emerged worldwide, UTIs caused by these 
bacteria normally affected only hospitalized patients or with previous pathologies. 
Unfortunately, the KPC resistance associated with the clonal group CC258 began to spread in 
the 2000s. Thus, this clonal group was reported in outbreaks of New York hospitals (Bradford 
et al., 2004) as well as elsewhere on the east coast of the United States, and in countries as far 
away as Israel (Schwaber et al., 2011).  
 
In 1998, it was the first time that a case of sepsis attributed to K. pneumoniae and E. coli  
was associated with the ingestion of food, in this case a hamburger (Sabota et al., 1998). In 
2008, in different hospitals in Barcelona, many cases of patients infected and intestinal 
colonization by Klebsiella spp. were registered in a period of nine months, and all the isolates 
showed the same PFGE profile. The researchers concluded that both infections and colonization 
were originated from a food-borne outbreak (Calbo et al., 2011), although the food product that 
DAFNE DÍAZ JIMÉNEZ 
42 
 
caused the outbreak was not identified. A more recent study carried out by Davis et al. (Davis 
et al., 2015) establishes more clearly the relationship between food and an outbreak of 
extraintestinal infections associated with Klebsiella spp. The authors performed WGS of 82 
strains recovered from meat (chicken, turkey, and pig) and from clinical human cases, 
evidencing an overlap of STs between both sources (ST14, ST76, ST188 and ST111) and 
similar virulence patterns in a murine model. 
 
The fact that retail meat contaminated with AMR K. pneumoniae is a potential vehicle for 
the transmission of resistance and / or virulent genes is supported by diverse studies (Davis et 
al., 2015; Davis and Price, 2016; Hu et al., 2021). As an example, it is important to highlight 
the report of one K. pneumoniae isolate recovered in February 2016 from unfrozen chicken 
from a local grocer in Japan. This isolate showed resistance to a wide range of antibiotics 
including carbapenems. In the study, the authors performed WGS of the isolate and detected 
the presence of six plasmids, two of which carried different antibiotic and heavy metal 
resistance genes, including mcr-9 and blaVIM-1 in an IncHI2A plasmid. Furthermore, the blaNDM-
1 gene was found in a large IncFII(K) plasmid alongside with other resistance genes. The isolate 
belonged to ST30, a ST previously reported in patients in the United States as well as in China 
(Khalifa et al., 2020). In another recent study conducted in Singapore, K. pneumoniae was 
recovered from 21% (147 of 698) of the raw and ready-to-eat retail food screened. In this study, 
the results showed that 10% of the isolates analyzed were MDR. 98% of isolates tested were 
resistant to ampicillin and 14% to tetracycline. Ciprofloxacin resistance was shown by 8% of 
the isolates, 7% were resistant to chloramphenicol, 6% to sulfamethoxazole-trimethoprim, 5% 
to amoxicillin-clavulanic acid, 2% to nalidixic acid, 1% to amikacin and 1% resistant to 
ceftriaxone. Although only 7% of the total isolates showed genetic virulence determinants, the 
finding of them could potentially be a public health hazard as they make resistance genes 



























The motivation for this doctoral thesis was based on the findings reported in 
previous theses (Herrera, 2015; Viso, 2017; Meniño, 2019) and research project 
AGL2013-47852-R, which indicated that  “food, especially poultry products, may act 
as an ESBL-producing ExPEC reservoir for humans”, and that “there has been a rapid 
dissemination of ESBL-producing strains associated with successful clonal groups such 
as the pandemic ST131 within different niches”. 
 
The HYPOTHESIS of the present thesis was that poultry meat would act as a 
reservoir, and potentially transmitter, of pathogenic strains that might be implicated in 
human UTI. To demonstrate this hypothesis, the STRATEGY was: 
 
a) To analyze retail poultry meat directly acquired at points of sale with the idea 
that the final product provides data on what is happening on the farm, at the 
slaughterhouse, and what goes into the consumer's kitchen. 
b) To identify potential uropathogenic clonal groups of E. coli based on specific 
genetic markers. 
c) To consider “high-risk” strain that with the capacity to develop a serious 
extraintestinal infection in humans, due to either its virulence potential and / or its 
antibiotic resistance. 
 
The specific OBJECTIVES were: 
 
1. To design an efficient protocol for the recovery of food-borne E. coli and other 
pathogenic and / or antimicrobial-resistant Enterobacteriaceae. 
 
2. To acquire knowledge on the current situation regarding AMR in poultry farming, 
paying special attention to antimicrobial categories A and B of EMA.  
 
3. To assess the consumer exposure, via poultry meat, to high-risk E. coli and other 
Enterobacteriaceae isolates with potential to develop severe infections by either 
bacterial virulence and / or antibiotic resistance traits. 
 
4. To explore the food transmission route of specific E. coli clones of human and animal 
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3. MATERIAL AND METHODS 
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3.1. BACTERIAL COLLECTIONS 
 
3.1.1. Control strains and conservation 
 
Positive and negative control strains from the LREC-USC collection were used in all 
phenotypic and genotypic tests (Table 9). The Enterobacteriaceae strains characterized in this 
study, as well as all the reference control strains, were preserved on nutrient agar with 0.75% 
(w / v) agar and were stored at room temperature in Vacutainer ™ tubes. Under these 
conditions, the strains maintain their viability for at least five years. For the preparation of the 
preservation medium, a mixture of nutrient agar (11.5 g / l) (Applichem-Panreac) and nutrient 
broth (4 g / l) (Applichem-Panreac) was used. 
 





FV14504 iutA, iucD, tsh, neuC-K1 
Daec II afa/draBC 
pap papEF 
FV10041 fimH, fimAvMT78, papEF, papG III, sfa/focDE, cnf1, hlyA, iroN, 
KpsM II, KpsM II-K2, neuC-K1, ibeA, malX, usp, uitA 
FV10042 fimH, papEF, cnf1, hlyA, iroN, KpsM II, KpsM II-K2, kpsM II-K5, 
neuC-K1, malX, usp 
FV14043 fimH, papEF, papG II, cdtB, sat, iroN, kpsM II, kpsM II-K2, kpsM 
II-K5, malX, usp 
FV10044 iutA, cvaC, iss, traT, tsh 
FV10045 afa/draBC, sat, iutA, traT 
FV14390 FV14391 fimH, fimAvMT78 
FV14067 ibeA 
FV12671 sfa/focDE, cdtB 
FV17090 afaFM 
FV17134 kpsM III 
FV 17132 hlyF, ompT, vat, yfcV, fyuA 
EPEC 
IH2859f eae, bfpA 
ETEC/VTEC 
FV15560 estB, k88, hlyA 
FV 15556 stx2/vt2, estA, estB ,f18, hlyA 
FV15568 stx2/vt2, f18, hlyA 
FV15525 estA, estB, p987 
FV15498 eltA , estB, k88, hlyA 
FV15553 estA, p987 
FV15567 estA, k99, f41 
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FV15528 estA, k99, f41 










FV 167 aatA 
Resistance 
FV9650 blaCTX-M, blaCTX-M group 9 
FV19247 blaSHV 
FV17090 blaCTX-M group 1, blaCTX‐M-15 end 3´ 
FV14390 blaTEM 
FV17811 LAT-1 a LAT-4, CMY-2 a CMY-7, BIL-1 
FV20151 mcr-1 
FV 21136 mcr-2 
FV 21074 mcr-4 
FV 21078 mcr-5 
FV 18691 colEX 
Phylogenetic group 
FV10042 chuA, yjaA, TSPE 
O157-1103 arpA, phylogroup E 
O and H antigens 
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3.1.2. Poultry meat Enterobacteriaceae collection  
 
In total, 358 different Enterobacteriaceae isolates were recovered from 100 poultry meat 
samples (170 isolates recovered from 50 chicken samples and 188 isolates recovered from 50 
turkey samples). Bacterial identification revealed that 323 out of 358 isolates were E. coli, 28 
K. pneumoniae, six Serratia fonticola and one Enterobacter cloacae. This collection was fully 
characterized as detailed in section Material and Methods, Results and in Table 41. 
 
3.1.3. EPEC O153 collection  
 
Collections obtained during the period of 2005 to 2015 from different surveillance studies 
performed at LREC, in Lugo, Spain, aimed the detection of ESBL-producing E. coli within 
different sources of our region. These studies included samples from chicken, beef and pork 
meat, as well as poultry farm environment and wildlife. 
 
On the other hand, human diarrheagenic E. coli isolates, mainly from the Hospital 
Universitario Lucus Augusti (HULA) of our city (Lugo, northwest Spain), were routinely 
screening in our laboratory for intestinal VF, and those positive, further analysed for 
extraintestinal traces and ESBL genes, as described below. 
 
The number of isolates, origin and period of isolation of the collections are detailed in 
Table 10. 
 
Table 10. Thirty-two isolates included in the study (in red) from our own collections. 
Origin of isolation 
Sampling 
period 
No. ESBL aEPEC O153 
isolates / total ESBL 
isolates a 
No. NON-ESBL 
aEPEC O153 isolatesb 
Chicken meat study 2009-2010 7 / 127 NA 
Beef meat 1st study 2005-2009 5 / DNA 2 
Beef meat 2nd study 2011-2012 1 / 5 NA 
Pork meat study 2011-2012 1 / 13 NA 
Poultry farm environment 2010-2012 1 / 96 NA 
Wildlife study 2014-2015 1 / 95 NA 
Human diarrhoea 2006-2012 5 / DNA 9 
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3.2. MEAT SAMPLING AND ENTEROBACTERIACEAE CHARACTERIZATION 
 
3.2.1. Sampling, screening and Enterobacteriaceae recovery  
 
Between September 2016 and September 2017, 100 poultry meat products were acquired 
in eight points of sale in the city of Lugo (northwest Spain), including six supermarket chains 
(Table 11). The meat products were transported in an isothermal container and processed within 
the next two hours after collection. Of the 100 meat samples, 50 were chicken breast (24 
packaged in a modified atmosphere and 26 freshly cut by the butcher at the moment of 
sampling), and another 50 were turkey meat (25 in modified atmosphere and 25 freshly cut). 
The lab method designed was oriented to investigate i) the microbiological quality of poultry 
meat based on E. coli counts and ii) the prevalence of pathogenic and AMR food-borne E. coli 
and other Enterobacteriaceae. For the latter (AMR and potential pathogens), the method was 
subdivided in six protocols (I to VI) based on a combination of selective media and incubation 
temperatures, whose bacterial growth was eventually screened by PCR for specific genetic 
targets. Through the characterization of the recovered isolates, the adequacy of each protocol 
was finally evaluated. 
 




Sampling date Meat type (no. of samples) 
Packaging system 
(C=chicken; T=turkey) 
a Points of sale 
1 05/09/2016 Chicken (10) 5 modified atmosphere 5 freshly cut A, B, C, D, E 
2 20/09/2016 Turkey (8) 4 modified atmosphere 4 freshly cut B, C, E, F, G 
3 19/10/2016 Chicken (2) 2 freshly cut H 
4 02/11/2016 Chicken (4) Turkey (4) 4 modified atmosphere (2 C + 2 T) 4 freshly cut (2 C + 2 T) C, D, E 
5 22/11/2016 Chicken (4) Turkey (4) 4 modified atmosphere (2 C + 2 T) 4 freshly cut (2 C + 2 T) A, B, C, G 
6 13/03/2017 Chicken (4) Turkey (4) 4 modified atmosphere (2 C + 2 T) 4 freshly cut (2 C + 2 T) B, C, E, G 
7 03/04/2017 Chicken (4) Turkey (4) 4 modified atmosphere (2 C + 2 T) 4 freshly cut (2 C + 2 T) B, C D, E, G 
8 24/04/2017 Chicken (4) Turkey (4) 4 modified atmosphere (2 C + 2 T) 4 freshly cut (2 C + 2 T) A, B, D, E 
9 22/05/2017 Chicken (4) Turkey (4) 4 modified atmosphere (2 C + 2 T) 4 freshly cut (2 C + 2 T) B, C, E, G 
10 08/06/2017 Chicken (4) Turkey (4) 4 modified atmosphere (2 C + 2 T) 4 freshly cut (2 C + 2 T) B, D, E, G 
11 27/06/2017 Chicken (4) Turkey (4) 4 modified atmosphere (2 C + 2 T) 4 freshly cut (2 C + 2 T) B, C, E, G 
12 04/09/2017 Chicken (6) Turkey (4) 5 modified atmosphere (3 C + 2 T) 5 freshly cut (3 C + 2 T) C, D, E 
13 18/09/2017 Turkey (6) 3 modified atmosphere 3 freshly cut D, E, B, C 
a Points of sale: A to F (supermarket chains); G, H (local retailers). 
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Briefly, 25 g of each meat sample were aseptically cut and homogenized (2 min in a 
stomacher) with 225 ml of Buffer Peptone Water (BPW; ApplyChem Panreac). From the 
homogenate, 1 ml was plated into a 3M Petrifilm™ Select E. coli, which was examined after 
incubation 24 h/44 ºC for the E. coli counts following manufacturer’s instructions. Then, the 
homogenized meat samples were incubated 6 h/37 ºC, from which 1 ml was inoculated in 
duplicate into 9 ml MacConkey Lactose broth (Oxoid) tubes, growth for 18-24 h at 37 ºC and 
44 ºC, respectively. Finally, different selective agar media (protocols I to VI) were inoculated 
from the MacConkey Lactose broth tubes (Figure 2). The protocols I to IV were meant for the 
detection of potentially pathogenic E. coli (carriers of diarrheagenic or extraintestinal virulence 
traits): protocol I. MacConkey Lactose agar (ML) (Oxoid), 18-24 h/37 ºC; protocol II. 
MacConkey Sorbitol agar enriched with tellurite and cefixime (MSTC) (Oxoid), 18-24 h/37 ºC; 
protocol III. ML, 18-24 h/44 ºC; protocol IV. MSTC, 18-24 h/44 ºC. Additionally, ESBL-
producing Enterobacteriaceae were screened by means of CHROMID® ESBL agar plates 
(bioMérieux) in protocol V, while the protocol VI screened carbapenemase-producing E. coli 
in CHROMID® CARBA SMART plates (bioMérieux).  
 
As shown in Figure 2, the confluent growth of plates I to IV and the pooled colonies 
recovered from I to VI and plated on Tryptone Soy Agar (TSA) (Oxoid) were analysed by PCR 
for specific virulence factors (VF) associated with the InPEC pathotypes EPEC (eae, bfpA), 
STEC (stx1, stx2, eae) and EAEC (aaiC, aggR). Likewise, specific VF linked to the pathogenic 
potential of extraintestinal pathogenic E. coli (ExPEC status) and uropathogenic E. coli (UPEC 
status) were tested (Table 28; Table 29). The ExPEC status was assigned to isolates positive for 
≥2 of these five markers (papAH, sfa/focDE, afa/draBC, kpsM II and iutA) (Johnson et al., 
2003c), while the UPEC status was assigned to isolates positive for ≥ 3 of these four markers 
(chuA, fyuA, vat and yfcV) (Spurbeck et al., 2012). For those isolates exhibiting ExPEC and / 
or UPEC status, other extraintestinal VF were analyzed to complete their characterization 
(Table 28; Table 29). The O25b subtype (rbfO25b) associated with the clonal group ST131 was 
also screened by PCR (Clermont et al., 2008) and positive isolates were confirmed by 
multilocus sequence typing (MLST). PCR amplification of the β-D-glucuronidase-encoding 
gene (uidA) was routinely used to specifically identify E. coli (Gómez-Duarte et al., 2010) 
(Table 28; Table 29). Additionally, isolates suspected of being E. coli but uidA negative, as well 
as other Enterobacteriaceae, were identified by MALDI-TOF MS (Bruker Daltonik, Bremen, 
Germany) in duplicated; a reliable result (at the species level) was only considered if the score 
obtained was higher than 2. All the isolates recovered in this study were stored at room 
temperature in nutrient broth (DifcoTM) with 0.75% nutrient agar (DifcoTM) for further 
characterization. 
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Figure 2. Lab workflow designed in this study to investigate the level of contamination, and the rates of 
AMR and food-borne pathogenic E. coli. Note: AMR: antimicrobial resistance; ML: MacConkey Lactose agar; MSTC: 
MacConkey Sorbitol agar enriched with tellurite and cefixime; TSA: tryptone soy agar; CFU: colony forming units; 
EPEC: enteropathogenic E. coli; STEC: Shiga toxin-producing E. coli; EAEC: enteroaggregative E. coli; ExPEC: 
extraintestinal pathogenic E. coli. From protocols V and VI, other Enterobacteriaceae were also investigated. 
 
 
3.1.2.1.Rapid detection of E. coli conforming ExPEC status in meat samples 
 
We designed a duplex PCR for a rapid and effective recovery of isolates with ExPEC status. 
Previous results indicated that >95% of the isolates present in meat and conforming ExPEC 
status were carriers of both iutA and KpsM II genes; furthermore, 100% of them were carriers 
of at least one of those genes (Herrera, 2015).  Using these targets, the duplex PCR amplifies a 
DAFNE DÍAZ JIMÉNEZ 
52 
fragment of 272 bp with the kpsII f and r primers described elsewhere for KpsM II (Johnson 
and Stell, 2000), and 441 bp of iutA. For the latter, we designed the new primer “iutA-Al f” 
5’GCCGGAGCTGTCTCCGGCGG 3´ within the locus tag "NRG857 30235” of iutA from the 
GenBank CP001856 genomic sequence, which was used with the previously aer-1152r primer 
described by Johnson et al. (Johnson et al., 1997) (Figure 3). For a 25 µl PCR reaction, the 
amplification mix includes 12,5 µl of NZYTaq 2x Green MasterMix (2,5 U), 0.6 µl of 20 µM 
of KpsM II primers, 1 µl of 20 µM of iutA primers, and 5 µl of sample DNA. The PCR 
conditions were validated with DNA pools of negative and positive isolates for one or both 
genes, as well as with individual colonies (Figure 3).  
 
 
Figure 3. Duplex PCR based on iutA (441 bp) and KpsM II (272 bp) targets and designed for the ExPEC 
screening on confluent growth, pooled and individual isolates. Note: Lines 1 and 11, positive control (+ +); line 
2, negative control (- -); lines 3 and 4, iutA carriers (+ -); lines 5 and 6, KpsM II carriers (- +); lines 7 and 8, iutA 
and KpsM II carriers (+ +) and lines 9 and 10, negative carriers (- -). PCR products were loaded on a 1.5% agarose 
gels with nzytech GreenSafe as stain. After electrophoresis, images were captured in an ultraviolet BioRad 
GelDoc. The thermal cycle included 35 cycles of amplification (denaturation 94°C, 1 min; annealing 60°C, 1 min; 
extension 72°C, 1.30 min).  
 
3.2.2. Phylogroups and clonotypes of E. coli 
 
The phylogenetic relatedness of the E. coli  population recovered from the poultry meat 
was determined by means of the phylogroup, sequence type (ST), clonotype (CH) and serotype 
assignment as described elsewhere (Díaz-Jiménez et al., 2020b). In brief, the Clermont method 
(Clermont et al., 2013, 2019) recognizes eight phylogroups (A, B1, B2, C, D, E, F, G) belonging 
to E. coli sensu stricto and also discriminates those belonging to Escherichia cryptic clades. 
The MLST was performed following Achtman’s scheme based on seven genes (adk, fumC, 
gyrB, icd, mdh, purA and recA) (Wirth et al., 2006) (Table 28; Table 29). The CHs were 
established based on the internal 469-nucleotide (nt) and 489-nt sequence of the fumC (allele 
obtained from MLST) and fimH genes, respectively (Weissman et al., 2012) (Table 28; Table 
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29). The isolates confirmed as ST131 were characterized for their virotypes according to the 
scheme defined by Dahbi et al. (Dahbi et al., 2014), based on the presence or absence of certain 
extraintestinal VF (afa/draBC, afa operon FM955459, iroN, sat, ibeA, papG II, papG III, cnf1, 
hlyA, cdtB, kpsM II-K1, -K2 and -K5) (Table 28; Table 29). The collection was also investigated 
by PCR for specific bla genes using the TEM, CIT, SHV, CTX-M-1 and CTX-M-9 group-
specific primers, and further sequencing, as well as for the mcr genes (1 to 5) as previously 
described (Díaz-Jiménez et al., 2020b) (Table 28; Table 29). 
 
 
3.2.3. O and H typing of E. coli 
 
O:H antigens of E. coli were determined following the method described by Guinée et al. 
(Guinée et al., 1981b) with O1 to O185 and H1 to H56 antisera, respectively. Isolates that did 
not react with any O antisera were classified as non-typeable (ONT), and non-motile isolates 
(HNM) were further analyzed by PCR for their flagellar genes (Mora et al., 2018) (Table 28). 
 
 
3.2.4. Antimicrobial susceptibility and genetic characterization of β-lactamase and 
mcr genes of Enterobacteriaceae isolates 
 
Antimicrobial susceptibility testing was conducted by disc diffusion assay and / or by the 
Microscan system (Beckman Coulter, CA, USA). The antibiotics tested included ampicillin 
(AMP), amoxicillin-clavulanic acid (AMC), ceftazidime (CAZ), cefotaxime (CTX), cefoxitin 
(FOX), aztreonam (ATM), imipenem (IMP), gentamicin (GEN), tobramycin (TOB), amikacin 
(AMK), fosfomycin (FOF), doxycycline (DOX), chloramphenicol (CHL), nitrofurantoin 
(NIT), sulfamethoxazole-trimethoprim (SXT), ciprofloxacin (CIP), nalidixic acid (NAL) and 
tigecycline (TGC). Furthermore, MICs for colistin (CST) were manually obtained by broth 
microdilution for those suspected colonies. All results were interpreted according to the CLSI 
guidelines  (The Clinical and Laboratory Standards Institute, 2020). Multidrug-resistant (MDR) 
isolates were defined according to Magiorakos et al. criteria, as those showing acquired non-
susceptibility to at least one agent in three or more antimicrobial categories (Magiorakos et al., 
2012). The collection was also investigated by PCR for screening of specific bla genes using 
the TEM, CIT, SHV, CTX-M-1 and CTX-M-9 group-specific primers, and further sequencing 
(Mora et al., 2013), as well as for the mcr genes (1 to 5) (Table 28). 
 
 
3.2.5. Screening of ST131 and virotypes 
 
The O25b subtype associated with the clonal group ST131 was screened by PCR (Clermont 
et al., 2008) within the E. coli collection (Table 28; Table 29). The isolates confirmed as 
O25b:H4-B2-ST31 were characterized for their virotypes according to the scheme defined by 
Dahbi et al. (Dahbi et al., 2014), based on the presence or absence of certain extraintestinal VF 
(afa/draBC, afa operon FM955459, iroN, sat, ibeA, papG II, papG III, cnf1, hlyA, cdtB, kpsM 
II-K1, -K2 and -K5). The assignment to the corresponding virotype is also detailed in Table 3 
of the introduction section. 
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3.2.6. K. pneumoniae characterization 
 
Those K. pneumoniae recovered from CHROMID® plates, and identified by MALDI-TOF 
MS, were further characterized for their STs following the Institute Pasteur MLST scheme 
(Diancourt et al., 2005) (Table 28). 
 
 
3.2.7. Pulsed field gel electrophoresis (PGFE) 
 
XbaI-PFGE profiles were performed following the PulseNet protocol 
(https://www.cdc.gov/pulsenet/participants/international/index.html), and imported into 
BioNumerics (Applied Maths, St-Martens-Latern Belgium) to obtain a dendrogram with the 
UPGMA algorithm based on the Dice similarity coefficient and applying 1% of tolerance in the 
band position.  
 
 
3.2.8. WGS of mcr-positive isolates 
 
Two isolates positive by PCR for the presence of mcr genes were further characterized by 
WGS. Genomic libraries were constructed using the Nextera XT DNA library preparation kit 
(Illumina) following the manufacturer’s instructions and sequenced on an Illumina HiSeq X 
with 150 bp x 2 read length. Quality control checks on the obtained raw sequence data was 
performed using FastQC version 0.11.3. Genome assembly was performed de novo using 
SPAdes 3.11 (Bankevich et al., 2012) and were in silico analyzed using the bioinformatics tools 
of the Center for Genomic Epidemiology (CGE) (https://cge.cbs.dtu.dk/services/) for the 
presence of antibiotic resistance (ResFinder V2.1.), virulence genes (VirulenceFinder v1.5.), 
plasmid replicon types (PlasmidFinder 1.3./PMLST 1.4.), and identification of clonotypes 
(CHTyper 1.0), sequence types (MLST 2.0) and serotypes (SerotypeFinder 2.0). All the CGE 
predictions were called applying a select threshold for identification and a minimum length of 
95% and 80%, respectively. Phylogroups were predicted using the ClermonTyping tool at the 
iame-research center web (http://clermontyping.iame-research.center/). 
 
 
3.2.9. WGS of EPEC O153 isolates 
 
DNA from 17 isolates was extracted with the QIAamp 96 DNA Qiacube HT kit (Qiagen, 
Hilden, Germany) and libraries were prepared using the Nextera XT kit (Illumina). Pooled 
libraries were denatured following the Illumina protocol and 600 μl (approx. 20 pM) were 
loaded onto a MisSeq V2 -500 cycle cartridge (Illumina) and sequenced on a MiSeq to produces 
fastq files. Raw reads were uploaded and automatically assembled in EnteroBase using SPAdes 
Genome Assembler v 3.5. with a contig threshold of minimum 200 nucleotides. Subsequently, 
the de novo assembled contigs were MLST (7 gene Achtman ST scheme, whole genome MLST, 
core genome MLST and ribosomal MLST) and serotyped in silico using EnteroBase typing 
tools (Alikhan et al., 2018). The raw reads were also analyzed using the CGE databases: 
SerotypeFinder⁠, MLSTtyper⁠, CHtyper⁠, PlasmidFinder, ResFinder, and VirulenceFinder 
(Camacho et al., 2009; Larsen et al., 2012; Zankari et al., 2012; Carattoli et al., 2014; Joensen 
et al., 2015). For genomic relatedness comparison, we used different approaches based on the 
cgMLST of EnteroBase. Thus, a MSTree was inferred using the MSTree V2 algorithm and the 
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asymmetric distance matrix based on the cgMLST scheme from EnteroBase. This cgMLST 
scheme consists of 2,513 genes present in over 98% of 3,457 genomes, which represented most 
of the diversity in EnteroBase https://enterobase.readthedocs.io/en/latest/pipelines/escherichia-
statistics.html. We also investigated the HierCC designations for our collection and other 
related genomes of EnteroBase within each cluster group (Zhou et al., 2017; Alikhan et al., 
2018). The SNP tree was also built in EnteroBase, where all assemblies were aligned against 
LREC-113 using Last (Hamada et al., 2011), and SNPs from these alignments were filtered to 
remove regions with low base qualities or ambiguous alignment. Specifically, any sites with 
low base qualities (Q < 10) or sites which could not be aligned unambiguously (ambiguity of 
alignment ≥ 0.1, as reported by Last) were excluded. Additionally sites were removed if 
disperse repetitive regions were aligned with ≥ 95% identities and longer than ≥ 100 bps 
according to nucleotide BLAST; or they were part of tandem repeats that were identified by 
TRF (Benson, 1999); or within CRISPR regions, which were identified by PILER-CR (Edgar, 
2007). After removing repetitive regions, all core SNPs were then called in the core genomic 
regions that were conserved in ≥ 90% of the genomes. 
 
 
3.2.10. Statistical analysis  
 
Differences within groups were analyzed by a two-tailed Fisher’s exact test. P values < 
























4.1. STUDY 1: CHICKEN AND TURKEY MEAT: CONSUMER EXPOSURE TO MULTIDRUG-
RESISTANT Enterobacteriaceae INCLUDING MCR-CARRIERS, UROPATHOGENIC E. coli 
AND HIGH-RISK LINEAGES SUCH AS ST131 
 
We aimed to design a protocol applicable in the routine of food microbiological 
laboratories to evaluate consumer exposure to antibiotic-resistant and / or potentially 
pathogenic Enterobacteriaceae. Thus, we assessed a reduced protocol based on the recovery of 
one representative E. coli isolate per sample and the recovery of ESBL/Carbapenemase-
producing Enterobacteriaceae in chromogenic media.    
 
4.1.1. Representative E. coli isolate per sample recovered from Lactose MacConkey 
agar (ML) 
 
Of the 100 meat samples analyzed, 84% were positive for the presence of E. coli growth in 
ML (86% of the chicken and 82% of the turkey samples). From those positive, 84 representative 
E. coli (one colony per sample) were collected and characterized for their phylogroups, STs, 
clonotypes, serotypes, blaESBL genes, resistance profiles, ExPEC/UPEC status and VF 
associated with EPEC, STEC and EAEC (Table 12). As a result, most isolates belonged to 
phylogroups B1 (25 isolates; 29.8%) and A (24; 28.6%); however, the other five phylogroups 
of E. coli sensu stricto were also present, without differences regarding the type of meat 
(chicken or turkey): C (15; 17.9%), F (8; 9.5%), E (6; 7.1%), B2 (5; 6%) and D (1; 1.2%) 
(Figure 15).  
 
The analysis by MLST showed 41 different STs (Figure 4), including three new (STnew1, 
STnew2, and ST117-like with one single nucleotide of difference in fumC45). Despite this 
diversity, eight STs accounted for 52.4% of the isolates: ST10-A (eight isolates); ST23-C, 
ST58-B1 (seven isolates each); ST162-B1 (six isolates); ST410-C (five isolates); ST38-E, 
ST1485-F (four isolates each) and ST744-A (three isolates) (Table 30). Clonotyping also 
showed high heterogeneity, with 23 different fimH alleles (seven isolates were negative for the 
amplification of the 489-nt internal sequence) and 39 fumC-fimH combinations, but 51.2% of 
the isolates showed any of the following seven clonotypes: CH11-54 (13 isolates of the CC10-
A); CH4-35 (seven ST23-C); CH4-32 (six CC155-B1), CH65-32 (four ST162-B1 and two 
ST3580-B1 isolates), CH26-65 (four ST38-E), CH231-58 (four ST1485-F) and CH4-24 (three 
ST410-C) (Table 30). Regarding the serotyping, only three O:H combinations were detected in 
more than two isolates belonging to the clonal groups O78:HNM-C-ST23 (three isolates), 
O83:H42-F-ST1485 (three isolates), ONT:H7-B1-ST3580 and ONT:H7-A- ST5826 (two and 
one isolate, respectively) (Table 12). 
 








4Serotype 5PG 6ST 7Clonotype 8MDR 9Phenotypic resistance 
10ESBL  
and mcr  
Ch-15-R - - O84:HNM A 10 11-54 + AMP, GEN, DOX, CIP, NAL  
Ch-17-R - - O64:HNT A 10 11-54 + AMP, CAZ, ATM, DOX, CHL, 
CIP, NAL 
SHV-12 
Ch-18-R - - O132:HNM A 10 11-54 - -  
Ch-25-R - - O140:HNM A 10 11-54 - DOX  
Ch-29-R - - O113:H4 A 10 11-24 - GEN, TOB, CIP, NAL  








4Serotype 5PG 6ST 7Clonotype 8MDR 9Phenotypic resistance 
10ESBL  
and mcr  
Ch-36-R* - - O153:H10 A 10 11-54 + AMP, DOX, CHL, CIP, NAL  
T-2-R - - O16:HNM A 10 11-54 - AMP, SXT  
T-16-R - - O18:H25 A 10 11-54 + AMP, CHL, CIP, NAL  
T-32-R - - O6:H10 A 43 11-54 - AMP  
T-24-R - - O20:HNM A 48 11-neg - AMP, SXT  
T-44-R - - O176:H11 A 48 11-neg - AMP, NAL  
T-35-R - - O7:H4 A 93 11-41 + AMP, DOX, CHL, SXT, CIP, 
NAL 
 
T-29-R - - O101:HNM A 744 11-54 + AMP, DOX, CHL, CIP, NAL  
T-31-R - - O101:HNM A 744 11-54 + AMP, DOX, CHL, SXT, CIP, 
NAL 
 
T-39-R - - O101:H9 A 744 11-54 + AMP, DOX, CHL, SXT, CIP, 
NAL 
 
Ch-40-R* - - O145:H40 A 752 11-24 - AMP, NAL  
T-17-R - - O162/O89:H37 A 853 11-54 + AMP, CST, SXT mcr-1 
Ch-4-R - - O8:H10 A 2705 11-23 + AMP, DOX, CHL  
Ch-26-R - - O101:H9 A 5507 11-54 + AMP, AMC, DOX, NAL  
Ch-31-R - - ONT:H7 A 5826 4-60 - AMP  
Ch-3-R - - O40:HNM A 7199 7-neg - AMP  
T-45-R - - O33-HNM A 7315 11-398 + 
AMP, GEN, TOB, CHL, CIP, 
NAL  
Ch-28 - - O88:HNT A new1 153-39 + AMP, AMC, DOX, CIP, NAL  
T-12-R - - ONT:HNM A new2 11-neg + AMP, CHL, SXT, CIP, NAL  
T-6-R - - ONT:H4 B1 58 4-32 - SXT  
T-18-R - - O9:HNM B1 58 4-32 + AMP, GEN, CIP  
T-25-R - - O8:HNM B1 58 4-32 - AMP, CIP  
T-26-R - - O9:H12 B1 58 4-27 - AMP  
T-27-R - - O48:H30 B1 58 4-neg + AMP, CHL, SXT  
T-34-R - - O8:HNT B1 58 4-32 + AMP, SXT, CIP, NAL  
T-36-R - - O8:H25 B1 58 4-32 + AMP, DOX, SXT, CIP, NAL  
Ch-21-R - - O88:H8 B1 101 41-86 - -  
Ch-49-R - - O103:H21 B1 101 41-86 - AMP  
T-13-R - - O29:H9 B1 155 4-32 - AMP, CIP, NAL  
T-43-R - - O64HNM B1 155 4-neg + AMP, AMC, CAZ, ATM SHV-12 
Ch-8-R - - O109:HNT B1 162 65-32 + AMP, DOX, SXT, CIP, NAL  
Ch-14-R - - O88:H10 B1 162 65-32 - CIP, NAL  
Ch-32-R - - O8:H19 B1 162 65-27 + AMP, GEN, TOB, NAL  
Ch-33-R - - O8:H19 B1 162 65-38 - AMP, NAL  
T-5-R - - O9:HNM B1 162 65-32 + AMP, DOX, CIP, NAL  
T-11-R - - O9:H19 B1 162 65-32 - SXT, CIP, NAL  









4Serotype 5PG 6ST 7Clonotype 8MDR 9Phenotypic resistance 
10ESBL  
and mcr  
T-21-R - - O149:H45 B1 297 65-38 - AMP  
T-7-R - - O9:H53 B1 345 4-31 - AMP, CIP, NAL  
T-9-R - - O29:H10 B1 1720 270-54 + AMP, DOX, SXT  
Ch-43-R - - O7:HNT B1 1730 69-32 - AMP, CHL  
T-3-R - - ONT:H2 B1 2599 6-32 + AMP, SXT, CIP, NAL  
T-8-R - - ONT:H7 B1 3580 65-32 - AMP, GEN  
T-38-R - - ONT:H7 B1 3580 65-32 - -  
T-22-R + + O1:H7 B2 95 38-30 - AMP, NAL  
Ch-2-R + + O25:H4 B2 131 40-22 + GEN, DOX, NAL  
Ch-13-R + + O25:H4 B2 131 40-22 + GEN, DOX, NAL  
Ch-19-R + + O120:H4 B2 428 40-neg - AMP, SXT  
T-14-R + + O120:H4 B2 428 40-22 - AMP, SXT  
Ch-1-R - - O78:H9 C 23 4-35 - DOX, NAL  
Ch-5-R - - O78:HNM C 23 4-35 - NAL  
Ch-7-R - - O78:HNM C 23 4-35 - NAL  
Ch-20-R - - O15:HNT C 23 4-35 + AMP, TOB, DOX, SXT, CIP, 
NAL 
 
Ch-37-R - - O78:HNM C 23 4-35 - AMP, NAL  
Ch-45-R - - O60:H9 C 23 4-35 - AMP  
Ch-48-R - - O8:H9 C 23 4-35 - AMP, CHL  
T-4-R - - O8:H4 C 88 4-39 + AMP, GEN, SXT, CIP, NAL  
Ch-10-R - - O159:H16 C 295 4-38 - AMP, NAL  
Ch-42-R - - O162:H42 C 295 4-38 - AMP, NAL  
T-15-R - - O86:H9 C 410 4-24 + AMP, DOX, CIP, NAL  
T-19-R - - O86:H9 C 410 4-24 - AMP, CIP, NAL  
T-41-R - - O20:HNT C 410 4-24 - AMP, CIP, NAL  
T-42-R - - O60:HNT C 410 4-53 - AMP, DOX  
T-46-R - - O19:HNT C 410 4-45 - AMP, CIP, NAL  
Ch-24-R + - O73:HNT D 4243 3-1002 - GEN, NAL  
Ch-23-R - - O123:H15 E 38 26-65 - NAL  
Ch-46-R - - O7:H15 E 38 26-65 - AMP, GEN, TOB  
Ch-50-R - - O99:H15 E 38 26-65 + AMP, DOX, SXT, NAL  
T-33-R - - O7:H15 E 38 26-65 - AMP, DOX  
T-30-R - - ONT:H25 E 57 31-27 - -  
Ch-34 - - O45:HNM E 371 31-142 - GEN, NAL  
Ch-35-R - - O143:H4 F 117 45-97 - AMP  
Ch-47-R - + O53:HNM F 117-like new - 97 + AMP, GEN, DOX, NAL  
Ch-16-R + + O11:H25 F 457 88-145 - GEN, DOX  
Ch-6-R + + O15:H42 F 1485 231-58 + AMP, AMC, GEN, TOB, SXT, 
CIP, NAL 
 








4Serotype 5PG 6ST 7Clonotype 8MDR 9Phenotypic resistance 
10ESBL  
and mcr  
Ch-9-R + + O83:H42 F 1485 231-58 + AMP, GEN, SXT, NAL  
Ch-38-R + + O83:H42 F 1485 231-58 + AMP, SXT, CIP, NAL  
T-20-R + + O83:H42 F 1485 231-58 + AMP, SXT, CIP, NAL  
T-40-R - + O8:HNM F 5340 271-58 - AMP, SXT  
1Origin of isolation-sample number-type of isolate: Ch (chicken meat), T (turkey meat), R (representative E. coli). *Isolates 
Ch-36-R and Ch-40-R showed a hybrid pathotype aEPEC/ExPEC, being both carriers of eae-beta1 and extraintestinal 
pathogenic genes. 2ExPEC status +: E. coli  strains considered with higher capacity of developing extraintestinal 
pathologies when positive for two or more of five markers, including papAH and / or papC, sfa/focDE, afa/draBC, kpsM 
II and iutA; ExPEC -: strains negative for those markers (Johnson et al., 2003b). 3UPEC status +: strains considered with 
higher capacity of developing UTI pathologies when positive for three or more of four markers, including chuA, fyuA, vat 
and yfcV; UPEC -: strains negative for those markers (Spurbeck et al., 2012). 4O antigen: non-typeable isolates were 
designated as ONT; H antigen: HNM for non-motile isolates and HNT for those which did not react with any antisera. 
5Phylogroup (PG) was designated by PCR according to Clermont scheme (Clermont et al., 2013). 6Sequence type (ST) was 
performed following the Achtman scheme (Wirth et al., 2006). 7Clonotype based on the internal 469-nucleotide (nt) and 
489-nt sequence of the fumC (allele obtained from MLST) and fimH genes, respectively (Weissman et al., 2012). Seven 
isolates were negative (neg) for the amplification of the 489-nt internal sequence. 8Multidrug-resistance (MDR) +: resistant 
to at least 1 agent of ≥ 3 different antimicrobial categories as defined by Magiorakos (Magiorakos et al., 2012). 9Phenotypic 
resistance interpreted according to the CLSI standard guidelines: ampicillin (AMP), amoxicillin-clavulanic acid (AMC), 
ceftazidime (CAZ), cefotaxime (CTX), cefoxitin (FOX), aztreonam (ATM), imipenem (IMP), gentamicin (GEN), tobramycin 
(TOB), amikacin (AMK), fosfomycin (FOF), doxycycline (DOX), chloramphenicol (CHL), nitrofurantoin (NIT), 
sulfamethoxazole-trimethoprim (SXT), ciprofloxacin (CIP), nalidixic acid (NAL), tigecycline (TGC) and colistin (CST).  
10blaESBL and mcr typing. The collection was also investigated by PCR for specific mcr (1 to 5) and bla genes using the TEM, 
CIT, SHV, CTX-M-1 and CTX-M-9 group-specific primers, followed by amplicon sequencing for those positive. 
 
Of the 84 representative E. coli  isolates, 36 (42.9%) showed resistance to at least one agent 
of ≥ three different antimicrobial categories and were defined as MDR (Magiorakos et al., 
2012). Moreover, only the isolates from four samples showed susceptibility to the 19 antibiotics 
tested. The highest rates of resistance were to AMP (78.6%), NAL (60.7%), CIP (39.3%), SXT 
(31.0%), DOX (29.8%) and GEN (19.0%), being of note that the isolates recovered from turkey 
meat showed higher values compared to those of chicken for AMP (90.2% vs 67.4%; P = 0.016), 
CIP (53.7% vs 25.6%; P = 0.013) and SXT (43.9% vs 18.6%; P = 0.018) (Table 13). The 
screening and typing of blaESBL and mcr genes determined that two ceftazidime-resistant 
isolates (one from chicken and one from turkey meat) were SHV-12, and one colistin-resistant 
E. coli recovered from turkey was mcr-1 (Table 12). 
 
Table 13. Phenotypic resistances of the 256 isolates recovered from the 100 meat samples 
Antibiotics 
tested 















































AMC 4 (9.3) 1 (2.4) 5 (6.0) 4 (6.3) 6 (8.2) 10 (7.3) 8 (11.3) 7 (6.9) 15 (8.7) AMC 
CAZ 1 (2.3) 1 (2.4) 2 (2.4) 36 (56.3) 51 (69.9) 87 (63.5) 37 (52.1) 58 (57.4) 95 (55.2) CAZ 
CTX 0 0 0 43 (67.2) 42 (57.5) 85 (62.0) 50 (70.4) 70 (69.3) 
120 
(69.8) CTX 
FOX 0 0 0 1 (1.6) 0 1 (0.7) 2 (2.8) 1 (1.0) 3 (1.7) FOX 
ATM 1 (2.3) 1 (2.4) 2 (2.4) 43 (67.2) 57 (78.1) 100 
(73.0) 
44 (62.0) 66 (65.3) 110 
(63.9) 
ATM 





(27.9) 4 (9.8) 
16 
(19.0) 10 (15.6) 5 (6.8) 15 (10.9) 11 (15.5) 12 (11.9) 23 (13.4) GEN 
TOB 5 (11.6) 1 (2.4) 6 (7.1) 4 (6.3) 4 (5.5) 8 (5.8) 5 (7.0) 15 (14.8) 20 (11.6) TOB 
AMK 0 0 0 0 0 0 0 0 0 AMK 
FOF 0 0 0 0 0 0 0 1 (1.0) 1 (0.6) FOF 







26 (40.6) 45 (61.6) 71 (51.8) 29 (40.8) 64 (63.4) 93 (54.1) DOX 
CHL 5 (11.6) 8 (19.5) 13 
(15.5) 
22 (34.4) 40 (54.8) 62 (45.3) 24 (33.8) 47 (46.5) 71 (41.3) CHL 
NIT 0 0 0 1 (1.6) 1 (1.4) 2 (1.5) 2 (2.8) 7 (6.9) 9 (5.2) NIT 




















(60.7) 46 (71.9) 54 (74.0) 
100 
(73.0) 49 (69.0) 76 (75.2) 
125 
(72.7) NAL 



















Antimicrobial susceptibility tested by disc difussion assay and interpreted according to the CLSI standard breakpoints (CLSI, 
2019): ampicillin (AMP), amoxicillin-clavulanic acid (AMC), ceftazidime (CAZ), cefotaxime (CTX), cefoxitin (FOX), aztreonam 
(ATM), imipenem (IMP), gentamicin (GEN), tobramycin (TOB), amikacin (AMK), fosfomycin (FOF), colistin (CST), doxycycline 
(DOX), chloramphenicol (CHL), nitrofurantoin (NIT), sulfamethoxazole-trimethoprim (SXT), ciprofloxacin (CIP), nalidixic acid 
(NAL) and tigecycline (TGC). Highlighted in blue the statistically significant values (P values < 0.05), and in red the highest 
rates of prevalence. 
 
The screening of VF associated with diarrheagenic and extraintestinal pathotypes of E. coli 
determined that 11 out of the 84 representative E. coli (13.1%) satisfied the status ExPEC, and 
12 isolates (14.3%) the status UPEC (the late comprised 10 of those conforming also the ExPEC 
status). The 12 isolates positive for the UPEC status belonged to the B2 and F phylogroups, and 
seven exhibited STs associated with high-risk clonal groups (ST131-B2, ST95-B2, CC648-F) 
(Table 12; Table 14). None of the 84 isolates was positive for the presence of the diarrheagenic 
genes bfpA, stx1, stx2 aaiC, or aggR. However, two E. coli isolates characterized as O153:H10-
A-ST10 (CH11-54) and O145:H40-A-ST752 (CH11-24) exhibited a hybrid atypical 
EPEC/ExPEC pathotype, since both were carriers of the intimin-encoding gene eae-beta1 as 
well as of extraintestinal VF (Table 31). 
 




Figure 4. Representative E. coli collection. Phylogenetic tree based on concatenated sequences of the seven 
housekeeping genes from the MLST Achtman scheme by the Neighbor-Joining method using MEGA6. The optimal 
tree with the sum of branch length = 0.13442852 is shown. The percentage of replicate trees in which the 
associated taxa clustered together in the bootstrap test (1000 replicates) are shown next to the branches 
(Felsenstein, 1985). The tree is drawn to scale, with branch lengths in the same units as those of the 
evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using 
the p-distance method (Nei and Kumar, 2000) and are in the units of the number of base differences per site. 
The analysis involved 41 nucleotide sequences determined within the 84 representative E. coli. All positions 
containing gaps and missing data were eliminated. Highlighted in red those STs of E. coli associated with 




Table 14. Phenotypic and genotypic characterization of the 18 E. coli conforming UPEC status: 12 from the representative collection (“R” code) plus six recovered from 
CHROMID® (“ESBL” code) 
1Isolate 
code 
2Serotype 3PG 4ST 5CH 6ESBL 7Resistances 8Virulence-gene profile 
T-24-ESBL O50/O2:H6 B2 141 52-14 SHV-12 AMP, CAZ, ATM, DOX, CHL fimH14 hlyF iucD iutA iroN kpsM II-K1 cvaC traT ibeA malX usp  tsh  ompT iss chuA vat fyuA yfcV 
T-40-ESBL O113:H5 B2 8611 24-26 SHV-12 AMP, CAZ, ATM, DOX, CHL, NAL fimH26 iroN traT malX usp ompT chuA vat fyuA yfcV 
T-48-ESBL O115:HNM B2 919 24-187 SHV-12 AMP, CAZ, CTX, ATM, SXT, NAL fimH187 iucD iutA iroN traT ibeA malX hlyF ompT iss chuA vat fyuA yfcV 
Ch-2-R O25:H4 B2 131 40-22 - GEN, DOX, NAL fimH22 iucD iutA iroN kpsM II-K1 traT ibeA malX usp tsh ompT iss chuA fyuA yfcV 
Ch-13-R O25:H4 B2 131 40-22 - GEN, DOX, NAL fimH22 hlyF iucD iutA iroN kpsM II-K1traT ibeA malX usp tsh ompT iss chuA fyuA yfcV 
Ch-19-R O120:H4 B2 428 40-neg - AMP, SXT fimH fimAvMT78 hlyF iucD iutA iroN kpsM II-K1 cvaC traT ibeA malX usp ompT iss chuA vat fyuA yfcV 
T-14-R O120:H4 B2 428 40-22 - AMP, SXT fimH22 hlyF iucD iutA iroN kpsM II-K1 cvaC traT ibeA malX usp ompT iss chuA vat fyuA yfcV 
T-22-R O1:H7 B2 95 38-30 - AMP, NAL fimH30 hlyF papAH papaEF papC papG II cdtB iucD iutA iroN kpsM II-K1 cvaC traT malX usp ompT iss chuA vat fyuA yfcV 
Ch-1-ESBL O24:H18 F 117 45-151 SHV-12 AMP, CAZ, ATM, DOX, CHL, CIP, NAL fimH151 cdtB hlyF iucD iutA traT malX ompT chuA vat fyuA 
Ch-43-ESBL O57:HNM F 117 45-97 SHV-12 AMP, CAZ, ATM, DOX, CHL fimH97 cdtB iucD iutA iroN traT malX tsh ompT iss chuA vat fyuA 
T-9-ESBL O118:H4 F 117 45-97 SHV-12 AMP, CAZ, CTX, ATM, DOX, CHL fimH97 cdtB iucD iutA iroN traT malX tsh ompT iss chuA vat fyuA 
Ch-6-R O15:H42 F 1485 231-58 - AMP, AMC, GEN, TOB, SXT, CIP, NAL fimH58 hlyF iucD iutA iroN kpsM II-K5 cvaC traT malX tsh ompT iss chuA vat yfcV 
Ch-9-R O83:H42 F 1485 231-58 - AMP, GEN, SXT, NAL fimH58 hlyF iucD iutA iroN kpsM II-K5 cvaC traT malX tsh ompT iss chuA vat yfcV 
Ch-16-R O11:H25 F 457 88-145 - GEN, DOX fimH145 hlyF iucD iutA iroN kpsM II-K2 cvaC traT malX tsh ompT iss chuA vat fyuA yfcV 
Ch-38-R O83:H42 F 1485 231-58 - AMP, SXT, CIP, NAL fimH58 hlyF iucD iutA iroN kpsM II-K5 cvaC traT malX tsh ompT iss chuA vat yfcV 
Ch-47-R O53:HNM F 117-like new - 97 - AMP, GEN, DOX, NAL fimH97 hlyF iucD iutA iroN traT malX tsh ompT iss chuA vat fyuA 
T-20-R O83:H42 F 1485 231-58 - AMP, SXT, CIP, NAL fimH58 hlyF iucD iutA iroN kpsM II-K5 cvaC traT malX tsh ompT iss chuA vat yfcV 
T-40-R O8:HNM F 5340 271-58 - AMP, SXT fimH58 hlyF iucD iutA iroN cvaC traT malX tsh iss chuA vat yfcV 
1Origin of isolation-sample number-type of isolate: Ch (chicken meat), T (turkey meat), R (representative E. coli), ESBL (ESBL-producing E. coli). 2H antigen: HNM for non-motile 
isolates. 3Phylogroup (PG) was designated by PCR according to Clermont scheme (Clermont et al., 2013). 4Sequence type (ST) was performed following the Achtman scheme (Wirth 
et al., 2006). 5Clonotype based on the internal 469-nucleotide (nt) and 489-nt sequence of the fumC (allele obtained from MLST) and fimH genes, respectively (Weissman et al., 
2012): neg when PCR was negative for the 489-nt internal sequence amplification. 6blaESBL typing (Garcia-Meniño et al., 2018).  7Phenotypic resistance interpreted according to the 
CLSI guidelines (CLSI, 2019): ampicillin (AMP), ceftazidime (CAZ), cefotaxime (CTX), aztreonam (ATM), gentamicin (GEN), tobramycin (TOB), doxycycline (DOX), chloramphenicol 
(CHL), sulfamethoxazole-trimethoprim (SXT), ciprofloxacin (CIP), nalidixic acid (NAL). 8Specific extraintestinal VF (Johnson et al., 2003; Spurbeck et al., 2012). 
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4.1.2. ESBL-producing Enterobacteriaceae recovered from CHROMID® ESBL 
 
While none carbapenemase-producing colony was recovered from the 
CHROMID®CARBA SMART medium, 82% of the 100 meat samples (40 of chicken 
and 42 of turkey) were positive in CHROMID® ESBL. From those 82 samples, 172 
different ESBL-producing isolates (71 of chicken and 101 of turkey) were recovered and 
identified as Escherichia coli (137 isolates), Klebsiella pneumoniae (28 isolates), Serratia 
fonticola (six isolates) and Enterobacter cloacae (one isolate). Significantly, we found 
that 23 of the 50 turkey meat samples versus five of 50 chicken meat carried more than 
one ESBL-producing species (46% vs 10%; P = 0.00) (Figures 16a and 16b). All but one 
of the 172 ESBL-producing Enterobacteriaceae were MDR, showing the highest rates of 
resistance to AMP (100%), NAL (72.7%), CTX (69.8%), ATM (63.9%), CIP (63.4%), 
CAZ (55.2%), DOX (54.1%), CHL (41.3%) and SXT (36.6%). ESBL-producing isolates 
obtained from turkey were significantly more resistant to DOX (63.4% vs 40.8%; P = 
0.005), SXT (49.5% vs 18.3%; P = 0.000), CIP (73.3% vs 49.3%; P = 0.002) and TGC 
(17.8% vs 2.8%; P = 0.003) (Table 13). Nineteen isolates showed resistance to colistin: 
11 K. pneumoniae, two E. coli (MICs >4 mg/L) (Table 32), and the intrinsically resistant 
S. fonticola (six isolates). 
 
4.1.2.1. ESBL-producing E. coli recovered from CHROMID® ESBL 
E. coli represented 80% of the 172 ESBL-producing Enterobacteriaceae recovered 
by means of the CHROMID® ESBL (Figure 16b). The 137 ESBL-producing E. coli (64 
isolates of chicken and 73 of turkey) from 76 meat samples (38 chicken and 38 turkey) 
showed a similar phylogroup distribution to that found within the representative E. coli 
collection obtained from ML. Thus, most isolates belonged to the phylogroups A (55 
isolates; 40.1%) and B1 (40; 29.2%), but there was also presence of phylogroups E (18; 
13.1%), F (10; 7.3%), C (4; 2.9%), B2 (3; 2.2%) and D (2; 1.4%). Interestingly, five 
isolates (5; 3.6%) belonged to Clade I (Figure 5). By MLST, the ESBL-producing E. coli 
showed high heterogeneity with 51different STs, including five new: STnew3 (related 
with the ST665-A), STnew4 (related with the ST350-E), STnew5 (related with the 
ST906-B1), STnew6 and STnew7 (Table 33). In fact, only seven STs (ST10-A, ST93-A, 
ST117-F, ST155-B1, ST354-F, ST602-B1 and ST770-Clade I) were found in ≥ three 
isolates. Sixteen of the 51 STs were also present within the representative E. coli 
collection (Figure 5). Accordingly, clonotyping also showed high diversity with 46 fumC-
fimH different combinations, of which only six were determined in ≥ three isolates: CH4-
32 (seven isolates of the CC155-B1), CH11-54 (ten CC10-A), CH19-86 (three ST602-
B1), CH31-54 (three CC350-E), CH45-97 (six ST117-F) and CH116-552 (five ST770-
Clade I) (Table 33). ESBL-typing determined that 68.6% of the 137 E. coli produced 
SHV (93 isolates SHV-12 and one SHV-2), 27% CTX-M (14 isolates CTX-M-1, nine 
CTX-M-32, six CTX-M-14, five CTX-M-15 and three CTX-M-9), and 4.4% showed type 
TEM-52. All but one chicken isolate were MDR, showing the highest rates of resistance 
to AMP (100%), NAL and ATM (73.0%), CAZ (63.5%), CTX (62.0%), CIP (59.8%), 
DOX (51.8%), CHL (45.3%). ESBL-producing E. coli from turkey were significantly 
more resistant to DOX (61.6% vs 40.6%; P = 0.023), CHL (54.8% vs 34.4%; P = 0.025); 
SXT (38.4% vs 17.2%; P = 0.008) and CIP (68.5% vs 50.0%; P = 0.036) (Table 13). Of 
note that one SHV-12 colistin-resistant E. coli recovered from turkey was positive for the 
mcr-1 gene. The screening of VF determined that 18 out of the 137 ESBL-E. coli (13.1%) 
satisfied the status ExPEC, including isolates of phylogroups A, B1, B2, D, E, F and the 
five isolates of Clade I. Besides, six isolates (4.4%) conformed the UPEC status and 
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included risk clonal groups such as ST141-B2 and ST117-F (Table 12). Interestingly, two 
E. coli isolates from the ESBL-producing collection, recovered from different samples, 
also exhibited a hybrid atypical EPEC/ExPEC pathotype, being carriers of eae-beta1 and 
extraintestinal VF: O153:H10-A-ST10 (CH11-54), CTX-M-32, and O123/186:H34-A-
ST752 (CH11-24), CTX-M-1 (Table 31). 
 
 
Figure 5. ESBL-producing E. coli collection. Phylogenetic tree based on concatenated sequences of 
the seven housekeeping genes from the MLST Achtman scheme by the Neighbor-Joining method using 
MEGA6. The optimal tree with the sum of branch length = 0.15093159 is shown. The percentage of 
replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) 
are shown next to the branches (Felsenstein, 1985). The tree is drawn to scale, with branch lengths in 
the same units as those of the evolutionary distances used to infer the phylogenetic tree. The 
evolutionary distances were computed using the p-distance method (Nei and Kumar, 2000) and are in 
the units of the number of base differences per site. The analysis involved 51 nucleotide sequences 
determined within the 137 ESBL-producing E. coli collection. All positions containing gaps and missing 
data were eliminated. There was a total of 3414 positions in the final dataset. Highlighted in red those 
STs of E. coli associated with human extraintestinal and / or uropathogenic pathologies. 
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4.1.2.2. ESBL-producing K. pneumoniae recovered from CHROMID® 
ESBL 
Twenty-eight K. pneumoniae were recovered from 27 different samples, representing 
16% of the ESBL-producing isolates (Figure 16b). Significantly, only two isolates were 
from chicken meat compared to 26 isolates from turkey. All isolates were MDR, with the 
highest rates of resistances to AMP and CTX (100%), CIP (89.3%), SXT and NAL 
(82.1%), DOX (67.9%), TGC (62.3%), TOB (42.9%), CST (39.3%), ATM (35.7%), CAZ 
(28.6%). The ESBL typing revealed that 13 isolates were CTX-M-15, and eight of those 
also positive for SHV-28. All isolates were negative by PCR for the presence of mcr-1 to 
mcr-5 genes, including eleven phenotypically resistant to colistin (Table 32). The 28 K. 
pneumoniae were further characterized by MLST and PFGE as shown in Figure 6. Eleven 
different STs were established, being the most prevalent: ST307 (seven isolates), ST147 
(four isolates), the new assignation ST4028 (four isolates) and ST15 (three isolates). The 
28 K. pneumoniae isolates exhibited 25 macrorestriction profiles which grouped in the 
XbaI-PFGE dendrogram according to their ST, with five clusters of similarity ≥85% (the 
two ST111 isolates, the four ST147, six of the seven ST307, two of the three ST15 and 
the four ST4028) (Figure 6). 
 
 
Figure 6. Dendrogram of the XbaI macrorestriction profiles of the 28 Klebsiella pneumoniae 
isolates. The dendrogram was obtained with the UPGMA algorithm based on the Dice similarity 
coefficient and applying 1% of tolerance in the band position using the BioNumerics software (Applied 
Maths, St-Martens-Latern Belgium). Association between isolation code, ST, ESBL type (NT: not typable) 
and resistance profile is indicated on the right. Clusters of ≥85% identity are highlighted in red. 
 
4.1.3. WGS of mcr-E. coli isolates 
 
Within the collection analyzed here (84 representative E. coli and 172 ESBL-
producing Enterobacteriaceae), two colistin-resistant E. coli recovered from two meat 
turkey samples were mcr-carriers (2/50; 4% turkey and 0/50 chicken meat). They showed 
MIC values of >4 mg/L (ESBL-producing E. coli) and >32 mg/L (representative E. coli) 
(Table 32). Table 15 summarizes their phenotypic traits and in silico characterization 
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using CGE tools. The two isolates belonged to the clonal group CC10-A (CH11-54). The 
resistome analysis revealed that both genomes encoded mechanisms of antibiotic 
resistance for ≥ three different antimicrobial categories, and both were carriers of the mcr-
1.1 variant located in an IncX4 plasmid type. Furthermore, PlasmidFinder showed a high 
plasmid diversity based on the identified replicons, with five to seven different plasmid 
types per genome (Table 15). To highlight the fact that LREC-204 carried double-serine 
mutations in gyrA S83L and parC S80I, with additional substitutions in gyrA D87N and 
parC A56T, which corresponded to the fluoroquinolone resistance determined in vitro for 
its isolate. 
 
4.1.4. Food-borne risk assessment 
 
In order to assess the level of microbiological risk exposure for consumers, each meat 
sample was qualified between zero (lowest risk) to five (highest), on the basis of five 
parameters which were individually analyzed and considered as positive when happened: 
i) the recovery of more than one ESBL-producing Enterobacteriaceae species; ii) the 
identification of a high-risk clonal group of E. coli, according to recent studies, due to 
their association within human extraintestinal and uropathogenic pathologies (Yamaji et 
al., 2018b; Mamani et al., 2019; Manges et al., 2019); iii) the presence of E. coli 
conforming ExPEC status; iv) the presence of E. coli conforming UPEC status; v) the 
recovery of Enterobacteriaceae resistant to antimicrobials of categories A (“Avoid”) or B 
(“Restrict”) (EMA, 2019). 
 
The results determined that the majority (97%) of meat samples were positive for the 
presence of Enterobacteriaceae. Besides, a comprehensive analysis based on the 
assessment of five parameters showed that 96% of the samples meant a consumer 
exposure to ≥ one risk, and 82% to ≥ two risks (Table 16). In detail, the result for each 
parameter was: i) 96 out of the 100 samples with positive recovery of isolates resistant to 
antimicrobials of the EMA categories A (“Avoid”) or B (“Restrict”), including 64 meat 
(31 chicken and 33 turkey) carriers of isolates resistant to monobactams (ATM), and one 
of those also to FOF (category A). ii) Sixty-two samples (31 chicken and 31 turkey) with 
presence of high-risk clonal groups of E. coli associated with human extraintestinal and / 
or uropathogenic pathologies (ST10, ST23, ST38, ST48, ST58, ST69, ST88, ST93, ST95, 
ST101, ST115, ST117, ST131, ST141, ST167, ST350, ST345, ST354, ST359, ST410, 
ST602, ST617, ST641, ST906, ST1485). iii) The ExPEC and iv) UPEC status, based on 
the presence of certain virulence markers associated with a higher capacity of developing 
extraintestinal or UTI pathologies, was determined in E. coli isolates recovered from 25 
and 17 samples, respectively. v) More than one ESBL-producing bacterial species were 
recovered from 28 samples (23 turkey meat and five chicken; P = 0.000). Although it was 
not considered as an additional risk, it is of note that 37 samples carried more than one 
type of ESBL-producing E. coli. 
 
4.1.5. Nucleotide sequence accession numbers 
 
The nucleotide sequence of the mcr-positive isolates have been deposited in the 
NCBI sequence databases with accession codes SAMN12430141 (isolate T-1-V-e; 
genome LREC-204) and SAMN12430147 (isolate T-17-R; genome LREC-210) and 
these sequences are part of BioProject ID PRJNA558228.  
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Table 15. In silico characterization and phenotypic traits of the mcr positive isolates recovered from two turkey meat samples 
Code1 O:H antigens2 
Phylo 
Group3 ST
















O89:H9 A  744 11-54 
blaSHV-12; aadA1, aadA2, aadA5, 
aph(3'')-Ib, aph(6)-Id; catA1, 
cmlA1; dfrA17; mdf(A); sul1, 
sul2, sul3; tet(A), tet(B); mcr-1 






















iutA, iucD, iroN, 





O89:H37 A  853 11-54 
blaTEM-1B; aadA1, aph(3'')-Ib, 
aph(6)-Id; dfrA1; mdf(A); 














iutA, iucD, iroN, 
iss, traT, ompT 
1Genomic and isolate reference, respectively; 2serotypes, 4sequence types, 5clonotypes, 6acquired antimicrobial resistance genes and / or chromosomal mutations, 
7replicon/plasmid STs, and 9virulence genes were determined using SerotypeFinder 2.0, MLST 2.0, CHtyper 1.0, ResFinder 3.1, PlasmidFinder 2.0, pMLST 2.0, and 
VirulenceFinder 2.0 online tools at the Center of Genomic Epidemiology, respectively; 3phylogroups were predicted using the ClermonTyping tool at the Iame-research 
Center web (http://clermontyping.iame-research.center/) 6Resistome. Acquired resistance genes: β-lactam: blaTEM-1B, blaSHV-12, aminoglycosides: aadA, aph(3'')-Ib, 
aph(6)-Id; phenicols: catA1, cmlA1; macrolides: mdf(A); sulphonamides: sul1, sul2, sul3; tetracycline: tet(A), tet(B); trimethoprim: dfrA1, dfrA17; colistin: mcr. 
Point mutations: quinolones and fluoroquinolones: gyrA S83L: TCG-TTG, gyrA D87N: GAC-AAT, parC S80I: AGC-ATC, parC A56T: GCC-ACC. 7Plasmid STs: “*” indicates 
the nearest ST allele (with less than 100% but >95% identity and 100% coverage). 8mcr gene location determined by PlasmidFinder/ResFinder predictions.9Virulence 
genes: cba: colicin B, celb: endonuclease colicin E2, cma: colicin M, iroN: enterobactin siderophore receptor protein, iss: increased serum survival, mchF: ABC 
transporter protein MchF, tsh: temperature-sensitive hemagglutinin.  10Phenotypic resistance interpreted according to the CLSI standard breakpoints (Clinical and 
Laboratory Standards Institute, 2019): ampicillin (AMP), ceftazidime (CAZ), cefotaxime (CTX), aztreonam (ATM), colistin (CST), doxycycline (DOX), chloramphenicol 
(CHL), sulfamethoxazole-trimethoprim (SXT), ciprofloxacin (CIP), nalidixic acid (NAL). 11Specific extraintestinal VF determined by PCR (Johnson et al., 2003; Spurbeck 

















2ESBL-producing spp. 3High-risk clonal groups of E. coli  4ExPEC 5UPEC 
6Resistances to antimicrobials of 
categories A or B 
7TOTAL 
risk 
Ch 1 E. coli, S. fonticola ST23-C (CH4-35); ST117-F 0 1 MB-CF3rd-FQ-CST* (S. fonticola) 4 
Ch 2 E. coli  ST131-B2 (CH40-22) 1 1 MB-CF3rd-Q 4 
Ch 3 E. coli  - 0 0 MB-CF3rd-FQ 1 
Ch 4 E. coli  ST117-F 0 0 CF3rd 2 
Ch 5 E. coli  ST23-C (CH4-35); ST69-D (CH35-27); ST115-E 1 0 MB-CF3rd-FQ 3 
Ch 6 E. coli  CC648-F 1 1 CF3rd-FQ 4 
Ch 7 E. coli  ST23-C (CH4-35); ST93-A 1 0 MB-CF3rd-FQ 3 
Ch 8 E. coli, S. fonticola - 0 0 MB-CF3rd-FQ-CST* (S. fonticola) 2 
Ch 9 0 CC648-F 1 1 Q 4 
Ch 10 E. coli  ST117-F; CC10-A (eae-beta1) 0 0 MB-CF3rd-Q 2* 
Ch 13 E. coli  ST131-B2 (CH40-22) 1 1 MB-CF3rd-FQ 4 
Ch 14 0 - 0 0 FQ 1 
Ch 15 0 ST10-A (CH11-54) 0 0 FQ 2 
Ch 16 E. coli  - 1 1 MB-CF3rd-Q 3 
Ch 17 E. coli  ST10-A (CH11-54) 0 0 MB-CF3rd-FQ 2 
Ch 18 E. coli, S. fonticola ST10-A (CH11-54) 0 0 CF3rd-FQ-CST* (S. fonticola) 3 
Ch 19 E. coli  - 1 1 MB-CF3rd-Q 3 
Ch 20 E. coli  ST23-C (CH4-35) 0 0 MB-CF3rd-FQ 2 
Ch 21 E. coli  ST101-B1 0 0 MB-CF3rd-FQ 2 
Ch 22 E. coli  - 0 0 MB-CF3rd-FQ 1 
Ch 23 E. coli  ST38-E 0 0 MB-CF3rd-FQ 2 
Ch 24 E. coli  ST10-A (CH11-54) eae-beta1 1 0 MB-CF3rd-Q 3* 
Ch 25 E. coli  ST10-A (CH11-54) 0 0 MB-CF3rd-FQ 2 







2ESBL-producing spp. 3High-risk clonal groups of E. coli  4ExPEC 5UPEC 
6Resistances to antimicrobials of 
categories A or B 
7TOTAL 
risk 
Ch 26 0 - 0 0 Q 1 
Ch 27 E. coli  ST10-A (CH11-54) 0 0 MB-FQ 2 
Ch 28 E. coli  - 1 0 MB-CF3rd-FQ 2 
Ch 29 0 ST10-A (CH11-54) 0 0 FQ 2 
Ch 30 S. fonticola - 0 0 CF3rd-CST* (S. fonticola) 1 
Ch 31 E. coli  ST93-A 1 0 MB-CF3rd-Q 3 
Ch 32 E. coli  - 0 0 Q 1 
Ch 33 E. coli  - 1 0 MB-CF3rd-FQ 2 
Ch 34 E. coli  - 1 0 MB-CF3rd-FQ 2 
Ch 35 E. coli, K. pneumoniae ST101-B1; ST117-F 0 0 MB-CF3rd-FQ-CST 3 
Ch 36 E. coli  ST10-A (CH11-54) eae-beta1; ST93-A 1 0 FQ 3* 
Ch 37 0 ST23-C (CH4-35) 0 0 Q 2 
Ch 38 0 CC648-F 1 1 FQ 4 
Ch 39 E. coli  - 0 0 MB 1 
Ch 40 E. coli  CCT10-A eae-beta1 1 0 MB-CF3rd-FQ 3* 
Ch 41 E. coli, K. pneumoniae - 1 0 MB-CF3rd-FQ 3 
Ch 42 0 - 0 0 Q 1 
Ch 43 E. coli  ST117-F 0 1 MB-CF3rd 3 
Ch 44 E. coli  - 1 0 CF3rd-FQ 2 
Ch 45 E. coli  ST23-C (CH4-35); ST410-C (CH4-24) 0 0 MB-CF3rd-FQ 2 
Ch 46 E. coli  ST38-E; ST641-B1 0 0 MB-CF3rd-Q 2 
Ch 47 E. coli  - 0 1 CF3rd-FQ 2 
Ch 48 E. coli  ST23-C (CH4-35); ST10-A (CH11-54) 0 0 MB-CF3rd-FQ 2 








2ESBL-producing spp. 3High-risk clonal groups of E. coli  4ExPEC 5UPEC 
6Resistances to antimicrobials of 
categories A or B 
7TOTAL 
risk 
Ch 50 S. fonticola ST38-E 0 0 CF3rd-Q-CST* (S. fonticola) 2 
T 1 E. coli, K. pneumoniae - 0 0 
MB-CF3rd-FQ-CST (mcr-carrying E. 
coli) 2 
T 2 E. coli  ST10-A (CH11-54) 0 0 MB-CF3rd-FQ 2 
T 3 E. coli  - 0 0 MB-CF3rd-FQ 1 
T 4 E. coli  ST88-C (CH4-39); ST354-F 0 0 MB-CF3rd-FQ 2 
T 5 E. coli, K. pneumoniae - 0 0 CF3rd-FQ-CST 2 
T 6 E. coli, K. pneumoniae ST58-B1 (CH4-32) 0 0 MB-CF3rd-FQ 3 
T 7 E. coli, K. pneumoniae ST345-B1 0 0 MB-CF3rd-FQ 3 
T 8 E. coli, K. pneumoniae - 0 0 MB-CF3rd-FQ 2 
T 9 E. coli  ST117-F 0 1 MB-CF3rd-FQ 3 
T 10 E. coli, K. pneumoniae - 0 0 CF3rd-FQ 2 
T 11 E. coli, K. pneumoniae - 0 0 MB-CF3rd-FQ-CST 2 
T 12 E. coli  - 0 0 MB-FQ 1 
T 13 E. coli  ST117-F 0 0 MB-CF3rd-FQ 2 
T 14 0 - 1 1  2 
T 15 E. coli  ST410-C (CH4-24) 0 0 MB-CF3rd-FQ 2 
T 16 0 ST10-A (CH11-54) 0 0 FQ 2 
T 17 E. coli, K. pneumoniae - 0 0 
MB-CF3rd-FQ-CST (mcr-carrying E. 
coli) 2 
T 18 E. coli  ST58-B1 (CH4-32) 0 0 MB-CF3rd-FQ 2 
T 19 0 ST410-C (CH4-24) 0 0 FQ 2 
T 20 E. coli, K. pneumoniae CC648-F 1 1 MB-CF3rd-FQ 5 
T 21 E. coli, K. pneumoniae - 0 0 MB-CF3rd-FQ 2 
T 22 0 ST95-B2 1 1 Q 4 







2ESBL-producing spp. 3High-risk clonal groups of E. coli  4ExPEC 5UPEC 
6Resistances to antimicrobials of 
categories A or B 
7TOTAL 
risk 
T 23 K. pneumoniae - 0 0 MB-CF3rd-FQ 1 
T 24 E. coli, K. pneumoniae 
ST48-A; ST141-B2 (CH52-14); 
ST354-F (CH88-58) 1 1 MB-FOF-CF3rd-FQ-CST 5 
T 25 E. coli, K. pneumoniae ST58-B1 (CH4-32); ST350-E 0 0 MB-CF3rd-FQ-CST 3 
T 26 E. coli  ST58-B1 (CH4-27); ST93-A 1 0 Q 3 
T 27 E. coli, K. pneumoniae ST58-B1 (CH4-32); ST350-E 0 0 MB-CF3rd-FQ-CST 3 
T 28 E. coli  ST10-A (CH11-54) 0 0 MB-CF3rd-FQ 2 
T 29 0 - 0 0 FQ 1 
T 30 K. pneumoniae - 0 0 CF3rd-FQ-CST 1 
T 31 E. coli, K. pneumoniae - 0 0 MB-CF3rd-FQ 2 
T 32 E. coli  ST10-A (CH11-54); ST617-A (CH11-neg) 1 0 MB-CF3rd-FQ 3 
T 33 E. coli, E. cloacae* ST88-C (CH4-39); ST38-E 0 0 CF3rd-FQ 3 
T 34 0 ST58-B1 (CH4-32) 0 0 FQ 2 
T 35 E. coli, K. pneumoniae ST93-A 0 0 MB-CF3rd-FQ 3 
T 36 0 ST58-B1 (CH4-32) 0 0 FQ 2 
T 37 E. coli, K. pneumoniae ST48-A 0 0 CF3rd-FQ 3 
T 38 E. coli  - 0 0 MB-CF3rd-Q 1 
T 39 E. coli, S. fonticola* - 0 0 MB-CF3rd-FQ-CST* (S. fonticola) 2 
T 40 E. coli, K. pneumoniae ST58-B1 (CH4-27); ST38-E 0 1 MB-CF3rd-FQ 4 
T 41 E. coli, K. pneumoniae ST410-C (CH4-24) 0 0 MB-CF3rd-FQ 3 
T 42 E. coli, K. pneumoniae 
ST410-C; ST10-A (CH11-54); 
ST602-B1 (CH19-86) 0 0 MB-CF3rd-FQ 3 
T 43 E. coli, K. pneumoniae ST354-F (CH88-58) 1 0 MB-CF3rd-FQ-CST 4 
T 44 E. coli, K. pneumoniae ST48-A; ST359-B1 (CH41-35) 0 0 MB-CF3rd-FQ 3 








2ESBL-producing spp. 3High-risk clonal groups of E. coli  4ExPEC 5UPEC 
6Resistances to antimicrobials of 
categories A or B 
7TOTAL 
risk 
T 46 K. pneumoniae ST410-C 0 0 CF3rd-FQ-CST 2 
T 47 E. coli  ST167-A 0 0 CF3rd-FQ 2 
T 48 E. coli  - 0 1 MB-CF3rd-FQ 2 
T 50 E. coli  ST602-B1 (CH19-86); ST906-B1 0 0 MB-CF3rd-FQ 2 
1Type of sample: Ch (chicken meat), T (turkey meat). Highlighted in red those samples with recovery of more than one ESBL-producing type of E. coli. 
*Presumptively ESBL-producers since they were recovered from CHROMID® ESBL (the ESBL type could not be determined in those two isolates). 2ESBL-producing 
bacteria recovered from CHROMID® ESBL, 0 = none recovered. 3High-risk clonal groups of E. coli  associated with human extraintestinal and / or uropathogenic 
pathologies according to recent studies (Yamaji et al., 2018b; Mamani et al., 2019; Manges et al., 2019); highlighted in bold those reported within our collection 
of clinical human isolates (Mamani et al., 2019). 4ExPEC status +: E. coli strains considered with higher capacity of developing extraintestinal pathologies when 
positive for two or more of five markers, including papAH and / or papC, sfa/focDE, afa/draBC, kpsM II and iutA; ExPEC -: strains negative for those markers 
(Johnson et al. 2003). 5UPEC status +: strains considered with higher capacity of developing UTI pathologies when positive for three or more of four markers, 
including chuA, fyuA, vat and yfcV; UPEC -: strains negative for those markers (Spurbeck et al., 2012). 6Detection of isolates resistant to antimicrobials categorized 
as A or B (EMA/CVP/CHMP, 2019); FOF (fosfomycin); MB (monobactams); CF3rd (3rd-generation cephalosporins); FQ (fluoroquinolones); Q (quinolones); CST 
(colistin), *intrinsic resistance. 7Meat samples were qualified between zero (lowest risk) to five (highest), being positive when happened:  i) the recovery of more 
than one ESBL-producing bacterial species; ii) the presence of ExPEC and / or UPEC lineages of E. coli; iii) the presence of isolates conforming ExPEC status; iv) 
UPEC status; v) the recovery of resistant isolates to antimicrobials of categories A or B, *presence of an atypical EPEC/ExPEC hybrid pathotype. 
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4.2. STUDY 2: MICROBIOLOGICAL RISK ASSESSMENT OF TURKEY AND CHICKEN 
MEAT FOR CONSUMER: SIGNIFICANT DIFFERENCES REGARDING MULTIDRUG 
RESISTANCE, MCR OR PRESENCE OF HYBRID AEPEC/EXPEC PATHOTYPES OF 
E. coli  
 
Based on the same sampling as referred in 4.1. Study 1, we performed here a 
comprehensive analysis of all the pathogenic and AMR E. coli recovered within the VI 
protocols detailed in Figure 2 from 3.2.1. Sampling, screening and Enterobacteriaceae 
recovery.  
 
Ninety-two of the 100 samples (46 of chicken and 46 of turkey) were positive for the 
presence and recover of E. coli isolates. From those, 323 isolates constituted the collection 
of study (163 E. coli from chicken and 160 from turkey). Per protocol, 137 (42.4%) E. 
coli were recovered from protocol V, 86 (26.6%) from protocol II, 79 (24.5%) from 
protocol I, 16 (5.0%) from protocol IV and 5 (1.5%) from protocol III. None 
carbepenemase-producing isolate was recovered in this study, which were specifically 
searched in the protocol VI. The screening of VF associated with InPEC pathotypes 
determined the presence of aEPEC (eae-positive, bfp-negative), but no STEC or EAEC. 
The screening of VF associated with the ExPEC and UPEC status, rfbO25b, bla and mcr 
were also positive as it is detailed below.  
 
4.2.1. Microbiological quality of the poultry meat 
 
As noted above, 92% of the meat samples were positive for E. coli isolation in 3M 
Petrifilm™ Select E. coli.  While 27 samples showed < 10 cfu of E. coli per g, 43 showed 
≥ 50 cfu/g with significant differences regarding meat origin (28 of 50 turkey vs 15 of 50 
chicken; P = 0.015) (Table 17). Besides, five of the 100 samples obtained 
"not satisfactory" E. coli counts (> 500), if we take as reference the Commission 
Regulation (EC) No 2073/2005 for meat preparations at the end of the manufacturing 
process. In this Regulation, the limits to recommend improvements in selection and / or 
origin of raw materials are “m = 500 and M = 5000” cfu/g. Finally, similar levels of 
contamination were observed for the two packaging systems (modified atmosphere and 
freshly butchered) (P > 0.05) (Table 17). 
 
Table 17. Association of E. coli counts with meat origin (chicken vs turkey) and packaging 
(modified atmosphere vs freshly butchered) 
 









butchered P two-tailed 
value 
E. coli n = 100 n = 50 n = 50 n = 49 n = 51 
< 10 27 16 (32%) 11 (22%) 0.367 10 (20.4%) 17 (33.3%) 0.179 
oct-49 30 19 (38%) 11 (22%) 0.125 15 (30.6%) 15 (29.4%) 1.000 
50-500 38 14 (28%) 24 (48%) 0.063 22 (44.9%) 16 (31.4%) 0.216 
> 500 5 1 (2%) 4 (8%) 0.322 2 (4.1%) 3 (5.9%) 1.000 
≥ 50 43 15 (30%) 28 (56%) 0.015 24 (49%) 19 (37.3%) 0.419 




4.2.2. Evaluation of protocols I to V 
 
The method designed here was thought to detect E. coli potentially pathogenic for 
humans (diarrheagenic, extraintestinal and MDR), using different media, temperatures of 
incubation and specific genetic targets (named as protocols I to VI within the method). 
As summarized in Table 18 and Table 34, we evaluated the adequacy of this method 
through the characterization of 323 E. coli and the assessment of six virulence traits. We 
found that the protocols I and II (ML and MSTC incubated at 37 ºC, respectively) were 
the most effective for the recovery of isolates satisfying the ExPEC and UPEC status. In 
detail, of the 150 isolates from 78 different meat samples that satisfied the ExPEC status, 
118 (78.7%) from 71 samples were recovered in plates of protocols I and II. Likewise, of 
the 83 isolates positive for UPEC status from 53 individual samples, 69 (83.1%) 
recovered in 47 samples come from plates of protocols I and II. The protocol V 
(CHROMID® ESBL agar plates 37 ºC) was key for the recovery of ESBL or pAmpC-
producing E. coli. In fact, of 155 ESBL/pAmpC-producing E. coli isolated from 78 
samples, 137 (88.4%) isolates and 76 samples were detected in protocol V. Although 
most mcr isolates were from protocols I and II, with 10 of 13 (76.9%) mcr E. coli 
recovered in six of the seven positive meat samples, they were also isolated in plates of 
protocols IV and V (two and one isolate, respectively). Of the 323 isolates analyzed here, 
253 E. coli  recovered from 88 meat samples were MDR according to Magiorakos et al. 
(Magiorakos et al., 2012). MDR isolates were mostly those 137 (54.1%) ESBL/pAmpC-
producing E. coli recovered from 76 meat samples (protocol V), and 100 E. coli from 
protocols I and II. Finally, the screening by PCR of the rbfO25b associated with the clonal 
group ST131 allowed the detection of 13 isolates; 12 (92.3%) from nine samples were 
recovered in plates of protocols I and II (Table 18, Table 34) (Figure 7). 
 
 


























1 ExPEC status (%)  
57 (38) 61 (40.7) 4 (2.7) 10 (6.6) 18 (12) 87 (58) 63 (42) 0.014 
N = 150 
2 UPEC status (%) N 
= 83 32 (38.6) 37 (44.6) 1 (1.2) 7 (8.4) 6 (7.2) 47 (56.6) 36 (43.4) 0.205 
3 ESBL/ pAmpC 
producer (%) 7 (4.5) 9 (5.8) 0 2 (1.3) 137 (88.4) 71 (45.8) 84 (54.2) 0.119 
N = 155 
4 mcr-1 carrier (%) 4 (30.8) 6 (46.1) 0 2 (15.4) 1 (7.7) 1 (7.7) 12 (92.3) 0.001 
 N = 13 
5 MDR (%)  
48 (19.0) 52 (20.6) 3 (1.2) 13 (5.1) 137 (54.1) 118 (46.6) 135 (53.4) 0.010 
N = 253 
6 rbfO25b (%) N = 
13 6 (46.1) 6 (46.1) 1 (7.7) 0 0 10 (76.9) 3 (23.1) 0.086 
No. isolates per 
protocol 79 86 5 16 137 163 160 - 
and meat origin 
1No. of isolates conforming ExPEC status (Johnson et al., 2003). 2No. of isolates conforming status UPEC (Spurbeck et al., 
2012). 3No. of ESBL/pAmpC-producing E. coli.  4No. of isolates carriers of the mcr-1 gene.  5No. of MDR isolates according 
to Magiorakos et al. (Magiorakos et al., 2012) criteria. 6No. of rbfO25b-positive isolates: O25b subtype associated with 








Figure 7. No. of E. coli isolates recovered per protocol in correlation with the six VF 
 
Regarding meat origin, we found a significant higher prevalence of isolates with 
ExPEC status in chicken meat (58% vs 42% in turkey), while MDR and mcr-1 isolates 
were more prevalent within E. coli of turkey origin (53.4% vs 46.6% in chicken and 




Figure 8. No. of E. coli isolates recovered per VF in correlation with the meat origin. 
 
In summary, the microbiological method applied in this study showed high 
prevalence rates of ExPEC and UPEC status, ESBL/AmpC enzymes, mcr-1 gene, MDR, 
or rbfO25b gene (positive isolates present in 78%, 53%, 78%, 7%, 88% and 10% of the 
meat samples, respectively). Importantly, the protocols I+II+V allowed the detection of 
around 85-90% of those positive samples (ML, MSTC and CHROMID® ESBL media 
incubated at 37 ºC), conforming an optimized workflow combination that would capture 


























Figure 9. Proposal of optimized workflow to investigate the level of contamination, and the rates of 
AMR and food-borne pathogenic E. coli. AMR: antimicrobial resistance; ML: MacConkey Lactose agar; 
MSTC: MacConkey Sorbitol agar enriched with tellurite and cefixime; TSA: tryptone soy agar; CFU: 
colony forming units; EPEC: enteropathogenic E. coli; STEC: Shiga toxin-producing E. coli; EAEC: 
enteroaggregative E. coli; ExPEC: extraintestinal pathogenic E. coli. 
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4.2.3. E. coli characterization 
 
The phylogenetic analysis revealed that the 323 E. coli isolates belonged to 
Escherichia clade I (8 isolates; 2,5%) and the eight phylogroups of E. coli sensu stricto: 
A (105 of 323; 32.5%), B2 (57; 17.6%), B1 (56; 17.3%), E (35; 10.8%), F (33; 10.2%), 
D (11; 3.4%), C (9; 2.8%), G (9; 2.8%). The isolates which exhibited ExPEC status were 
mainly of phylogroups B2, F, A and E (122 of 150; 81.3%), while the UPEC status 
appeared associated with phylogroups B2 and F (78 of 83; 94%). The ESBL producers, 
as well as MDR isolates, belonged mostly to phylogroups A, B1 and E, accounting for 
127 of 155 (81.9%) and 179 of 253 (70.7%), respectively (Table 19) (Figure 10).  
 
Table 19. Association of virulence traits with phylogroup distribution for the E. coli collection (N = 323) 
 
Virulence trait PG. A PG. B1 PG. B2 PG. C PG. D PG. E PG. F PG. G Clade I 
1ExPEC status (%) 














 (5.3) N = 150 
2UPEC status (%) 




(6) 0 N = 83 
3ESBL/ pAmpC 
producer (%)  



















4mcr-1 carrier (%) 
6 (46.2) 4  (30.8) 
2 
 (15.4) 0 
1  
(7.7) 0 0 0 0 N = 13 
5MDR (%) 














(2.4) N = 253 
6rbfO25b (%) 
0 0 12  (92.3) 0 0 
1  
(7.7) 0 0 0 N = 13 
No. isolates per phylogroup (%) (N = 323) 

















1No. of isolates conforming ExPEC status (Johnson et al., 2003). 2No. of isolates conforming UPEC status (Spurbeck 
et al., 2012). 3No. of ESBL/pAmpC-producing E. coli.  4No. of isolates carriers of the mcr-1 gene. 5No. of MDR isolates 
according to Magiorakos et al. (Magiorakos et al., 2012) criteria. 6No. of rbfO25b-positive isolates: O25b subtype 







Figure 10. Phylogroup distribution within the isolates positive for the traits ESBL/pAmpC 
production, UPEC and ExPEC status 
 
MLST was performed for 272 representative isolates. As a result, 89 different STs 
were determined, including eight new (Figure 11). However, 16 of those 89 STs detected 
in at least five isolates accounted for 153 of 272 isolates (56.2%): 10, 93, 95, 115,117, 
131, 155, 355, 428, 648, 770, 752, 1158, 1485, 4243, 10740. And the most prevalent 
combination of STs and CHs revealed the following clonal groups: ST1485-F (CH231-
58) (19 isolates); ST10-A (CH11-54) (12 isolates); ST93-A (CH11-neg) (11 isolates); 
ST752-A (CH11-24) (nine isolates); ST131-B2 (CH40-22) (eight isolates); ST117-G 
(CH45-97) (eight isolates); ST155-B1 (CH4-32) (seven isolates); ST355-B2 (24-154) 
(seven isolates); ST115-E (CH26-270) (seven isolates); ST770-clade I (CH116-552) 
(seven isolates); ST95-B2 (CH38-27) (six isolates); ST1158-E (CH3-47) (six isolates); 
ST648-F (CH4-58) (six isolates); ST10740-B2 (1544-9) (five isolates); and ST4243-D 
(3-1002) (five isolates) (Table 35). Besides, different clones could be distinguished within 
these prevalent clonal groups by serotype. In fact, serotyping showed high heterogeneity 
with 184 different O:H antigen combinations and only five serotypes determined for > 5 
isolates in the characterized collection: O83:H42 (14 isolates); O25:H4 (12); O2:H5 (8); 
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Figure 11. Representative E. coli collection. 
Phylogenetic tree based on concatenated sequences 
of the seven housekeeping genes from the MLST 
Achtman scheme by the Neighbor-Joining method. 
Note: The optimal tree with the sum of branch length 
= 0.21789331 is shown. The percentage of replicate 
trees in which the associated taxa clustered together 
in the bootstrap test (1000 replicates) are shown next 
to the branches. The tree is drawn to scale, with 
branch lengths in the same units as those of the 
evolutionary distances used to infer the phylogenetic 
tree. The evolutionary distances were computed 
using the p-distance method and are in the units of 
the number of base differences per site. The analysis 
involved 89 nucleotide sequences determined for 272 
isolates. All positions containing gaps and missing 
data were eliminated. There were a total of 3423 
positions in the final dataset. Evolutionary analyses 
were conducted in MEGA7. Marked with a black dot 
those STs of E. coli associated with human 




An important finding in this study was the high prevalence of meat samples with 
isolation of hybrid pathotypes aEPEC/ExPEC (19% of samples and 22 isolates). Table 20 
shows the characterization of the 22 aEPEC/ExPEC, which were all positive for the eae-
beta1 intimin, belonged to phylogroup A and mostly to the CC10. Besides, four of the 22 
were ESBL/pAmpC producers. 
 
Table 20. Characterization of the 22 isolates exhibiting hybrid pathotype aEPEC/ExPEC recovered 
from 19 meat samples.  
 











40 Ch2 IV ONT:H40-A-ST752-CC10 (CH11-24) β1 
fimH24 hlyF iucD iutA 
traT iss 
AMP, GEN, DOX, CIP, 
NAL - 




β1 fimH24 hlyF iucD iutA traT 
AMP, GEN, TOB*, 
DOX, SXT, CIP*, NAL - 




β1 fimH24 hlyF iucD iutA traT AMP, NIT*, CIP*, NAL - 
20 Ch5 II O11:H40-A-ST752-CC10 (CH11-24) β1 
fimH24 hlyF iucD iutA 
traT iss DOX, CIP*, NAL - 
20 Ch5 II O80:H26-A-ST165-CC189 * β1 
fimH fimAvMT78 traT 
fyuA 
AMP, GEN, TOB*, 
CIP, NAL - 




β1 fimH24 traT CIP*, NAL - 
100 Ch7 II ONT:HNT-A-ST19-CC10 (CH11-122) β1 
fimH122 hlyF iucD iroN 
cvaC traT tsh, ompT iss 
chuA yfcV 
AMP, CIP*, NAL - 
70 Ch8 II O132:H37-ST10-CC10 (CH11-24) β1 fimH24 traT CIP*, NAL - 




β1 fimH24 hlyF iucD iutA traT 
AMP, CXM, CTX, 
FOX*, ATM*, CHL*, 
NIT*, CIP, NAL 
CTX-M-1 
10 Ch14 I O153:H10-A-ST10-CC10 (CH11-54) β1 
fimH54 fimAvMT78 
traT fyuA - - 
<10 Ch16 II O68:H51-A-ST10-CC10 (CH11-24) β1 fimH24 traT 
AMP, GEN, TOB*, 
NAL - 




β1 fimH54 fimAvMT78 traT fyuA AMP, DOX, CHL - 
440 Ch18 IV O153:H10-A-ST10-CC10 (CH11-54) β1 
fimH54 fimAvMT78 
traT fyuA AMP, GEN, DOX, CHL - 
40 Ch20 II O11:HNT-A-ST752-CC10 (CH11-54) β1 fimH54 traT fyuA AMP, CIP*, NAL - 
40 Ch20 II O123:H34-A-ST10-CC10 (CH11-54) β1 fimH54 AMP*, CIP*, NAL - 
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β1 fimH823 fimAvMT78 traT usp 
AMP, DOX*, SXT, 
CIP, NAL - 
200 Ch24 V O153:H10-A-ST10-CC10 (CH11-54) β1 
fimH54 fimAvMT78 
traT fyuA 
AMP, CFZ, CXM, 
CAZ*, CTX, ATM, 
GEN, DOX, CHL 
CTX-M-32 
20 Ch36 I O153:H10-A-ST10-CC10 (CH11-54) β1 
fimH54 papEF papC 
papG II traT fyuA 
AMP, DOX, CHL, CIP, 
NAL - 




β1 fimH24 traT AMP, NAL - 
40 T18 II O57:HNT-A-ST165-CC189 * β1 
fimH fimAvMT78 hlyF 
iucD iroN cvaCtraT usp  
iss fyuA 
AMP, GEN, TOB, 
DOX, SXT, CIP, NAL - 
40 T47 II O2:H40-A-ST10-CC10 (CH11-24) β1 fimH24 hlyF traT 
AMP, AMC, CFZ, 
CXM, CAZ, CTX, 
FOX, SXT, CIP, NAL 
CMY-2 
40 T47 II O2:H40-A-ST10-CC10 (CH11-24) β1 
fimH24 hlyF iucD iroN 
cvaC traT iss 
AMP, AMC, CFZ, 
CXM, CAZ, CTX, 
FOX, DOX, SXT, CIP, 
NAL 
CMY-2 
1cfu: colony forming units. 2Ch (chicken meat), T (turkey meat).  3Clone defined as combination of serotype-
phylogroup-Sequence Type-Clonal Complex (Clonotype); *CH not determined. 4Antimicrobial susceptibility tested by 
disc diffusion assay and interpreted according to the CLSI standard breakpoints (The Clinical and Laboratory Standards 
Institute, 2020): ampicillin (AMP), amoxicillin-clavulanic acid (AMC), cefuroxime (CXM), ceftazidime (CAZ), cefotaxime 
(CTX), cefoxitin (FOX), aztreonam (ATM), gentamicin (GEN), tobramycin (TOB), doxycycline (DOX), chloramphenicol 
(CHL), sulfamethoxazole-trimethoprim (SXT), ciprofloxacin (CIP), nalidixic acid (NAL). Intermediate values are 




The study of susceptibility showed that only 13 out of 323 isolates were susceptible 
to all the antibiotics tested. On the contrary, 258 (79.9%) were MDR, with acquired non-
susceptibility to at least one agent in three or more antimicrobial categories (Magiorakos 
et al., 2012) (Table 21). The highest prevalence was against ampicillin (82.7%), nalidixic 
acid (74.0%), ciprofloxacin (71.8%), doxycycline (65.9%) and cefotaxime (46.7%). We 
found that turkey isolates exhibited significant higher rates of resistance against 
ampicillin, amoxicillin-clavulanic acid, ceftazidime, cefotaxime, aztreonam, 
doxycycline, chloramphenicol, sulfamethoxazole-trimethoprim, as well as in the number 
of MDR (P < 0.05). Chicken isolates only showed a significant difference in gentamicin 
resistance (Table 21). While the disc diffusion method for colistin resistance gave non-
susceptible values only for six mcr-positive isolates out of the 323, the broth 
microdilution method, performed only for the mcr-bearing E. coli, showed CMI values 








Table 21. Study of susceptibility for the for the E. coli collection (N = 323) 
 
11ATB 
E. coli from chicken E. coli from turkey Total  Chicken 
vs turkey 










AMP 118 72.4 149 93.1 267 82.7 0.000 
AMC 26 16.0 47 29.4 73 22.6 0.005 
CXM 54 33.1 58 36.3 112 34.7 0.561 
CAZ 55 33.7 73 45.6 128 39.6 0.031 
CTX 69 42.3 82 51.3 151 46.7 0.119 
FOX 3 1.8 5 3.1 8 2.5 0.499 
ATM 57 35.0 77 48.1 134 41.5 0.018 
IPM 0 0.0 0 0.0 0 0.0 - 
GEN 48 29.4 16 10.0 64 19.8 0.000 
TOB 21 12.9 13 8.1 34 10.5 0.205 
AMK 0 0.0 0 0.0 0 0.0 - 
FOF 0 0.0 0 0.0 0 0.0 - 
CST* 1 0.6 5 3.1 6 1.9 0.119 
DOX 96 58.9 117 73.1 213 65.9 0.010 
CHL 35 21.5 69 43.1 104 32.2 0.000 
NIT 11 6.7 11 6.9 22 6.8 1 
SXT 47 28.8 74 46.3 121 37.5 0.001 
CIP 115 70.6 117 73.1 232 71.8 0.623 
NAL 123 75.5 116 72.5 239 74.0 0.612 
TGC 0 0.0 1 0.6 1 0.3 0.495 
MDR 121 74.2 137 85.6 258 79.9 0.012 
1Antimicrobial susceptibility tested by disc diffusion assay and interpreted according to the CLSI standard 
breakpoints (The Clinical and Laboratory Standards Institute, 2020), where number of isolates and prevalence 
include intermediate values:  ampicillin (AMP), amoxicillin-clavulanic acid (AMC), cefuroxime (CXM), 
ceftazidime (CAZ), cefotaxime (CTX), cefoxitin (FOX), aztreonam (ATM), imipenem (IMP), gentamicin (GEN), 
tobramycin (TOB), amikacin (AMK), fosfomycin (FOF), colistin (CST), doxycycline (DOX), chloramphenicol (CHL), 
nitrofurantoin (NIT), sulfamethoxazole-trimethoprim (SXT), ciprofloxacin (CIP), nalidixic acid (NAL), tigecycline 
(TGC) and multidrug-resistance (MDR) according to Magiorakos definition (Magiorakos et al., 2012). *Resistance 
to colistin was also performed by broth microdilution for the 13 mcr-positive isolates, which gave MIC values of 
4 μg/mL (11 isolates), 2 and 1 μg/mL (1 isolate each). 2 In bold, the statistically significant values (P < 0.05). 
 
Seventy-eight meat samples (39 from chicken and 39 from turkey) were carriers of 
153 different ESBL/pAmpC-producing isolates, of which 108 (70.6%) carried blaSHV: 
blaSHV-12 (107 isolates) and blaSHV-2 (1 isolate). Besides, 39 (25.5%) were positive for 
blaCTX-M: blaCTX-M-1 (14), blaCTX-M-14 (6), blaCTX-M-15 (5), blaCTX-M-32 (9), blaCTX-M-9 (3) 
and two were not-typeable (NT) (2). In addition, six isolates (3.9%) from different meat 
samples were carriers of blaTEM-52. We also recovered two blaCMY-2 isolates from one 
turkey sample (Table 24). 
 
The mcr (1 to 5) screening resulted in 13 mcr-1.1. isolates recovered from seven 
samples. As shown in Table 22, the isolates belonged to different phylogroups (A, B1, 
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B2, D) and STs (10, 69, 101, 140, 155, 212, 522, 744, 853). To highlight three samples 
that carried more than one different mcr-positive clone. The MIC values for colistin were 
of 4 μg/mL (11 isolates), 2 and 1 μg/mL (1 isolate each). 
 
Table 22. Characterization of the 13 mcr-1 isolates recovered from seven meat samples. 
 
















4 Resistance profile Virulence profile 
30 Ch9 II (a) O18ac:H49-B1-ST212 (CH29-38) mcr1.1 4 µg/mL 
AMP, AMC*, GEN, TOB*, 
CST, DOX, CHL, NIT*, 
SXT, CIP, NAL 
fimH38 traT 
510 




mcr1.1 4 µg/mL AMP, AMC*, GEN, DOX, CHL, CIP, NAL 
fimH32 hlyF iroN 
traT iss 





/ mcr1.1 4 µg/mL 
AMP, CXM*, CAZ, CTX, 
ATM, CST, DOX, CHL, 
SXT, CIP, NAL 
fimH54 fimAvMT78 
hlyF iucD iutA iroN 
cvaC traT tsh iss 
210 




mcr1.1 4 µg/mL AMP, AMC*, DOX, CHL, CIP*, NAL 
fimH23 hlyF iroN 
ompT iss 
T13 II (b) O15:H6-D-ST69-CC69 (CH35-27) mcr1.1 4 µg/mL AMP, DOX, CHL, NAL 
fimH27 hlyF iroN 
traT ompT iss chuA 
fyuA 
100 




mcr1.1 4 µg/mL AMP, DOX, CHL, SXT, CIP* fimH86 traT ompT 




mcr1.1 4 µg/mL AMP, CST, DOX, CHL, SXT, CIP* fimH86 traT ompT 
60 




mcr1.1 4 µg/mL AMP, CST, DOX*, SXT 
fimH54 fimAvMT78 
hlyF iucD iutA iroN 
traT ompT iss 




mcr1.1 4 µg/mL AMP, CST, DOX*, SXT 
fimH54 fimAvMT78 
hlyF iucD iutA iroN 
traT ompT iss 




mcr1.1 4 µg/mL AMP, CST, DOX*, SXT 
fimH54 fimAvMT78 
hlyF iucD iutA iroN 
traT ompT iss 
150 




mcr1.1 4 µg/mL AMP, GEN, TOB*, CHL, CIP* 
fimH15 fimAvMT78 
hlyF iucD iutA 
kpsM II-K1 traT 
ibeA malX usp 
ompT chuA vat 
fyuA yfcV 




mcr1.1 2 µg/mL AMP, GEN, TOB, CHL, CIP* 
fimH15 fimAvMT78 
hlyF iucD iutA 
kpsM II-K1 traT 
ibeA malX usp 
ompT chuA vat 
fyuA yfcV 




mcr1.1 1 µg/mL AMP, AMC*, CFZ, DOX, NIT, CIP*, NAL* hlyF iroN traT 
1CFU: colony forming units. 2Ch (chicken meat), T (turkey meat).3Clone defined as combination of serotype-
phylogroup-Sequence Type-Clonal Complex (Clonotype); “neg” when PCR was negative for the 489-nt internal 
sequence amplification of the fimH gene (Weissman et al., 2012). 4Antimicrobial susceptibility tested by disc 
diffusion assay and interpreted according to the CLSI standard breakpoints (The Clinical and Laboratory Standards 
Institute, 2020): ampicillin (AMP), amoxicillin-clavulanic acid (AMC), cefuroxime (CXM), ceftazidime (CAZ), 
cefotaxime (CTX), cefoxitin (FOX), aztreonam (ATM), gentamicin (GEN), tobramycin (TOB), colistin (CST), 
doxycycline (DOX), chloramphenicol (CHL), nitrofurantoin (NIT), sulfamethoxazole-trimethoprim (SXT), 




The screening of rbfO25b gave as a result 13 positive isolates from 10 meat samples. 
MLST typing confirmed 12 as ST131 from nine meat samples. The remaining one 
belonged to ST1011 and phylogroup E. The virulence profile of the ST131 isolates 
conformed virotype D (ibeA carriers) with subtypes: D4 (10 isolates; ibeA, kpsM II-K1 
positive), D1 (1 isolate; ibeA, cdtB, kpsM II-K5) and D-not typeable (1 isolate). The 13 
ST131 exhibited two clonotypes: CH40-22 (7 isolates) and CH40-neg (5 isolates) (Table 
23).   
 
Table 23. Characterization of the 13 rbfO25b isolates recovered from 10 meat samples. 
 















profile Virulence profile 
30 




D4 + / + GEN, DOX, CIP*, NAL 
fimH hlyF iucD iutA iroN kpsM II-
K1 traT ibeA malX usp tsh ompT 
iss chuA fyuA yfcV 




D4 + / + GEN, DOX*, CIP*, NAL 
fimH hlyF iucD iutA iroN kpsM II-
K1 traT ibeA malX usp tsh ompT 
iss chuA fyuA yfcV 




D4 + / + CIP*, NAL 
fimH hlyF iucD iutA iroN kpsM II-
K1 traT ibeA malX usp tsh ompT 
iss chuA fyuA yfcV 




D4 + / + NAL* 
fimH hlyF iucD iutA iroN kpsM II-
K1 cvaC traT ibeA malX usp tsh 






D4 + / + GEN*, DOX, CIP*, NAL 
fimH22 hlyF iucD iutA iroN kpsM 
II-K1 traT ibeA malX usp tsh 





D4 + / + GEN, DOX, CIP*, NAL 
fimH22 hlyF iucD iutA iroN kpsM 
II-K1 traT ibeA malX usp tsh 
ompT iss chuA vat fyuA yfcV 




- - / - AMP, DOX*, SXT, CIP, 
fimH31 hlyF iroN traT tsh ompT 
iss chuA fyuA 




D4 + / + CIP*, NAL 
fimH22 hlyF iucD iutA iroN kpsM 
II-K1 traT ibeA malX tsh ompT 
iss chuA vat fyuA yfcV 




D4 + / + CIP*, NAL 
fimH22 hlyF iucD iutA iroN kpsM 
II-K1 cvaC traT ibeA malX usp 
tsh ompT iss chuA vat fyuA yfcV 




D4 + / + GEN, DOX*, NAL 
fimH22 hlyF iucD iutA iroN kpsM 
II-K1 traT ibeA malX usp tsh 
ompT iss chuA vat fyuA yfcV 




D-nt + / + - 
fimH22 hlyF iucD iutA iroN kpsM 
II-K5 cvaC traT ibeA malX usp 
tsh ompT iss chuA vat fyuA yfcV 




D1 - / + AMP, AMC*, DOX*, 
fimH22 cdtB kpsM II-K5 traT ibeA 
malX usp ompT chuA fyuA yfcV 




D4 + / + AMP, DOX*, NAL 
fimH22 hlyF iucD iutA iroN kpsM 
II-K1 cvaC traT ibeA malX usp 
tsh ompT iss chuA fyuA yfcV 
1CFU: colony forming units. 2Ch (chicken meat), T (turkey meat).3Clone defined as combination of serotype-phylogroup-
Sequence Type-Clonal Complex (Clonotype); “neg” when PCR was negative for the 489-nt internal sequence amplification 
of the fimH gene (Weissman et al., 2012). 4Virotypes according to Dahbi et al. (2014).  5Antimicrobial susceptibility tested 
by disc diffusion assay and interpreted according to the CLSI standard breakpoints (The Clinical and Laboratory Standards 
Institute, 2020): ampicillin (AMP), amoxicillin-clavulanic acid (AMC), gentamicin (GEN), doxycycline (DOX), 
sulfamethoxazole-trimethoprim (SXT), ciprofloxacin (CIP), nalidixic acid (NAL). Intermediate values are indicated with *. 
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4.2.4. Risk assessment 
 
In order to evaluate the microbiological risk exposure for consumers, we performed 
an assessment based on the food-risk definition described by Díaz-Jiménez et al. (Díaz-
Jiménez et al., 2020a). In the present study, each meat sample was qualified between zero 
(lowest) to six (highest) in association with the following microbiological parameters, 
considered as summative risks when happened: i) E. coli counts > 500 cfu/g of poultry 
meat. We took as reference the Commission Regulation (EC) No 2073/2005 of 
15 November 2005 on microbiological criteria for foodstuffs. This Regulation establishes 
that for meat preparations at the end of the manufacturing process and using E. coli as an 
indicator of recent fecal contamination, the limits considered are “m = 500 and M = 5000” 
cfu/g to recommend improvements in production hygiene and improvements in selection 
and / or origin of raw materials. ii) The recovery of E. coli  resistant to antimicrobials of 
categories A (“Avoid”) or B (“Restrict”) (EMA, 2019). iii) The recovery of ≥ 2 different 
isolates of E. coli positive for typically plasmid borne ESBL, AmpC (pAmpC) or mcr 
resistance genes. iv) The identification of high-risk lineages of E. coli  associated with 
human extraintestinal pathologies (Yamaji et al., 2018b; Mamani et al., 2019; Manges et 
al., 2019; Flament-Simon et al., 2020a, 2020b). v) The isolation of E. coli  conforming 
ExPEC status (Johnson et al., 2003c). vi) The isolation of E. coli  conforming UPEC 
status (Spurbeck et al., 2012).  
 
The Table 24 summarizes the risk assessment of the 100 poultry meat samples 
analyzed in this study. We considered the summative presence of events, based on the six 
microbiological parameters described in section 2.3. The results determined that the 
majority (92%) of meat samples were positive for any of those parameters, with 61% 
positive for ≥ 4 risks and 84% for ≥ 3 risks.  
Per parameter, there was evidence of non-susceptible E. coli against monobactams, 
3rd-generation cephalosporins and / or fluoroquinolones in 71% of the meat samples. 
Besides, 47% of the samples showed presence of ≥2 different isolates of E. coli positive 
for ESBL, pAmpC or mcr genes. E. coli isolates belonging to STs/CCs identified as 
global ExPEC high-risk lineages were present in 86% of the samples and, what is more 
important, 73% showed carriage of the same clones as those determined within clinic 
human isolates of our Health Area. Besides, the isolates from 78% of the samples 
exhibited ExPEC status, and 53% were carriers of isolates positive for UPEC status. 












2 ESBL/pAmpC/mcr types (No. of 
isolates) 
3 High-risk lineages of E. coli 4ExPEC 5 UPEC 
6 Resistances to 
antimicrobials of 
categories A or B 





Ch 1 SHV-12 (1 isolate) ST648-F (CH4-58); ST117-G; ST162-B1 1 1 MB-CF3rd-FQ 10 4   
Ch 2 CTX-M-32 (1 isolate) O25b:H4-B2-ST131 (CH40-neg); ST115-E (CH26-270); CC10-A (eae-beta1) 1 1 MB-CF3rd-FQ 30 4 * 
Ch 3 SHV-12 (1 isolate) CC10-A (eae-beta1) 1 1 MB-CF3rd-FQ 40 4 * 
Ch 4 CTX-M-1 (1 isolate) ST117-G (CH45-97); ST428-B2 (CH40-22); CC10-A (eae-beta1) 1 1 CF3rd-FQ 410 4 * 
Ch 5 SHV-12, CTX-M-NT, CTX-M-9 (1 isolate each) 
O2:H9-E-ST115 (CH26-270); ST69-D (CH35-27); 
ST1485-F (CH231-58); CC10-A (eae-beta1) 1 1 MB-CF3rd-FQ 20 5 * 
Ch 6 TEM-52 ST1485-F (CH231-58); CC10-A (eae-beta1) 1 1 CF3rd-FQ 10 4 * 
Ch 7 SHV-12, CTX-M-32, CTX-M-1 (1 isolate each) ST23-C (CH4-35); ST93-A; ST10-A (eae-beta1) 1 1 MB-CF3rd-FQ 100 5 * 
Ch 8 SHV-12 (2 isolates) O25b:H4-B2-ST131 (CH40-neg); CC10-A (eae-beta1) 1 1 MB-CF3rd-FQ 70 5 * 
Ch 9 CTX-M-NT, mcr1.1 (1 isolate each) ST1485-F (CH231-58); ST48-A 1 1 CF3rd-FQ-CST* 30 5   
Ch 10 CTX-M-1 (2 isolates) ST117-G (CH45-97); CC10-A (eae-beta1) 1 1 MB-CF3rd-FQ 40 5 * 
Ch 11 - - 0 0 - <10 0   
Ch 12 - - 0 0 - <10 0   
Ch 13 SHV-12 (2 isolates) O25b:H4-B2-ST131 (CH40-22); ST1485-F (CH231-58) 1 1 MB-CF3rd-FQ 50 5   
Ch 14 - O153:H10-A-ST10 (CH11-54) (eae-beta1) 1 1 - 10 3 * 
Ch 15 - ST93-A (CH11-41) 1 0 FQ <10 3   







2 ESBL/pAmpC/mcr types (No. of 
isolates) 
3 High-risk lineages of E. coli 4ExPEC 5 UPEC 
6 Resistances to 
antimicrobials of 
categories A or B 





Ch 16 SHV-12, CTX-M-1 (2 isolates) ST10-A (eae-beta1) 1 1 MB-CF3rd-Q 20 5 * 
Ch 17 SHV-12 (2 isolates) O153:HNM-A-ST10 (CH11-54) (eae-beta1); ST428-B2 1 1 MB-CF3rd-FQ 20 5 * 
Ch 18 SHV-12, CTX-M-1 (1 isolate each) O153:H10-A-ST10 (CH11-54) (eae-beta1) 1 1 MB-CF3rd-FQ 440 5 * 
Ch 19 CTX-M-1, TEM-52 (1 isolate each) ST428-B2 1 1 MB-CF3rd-FQ 510 6   
Ch 20 SHV-12 (1 isolate) ST10-A (eae-beta1) 1 1 MB-CF3rd-FQ 40 4 * 
Ch 21 SHV-12, TEM-52 (1 isolate each) ST95-B2 (CH38-27) 1 1 MB-CF3rd-FQ 10 5   
Ch 22 SHV-12 (2 isolates) ST93-A (CH11-41) 1 0 MB-CF3rd-FQ 40 4 * 
Ch 23 SHV-12 (1 isolate) - 0 0 MB-CF3rd-FQ 310 1   
Ch 24 CTX-M-32 (1 isolate) ST117-G (CH45-97); O153:H10-A-ST10 (CH11-54) (eae-beta1) 1 1 MB-CF3rd-FQ 200 4 * 
Ch 25 SHV-12, CTX-M-32, TEM-52 (1, 2, and 1 isolates respectively) ST10-A (CH11-54) 0 0 MB-CF3rd-FQ 50 3   
Ch 26 - ST93-A (CH11-neg) 1 0 FQ <10 3   
Ch 27 SHV-12 (1 isolate) ST10-A (CH11-54) 1 0 MB-CF3rd-FQ 10 3   
Ch 28 SHV-12 (2 isolates) ST155-B1 1 0 MB-CF3rd-FQ <10 4   
Ch 29 - O25b:H4-B2-ST131 (CH40-22) 1 1 FQ <10 4   
Ch 30 - - 0 0 - <10 0   









2 ESBL/pAmpC/mcr types (No. of 
isolates) 
3 High-risk lineages of E. coli 4ExPEC 5 UPEC 
6 Resistances to 
antimicrobials of 
categories A or B 





Ch 32 SHV-12 (1 isolate) - 0 0 MB-CF3rd <10 1   
Ch 33 SHV-12 (3 isolates) ST162-B1 1 0 MB-CF3rd-FQ 20 3   
Ch 34 CTX-M-9 (1 isolate) ST93-A (CH11-neg) 1 0 MB-CF3rd-FQ 80 3   
Ch 35 SHV-12, TEM-52, CTX-M-1 (1, 1, and 2 isolates respectively) ST117-G (CH45-97); ST101-B1 (CH41-86) 1 0 MB-CF3rd-FQ 50 4   
Ch 36 SHV-12 (1 isolate) O153:H10-A-ST10 (CH11-54) (eae-beta1); ST93-A (CH11-41) 1 0 MB-CF3rd-FQ 20 3 * 
Ch 37 - ST1485-F (CH231-58) 1 1 FQ <10 4   
Ch 38 - ST1485-F (CH231-58) 1 1 FQ <10 4   
Ch 39 SHV-12 (1 isolate) O25b:H4-B2-ST131 (CH40-22) 1 1 MB-CF3rd-FQ <10 4   
Ch 40 SHV-12 (1 isolate) CC10-A (eae-beta1) 1 1 MB-CF3rd-FQ <10 4 * 
Ch 41 SHV-12 (3 isolates) ST69-D (CH35-27); ST155-B1 1 0 MB-CF3rd-FQ <10 4   
Ch 42 - - 0 0 - <10 0   
Ch 43 SHV-12 (3 isolates) ST117-G (CH45-97); ST1485-F (CH231-58); ST57-E 1 1 MB-CF3rd-FQ 30 5   
Ch 44 CTX-M-9 (1 isolate) ST95-B2 (CH38-27) 1 1 CF3rd-FQ 120 4   
Ch 45 SHV-12, CTX-M-14 (1 isolate each) O20:H9-C-ST410 (CH4-24); ST648-F (CH4-58) 1 1 MB-CF3rd-FQ 480 5   
Ch 46 SHV-12 (1 isolate) ST641-B1 0 0 MB-CF3rd-FQ <10 2   
Ch 47 CTX-M-32 (2 isolates) ST93-A (CH11-neg) 1 0 MB-CF3rd-FQ <10 4   







2 ESBL/pAmpC/mcr types (No. of 
isolates) 
3 High-risk lineages of E. coli 4ExPEC 5 UPEC 
6 Resistances to 
antimicrobials of 
categories A or B 





Ch 48 SHV-12 (2 isolates) ST10-A (CH11-54); ST48-A; ST744-A 1 0 MB-CF3rd-FQ 120 4   
Ch 49 SHV-12, CTX-M-15 (2 and 1 isolate, respectively) ST617-A (CH11-neg); ST155-B1 1 0 MB-CF3rd-FQ 30 4   
Ch 50 - O25b:H4-B2-ST131 (CH40-22) 1 1 FQ 80 4   
T 1 SHV-12 and mcr1.1 (1); SHV-12 (2); mcr1.1 (1) ST744-A (CH11-54); ST155-B1 1 1 MB-CF3rd-FQ-CST* 510 6   
T 2 SHV-12 (1 isolate) O46:H31-B2-ST569 (CH38-5); ST10-A (CH11-54) 1 1 MB-CF3rd-FQ 90 4   
T 3 CTX-M-1, CTX-M-15 (1 isolate each) - 0 0 MB-CF3rd-FQ 100 2   
T 4 SHV-12 (3 isolates) ST354-F 1 1 MB-CF3rd-FQ 40 5   
T 5 SHV-2, SHV-12 (1 isolate each) O51:H52-A-ST93 (CH11-neg) 1 0 MB-CF3rd-FQ 70 4   
T 6 SHV-12 (2 isolates) ST1485-F (CH231-58) 1 1 MB-CF3rd-FQ 180 5   
T 7 CTX-M-1, CTX-M-15 (1 isolate each) ST48-A 0 0 MB-CF3rd-FQ <10 3   
T 8 SHV-12, CTX-M-15 (1 isolate each) ST453-B1 (CH6-31) 1 0 MB-CF3rd-FQ 20 4   
T 9 SHV-12 (5 isolates) ST117-G (CH45-97) 1 1 MB-CF3rd-FQ 250 5   
T 10 CTX-M-32 (1 isolate) O51:H52-A-ST93 (CH11-neg) 1 0 MB-CF3rd-FQ 300 3   
T 11 SHV-12 (1 isolate) ST115-E (CH26-270); ST162-B1 1 0 MB-CF3rd-FQ 200 3   
T 12 SHV-12 (1 isolate) - 0 0 MB-CF3rd-FQ 440 1   
T 13 SHV-12, CTX-M-1, mcr1.1 (1, 1, and 2 isolates, respectively) 
ST10-A (CH11-23); ST69-D (CH35-27); ST117-G 









2 ESBL/pAmpC/mcr types (No. of 
isolates) 
3 High-risk lineages of E. coli 4ExPEC 5 UPEC 
6 Resistances to 
antimicrobials of 
categories A or B 





T 14 - O8:H4-C-ST88 (CH4-39); ST428-B2 (CH40-22) 1 1 FQ 150 4   
T 15 CTX-M-15 (1 isolate) ST117-G (CH45-97) 1 1 MB-CF3rd-FQ 70 4   
T 16 mcr1.1 (2 isolates) ST93-A (CH11-41); ST101-B1 (CH41-86); ST1485-F (CH231-58) 1 1 FQ-CST* 100 4   
T 17 SHV-12, TEM-52, mcr1.1 (1, 1 and 3 isolates, respectively) O153:H34-F-ST354 (CH88-58) 1 1 MB-CF3rd-FQ-CST* 60 5   
T 18 SHV-12 (1 isolate) ST648-F (CH4-58); ST93-A 1 0 MB-CF3rd-FQ 40 3 * 
T 19 - - 0 0 - <10 0   
T 20 SHV-12, CTX- 14 (2 and 1 isolates, respectively) ST1485-F (CH231-58) 1 1 MB-CF3rd-FQ 60 5   
T 21 SHV-12 (1 isolate) ST1485-F (CH231-58) 1 1 MB-CF3rd-FQ 130 4   
T 22 - O8:H4-C-ST88 (CH4-39); ST95-B2 1 1 FQ 80 4   
T 23 - - 0 0 - <10 0   
T 24 SHV-12, mcr1.1 (5 and 2 isolates, respectively) 
ONT:H9-A-ST744 (CH11-54); O153:H34-F-ST354 
(CH88-58); ST141-B2 (CH52-14); ST57-E; ST34-A 1 1 MB-CF3rd-FQ 150 5   
T 25 SHV-12 (1 isolate) ST350-E 0 0 MB-CF3rd-FQ 420 2   
T 26 SHV-12 (2 isolates) O25b:H4-B2-ST131 (CH40-22); ST93-A (CH11-neg); ST648-F (CH4-58) 1 1 MB-CF3rd-FQ 20 5   
T 27 SHV-12 (2 isolates) ST350-E; ST155-B1 0 0 MB-CF3rd-FQ 220 3   
T 28 SHV-12 (1 isolate) ST10-A (CH11-54); ST648-F (CH4-58) 1 1 MB-CF3rd-FQ 70 4   
T 29 - - 0 0 - <10 0   







2 ESBL/pAmpC/mcr types (No. of 
isolates) 
3 High-risk lineages of E. coli 4ExPEC 5 UPEC 
6 Resistances to 
antimicrobials of 
categories A or B 





T 30 - ST115-E (CH26-270) 1 0 FQ <10 3   
T 31 SHV-12, mcr1.1 (1 isolate each) - 0 0 MB-CF3rd-FQ 350 2   
T 32 SHV-12, CTX-M-14 (2 and 1 isolates, respectively) ST10-A (CH11-54); ST617-A (CH11-neg) 1 0 MB-CF3rd-FQ 100 4   
T 33 CTX-M-14 (2 isolates) O8:H4-C-ST88 (CH4-39); ST1141-A 1 1 MB-CF3rd-FQ 30 5   
T 34 - ST453-B1 (CH6-31) 1 0 FQ <10 3   
T 35 SHV-12 (1 isolate) - 0 0 MB-CF3rd-FQ <10 1   
T 36 - O7:H6-E-ST362 (CH100-96) 1 0 FQ <10 3   
T 37 CTX-M-1 (1 isolate) ST48-A 1 0 MB-CF3rd-FQ 20 3   
T 38 SHV-12 (3 isolates) ST155-B1 (CH4-neg) 0 1 MB-CF3rd-FQ 30 4   
T 39 SHV-12 (2 isolates) O51:H52-A-ST93 (CH11-neg); ST10328-B1 1 0 MB-CF3rd-FQ 210 4   
T 40 SHV-12, CTX-M-14 (3 and 1 isolates, respectively) O8:HNM-B1-ST58 (CH4-27); ST38-E (CH26-65) 1 1 MB-CF3rd-FQ 2320 6   
T 41 SHV-12 (1 isolate) ST1485-F (CH231-58); ST95-B2 (CH38-30) 1 1 MB-CF3rd-FQ <10 4   
T 42 SHV-12 (2 isolates) ST10-A (CH11-54); ST602-B1 (CH19-86) 0 0 MB-CF3rd-FQ 680 4   
T 43 SHV-12 (5 isolates) ST95-B2 (CH38-27); ST155-B1 (CH4-neg); ST354-F (CH88-58); ST34-A 1 1 MB-CF3rd-FQ <10 5   









2 ESBL/pAmpC/mcr types (No. of 
isolates) 
3 High-risk lineages of E. coli 4ExPEC 5 UPEC 
6 Resistances to 
antimicrobials of 
categories A or B 





T 45 - - 0 0 - <10 0   
T 46 SHV-12 (1 isolate) O25b:H4-ST131-B2 (CH40-22); ST57-E 1 1 MB-CF3rd-FQ 1130 5   
T 47 CTX-M-1, CMY-2 (1 and 2 isolates, respectively) 
O101:HNM-A-ST167 (CH11-negative); ST10-A 
(eae-beta1) 0 0 MB-CF3rd-FQ 40 3 * 
T 48 SHV-12 (4 isolates) ST95-B2 (CH38-27); ST155-B1 (CH4-neg) 1 1 MB-CF3rd-FQ 20 5   
T 49 - ST1485-F (CH231-58) 1 0 FQ 20 3   
T 50 SHV-12, CTX-M-32 (2 and 1 isolates, respectively) 
ST115-E (CH26-270); ST1485-F (CH231-58); 
ST602-B1 (CH19-86); ST906-B1 1 0 MB-CF3rd-FQ 110 4   
 
1Type of sample: Ch (chicken meat), T (turkey meat). 2ESBL/pAmpC/mcr types determined by PCR and sequencing. Indicated in bold, the recovery of 2 different ESBL/pAmpC –
producing or mcr-bearing isolates. 3High-risk lineages of E. coli associated with human extraintestinal and / or uropathogenic pathologies according to recent studies (Yamaji et al., 
2018b; Manges et al., 2019). In bold, those clonal groups (phylogroup, ST and CH) found within our own collections of clinical human isolates (Mamani et al., 2019; Flament-Simon 
et al., 2020b, 2020c). 4ExPEC status = 1: E. coli strains considered with higher capacity of developing extraintestinal pathologies when positive for two or more of five markers, 
including papAH and / or papC, sfa/focDE, afa/draBC, kpsM II and iutA; ExPEC status = 0: strains negative for those markers (Johnson et al., 2003). 5UPEC status = 1: strains considered 
with higher capacity of developing UTI pathologies when positive for three or more of four markers, including chuA, fyuA, vat and yfcV; UPEC status 0: strains negative for those 
markers (Spurbeck et al., 2012). 6Detection of isolates resistant to antimicrobials categorized as A or B (European Medicines Agency, 2020); MB (monobactams); CF3rd (3rd-generation 
cephalo- sporins); FQ (fluoroquinolones); Q (quinolones); CST (colistin) performed by broth microdilution, * MIC values 4 μg/mL. 7Count of CFU (colony forming units) per g. 8Meat 
samples were qualified between zero (lowest) to six (highest) in association with the following microbiological parameters, considered as summative risks when happened: i) E. coli 
counts >500 cfu/g of poultry meat. ii) The recovery of E. coli resistant to antimicrobials of categories A (“Avoid”) or B (“Restrict”). iii) The recovery of ≥2 different ESBL/pAmpC –
producing or mcr-bearing isolates. iv) The identification of high-risk clonal groups of E. coli associated with human extra- intestinal pathologies. v) The isolation of E. coli conforming 
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4.3. STUDY 3: GENOMIC CHARACTERIZATION OF ESBL-PRODUCING ESCHERICHIA 
COLI ISOLATES BELONGING TO A HYBRID AEPEC/EXPEC PATHOTYPE 
O153:H10-A-ST10 EAE-BETA1 OCCURRED IN HUMAN DIARRHEAGENIC 
ISOLATES, MEAT, POULTRY AND WILDLIFE 
 
From previous food and clinical surveys, we were conscious of the presence of eae-
positive ESBL-producing isolates belonging to serogroup O153. Its recovery from the 
100 meat samples (Table 20) reinforces the hypothesis of the potential food transmission. 
This was the motivation to explore the genetic and genomic relatedness between human 
and animal/meta isolates.  
 
Thirty-two eae-positive E. coli (21 ESBL and 11 non-ESBL) belonging to the 
serotype O153:H10 constituted the collection of study. As detailed in Table 10 (3.1.3. 
EPEC O153 collection of Material and Methods), they were detected within different 
surveys in the period 2005 to 2015: 14 from human stools, eight from beef meat, seven 




4.3.1. Conventional typing 
 
Table 25 summarizes the main traits determined by conventional typing for the 32 
isolates. All were positive for the intimin eae-beta1, but negative for bfpA gene, 
conforming the aEPEC pathotype. Other virulence genes defining STEC, EIEC, EAEC 
or ETEC pathotypes were not detected; however, the fimAvMT78 gene, which is a virulence 
locus that codify a fimA variant MT78 of type 1 fimbriae (Marc and Dho-Moulin, 1996) 
was present in all isolates. Besides, the traT gene that codifies an outer membrane protein 
implicated in serum survival (Johnson and Stell, 2000) was also present in 17 of the 
isolates (Table 25). By means of the serotype, phylogroup, ST and clonotyping, the 
isolates were assigned to the clonal group O153:H10-A-ST10 (CH11-54).   
 
The highest rates of AMR were to: ampicillin (75%; 24/32), cefuroxime (68.7%; 
22/32), cefotaxime (65.6%, 21/32), ceftazidime (65.6%, 21/32), cefepime (59.4%, 19/32) 
and gentamicin (59.4%, 19/32). The ESBL-typing determined that 19 isolates were CTX-
M-32 and two SHV-12 (Table 25).  
 
 





1 Year Geographic origin Virulence gene profile Resistance profile
2 blaESBL 
type 
Pork meat *LREC-122 2011 Lugo fimH54, fimAvMT78, traT, eae-beta1 
AMP, CXM, CTX, CAZ, 
FEP, GEN CTX-M-32 
Chicken 
meat *LREC-115 2009 Lugo 
fimH54, fimAvMT78, 
traT, eae-beta1 
AMP, CXM, CTX, CAZ, 
FEP, GEN, TOB CTX-M-32 
Chicken 
meat FV 19517 2009 Lugo 
fimH54, fimAvMT78, eae-
beta1 
AMP, CXM, CTX, CAZ, 
FEP, GEN CTX-M-32 
Chicken 
meat *LREC-118 2009 Lugo 
fimH54, fimAvMT78, eae-
beta1 
AMP, CXM, CTX, CAZ, 
FEP, GEN CTX-M-32 
Chicken 
meat *LREC-110 2010 Lugo 
fimH54, fimAvMT78, eae-
beta1 
AMP, CXM, CTX, CAZ, 
FEP, GEN CTX-M-32 
Chicken 
meat FV 14703 2010 Lugo 
fimH54, fimAvMT78, eae-
beta1 
AMP, CXM, CTX, CAZ, 










meat LREC-126 2010 Lugo 
fimH54, fimAvMT78, eae-
beta1 
AMP, CXM, CTX, CAZ, 
FEP, GEN, TOB CTX-M-32 
Chicken 
meat *LREC-123 2010 Lugo 
fimH54, fimAvMT78, eae-
beta1 
AMP, CXM, CTX, CAZ, 
FEP, GEN, TOB CTX-M-32 
Beef meat *LREC-119 2007 Lugo fimH54, fimAvMT78, eae-beta1 
AMP, CXM, CTX, CAZ, 
FEP, GEN CTX-M-32 
Beef meat *LREC-117 2007 Lugo fimH54, fimAvMT78, eae-beta1 
AMP, CXM, CTX, CAZ, 
FEP, GEN CTX-M-32 
Beef meat 4-3a 2007 Lugo fimH54, fimAvMT78, traT, eae-beta1 AMP, CXM, CTX, CAZ SHV-12 
Beef meat 85-5a 2008 Lugo fimH54, fimAvMT78, traT, eae-beta1 AMP, GEN - 
Beef meat *LREC-125 2008 Lugo fimH54, fimAvMT78, eae-beta1 AMP, CXM, CTX, FEP CTX-M-32 
Beef meat *LREC-114 2008 Lugo fimH54, fimAvMT78, eae-beta1 
AMP, CXM, CTX, CAZ, 
FEP, GEN, TOB CTX-M-32 
Beef meat 65-6a 2009 Lugo fimH54, fimAvMT78, traT, eae-beta1 - - 
Beef meat *LREC-120 2011 Lugo fimH54, fimAvMT78, traT, eae-beta1 
AMP, CXM, CTX, CAZ, 
FEP SHV-12 
Wildlife 
(Fox) *LREC-111 2015 Lugo 
fimH54, fimAvMT78, 
traT, eae-beta1 
AMP, CXM, CTX, CAZ, 
FEP, GEN, TOB CTX-M-32 
Poultry farm *LREC-127 2010 Pontevedra fimH54, fimAvMT78, eae-beta1 
AMP, CXM, CTX, CAZ, 
FEP, GEN CTX-M-32 
Human *LREC-116 2006 Lugo fimH54, fimAvMT78, eae-beta1 
AMP, CXM, CTX, CAZ, 
FEP, GEN, TOB CTX-M-32 
Human *LREC-113 2007 Lugo fimH54, fimAvMT78, eae-beta1 
AMP, CXM, CTX, CAZ, 
FEP, GEN, TOB CTX-M-32 
Human *LREC-121 2007 Lugo fimH54, fimAvMT78, eae-beta1 
AMP, CXM, CTX, CAZ, 
FEP, GEN, TOB CTX-M-32 
Human *LREC-124 2007 Lugo fimH54, fimAvMT78, eae-beta1 
AMP, CXM, CTX, CAZ, 
FEP, GEN, TOB CTX-M-32 
Human 31952. 07 2007 Lugo fimH54, fimAvMT78, traT, eae-beta1 - - 
Human 32651. 07 2007 Lugo fimH54, fimAvMT78, traT, eae-beta1 NAL, CIP - 
Human 32884. 07 2007 Lugo fimH54, fimAvMT78, traT, eae-beta1 
AMP, CXM, CAZ, AMC, 
SXT - 
Human 34535. 07 2007 Lugo fimH54, fimAvMT78, traT, eae-beta1 NAL, CIP - 
Human 39044. 07 2007 Lugo fimH54, fimAvMT78, traT, eae-beta1 - - 
Human 21011. 08 2008 Lugo fimH54, fimAvMT78, traT, eae-beta1 - - 
Human 38506. 08 2008 Lugo fimH54, fimAvMT78, traT, eae-beta1 CIP - 
Human 40237. 08 2008 Lugo fimH54, fimAvMT78, traT, eae-beta1 NAL, CIP - 
Human *LREC-112 2011 Santiago de Compostela 
fimH54, fimAvMT78, 
traT, eae-beta1 
AMP, CXM, CTX, CAZ, 
FEP, NAL CTX-M-32 
Human 55515.12 2012 Lugo fimH54, fimAvMT78, traT, eae-beta1 AMP, GEN - 
1Strains further analyzed by WGS are those marked with (*); 2ampicillin (AMP), amoxicillin-clavulanic acid 
(AMC), cefuroxime (CXM), ceftazidime (CAZ), cefotaxime (CTX), cefepime (FEP), cefoxitin (FOX), gentamicin 
(GEN), tobramycin (TOB), fosfomycin (FOF), sulfamethoxazole-trimethoprim (SXT), ciprofloxacin (CIP) and 
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The PFGE comparison of the XbaI-macrorrestriction profiles of the ESBL-producing 
aEPEC isolates revealed high similarity. Thus, all but one clustered with an identity >85% 
in the dendrogram shown in Figure 12. It is of note that three human clinical isolates, 
recovered in different years, clustered each with a fox (95.2% of similarity) and with two 




Figure 12. PFGE of XbaI-digested DNA from 20 ESBL-producing aEPEC isolates of the clonal group 
O153:H10-A-ST10 (one autodigested). On the right of the dendrogram: Isolate designation, O:H 
serotype, ST, ESBL type, phylogroup, year of isolation, geographic origin, source and virulence-gene 
profile 
 
4.3.2. Whole genome sequencing (WGS) 
 
Based on the high similarity shown by PFGE and to further investigate the virulence 
profile, resistome, plasmid content and relatedness, 17 representative aEPEC/ExPEC 
isolates of different origins were WG sequenced. The de novo assembled contigs were 
then typed in silico using the EnteroBase tools (Table 36), as well as the Center for 
Genomic Epidemiology (CGE) databases (Table 26). 
 
SerotypeFinder and EnteroBase predictions corroborated O and H antigens, except 
for LREC-120 and LREC-121, for which O153 was solved by serotyping. MLST (CGE 
and EnteroBase), CHtyper and ClermonTyping also confirmed conventional data for ST 
(10), CH (11-54) and phylogroup (A) (Table 26, Table 36). Additionally, the wgST, cgST, 
and rST of the genomes were determined using the schemes of EnteroBase based on 
25,002; 2,513 and 53 loci, respectively (Table 36). WgMLST and cgMLST are powerful 
schemes with extreme and high resolution, respectively, which determined different STs 
for each of the 17 genomes analyzed, while rST (medium resolution) established the same 
ST (2021) for all genome but for LREC-127 (58738) (Table 36). 
 
VirulenceFinder corroborated the hybrid pathotype nature of the isolates, predicting 
in all genomes the eae gene (intimin) together with other components encoded in the LEE 
pathogenicity island, as well as the increased serum survival gene iss recognized for its 
role in ExPEC virulence (Johnson et al., 2008). Besides, the astA gene, which encodes 





ResFinder identified the genes associated to resistances observed in vitro (acquired 
resistances for β-lactams, aminoglycosides, and point mutations for quinolones). Only, 
the blaCTX-M-32 was not predicted in silico for LREC-112 and LREC-119, but by 
conventional sequencing. Furthermore, ResFinder determined other acquired resistances 
which had not been tested in vitro, such as to phenicols and macrolides in all genomes, 
and to tetracyclines in 16 out of the 17 genomes (Table 26).  
 
Based on replicon identification, PlasmidFinder revealed a homogenous profile of 
four/five plasmid types. Thus, the concomitant presence of IncF (F2:A-:B-), IncI1 (ST 
unknown) and IncX1, together with non-conjugative Col156-like plasmids, was detected 
in 15 of 17 genomes. Four of those 15 genomes were also carriers of Col (MG828)-like 
plasmids (Table 26). 
 
In the asymmetric distance matrix on the cgMLST scheme from EnteroBase, based 
on the presence/absence of 2,513 genes, the 17 genomes showed <20 differences (range 
5-19) in relation to the human diarrheagenic isolate LREC-113 (Table 27, Figure 13). We 
also looked into the static Hierarchical Clustering (HierCC) designations in EnteroBase. 
The 17 genomes were assigned into the same HierCC HC50 (37600), which means all 
strains in this cluster have links no more than 50 alleles apart. Besides, using HC20, three 
human genomes (LREC-113, LREC-116, LREC-124) and two beef meat (LREC-119, 
LREC-125) clustered together (37606) with links no more than 20 alleles apart (Table 
37). A dendrogram based on the SNPs of the core genomic regions present in 90% of the 
compared genomes and using LREC-113 as reference, was also built in EnteroBase, 
downloaded and modified with FigTree v1.4.3 (Figure 14). Within 1,068 variant sites, 
the number of SNPs was <62 for 13 of the 17 genomes (Table 37). 
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Table 26. In silico characterization of 17 E. coli genomes from the study collection using CGE databases and ClermonTyping (in red, results obtained only by 
conventional typing) 
 
Code Serotype1 PG2 CHType3 ST4 
Plasmid content 
Inc group (pMLST)5 
Acquired resistances (black) and 
point mutations (blue)6 
Virulence genes7 
LREC-110 O153:H10 A 11-54 10 IncF (F2:A-:B-); IncI1 (ST 
unknown); IncX1; Col156 
blaCTX-M-32, blaTEM-1A; aac(3)-IIa, 
aadA1; catA1; mdf(A); tet(A) 
astA, eae, espA, espB, espF, gad, iss, mchF, 
nleA, tccP, tir 
LREC-111 O153:H10 A 11-54 10 
IncF (F2:A-:B-); IncI1 (ST 
unknown); IncX1; Col156; Col 
(MG828) 
blaCTX-M-32, blaTEM-1A; aac(3)-IIa, 
aadA1; catA1; mdf(A); tet(A) 
astA, eae, espA, espB, gad, iss, mchF, nleA, 
tccP, tir 
LREC-112 O153:H10 A 11-54 10 IncF (F2:A-:B-); IncX1; Col156; 
Col (MG828) 
blaCTX-M-32; aadA1; catA1; mdf(A); 
tet(A); gyrA S83L 
astA, eae, espA, espB, espF, gad, iss, mchF, 
nleA, tccP 
LREC-113 O153:H10 A 11-54 10 IncF (F2:A-:B-); IncI1 (ST 
unknown); IncX1; Col156 
blaCTX-M-32, blaTEM-1A; aac(3)-IIa, 
aadA1; catA1; mdf(A); tet(A) 
astA, eae, espA, espB, espF, gad, iss, mchF, 
tir 
LREC-114 O153:H10 A 11-54 10 
IncF (F2:A-:B-); IncI1 (ST 
unknown); IncX1; Col156; Col 
(MG828) 
blaCTX-M-32, blaTEM-1A; aac(3)-IIa, 
aadA1; catA1; mdf(A); tet(A) 
astA, eae, espA, espB, espF, gad, iss, mchF, 
nleA, tir 
LREC-115 O153:H10 A 11-54 10 IncF (F2:A-:B-); IncI1 (ST 
unknown); IncX1; Col156 
blaCTX-M-32, blaTEM-1A; aac(3)-IIa, 
aadA1; catA1; mdf(A); tet(A) 
astA, eae, espA, espB, espF, gad, iss, mchF, 
nleA, tccP, tir 
LREC-116 O153:H10 A 11-54 10 IncF (F2:A-:B-); IncI1 (ST unknown); IncX1; Col156 
blaCTX-M-32, blaTEM-1A; aac(3)-IIa, 
aadA1; catA1; mdf(A); tet(A) astA, eae, espA, espB, gad, iss, mchF, tccP, tir 
LREC-117 O153:H10 A 11-54 10 IncF (F2:A-:B-); IncI1 (ST 
unknown); IncX1; Col156 
blaCTX-M-32; aadA1; mdf(A); tet(A) astA, eae, espA, espB, gad, iss, mchF, tccP, tir 
LREC-118 O153:H10 A 11-54 10 
IncF (F2:A-:B-); IncI1 (ST 
unknown); IncX1; Col156; 
Col(MG828) 
blaCTX-M-32, blaTEM-1A; aac(3)-IIa, 
aadA1; catA1; mdf(A); tet(A) 
astA, eae, espA, espB, espF, gad, iss, mchF, 
nleA, tccP, tir 




Code Serotype1 PG2 CHType3 ST4 
Plasmid content 
Inc group (pMLST)5 
Acquired resistances (black) and 
point mutations (blue)6 Virulence genes
7 
LREC-120 O153:H10 A 11-54 10 IncI1 (ST22-CC2); IncQ1; IncX1; Col156; Col (MG828) 
blaSHV-12; aadA1, aadA2; catA1, 
cmlA1; mdf(A); sul3; tet(A) 
astA, eae, espA, espB, gad, iss, mchF, nleA,  
tccP, tir 
LREC-121 O153:H10 A 11-54 10 IncF (F2:A-:B-); IncI1 
(STunknown); IncX1; Col156 
blaCTX-M-32, blaTEM-1A; aac(3)-IIa, 
aadA1; catA1; mdf(A); tet(A) 
astA, eae, espA, espB, gad, iss, mchF, nleA, 
tccP, tir 
LREC-122 O153:H10 A 11-54 10 
IncF (F2:A-:B-); IncI1 
(STunknown); IncX1; Col156; 
Col (MG828) 
blaCTX-M-32; aac(3)-IIa, aadA1; catA1; 
mdf(A); tet(A) 
astA, eae, espA, espB, gad, iss, mchF, nleA, 
tccP, tir 
LREC-123 O153:H10 A 11-54 10 
IncF (F2:A-:B-); IncI1 
(STunknown); IncX1; Col156; 
Col (MG828) 
blaCTX-M-32, blaTEM-1A; aac(3)-IIa, 
aadA1; catA1; mdf(A); tet(A) 
astA, eae, espA, espB, gad, iss, mchF, nleA, 
tccP, tir 
LREC-124 O153:H10 A 11-54 10 
IncF (F2:A-:B-); IncI1 
(STunknown); IncX1; IncY; 
Col156 
blaCTX-M-32, blaTEM-1A; aac(3)-IIa, 
aadA1; catA1; mdf(A); tet(A) 
astA, eae, espA, espB, espF, gad, iss, mchF, 
tccP, tir 
LREC-125 O153:H10 A 11-54 10 IncF (F2:A-:B-); IncI1 (STunknown); IncX1; Col156 
blaCTX-M-32; aadA1; catA1; mdf(A); 
tet(A) 
astA, eae, espA, espB, espF, gad, iss, mchF, 
nleA, tccP, tir 
LREC-127 O153:H10 A 11-54 10 
IncF (F2:A-:B-); IncI1 
(STunknown); IncX1; Col156; 
Col (MG828) 
blaCTX-M-32, blaTEM-1A; aac(3)-IIa, 
aadA1; catA1; mdf(A); tet(A) 
astA, eae, espA, espB, espF, gad, iss, mchF, 
nleA, tccP, tir 
1Serotypes, 3clonotypes, 4sequence types, 5replicon/plasmid STs, 6acquired antimicrobial resistance genes and / or chromosomal mutations, 7virulence genes were 
determined using SerotypeFinder 2.0, CHtyper 1.0, MLST 2.0, PlasmidFinder 2.0, pMLST 2.0, ResFinder 3.1 and VirulenceFinder 2.0 online tools at the CGE, respectively. 
While 2PG; phylogroups were predicted using the ClermonTyping tool at the Iame-research Center web. 1Serotypes: underlined and in red those (LREC-121, LREC-120) 
that were not predicted (ONT) by SerotypeFinder but assigned as O153 by conventional typing.6Resistome: Acquired resistance genes: β-lactam: blaTEM-1A, blaCTX-M-32, 
blaSHV-12; aminoglycosides: aac(3)-IIa, aadA1, aadA2; phenicols: catA1, cmlA1; macrolides: mdf(A); sulphonamides: sul3; tetracycline: tet(A). Point mutations (marked 
in blue): quinolones and fluoroquinolones: gyrA S83L: TCG-TTG. Underlined and in red those blaCTX-M-32 genes (LREC-112, LREC-119) that were not predicted by ResFinder 
but determined in conventional typing 8Virulence genes: astA: EAST-1, eae: intimin, espA: type III secretions system, espB: secreted protein B, espF: type III secretions 
system, gad: glutamate descarboxylase, iss: increased serum survival, mchF: ABC transporter protein MchF, nleA: non LEE encoded effector A, tccP: Tir cytoskeleton 
coupling protein, tir: translocated intimin receptor protein. bp: base pairs; CHType: clonotype (fumC-fimH); ST: sequence type according to Achtman scheme; pMLST: 
plasmid sequence type.  
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Table 27. Asymmetric distance matrix based on the cgMLST scheme from EnteroBase in which D (a, b) equals all sites that are present in (b) and different from (a) 
 




































37600 37601 37602 37605 37606 37607 37609 37610 37611 37612 37613 37614 37615 37616 37617 37618 38299 
LREC-
110 37600 0 14 17 19 13 12 18 19 12 15 27 8 15 15 18 16 14 
LREC-
111 37601 14 0 21 23 16 20 22 23 16 19 30 11 19 18 22 20 17 
LREC-
127 37602 17 21 0 24 9 22 14 16 9 11 24 15 13 13 15 13 13 
LREC-
112 37605 19 23 24 0 19 25 24 25 18 21 33 17 22 22 24 23 21 
LREC-
113 37606 13 16 9 19 0 18 9 11 5 6 18 10 9 8 11 9 8 
LREC-
120 37607 12 20 22 25 18 0 23 23 18 20 33 14 20 20 24 22 19 
LREC-
117 37609 18 22 14 24 9 23 0 17 8 12 22 15 14 13 14 12 13 
LREC-
121 37610 19 23 16 25 11 23 17 0 10 13 25 15 16 16 16 14 14 
LREC-
119 37611 12 16 9 18 5 18 8 10 0 6 17 10 9 9 7 6 8 
LREC-
116 37612 15 19 11 21 6 20 12 13 6 0 22 12 11 11 13 11 10 
LREC-
115 37613 27 30 24 33 18 33 22 25 17 22 0 22 24 23 23 15 20 
LREC-
114 37614 8 11 15 17 10 14 15 15 10 12 22 0 13 12 15 14 11 
LREC-
123 37615 15 19 13 22 9 20 14 16 9 11 24 13 0 7 15 13 8 
LREC-
122 37616 15 18 13 22 8 20 13 16 9 11 23 12 7 0 15 13 9 
LREC-
124 37617 18 22 15 24 11 24 14 16 7 13 23 15 15 15 0 12 14 
LREC-
125 37618 16 20 13 23 9 22 12 14 6 11 15 14 13 13 12 0 12 
LREC-





Figure 13. GrapeTree inferred using the MSTree V2 algorithm based on the cgMLST V1 + HierCC V1 scheme from EnteroBase 
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Figure 14. Dendrogram based on the SNPs of the core genomic regions present in 90% of the compared genomes and using LREC-113 as reference, built in EnteroBase and 
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5.1. CONSUMER EXPOSURE TO HIGH RISK ENTEROBACTERIACEAE FROM CHICKEN 
AND TURKEY MEAT 
 
Common human extraintestinal diseases, namely, UTIs or blood stream infections, 
may be caused by bacteria not traditionally defined as food-borne pathogens. Currently, 
there is not a surveillance system of ExPEC genotypes, or other Enterobacteriaceae 
causing extraintestinal infections, to elucidate their real role (Riley, 2020). For first time, 
and based on a comprehensive characterization of 256 isolates, this study evaluates the 
consumer exposure via poultry meat to Enterobacteriaceae with capacity to develop, not 
only intestinal, but also severe extraintestinal infections by either bacterial virulence and 
/ or antibiotic resistance traits. For this purpose, we aimed to develop a suitable protocol 
potentially applicable in the routine of food microbiological laboratories. This protocol 
comprises a meat sample enrichment, followed by the characterization of one 
representative E. coli colony grown on Lactose MacConkey agar (LMA), and those 
species suspected of being ESBL/Carbapenemase-producing Enterobacteriaceae grown 
on CHROMID® ESBL or CHROMID®CARBA SMART.  The combination of these 
selective media effectively provided complementary information on the presence and 
prevalence of specific high-risk clonal groups of E. coli, as well as other ESBL-producing 
Enterobacteriaceae. 
 
A high-risk clone, such as the ST131 of E. coli , is that defined as globally distributed, 
associated with multiple AMR determinants, able to colonize and persist in hosts for more 
than six months, capable of effective transmission between hosts, enhanced pathogenicity 
and fitness, and able to cause severe and / or recurrent infections (Mathers et al., 2015). 
It is within the group of ExPEC where the successful risk clones of E. coli emerge. 
According to a recent meta-analysis, 20 major ExPEC STs accounted for 85% of the 
studies included, being considered global extraintestinal pathogenic lineages (Manges et 
al., 2019). In this study, 13 of those top 20 ExPEC lineages were detected in 50% of our 
meat samples (ST10, ST23, ST38, ST58, ST69, ST88, ST95, ST117, ST131, ST167, 
ST354, ST410, ST617). Seven of the 13 STs were determined within both the 
representative 84 E. coli and the 137 ESBL-E. coli; however, certain isolates could be 
recovered only via LMA (those belonging to ST23, ST95 and the pandemic ST131) while 
others (ST69, ST167, ST354, and ST617) of the ESBL-producing isolates, were detected 
mostly via CHROMID® ESBL. 
 
The increasing evidence that retail food may serve as a source of E. coli  implicated 
in UTIs was recently analyzed by Yamaji et al. (Yamaji et al., 2018a) through the 
characterization of 233 E. coli  isolates from human urine samples and 177 E. coli  from 
retail meat (poultry, pork and beef) collected in the same geographic region. Within their 
collection, 21% of E. coli isolates from suspected cases of UTIs belonged to STs found 
in poultry, stating that poultry may serve as possible reservoir of UPEC. In our study, 
40% of the meat poultry samples carried E. coli belonging to STs (ST10, ST38, ST69, 
ST88, ST95, ST101, ST117, ST131, ST141, ST354, ST906) identified by Yamaji et al. 
(2018) within the UTI human cases, corresponding to 20.8% of our 221 E. coli isolates. 
Significantly, we found a higher prevalence of turkey isolates belonging to STs associated 
to UPEC in comparison with those of chicken origin (32 of 114; 28.1% vs 16 of 107; 
14.9%) (P = 0.022). 
 
We further investigated, within the 221 E. coli , the presence of four genes (yfcV, vat, 





than E. coli  isolates without these genes (Spurbeck et al., 2012). We found that 18 E. coli 
from 17 different meat samples conformed the UPEC status (Table 14). The 18 isolates 
belonged to B2 and F phylogroups, exhibited a high number of extraintestinal VF and 
included reported ST/CC linked to UTIs, such as ST95, ST117, ST131, ST141 or CC648. 
Importantly, the isolates of the following seven clones carried the four genes yfcV, vat, 
fyuA, and chuA: O1:H7-B2-ST95 (CH38-30); O50/O2:H6-B2-ST141 (CH52-14); 
O115:HNM-B2-ST187 (CH24-187); O120:H4-B2-ST428 (CH40-22); O120:H4-B2-
ST428 (CH40-neg); O11:H25-F-ST457 (CH88-145); O113:H5-B2-ST8611 (CH24-26). 
 
E. coli ST131 has clearly become the major cause of MDR UTIs worldwide within 
healthcare and community settings. WGS-analysis of the population structure of E. coli  
ST131 identified three genetically distinct Clades (A, B, C), and numerous subclades 
from the dominant fluoroquinolone-resistant Clade C (Johnson et al., 2010; Price et al., 
2013; Stoesser et al., 2016); Clade C carries a type 1 fimbrial adhesin gene H30 variant 
(fimH30; clonotype CH40-30), and compensatory mutations at regulatory regions which 
seems to confer adaptive advantages for the fitness cost of AMR, plasmid acquisition and 
maintenance, differently from the fluoroquinolone-susceptible Clades A (fimH41; 
clonotype CH40-41) and B (fimH22; clonotype CH40-22) (Stoesser et al., 2016; Decano 
and Downing, 2019). While ST131-H30 is the most prevalent, Clades A and B are also 
important agents of community and hospital-acquired UTIs (Mora et al., 2014; de Toro 
et al., 2017b; Liu et al., 2018). ST131 isolates can be further classified into 12 virotypes 
(A to F), regarding the presence/absence of certain virulence genes, which show different 
host distribution, prevalence, and in vivo virulence in the mouse model (Blanco et al., 
2013; Dahbi et al., 2014; Mora et al., 2014). In this study, ST131-H22 (CH40-22) was 
determined in two E. coli isolates recovered from two chicken samples in the LMA 
medium. Both ST131 isolates conformed virotype D4 (carriers of ibeA gene and K1 
variant of group II capsule) and showed MDR to aminoglycosides, tetracyclines and 
quinolones. In previous studies, we proved that the ST131 poultry linage typically 
conforms virotype D4 (Cortés et al., 2010; Mora et al., 2010; Solà-Ginés et al., 2015). 
Importantly, we also found virotype D4 within clinical human ST131, with a prevalence 
of 3.8% among 157 isolates (unpublished data), and some of them showing a high genetic 
similarity compared to avian isolates (Mora et al., 2010). Recently, we also proved by 
WGS, that porcine (meat and animal origin) and clinical human ST131-H22 isolates of 
new subclades B6 and B7, were strongly related (average distance of 20 and 15 SNP/Mb, 
respectively) (Flament-Simon et al., 2020c). Liu et al. (2018), combining detection of 
poultry associated ColV plasmids with high-resolution phylogenetics, quantified the 
proportion of human infections (from urine and blood cultures). From their results, the 
authors stated that sub lineage ST131-H22 has become established in poultry populations 
around the world and that meat may serve as a vehicle for human exposure and infection. 
According to the authors, ST131-H22 would be just one of many E. coli lineages that 
may be transmitted from food animals to humans.  
 
We also studied within meat isolates the presence of diarrheagenic E. coli. While 
none of the 221 E. coli was positive for the specific VF associated with the verotoxigenic 
(stx1, stx2) or enteroaggregative (aaiC, aggR) pathotypes, four CC10-A isolates obtained 
from four different meat samples carried the eae-beta1 intimin gene, together with 
extraintestinal pathogenic genes, and conforming an atypical EPEC/ExPEC hybrid 
pathotype: two isolates O153:H10-A-ST10 (CH11-54); one O145:H40-A-ST752 (CH11-
24) and one O123/186:H34-A-ST752 (CH11-24). In our geographical region (NW 
Spain), we have been periodically detecting a hybrid MDR aEPEC/ExPEC of clonal 
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group O153:H10-A-ST10 (CH11-54) recovered from different sources (food-producing 
animals; chicken, beef and pork meat; wildlife and human clinical samples). Importantly, 
we proved genomic evidence of the close relatedness of the isolates that may be playing 
a successful role in spreading ESBLs (CTX-M-32) in our region within different hosts, 
including wildlife. Besides, it would be potentially implicated in human diarrhea via food 
(meat) transmission (Díaz-Jiménez et al., 2020b). Since 2011, when a novel STEC/EAEC 
E. coli  O104:H4 emerged in Germany and neighboring countries (Mora et al., 2011b), 
other hybrid virulent E. coli  have been reported. The most outstanding is the recently 
emerged STEC/ExPEC O80:H2 hybrid reported to cause HUS and bacteremia (Mariani-
Kurkdjian et al., 2014), but there are also STEC/UPEC hybrids which have been 
identified from hospitalized patients (Toval et al., 2014), or some STEC/ETEC strains 
associated with diarrheal disease and HUS in humans (Nyholm et al., 2015). Given the 
public health importance of hybrid pathotypes, it seems necessary the surveillance of 
potentially emerging types. 
 
According to the diversity of STs found within the 221 E. coli isolates of our study, 
and despite more than 50% of the 84 representative E. coli as well as the ESBL-producing 
E. coli belonged to the phylogroups A + B1, the other five (B2, C, D, E, F) of E. coli 
sensu stricto were represented in the collection. The most anciently diverged phylogroups 
B2, F and D comprises the majority of ExPEC isolates, whereas the intestinal pathologies 
are linked to the most recently diverged phylogroups (E, C, B1 and A) (Clermont et al., 
2019). Interestingly, five isolates from different samples belonged to Escherichia clade I, 
which is also considered a phylogroup of E. coli  based on the extent of recombination 
detected between strains belonging to clade I and E. coli  (Clermont et al., 2013). The five 
isolates, recovered from CHROMID® ESBL, belonged to the clonal group ST770 
(CH116-552), conformed the ExPEC status, were CTX-M-9 (two) or SHV-12 (three 
isolates) and MDR (the five FQ-resistant).  
 
Besides the virulence traits associated to intestinal and extraintestinal E. coli 
pathotypes, we investigated here the consumers´ exposure to antibiotic-resistant bacteria. 
Based on the complementary analysis of Enterobacteriaceae recovered from the two 
selective media, we found that 90% of the meat samples were carriers of MDR isolates. 
Specifically, 96% samples carried resistant isolates to antimicrobials of categories A or 
B, including 18% of the meat samples with colistin-resistant isolates, 64% with resistance 
to monobactams, and one of those also to FOF (category A). Resistance prevalence was 
significantly higher among turkey isolates (in both representative E. coli and ESBL-
producing Enterobacteriaceae) for SXT and CIP. In a study conducted in USA on poultry 
meat, the authors found higher resistance prevalence among E. coli  isolates from 
conventionally-raised turkey for most of the antibiotics tested compared to chicken meat 
(Davis et al., 2018). We also found in our study that turkey meat was significantly more 
contaminated with other ESBL-producing species than chicken. The differences found 
for turkey meat can be probably associated with a longer exposition to antibiotics due to 
the much longer fattening period.  
 
On the other hand, the marked variation of prevalence and type of antibiotic  
resistances reported by the countries would be linked to the current and past usage of 
antibiotics in the respective animal species. The European Union summary report on 
AMR in indicator E. coli  (EFSA, 2021) shows comparable results to ours from the 84 
representative E. coli , however, this E. coli  collection alone would not reflect the real 





The ESBL types determined in our study within the E. coli  isolates are mostly the 
same as those reported in other studies for poultry meat (Egea et al., 2012; Kaesbohrer et 
al., 2019; Nüesch-Inderbinen et al., 2019), but with an outstanding prevalence of SHV 
(SHV-12, mainly) (71.5% of the 172 ESBL-producing Enterobacteriaceae and 68.6% of 
the 137 ESBL-producing E. coli ). In the south of Spain, Egea et al. also found this 
predominance, but with a decrease in favor of CTX-M ESBLs in comparison with a 
previous study (Doi et al., 2010; Egea et al., 2012). Interestingly, our studies on poultry, 
suggest an increase of the SHV isolates. Thus, of the 84 avian ESBL-producing E. coli  
recovered from faecal avian samples in 52 farms located in the same geographical area 
(2010-2012), 70.2% were of CTX-M type and 29.8% of SHV (García et al., 2018). 
Likewise, 62.8% and 37.2% of 98 ESBL-producing E. coli  from chicken meat sampled 
in our city (2010-2011) were CTX-M and SHV, respectively (Herrera, 2015). 
 
We also investigated here the colistin resistance linked to mcr genes within the meat 
isolates. Since the mcr-1 plasmid gene was first described (Liu et al., 2016), different 
authors corroborate that large conjugative plasmids of types IncHI2, IncX4 and IncI2 
would be the maximum responsible for the dissemination of the mcr-1 gene among E. 
coli  isolates from different sources and geographical locations (Hasman et al., 2015; 
Doumith et al., 2016; Dominguez et al., 2019). We report in this study two CC10-A 
(CH11-54) carriers of the mcr-1.1 variant located in an IncX4 plasmid type. Based on the 
different replicons identified by PlasmidFinder, it is of note the high plasmid diversity 
found within these isolates. In a recent study, we investigated the characteristics of 
colistin-resistant E. coli clones successfully spread in swine in Spain. We found high 
variability in the location of mcr-1.1 genes, although they were located mainly on 
plasmids of the IncHI2 and IncX4 types (six and four of the 12 mcr-1.1 plasmid-located 
genes, respectively); however, mcr-1.1 also appeared integrated in the chromosome of 
four genomes (García-Meniño et al., 2019). 
 
We also recovered 28 ESBL-producing K. pneumoniae from 27 meat samples 
(mainly from turkey). K. pneumoniae is a major cause of nosocomial infections 
worldwide, capable to persist in a wide range of reservoirs including health care settings, 
retail meat, livestock and wastewater (Holt et al., 2015; Ludden et al., 2020). A recent 
study explored the genetic relatedness of K. pneumoniae isolated from the same and 
different reservoirs within a defined geographic region of England. The authors found 
few STs shared between the different sources, and the WGS-based analysis showed no 
evidence for livestock as a source of K. pneumoniae infecting humans (Ludden et al., 
2020). In our collection, at least eight of the 11 STs identified were previously reported 
within human clinic isolates: ST15, ST45, ST111, ST147, ST307, ST627, ST966 and 
ST1086 (Hu et al., 2013; uz Zaman et al., 2014; Holt et al., 2015; Moradigaravand et al., 
2017; Esposito et al., 2018). Since K. pneumoniae is an opportunistic pathogen, the main 
concern here would be the high rates of resistance to CTX, CIP, SXT, DOX and TGC 
(more than 60% of isolates), together with the high prevalence of blaCTX-M-15 (13 isolates 
from 12 meat samples). In contrast, CTX-M-15 producing E. coli was recovered only 
from five samples, and two of them with co-occurrence of K. pneumoniae SHV-28, CTX-
M-15 isolates. 
 
Our results show that poultry meat microbiota is a source of genetically diverse 
Enterobacteriaceae, resistant to relevant antimicrobials and potentially pathogenic for 
humans, including hybrid pathotypes of E. coli, high-risk clonal groups of E. coli 
associated with human extraintestinal and / or uropathogenic pathologies, as well as K. 
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pneumoniae clonal groups of clinical interest. Given this scenario, antibiotic pressure 
reduction in poultry as well as surveillance of bacterial evolution is a public health 
priority. It would be highly recommended the implementation of a systematic AMR and 
ExPEC monitoring of food at retail as a follow-up tool “from the farm to the table” under 
the One Health strategy. 
 
5.2. LABORATORY WORKFLOW FOR THE COMPREHENSIVE ANALYSIS IN FOOD OF 
AMR AND PATHOGENIC E. COLI, INCLUDING EXPEC ISOLATES 
 
We aimed to develop a standardized protocol to assess exposure risk via food to drug-
resistance genes and E. coli strains potentially pathogenic to humans. To the best of our 
knowledge, this would be the first study that reports a comprehensive typing of the E. coli 
isolates per food sample, which, on the other side, helped us to show the relevance of our 
proposal. In previous studies, we had observed the genetic similarity between isolates of 
certain ExPEC clonal groups recovered from poultry and human pathologies (Mora et al., 
2009b, 2010, 2013). We had also demonstrated close genomic relatedness between 
isolates of a hybrid MDR aEPEC/ExPEC O153:H10-A-ST10 (CH11-54) from different 
sources, including avian farm, chicken meat and human diarrheagenic samples (Díaz-
Jiménez et al., 2020b). We had found, in another study, a short distance of less than 55 
SNPs on the core genome comparison between a human and an avian isolates of ST131 
subclade B3 (Flament-Simon et al., 2020c). Other authors also investigated the genomic 
overlap between APEC and human ExPEC of the specific ST95, and found that certain 
ExPEC clones may indeed have the potential to cause infection in both poultry and 
humans (Jørgensen et al., 2019). For those evidences, and in agreement with Riley (Riley, 
2020), we claim the need of looking at ExPEC genotypes to elucidate their role as 
extraintestinal food-borne pathogen.  
 
The selective media, genetic targets and virulence traits of the protocol proposed here 
are based on results from previous studies. In relation to InPEC targets, we included 
clinically important E. coli for humans, and potentially prevalent in poultry meat. Thus, 
the analysis of all InPEC pathotypes in 200 poultry samples showed that none of the 200 
meat samples was positive for EIEC or ETEC (Herrera, 2015). Nor were these pathotypes 
relevant within the diarrheagenic stools of patients of our Health Area (Mora et al., 
2011b). Also, in the study of Herrera (2015), we had isolated ESBL-producing E. coli in 
45.5% of the samples by means of ML and MLST. Subsequently, we proved that the 
CHROMID® ESBL medium is essential for the rapid and accurate recovery of ESBL-
producing isolates (Díaz-Jiménez et al., 2020a). We performed here the selective 
characterization of ESBL-producing E. coli as indicator of drug-resistance gene exposure 
via food, due to being by far the most prevalent species isolated in CHROMID® ESBL 
(77%). Taken into account the presence of other ESBL-producers, the global rate of 
positive samples would be 82% (Díaz-Jiménez et al., 2020a). To assess exposure risk to 
ExPEC, we used the virulence traits which are statistically associated with the pathogenic 
potential of causing extraintestinal infections, conforming the ExPEC status (Johnson et 
al., 2003c); and then, those specifically linked to uropathogenic isolates, conforming the 
UPEC status (Spurbeck et al., 2012). The duplex PCR based on iutA and KpsM II genes 
on ML and MLST was essential for the accurate screening of the isolates with ExPEC 
status, as well as for the recovery of those with UPEC status since most of the latter also 
satisfies the ExPEC status (but not the other way around). As a result, we found worrying 
prevalence rates of positivity for the ExPEC and the UPEC status (78% and 53%, 





in retail foods performed in Minneapolis (1999-2000 and 2001-2003), found a prevalence 
of 35.7% and 46% of ExPEC contamination in poultry meat, respectively (Johnson et al., 
2005a, 2005b). The media used here, ML and MSTC, inoculated with the MacConkey 
Lactose broth (growth for 18-24 h at 37 ºC), together with the specific PCR on confluents 
and pools of colonies, probably explains the significant differences with the US findings. 
In those, the virulence traits associated to ExPEC status were investigated on a selection 
of colonies obtained from a non-specific protocol (Johnson et al., 2005a, 2005b). 
 
The finding here of aEPEC/ExPEC O153:H10-A-ST10 (CH11-54) eae-beta1 and 
similar hybrids in 19% of the meat sampled, reinforces the role of poultry meat in their 
maintenance and transmission. The prevalence and implication of hybrid pathotypes of 
E. coli in food and infections are probably underestimated since there is no systematic 
search of them.  Recently, we described the hybrid MDR aEPEC/ExPEC of the clonal 
group O153:H10-A-ST10 (CH11-54) found within different surveillance studies (2005-
2015), and the close genomic relatedness between isolates of human and animal origin 
belonging to it. This hybrid has been circulating in our region within different hosts, 
including wildlife, and seems implicated in human diarrhea via meat transmission and in 
the spreading of ESBL genes. Furthermore, we found genomic evidence of a related 
hybrid in at least one other country (Díaz-Jiménez et al., 2020b). Curiously, Flament-
Simon et al. (Flament-Simon et al., 2020b) detected a hybrid EAEC/ ExPEC isolate 
O153:HNT-A-ST10 (CH11-54) among 96 E. coli  implicated in UTIs and other 
extraintestinal human infections in the Hospital of Beaujon (Clichy, Paris) in 2016. 
Lindstedt et al. (Lindstedt et al., 2018) reported that a high frequency (> 93%) of routinely 
submitted faecal E. coli  isolates from Norwegian hospitals (2012-2013), previously 
characterized as DEC, harbored ExPEC virulence factors. In view of our and other 
author´s findings, we believe that hybrid E. coli isolates should be monitored as a pre-
warning of altered virulence capabilities. 
 
In addition to O153:H10-A-ST10 (CH11-54), other human-associated clonal groups 
characterized in our own Health Area (Flament-Simon et al., 2020a, 2020b) were 
determined in 73% of our meat samples (as detailed in Table 24). What is more, around 
25% of the meat samples showed co-occurrence of two or more different human 
associated ExPEC clones. To highlight, the concomitant presence in four meat samples 
of isolates belonging to the pandemic clonal group O25b:H4-B2-ST131 (subclones 
CH40-22 and CH40-neg), together with others such as ST648-F (CH4-58); or a turkey 
meat sample (T40) with the co-occurrence of the human-associated ExPEC clones 
ONT:H9-A-ST744 (CH11-54), O153:H34-F-ST354 (CH88-58), ST141-B2 (CH52-14), 
together with mcr-1.1-positive ST140-B2 isolates.  
 
Within the 323 isolates analyzed in this study, we found representatives of the eight 
phylogroups of E. coli and of the Escherichia clade I, being the phylogroup A the most 
prevalent (32.5%), followed by phylogroups B1 and B2 (around 17.5% each) and 
phylogroups E and F (around 10.5% each). This would be a close picture of the E. coli 
population present in poultry farming and meat products, based on the comprehensive 
method performed here. Previous data showed that if we only take a representative E. coli  
recovered from ML into consideration, the phylogroups A and B1 would account for 
around 30% each, and B2 for 6%; while considering only ESBL-producing E. coli , the 
figures would be 40.1%, 29.2% and 2.2%, respectively (Díaz-Jiménez et al., 2020a). 
Similar distribution to the latter was observed within 84 ESBL-producing E. coli  
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recovered from 52 avian farms in our region (39.3% A, 33.3% B1, 3.5% B2) (García et 
al., 2018). 
 
It is outstanding here, the high prevalence of meat samples with carriage of E. coli 
exhibiting the UPEC status (53%). The 83 isolates recovered from positive samples 
belonged to phylogroups B2, F and G (68.7%, 25.3% and 6%, respectively). Within the 
22 STs established for the 83 meat isolates, we found some of the most prevalent in UPEC 
human collections, such as ST95-B2, ST131-B2 and ST141-B2 (Flament-Simon et al., 
2020b). In concordance with the referenced study, we observed that the 22 isolates 
belonging to STs 95, 131 or 141 of our study conformed to the UPEC status. The relevant 
presence of isolates belonging to phylogroups F and G within poultry meat was mostly 
due to the clones ST648-F (CH4-58), ST1485-F (CH231-58) and ST117-G (CH45-97), 
which were also in the human clinic collection, but especially within the ESBL-producing 
E. coli (Flament-Simon et al., 2020a). Isolates belonging to the phylogroup F seems to be 
of particular significance as they have been reported as extraintestinal pathogens of 
companion animals, food-producing animals and humans. Further, specific F lineages 
such as CC648 or CC354 are resistant to fluoroquinolones (FQ) and / or extended-
spectrum cephalosporins, and are increasingly associated with extraintestinal pathologies 
(Vangchhia et al., 2016; Johnson et al., 2017a; Abreu-Salinas et al., 2020). On the other 
hand, the phylogroup G has been recently defined as a group intermediate between the F 
and B2 phylogroups. CC117 is its most prevalent G lineage, whose isolates commonly 
possess many traits associated with extraintestinal virulence and exhibit multidrug 
resistance. Epidemiologic data suggest that CC117 is a poultry-associated lineage that 
appears also established in humans and cause extraintestinal diseases (Clermont et al., 
2019). In the present study, we recovered nine ST117 isolates, all of them MDR, seven 
were ESBL producers (three CTX-M-1 and four SHV-12) and five were positive for the 
UPEC status. 
 
We also recovered in this study eight isolates belonging to Escherichia clade I 
(ST770, 7 isolates; ST4994, 1 isolate). The eight isolates exhibited the ExPEC status and 
five were ESBL producers (2 CTX-M-9 and 3 SHV-12). Although ST770 
Escherichia clade I is infrequently reported, it has been associated with blaCTX-M-
1 carriage in poultry in the Netherlands and Switzerland (Dierikx et al., 2013; Vogt et al., 
2014). It has been also associated with pAmpC production, specifically CMY-2, isolated 
from rooks wintering in Czechia and from broilers in Sweden (Börjesson et al., 2013; 
Jamborova et al., 2015). Recently, we recovered blaCTX-M-14-carrying ST770  isolates 
from five  healthy dogs of our region (Abreu-Salinas et al., 2020). But importantly, ST770 
isolates have been also found implicated in UTI cases: in a dog in Argentina by an mcr-
1 and blaCTX-M-2 isolate, and in a patient in Spain (Valverde et al., 2009; Rumi et al., 
2019). 
 
Globally, we found significant differences regarding meat origin. Thus, turkey meat 
showed worse microbiological quality (56% of turkey samples with E. coli counts > 50 
cfu/g vs 30% of chicken), higher rates of multidrug resistance and higher rates of mcr-
carriage. These differences are probably associated with a longer fattening period and so, 
with a longer exposition to antibiotics. There are also different reports suggesting that 
poultry production systems alternative to the conventional broiler production are 
associated with reduced frequency of antibiotic-resistant E. coli  among the commensal 
gut microbiota, posing a lower risk to the environment and the consumer (Davis et al., 





varied by meat type and was higher among E. coli isolates from turkey for most antibiotics 
tested compared to chicken meat. 
 
The finding that more than 80% of the poultry meat samples posed ≥ 3 risks including 
resistance genes, virulence traits, and human-associated pathogenic clones of E. coli 
means that consumers are highly exposed to those threats. To which extend poultry 
participates in the human microbiota composition and extraintestinal pathologies such as 
MDR UTIs needs deep elucidation. But first it is necessary the implementation of a 
systematic AMR surveillance in food, together with the monitoring of ExPEC and DEC, 
which would enable effective food safety interventions under both “farm to fork strategy” 
and One Health perspective. Based on our observations, we propose an optimized 
workflow combination. The microbiological method (pre-enrichment, enrichment in ML 
broth, and inoculation onto ML/MSTC/CHROMID® ESBL), followed by the screening 
of six virulence/AMR traits, and including a duplex PCR for the screening of ExPEC, 
would estimate the greatest risk for consumers. 
 
5.3. GENETIC AND GENOMIC RELATEDNESS OF THE HYBRID AEPEC/EXPEC 
PATHOTYPE O153:H10-A-ST10 EAE-BETA1  
 
The recovery, over the time, of eae-positive isolates of serotype O153:H10 from 
different sources and its association with ESBL enzymes triggered this investigation. 
From independent studies on ESBLs, we found that O153 aEPEC represented 5.5% of 
the ESBL-producing E. coli  recovered from chicken meat (2009-2010), 7.7% of pork 
meat (2011-2012), 5.5% 20% of beef meat (2011-2012), 1% of poultry farm environment 
(2010-2012) and 1% of wildlife feces (2014-2015) in our region (Díaz-Jiménez et al., 
2017). Besides, we had detected 23 (0,24%) O153 aEPEC as the only pathogen within 
9,523 stools of epidemiologically unrelated patients (2006-2012), in the routine testing of 
human diarrheagenic samples. From those 23, 14 (0.15%) were O153:H10 eae-beta1 
fimAvMT78, and five of them blaCTX-M-32 producers (Table 38, Table 39, Figure 12). By 
conventional typing, all animal and human isolates were assigned to the clonal group 
O153:H10-A-ST10 (CH11-54), conforming a hybrid aEPEC/ExPEC pathotype. The 
symptomatology reported in humans was mainly mild diarrhoea, but there were also some 
cases of acute/haemorrhagic gastroenteritis (Table 39). Epidemiological studies have 
indicated that aEPEC are emerging enteropathogens, implicated in human diarrhoea, with 
higher prevalence than tEPEC in both developed and developing countries (Hu and 
Torres, 2015). aEPEC are present in both healthy and diseased animals and humans 
(Blanco et al., 2006; Alonso et al., 2017; Mora et al., 2018), are phylogenetically 
heterogeneous and carry virulence factors of other diarrheagenic E. coli  more often than 
tEPEC strains (Hernandes et al., 2009; Hu and Torres, 2015; Xu et al., 2017). However, 
the main feature of the EPEC diarrheagenic group is the ability to induce A/E lesions on 
intestinal epithelium encoded in the chromosomal pathogenicity island (LEE). Within 
more than 30 intimin types and subtypes based on the polymorphism of eae, the subtype 
determined here (β-1) is first or second in prevalence within different studies on isolates 
from humans with diarrhoea in Spain (Blanco et al., 2006), Australia (Robins-Browne et 
al., 2004), Brasil (Abe et al., 2009; Vieira et al., 2016), Peru (Contreras et al., 2010) or 
China (Xu et al., 2016). 
 
It is of note that we have detected this clonal group in subsequent and current studies 
on meat sampled in supermarkets of our city. In fact, we recovered aEPEC/ExPEC from 
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15 out of 100 poultry meat samples (2016-2017); from those, five were carriers of isolates 
belonging to the clonal group O153:H10-A-ST10, being one CTX-M-32 carrier 
(unpublished data). Recently, Zhang et al. (Zhang et al., 2018) reported a 2.75% 
prevalence of aEPEC in retail foods at markets in the People's Republic of China, being 
the β-1 intimin and the ST10 the second intimin and ST most prevalent within their 
isolates. According to the authors, the presence of virulent and MDR aEPEC in retail 
foods poses a potential threat to consumers. 
 
Since the occurrence of the major outbreak of HUS in Europe caused in 2011 by an 
EAEC/STEC O104:H4, other hybrid pathotypes have been recognized, and new are 
expected, either by novel assemblies of E. coli  virulence determinants or through 
acquisition of new virulence genes from other bacterial species (Robins-Browne et al., 
2016). In Norway, Lindstedt et al. (Lindstedt et al., 2018), expressed their concern 
regarding the detection of E. coli  from human faecal content with a combination of 
intestinal and ExPEC virulence genes (InPEC/ExPEC) in a high frequency (64.3%). 
Several other studies have also identified STEC‐ and ETEC‐associated virulence genes 
coexisting in E. coli  isolates from humans, animals or environmental origin (Nyholm et 
al., 2015; Michelacci et al., 2018). But probably one of the most outstanding is the 
EPEC/STEC O80:H2-ST301, emerged in France over the last few years and diffused 
within Europe, associated with invasive infections, which combines intestinal VFs (stx2d, 
eae-xi and ehxA genes) and extraintestinal genes characteristic of the plasmid pS88 
(Cointe et al., 2018, 2020). To highlight in this O80 clone, the location of MDR and pS88 
genes in the same plasmid; and in addition to this plasmid, another two (a carrier of ehxA 
gene and a cryptic one) were described within the isolates (Cointe et al., 2018, 2020). The 
clonal group described here also poses the threat of being MDR and characteristically 
associated with ESBL type CTX-M-32. CTX-M-32 enzyme is derived from CTX-M-1 
by a single amino acid replacement, being probably an ancestor among CTX-M-1 and 
CTX-M-15 (Cartelle et al., 2004). The blaCTX-M-32 gene was first described in 2004 in an 
Escherichia coli isolate in our Health Area (A Coruña, northwest Spain) (Cartelle et al., 
2004). Furthermore, it was described in three human isolates O25b:H4-ST131 ibeA-
positive of our region, as early as in 2008 (Mora et al., 2010). Of the 2,427 E. 
coli  bloodstream isolates recovered in the hospital of our city (HULA) in the period 2000-
2011, 96 were positive for ESBL production, from which 4.2% were CTX-M-32 and 
4.2% SHV-12 (Mamani et al., 2019). The same prevalence was observed in this hospital 
in 2015 (unpublished data). 
 
The in silico analysis of 17 representative genomes O153:H10-A-ST10 corroborated 
the main traits determined by conventional typing. In a recent study, we had proved the 
good correlation and usefulness of SerotypeFinder or EnteroBase predictions (Mora et 
al., 2018; García-Meniño et al., 2019). Here, only the serotype of two genomes could not 
be predicted in silico, probably due to the limitation of the assembly based on Illumina 
short reads (Wick et al., 2017). MLST, CHTyper from CGE and EnteroBase also 
confirmed conventional results. Like in the previous study, we found that 
VirulenceFinder properly identifies E. coli pathotypes (hybrid in this case), although 
based on different traits for the ExPEC pathotype. Thus, this clonal group O153:H10-A-
ST10 typically carries the locus that codify a fimA variant MT78 of type 1 fimbriae (Marc 
and Dho-Moulin, 1996) and the traT gene for an outer membrane protein implicated in 
serum survival (Johnson and Stell, 2000). Both VFs are not included in the 
VirulenceFinder scheme, and so they were not predicted. On the contrary, CGE tool 





ExPEC virulence (Johnson et al., 2008), which was not determined by PCR. This is 
because CGE database predicts 14 variants of the iss gene (Joensen et al., 2014), including 
the one described in E. coli IAI1 (CU928160), and harbored by the O153:H10-A-ST10 
genomes. Our specific PCR detects the plasmid-borne iss allele (designated type 1), 
which is highly prevalent among APEC  and NMEC isolates but not among UPEC  
isolates (Johnson et al., 2008). The phenotypic AMR determined in vitro correlated with 
the results based on ResFinder databases, with the exception of blaCTX-M-32 not predicted 
in two genomes but solved by conventional sequencing. Based on this and previous 
studies (de Toro et al., 2017a; García-Meniño et al., 2019), we consider both conventional 
and genomic-based analysis complementary for a better understanding and 
characterization of emerging isolates.  
 
An interesting trait of our isolates was the concomitant presence of IncF (F2:A-:B-), 
IncI1 (ST unknown) and IncX1, together with non-conjugative Col156-like plasmids. 
Although carriage of plasmids means a fitness cost on the hosts (San Millan and 
MacLean, 2017), different studies support the hypothesis that interference between 
conjugative plasmids may reduce fitness costs by decreasing the efficiency of transfer. 
However, the mechanisms of such inhibitory systems need further investigation (Dionisio 
et al., 2019). On the other hand, small plasmids was shown to increase its stability in cells 
containing big plasmids (San Millan and MacLean, 2017).   
 
Another objective in this study was to know if this was a restricted genetic lineage. 
For this purpose, we searched related genomes uploaded in EnteroBase based on the 
HierCC Cluster ID. As a result, we found a hybrid aEPEC/ExPEC pathotype A-ST10 
eae-beta1 within its database associated to five human, one avian, and one unknown 
isolates (Table 37). Of note, the two human isolates (Code Name: 853984 and 866428) 
from United Kingdom, which clustered with the 17 Spanish genomes in the HC100 
HierCC group (37600) (Table 37, Figure 17). The in silico analysis of these two genomes 
showed they belonged to the clonal group O153:H10-A-ST10 CH11-54 eae-beta1, were 
MDR carried similar virulence traits (conforming hybrid aEPEC/ExPEC pathotype), and 
plasmid combination: IncF (F2:A-:B-), IncX1, Col156-like (Table 40). To highlight that 
six of the seven genomes were carriers of IncF (F2:A-:B-) and Col156-like plasmids 
(Table 40). As above suggested, further investigation on the interplay between these 
plasmids and other MGEs affecting their transmission and persistence, as well as their 
role in the maintenance and acquisition of resistance genes is necessary. 
 
In summary, our results demonstrate that a hybrid MDR aEPEC/ExPEC belonging 
to the clonal group O153:H10-A-ST10 (et CH11-54) eae-beta1 is circulating in our region 
within different hosts, including wildlife. It seems implicated in human diarrhoea via food 
(meat) transmission, and in the spreading of ESBL genes (mainly of CTX-M-32 type). 
The concomitant presence of IncF (F2:A-:B-), IncI1 (STunknown) and IncX1, together 
with non-conjugative Col156-like plasmids might be implicated in the successful 
persistence of this hybrid pathotype. We found genomic evidence of a related hybrid 
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5.4. FINAL REMARKS 
 
COVID-19 has been threatening the world for almost two years now. Fortunately, 
the care of many researchers has allowed the development of precise combat weapons in 
the form of vaccines in record time. But this pandemic will leave us many absences, and 
many consequences, such as those derived from the temporary eclipse of the greatest 
health challenge: the AMR. So far 3.4 million lives have been lost due to COVID-19, but 
the death figures derived from AMR could be higher unless urgent action is not taken 
(Mora, 2021). Our group early warned on the impact of secondary infections by MDR 
bacteria in patients infected by COVID-19 (García-Meniño et al., 2021a), in agreement 
with the reports of increasing use of antibiotics in hospitals (Gonzalez-Zorn, 2021). We 
hope that the work showed in this thesis has also contributed to raising awareness about 
this global priority. 
 
Animals, like people, may carry resistant bacteria in their guts. These bacteria can 
get in food, contaminating meat or other animal products when animals are slaughtered 
and processed for food, or through animal waste contaminating soil, water, or fertilizer in 
contact with fruits and vegetables. People are exposed to resistant bacteria when handling 
or consuming contaminated vegetables and animal-derived food. The danger is not only 
because food-borne infections caused by MDR bacteria have more serious health 
consequences than infections caused by sensitive bacteria; the danger is also derived from 
these bacteria getting in contact with the host's normal microbiota, and sharing resistance 
genes ((CDC, 2020) last access: 08/06/2021) 
 
Traditionally, only InPEC have been accepted as food-borne pathogens (Kaper et al., 
2004; Kai et al., 2010). Recently, Riley (Riley, 2020) indicated that a surveillance system 
of ExPEC genotypes causing extraintestinal infections, which does not currently exist, 
could provide traceback investigations to elucidate their role as new extraintestinal food-
borne pathogens. Apart from InPEC and ExPEC, new hybrid pathotypes have been 
increasingly reported since it happened the major outbreak of HUS in Europe in 2011 by 
an EAEC/STEC O104:H4 (Mora et al., 2011a; Cointe et al., 2020). In fact, a 
comprehensive assessment of AMR in animals and the food chain is essential to reduce 
the burden of antimicrobial resistance in humans. However, food surveillance is 
considered commercially sensitive and so, the information derived from it is generally 
incomplete (Tacconelli et al., 2018). 
 
On this base, we analyzed 100 retail poultry meat directly acquired at points of sale 
with the idea that the final product provides data on what is happening throughout the 
entire food chain “from farm to fork”. Besides, we considered as “risk” strain that with 
the capacity to develop a serious extraintestinal infection in humans, either due to its 
virulence potential and / or due to its antibiotic resistance. 
 
As a result, we have designed a lab workflow for a comprehensive microbiological 
risk assessment, including a PCR for the screening of ExPEC (Díaz-Jiménez et al., 2021). 
For the first time, we evaluated consumer exposure via poultry meat to Enterobacteriaceae 
with capacity to develop severe extraintestinal infections by either bacterial virulence and 
/ or antibiotic resistance traits, and we showed the high level of consumer exposure to 
MDR bacteria via poultry meat. Our findings indicate that poultry meat is a rich source 







- E. coli CC10-A (CH11–54) isolates carrying mcr-1.1-bearing IncX4 plasmids in 
meat. 
 
- Presence of high-risk lineages of E. coli, including the pandemic ST131-H22, in 
more than 70% of the meat samples. 
 
- Clinical relevant ESBL-producing K. pneumoniae recovered from 27% of meat 
samples 
 
- Detection of a hybrid pathotype aEPEC / ExPEC CC10-A (eae-beta1). 
 
The latter confirms that the clonal group O153:H10-A-ST10 (CH11-54) is circulating 
in our region within different hosts, including poultry. It seems implicated in human 
diarrhea via meat transmission, and in the spreading of ESBL genes (mainly of CTX-M-
32 type). The core genome investigation based on the cgMLST scheme from EnteroBase 
proved close relatedness between isolates of human and animal origin. We also found 
genomic evidence of a related hybrid aEPEC/ExPEC in at least one other country (Díaz-
Jiménez et al., 2020b). 
 
As a general conclusion, and given this scenario, antibiotic pressure reduction in 
poultry farming as well as surveillance of bacterial evolution is a public health priority. 
It would be highly recommended the implementation of a systematic AMR and ExPEC 


















1. Our results determined that poultry meat microbiota is a source of genetically 
diverse Enterobacteriaceae, resistant to relevant antimicrobials (categories A and 
B of EMA) and potentially pathogenic for humans, including hybrid pathotypes 
of E. coli, high-risk clonal groups of E. coli associated with human extraintestinal 
and / or uropathogenic pathologies, as well as K. pneumoniae clonal groups of 
clinical interest. 
 
2. Our results would indicate that the industrial production system for turkey meat 
seems to exert greater selection pressure of antibiotic resistant strains compared 
to chicken, which is reflected in significant higher rates of mcr-positive E. coli 
and MDR isolates, including ESBL-producing K. pneumoniae, in turkey meat. 
 
3. The protocols I and II, based on MacConkey Lactose and MacConkey Sorbitol 
with telurite and cefixime agar incubated at 37 ºC, are the most effective for the 
recovery of isolates satisfying the ExPEC and UPEC status, as well as the 
rbfO25b-positive isolates associated with the clonal group STl31. 
 
4. The protocol V (CHROMID® ESBL agar plates 37 ºC) is key for the recovery of 
ESBL or pAmpC-producing Enterobacteriaceae. 
 
5. The duplex PCR based on iutA and KpsM II genes on MacConkey Lactose and 
MacConkey Sorbitol with telurite and cefixime agar is essential for the accurate 
screening of the isolates conforming ExPEC status, as well as for the recovery of 
those with UPEC status. 
 
6. The microbiological method proposed here (pre-enrichment, enrichment in ML 
broth, and inoculation onto MacConkey Lactose broth, and inoculation onto 
MacConkey Lactose agar / MacConkey Sorbitol with telurite and cefixime agar / 
CHROMID® ESBL), followed by the screening of six virulence/AMR traits 
(ExPEC status, UPEC status, ESBL/pAmpC producer, mcr-1 carrier, MDR, 
rfbO25b), would help to elucidate the role of ExPEC as new extraintestinal food-
borne pathogens. 
 
7. Our results prove that a hybrid MDR aEPEC/ExPEC belonging to the clonal group 
O153:H10-A-ST10 (CH11-54) eae-beta1 is circulating in our region within 
different hosts, including wildlife. It seems implicated in human diarrhea via food 
(meat) transmission, and in the spreading of ESBL genes (mainly of CTX-M-32 
type). The concomitant presence of IncF (F2:A-:B-), IncI1 and IncX1, together 
with non-conjugative Col156-like plasmids might be implicated in the successful 
persistence of this hybrid pathotype. 









7.1. GENERAL PRIMERS COMPILATION   
 
Table 28. Primers used for the detection and / or sequencing of E. coli and Klebsiella pneumoniae 
Target Primers Nucleotide sequence (5´- 3´) Size (bp) Reference 
blaCTX-M 
CTX-C3 ATGTGCAGCACCAGTAAAGTGATG 
























1049 (García-Meniño et al., 2018) bCTX-M14-24-R CTGCGTTGTCGGGAAGATACG 
blaSHV 
SHV-F2 TTGTCGCTTCTTTACTCGCC 
879 (Mora et al., 2013) SHV-R2 CCCGGCGATTTGCTGATTTCGC 
blaSHV 
bSHV-1 GGGTTATTCTTATTTGTCGC 
930 (Rasheed et al., 1997) bSHV-2 TTAGCGTTGCCAGTGCTC 
blaTEM 
aTEM-1-F ATGAGTATTCAACATTTCCG 
868 (Rasheed et al., 1997) aTEM-1-R CTGACAGTTACCAATGCTTA 
LAT-1 a 
LAT-4, CMY-
2 a CMY-7, 
BIL-1 
CITMF TGGCCAGAACTGACAGGCAAA 
462 (Pérez-Pérez and Hanson, 2002) CITMR TTTCTCCTGAACGTGGCTGGC 
CMY-2 
bCMY-2F AACACACTGATTGCGTCTGAC 
1226 (Pérez-Pérez and Hanson, 2002) bCMY-2R CTGGGCCTCATCGTCAGTTA 
mcr-1 
CLR5-F CGGTCAGTCCGTTTGTTC 
309 (Liu et al., 2016) 
CLR5-R CTTGGTCGGTCTGTAGGG 
mcr-2 
mcr-2 IF TGTTGCTTGTGCCGATTGGA 
567 (Xavier et al., 2016) mcr-2 IR AGATGGTATTGTTGGTTGCTG 
mcr-3 
MCR3-F TTG GCACTGTATTTTGCATTT 
542 (Yin et al., 2017) 
MCR3-R TTAACGAAATTGGCTGGAACA 
mcr-4 
mcr-4 FW ATTGGGATAGTCGCCTTTTT 
487 (Carattoli et al., 2017) mcr-4 RV TTACAGCCAGAATCATTATCA 
mcr-5 
MCR5_FW ATGCGGTTGTCTGCATTTATC 
1644 (Borowiak et al., 2017) MCR5_RV TCATTGTGGTTGTCCTTTTCTG 
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Target Primers Nucleotide sequence (5´- 3´) Size (bp) Reference 
mcr-1 
bmcrS1-F GGGATTGCGCAATGATTGC 
548 (García-Meniño et al., 2018) bmcrS1-R CACCCAAACCAATGATACG 
Target Primers Nucleotide sequence (5´- 3´) Size (bp) Reference 




(Clermont et al., 
2013) 
chuA.2 TGCCGCCAGTACCAAAGACA (Clermont et al., 2000) 
yjaA 
yjaA.1b CAAACGTGAAGTGTCAGGAG 
211 (Clermont et al., 2013) yjaA.2b AATGCGTTCCTCAACCTGTG 
TspE4C2 
TspE4C2.1b CACTATTCGTAAGGTCATCC 
152 (Clermont et al., 2013) TspE4C2.2b AGTTTATCGCTGCGGGTCGC 
arpA 
AceK.f AACGCTATTCGCCAGCTTGC 
400 (Clermont et al., 2013) ArpA1.r TCTCCCCATACCGTACGCTA 
trpAgpC 
trpAgpC.1 AGTTTTATGCCCAGTGCGAG 
219 (Lescat et al., 2013) trpAgpC.2 TCTGCGCCGGTCACGCCC 
arpA (E) 
ArpAgpE.f GATTCCATCTTGTCAAAATATGCC 
301 (Lescat et al., 2013) ArpAgpE.r GAAAAGAAAAAGAATTCCCAAGAG 
trpA 
trpBA.f CGGCGATAAAGACATCTTCAC 
489 (Clermont et al., 2008) trpBA.r GCAACGCGGCCTGGCGGAAG 
Target Primers Nucleotide sequence (5´- 3´) Size (bp) Reference 
fliCH1 
H1-F2 TATCCGGTCAGACCCAGTTC 
828 (García-Meniño et al., 2018) H1-R2 TTGCGGATGTATCACCGTTA 
fliCH2 
H2-F AACGACGGCGAAACAATTAC 
828 (Alonso et al., 2017) H2-R AGAACGCAACGAGTCAACCT 
fliCH4 
H4-F GCAGCGTATTCGTGAACTGA 
713 (Mora et al., 2011b) H4-R GCTGGATAATCTGCGCTTTC 
fliCH7 
H7-F GCGCTGTCGAGTTCTATCGAGC 




(Mora et al., 
2012) 




(Mora et al., 
2012) 
H9-R GCGGTATCGTTACCTGCATT (García-Meniño et al., 2018) 
fliCH10 
H10-F AGCAAGTGGCAGTAGGTGCT 
624 (Alonso et al., 2017) H10-R GCTGGATAATCTGCGCTTTC 
fliCH11 
H11-F ACTGTTAACGTAGATAGC 
248 (Durso et al., 2005) H11-R TCAATTTCTGCAGAATATAC 
fliCH18 
H18-F1 TTCTGACCTGGACTCCATCC 
827 (Mora et al., 2018) H18-R1 CGTTAGCAAACGTTGAAGCA 
fliCH21 H21-F GGCGATTGCTAACCGTTTTA 549-556 
ANNEX 
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Target Primers Nucleotide sequence (5´- 3´) Size (bp) Reference 
H21-R3 CGTAAGTGAACCATCCGCAG (Mora et al., 2012) 
fliCH25 
H25-F ATGAAATTGACCGCGTATCC 
212 (Alonso et al., 2017) H25-R TTGCGGGATAGATGTGATAGC 
fliCH28 
H28-F ACGAAATCAAATCCCGTCTG 
856 (Mora et al., 2012) H28-R GCCGATTGAAGAGACTCAGC 
rfbO25b 
rfb. 1bis.f ATACCGACGACGCCGATCTG 
300 (Clermont et al., 2008) rfbO25b.r TGCTATTCATTATGCGCAGC 
Primers used for amplification and sequencing in the clonotyping methodd 
fimH 
fimH-F CACTCAGGGAACCATTCAGGCA locus size 
469 
(Weissman et al., 
2012) fimH-R CTTATTGATAAACAAAAGTCAC 
Target Primers Nucleotide sequence (5´- 3´) Locus size (bp) Reference 


























































tonB tonB1F CTTTATACCTCGGTACATCAGGTT 414 
DAFNE DÍAZ JIMÉNEZ 
 
122 





aPrimer oF GTTTTCCCAGTCACGACGTTGTA 
  
ePrimer oR TTGTGAGCGGATAACAATTTC 
aPrimers used for amplification and sequencing. bPrimers used for sequencing. cPhylogroup assignment method of 
Clermont (2013). With this method, eight phylogroups are recognized based on the presence/absence of the four genetic 
targets arpA, chuA, yjaA and TspE4.C2: seven (A, B1, B2, C, D, E, F) belonging to E. coli sensu stricto, and the remaining 
one to Escherichia cryptic clade I. dAllele assignments for fimH were determined using the fimtyper database available at 
the Center for Genomic Epidemiology (CGE) website https://bit.ly/35jD3Qx, and the combination of fumC and fimH allele 
designations determined the CH “type”. eUniversal primers used for sequencing. The STs were assigned through the 
EnteroBase website for E. coli (http://enterobase.warwick.ac.uk/species/ecoli/allele_st_search), and the Institute 
Pasteur website (https://bigsdb.pasteur.fr/klebsiella/) for K. pneumoniae. Novel STs were submitted to curator to 
determine new designations. 
 
Table 29. Targets and primers associated with diarrheagenic and extraintestinal pathotypes of E. coli.  




















(Alonso et al., 2017) 
























508 (Johnson and Stell, 2000) FimH-r GCAGTCACCTGCCCTCCGGTA 
fimAvMT78 
fimA201 TCTGGCTGATACTACACC 
266 (Marc and Dho-Moulin, 1996) fimA215 ACTTTAGGATGAGTACTG 
papC 
Forward GTGGCAGTATGAGTAATGACCGTTA 
205 (Johnson and Manges, 2015) Reverse ATATCCTTTCTGCAGGGATGCAATA 
apapAH 
papA-F ATGGCAGTGGTGTCTTTTGGTG 
720 (Johnson and Stell, 2000) papA-R CGTCCCACCATACGTGCTCTTC 
papEF PapEF-F GCAACAGCAACGCTGGTTGCATCAT 336 
ANNEX 
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Pathotype Target Primers Nucleotide sequence (5´- 3´) Size (bp) Reference 
PapEF-R AGAGAGAGCCACTCTTATACGGACA (Yamamoto et al., 1995) 
papG I 
pap-I F TTAGCTGGATGGCACAATG 
335 
(Mora et al., 2013) 
pap-I R TTGTCCATGTATCCCATTCAT 
papG II 
pap-II F GGGCATTGCTACGGTAACCTG 
545 
pap-II R CGCTATTAATAGACAGATCACC 
papG III 
pap-III F CGGCAACTTTAAGCTATGTG 
720 



























937 (Johnson et al., 2003a) SatR CATTCAGAGTACCGGGGCCTA 
hlyA 
hly F AACAAGGATAAGCACTGTTCTGGCT 
1177 (Yamamoto et al., 1995) hly R ACCATATAAGCGGTCATTCCCGTCA 
hlyF 
hlyF f TCGTTTAGGGTGCTTACCTTCAAC 
444  (Morales et al., 2004) hlyF r TTTGGCGGTTTAGGCATTCC 
iucD 
Aer F TACCGGATTGTCATATGCAGACCGT 
602 (Yamamoto et al., 1995) Aer R AATATCTTCCTCCAGTCCGGAGAAG 
estA 
STa-A ATTTTTATTTCTGTATTGTCTTT 
176 (Penteado et al., 2002) STa-B GGATTACAACACAGTTCACAGCAGT 
estB 
Stb-F ATCGCATTTCTTCTTGCATC 




696 (Schultsz et al., 1994) LT-A-2 CCGAATTCTGTTATATATGTC 
ipaH 
EI1 GCTGGAAAAACTCAGTGCCT 
424 (Tornieporth et al., 1995)  EI2 CCAGTCCGTAAATTCATTCT 
aatA 
pCVD432/start CTGGCGAAAGACTGTATCAT 
630 (Schmidt et al., 1995)  pCVD432/stop CAATGTATAGAAATCCGCTGTT 
iroN 
Ironec-F AAGTCAAAGCAGGGGTTGCCCG 
665 (Johnson et al., 2000) Ironec-R GACGCCGACATTAAGACGCAG 
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Pathotype Target Primers Nucleotide sequence (5´- 3´) Size (bp) Reference 
aiutA 
aer-851F GGCTGGACATCATGGGAACTGG 
301 (Johnson et al., 1997) aer-1152R CGTCGGGAACGGGTAGAATCG 
akpsM II 
KpsII f GCGCATTTGCTGATACTGTTG 
272 (Johnson and Stell, 2000) KpsII r CATCCAGACGATAAGCATGAGCA 
kpsM II-K2 
KpsII f GCGCATTTGCTGATACTGTTG 
570 (Johnson and O’Bryan, 2004) KpsII-K2r AGGTAGTTCAGACTCACACCT 
kpsM II-K5 
K5-f CAGTATCAGCAATCGTTCTGTA 
159 (Johnson and Stell, 2000) KpsII r CATCCAGACGATAAGCATGAGCA 
neuC (K1) 
neu1 AGGTGAAAAGCCTGGTAGTGTG 
676 (Moulin-Schouleur et al., 2006) neu2 GGTGGTACATCCCGGGATGTC 
kpsM III 
KpsIII f TCCTCTTGCTACTATTCCCCCT 
392 (Johnson and Stell, 2000) KpsIII r AGGCGTATCCATCCCTCCTAAC 
cvaC 
ColV-CF CACACACAAACGGGAGCTGTT 
680 (Johnson and Stell, 2000) ColV-CR CTTCCCGCAGCATAGTTCCAT 
traT 
TraT f GGTGTGGTGCGATGAGCACAG 
290 (Johnson and Stell, 2000) TraT r CACGGTTCAGCCATCCCTGAG 
ibeA 
ibe10 f AGGCAGGTGTGCGCCGCGTAC 
170 (Johnson and Stell, 2000) ibe10 r TGGTGCTCCGGCAAACCATGC 
malX 
MALX-F GCATGAGCAGTGCGATACATCGC 








559 (Johnson et al., 2015) ompT-R CCCGGGTCATAGTGTTCATC 
tsh 
tsh03 GGTGGTGCACTGGAGTGG 




1100 (Spurbeck et al., 2012) vat-R GGCCAGAACATTTGCTCCCTTGTT 
bfyuA 
fyuA-F GTAAACAATCTTCCCGCTCGGCAT 
850 (Spurbeck et al., 2012) fyuA-R TGACGATTAACGAACCGGAAGGGA 
byfcV 
yfcV-F ACATGGAGACCACGTTCACC 
292 (Spurbeck et al., 2012) yfcV-R GTAATCTGGAATGTGGTCAGG 
bchuA 
ChuA-F CTGAAACCATGACCGTTACG 
652 (Spurbeck et al., 2012) ChuA-R TTGTAGTAACGCACTAAACC 
uidA 
uidA-F GCGTCTGTTGACTGGCAGGTGGTGG 
503 (Gómez-Duarte et al., 2010) uidA-R GTTGCCCGCTTCGAAACCAATGCCT 
aVirulence factors (VF) screened to assess the extraintestinal pathogenic E. coli status (ExPEC status). bVF screened to 
assess the uropathogenic E. coli status (UPEC status). c Primers used for the eae typing (sequencing). Those isolates 
exhibiting ExPEC and /or UPEC status, were further characterized for other extraintestinal VF: fimAvMT78, papEF, papC, 
papG I, papG II and papG III, cnf1, cdtB, sat, hlyA, hlyF, iucD, iroN, kpsM II (establishing neuC-K1, K2 and K5 variants), 
kpsM III, cvaC, iss, traT, ibeA, malX, usp, tsh and ompT. 
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7.2. STUDY 1: CHICKEN AND TURKEY MEAT: CONSUMER EXPOSURE TO 
MULTIDRUG-RESISTANT ENTEROBACTERIACEAE INCLUDING MCR-CARRIERS, 
UROPATHOGENIC E. COLI AND HIGH-RISK LINEAGES SUCH AS ST131 
 
 
Figure 15. Graph of phylogroup distribution within the 84 representative E. coli obtained from ML. 
The value on the y-axis and bars indicates number of isolates. 
 
Table 30. Clonotypes and ST combinations within the 84 representative E. coli isolates 







10 11 4 8 8 8 2 10 10 11-24 1C 
10 11 4 8 8 8 2 10 10 11-54 7 (5C+2T) 
24 11 4 8 8 8 2 10 43 11-54 1T 
6 11 4 8 8 8 2 10 48 11-neg 2T 
10 11 135 8 8 8 2 10 744 11-54 3T 
10 11 4 8 8 8 49 10 752 11-24 1C 
10 11 4 8 20 8 2 10 853 11-54 1T 
10 11 4 10 7 8 2 10 2705 11-23 1C 
10 11 4 560 8 8 2 10 5507 11-54 1C 
10 11 4 8 8 13 new 10 STnew2 11-neg 1T 
6 4 12 1 20 13 7 23 23 4-35 7C 
6 4 12 1 20 12 7 23 88 4-39 1T 
6 4 12 1 9 2 7 23 295 4-38 2C 
6 4 12 1 20 18 7 23 410 4-24 3T 
6 4 12 1 20 18 7 23 410 4-45 1T 
6 4 12 1 20 18 7 23 410 4-53 1T 
4 26 2 25 5 5 19 38 38 26-65 4 (3C+1T) 
9 270 33 131 24 8 7 86 1720 270-54 1T 
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43 41 15 18 11 7 6 101 101 41-86 2C 
53 40 47 13 36 28 29 131 131 40-22 2C 
6 4 4 16 24 8 14 155 58 4-27 1T 
6 4 4 16 24 8 14 155 58 4-32 5T 
6 4 14 16 24 8 14 155 155 4-32 1T 
6 4 14 16 24 8 14 155 155 4-neg 1T 
6 4 4 16 24 8 14 155 58 4-neg 1T 
6 11 4 10 7 8 6 168 93 11-41 1T 
6 31 5 28 1 1 2 350 57 31-27 1T 
6 31 83 28 1 1 67 350 371 31-142 1C 
9 65 5 1 9 13 6 469 162 65-27 1C 
9 65 5 1 9 13 6 469 162 65-38 1C 
9 65 5 1 9 13 6 469 162 65-32 4 (2C+2T) 
6 65 344 1 11 13 6 None 3580 65-32 2T 
92 231 87 96 70 58 2 648 1485 231-58 4 (3C+1T) 
new 153 188 83 7 8 6 new STnew1 153-39 1C 
20 45 41 43 5 32 2 None 117 45-97 1C 
20 new 41 43 5 32 2 None ST117-like New-97 1C 
6 29 4 18 11 8 6 None 212 29-38 1C 
6 65 32 26 9 8 2 None 297 65-38 1T 
6 69 158 18 9 8 7 None 1730 69-32 2C 
443 271 24 198 7 214 359 None 5340 271-58 1T 
80 4 57 18 55 8 6 None 5826 4-60 1C 
136 11 4 1 9 18 7 None 7315 11-398 1T 
6 4 14 1 20 62 7 None  345 4-31 1T 
96 40 13 100 23 28 66 None  428 40-22 1T 
96 40 13 100 23 28 66 None  428 40-neg 1C 
101 88 97 108 26 79 2 None  457 88-145 1C 
267 6 5 26 9 13 98 None  2599 6-32 1T 
79 3 206 451 5 16 182 None  4243 3-1002 1C 
6 7 5 1 618 8 2 None  7199 7-neg 1C 
1 Clonal complexes (CC) and Sequence types (ST) according to the Achtman scheme (Wirth et al., 
2006). 7 Clonotype based on the internal 469-nucleotide (nt) and 489-nt sequence of the fumC (allele 
obtained from MLST) and fimH genes, respectively (Weissman et al., 2012). Seven isolates were 












Table 31. E. coli isolates showing atypical EPEC (aEPEC)/ExPEC pathotypes 
1Isolate 
code Clonal group ESBL 
Phenotypic 
resistance Virulence gene profile 
Ch-10-ESBL O123/186:H34-A-ST752 (CH11-24) CTX-M-1 AMP, CTX, NAL  
fimH24 hlyF iucD iutA 
traT eae-beta1 
Ch-24-ESBL O153:H10-A-ST10 (CH11-54) CTX-M-32 
AMP, CTX, ATM,  
GEN, DOX, CHL 
fimH54 fimAvMT78 traT 
eae-beta1 
Ch-36-R O153:H10-A-ST10 (CH11-54) - AMP, DOX, CHL, CIP, NAL  
fimH54 fimAvMT78 
papGII traT eae-beta1 
Ch-40-R O145:H40-A-ST752 (CH11-24) - AMP, NAL  fimH24 traT eae-beta1 
1 Origin of isolation-sample number-type of isolate: Ch (chicken meat), T (turkey meat), R 
(representative E. coli), ESBL (ESBL-producing E. coli). 
 
 
Table 32. MIC values for colistin-resistant K. pneumoniae and E. coli isolates 
1Isolate 
code 
Identification MIC value mg/L 
Ch-35-ESBL Klebsiella pneumoniae  >4 
T-5-ESBL Klebsiella pneumoniae >4 
T-11-ESBL Klebsiella pneumoniae >16 
T-17-ESBL Klebsiella pneumoniae  >128 
T-24-ESBL Klebsiella pneumoniae >8 
T-25-ESBL Klebsiella pneumoniae >128 
T-27-ESBL Klebsiella pneumoniae >8  
T-30-ESBL Klebsiella pneumoniae >16 
T-43-ESBL Klebsiella pneumoniae >8 
T-45-ESBL Klebsiella pneumoniae >32 
T-46-ESBL Klebsiella pneumoniae >4 
T-1-ESBL Escherichia coli >4 
T-17-R Escherichia coli >32 
1 Origin of isolation-sample number-type of isolate: Ch (chicken meat), T 
(turkey meat), R (representative E. coli), ESBL (ESBL-producing isolates). 
 






Figure 16. a) Presence of ESBL-producing Enterobacteriaceae within the 100 meat samples analyzed. 
The value on the y-axis and bars indicates number of samples; b) Species identification of the 172 ESBL-
producing isolates recovered from 82 positive meat samples. 
 
Table 33. Clonotypes and ST combinations of the 137 ESBL-producing E. coli.  
adK fumC gyrB icD mdh purA recA 1ST 1CC 2CH 
10 11 183 8 8 8 2 1141 10 11-32 
6 11 4 8 8 8 2 48 10 11-41 
10 11 4 8 8 8 2 10 10 11-54 
10 11 135 8 8 8 2 744 10 11-54 
10 11 57 8 8 8 185 1970 10 11-54 
10 11 4 8 8 8 49 752 10 11-24 
10 11 4 8 8 13 2 167 10 11-neg 
10 11 4 8 8 13 73 617 10 11-neg 
6 4 12 1 20 12 7 88 23 4-39 
6 4 12 1 20 18 7 410 23 4-24 
18 3 17 6 5 5 4 1158 31 3-47 
4 26 39 25 5 31 19 115 38 26-270 
4 26 2 25 5 5 19 38 38 26-65 
21 35 27 6 5 5 4 69 69 35-27 
9 6 33 131 24 8 7 641 86 6-25 
43 41 15 90 11 8 6 359 101 41-35 
43 41 15 18 11 7 6 101 101 41-86 
6 4 14 16 7 8 14 1016 155 4-32 
6 4 14 16 24 2 14 4162 155 4-38 
6 4 4 16 24 8 14 58 155 4-27 
6 4 14 16 24 8 14 155 155 4-32 
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adK fumC gyrB icD mdh purA recA 1ST 1CC 2CH 
6 4 14 16 24 8 14 155 155 4-121 
6 4 14 16 24 8 14 155 155 4-neg 
6 11 4 10 7 8 6 93 168 11-41 
6 11 4 10 7 8 6 93 168 11-58 
6 11 4 10 7 8 6 93 168 11-neg 
10 27 5 8 8 7 2 226 226 27-41 
6 31 5 28 1 1 2 57 350 31-27 
6 31 5 28 1 1 2 57 350 31-31 
6 31 83 28 1 1 2 350 350 31-54 
6 31 83 28 1 1 new STnew4 350 31-54 
85 88 78 29 59 58 62 354 354 88-58 
85 88 78 29 59 58 62 354 354 88-neg 
6 19 33 26 11 8 6 602 446 19-86 
9 65 5 1 9 13 6 162 469 65-32 
6 new 4 16 7 13 2 STnew6 None new-new 
6 7 57 1 new 8 2 STnew7 None 7-54 
6 4 15 1 22 8 7 366 None 4-30 
122 11 125 12 96 8 2 665 None 11-30 
122 11 125 12 8 8 2 STnew3 None 11-30 
6 4 159 44 112 1 17 1011 None 4-31 
6 8 32 159 9 23 7 3519 None 8-31 
9 7 1 8 24 8 7 6215 None 7-34 
6 8 32 159 9 23 7 3519 None 8-39 
6 4 3 16 11 8 6 906 None 4-61 
6 4 14 16 11 8 6 STnew5 None 4-32 
136 11 4 1 9 18 7 7315 None 11-398 
52 116 55 101 113 40 38 770 None 116-552 
410 153 118 83 7 8 6 4980 None 153-39 
10 168 4 8 12 35 2 1785 None 168-54 
83 23 155 170 133 1 2 997 None 23-31 
38 24 84 13 17 30 34 919 None 24-187 
88 24 19 36 17 11 91 8611 None 24-26 
10 252 5 8 7 8 2 1564 None 252-neg 
6 41 33 18 9 8 6 707 None 41-60 
20 45 41 43 5 32 2 117 None 45-151 
20 45 41 43 5 32 2 117 None 45-97 
13 52 10 14 17 25 17 141 None 52-14 
6 65 32 26 9 8 2 297 None 65-38 
1Clonal complexes (CC) and Sequence types (ST) according to the Achtman scheme (Wirth et al., 2006). 
2Clonotype based on the internal 469-nucleotide (nt) and 489-nt sequence of the fumC (allele obtained from 
MLST) and fimH genes, respectively (Weissman et al., 2012). Seven isolates were negative (neg) for the 
amplification of the 489-nt internal sequence. 
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7.3. STUDY 2: MICROBIOLOGICAL RISK ASSESSMENT OF TURKEY AND CHICKEN 
MEAT FOR CONSUMER: SIGNIFICANT DIFFERENCES REGARDING MULTIDRUG 
RESISTANCE, MCR OR PRESENCE OF HYBRID AEPEC/EXPEC PATHOTYPES OF 
E. COLI  
 
Table 34. No. of positive isolates and positive samples regarding virulence traits and protocols 
 
Virulence traits 
Protocol I + II (ML + MSTC  37 
ºC) 
No. positive /total: 
a isolates (%); b samples (%) 
Protocol V (CHROMID® 37 ºC) 
No. positive /total: 
a isolates (%); b samples (%) 
1ExPEC status 
N = 150 from 78 meat 
samples 
a 118/150 (78.7); b 71/78 (91)  
2UPEC status 
N = 83 from 53 meat 
samples 
a 69/83 (83.1); b 47/53 (88.7)  
3ESBL/AmpC producer 
N = 155 from 78 meat 
samples 
 a 137/155 (88.4); b 76/78 (97.4) 
4mcr-1 carrier 
N = 13 from 7 meat samples 
a 10/13 (76.9); b 6/7 (85.7)  
5MDR 
N = 253 from 88 meat 
samples 
a 100/253 (39.5); b 59/88 (67) a 137/253 (54.1); b 76/88 (87.5) 
6rbfO25b 
N = 13 from 10 meat 
samples 
a 12/13 (92.3); b 9/10 (90)  
This table shows only the results for the protocol(s) of election in relation to each virulence trait.1 No. 
of isolates conforming ExPEC status (Johnson et al., 2003c). 2 No. of isolates conforming status UPEC 
(Spurbeck et al., 2012). 3 No. of extended-spectrum β-lactamase (ESBL) or AmpC-β-lactamase (pAmpC)-
producing E. coli.  4 No. of isolates carriers of the mcr-1 gene. 5 No. of MDR isolates according to 
Magiorakos et al. criteria (Magiorakos et al., 2012). 6 No. of rbfO25b-positive isolates: O25b subtype 
associated with the clonal group ST131 screened by PCR (Clermont et al., 2008). 
 
 
Table 35. STs and clonotypes of 272 E. coli isolates 
 
adk fumC gyrB icd mdh purA recA 1CC 2ST 3Clonotype No. isolates and origin (C=chicken; T=turkey) 
10 11 4 8 8 8 2 10 10 11-23 1T 
10 11 4 8 8 8 2 10 10 11-24 3 (1C + 2T) 
10 11 4 8 8 8 2 10 10 11-54 12 (8C + 4T) 
10 11 4 8 8 8 2 10 10 11-122 1C 
10 11 4 8 8 8 2 10 10 11-neg 2C 
10 11 4 1 8 8 2 10 34 11-neg 2T 
6 11 4 8 8 8 2 10 48 11-23 1C 
6 11 4 8 8 8 2 10 48 11-41 2 (1C + 1T) 
6 11 4 8 8 8 2 10 48 11-400 1T 
10 11 4 8 8 13 2 10 167 11-neg 1T 
10 11 4 8 8 13 73 10 617 11-neg 2 (1C + 1T) 
10 11 135 8 8 8 2 10 744 11-54 2T 
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adk fumC gyrB icd mdh purA recA 1CC 2ST 3Clonotype No. isolates and origin (C=chicken; T=turkey) 
10 11 135 8 8 8 2 10 744 11-58 1C 
10 11 4 8 8 8 49 10 752 11-24 9C 
10 11 4 8 20 8 2 10 853 11-54 3T 
10 11 183 8 8 8 2 10 1141 11-32 1T 
10 11 57 8 8 8 185 10 1970 11-54 1C 
6 4 12 1 20 13 7 23 23 4-35 1C 
6 4 12 1 20 12 7 23 88 4-39 4T 
6 4 12 1 20 18 7 23 410 4-24 1C 
18 3 17 6 5 5 4 31 1158 3-47 6C 
18 3 32 6 5 5 4 31 STnew8 (ST1158-like) 3-47 1C 
4 26 2 25 5 5 19 38 38 26-65 1T 
4 26 39 25 5 31 19 38 115 26-270 7 (4C + 3T) 
21 35 27 6 5 5 4 69 69 35-27 4 (2C + 2T) 
36 24 10 13 17 10 25 73 355 24-154 7 (3C + 4T) 
36 24 9 13 17 11 159 73 1618 24-9 2C 
99 6 33 33 24 8 7 86 453 6-31 2T 
9 6 33 131 24 8 7 86 641 6-25 2C 
9 270 33 131 24 8 7 86 1720 270-54 1T 
37 38 19 37 17 11 26 95 95 38-27 6 (4C + 2T) 
37 38 19 37 17 11 26 95 95 38-30 2T 
55 38 19 37 17 11 26 95 140 38-15 3T 
43 41 15 18 11 7 6 101 101 41-86 3 (1C + 2T) 
43 41 15 90 11 8 6 101 359 41-35 1T 
6 4 14 16 11 8 6 115 10328 4-32 1C 
53 40 47 13 36 28 29 131 131 40-22 8 (5C + 3T) 
53 40 47 13 36 28 29 131 131 40-neg 4C 
6 4 4 16 24 8 14 155 58 4-27 1T 
6 4 14 16 24 8 14 155 155 4-32 7 (3C + 4T) 
6 4 14 16 24 8 14 155 155 4-121 1C 
6 4 14 16 24 8 14 155 155 4-neg 3T 
6 4 14 16 7 8 14 155 1016 4-32 1C 
6 4 14 16 24 2 14 155 4162 4-38 1C 
10 27 5 10 12 8 49 165 189 27-neg 2 (1C + 1T) 
6 11 4 10 7 8 6 168 93 11-41 4 (3C + 1T) 
6 11 4 10 7 8 6 168 93 11-47 1T 
6 11 4 10 7 8 6 168 93 11-58 1C 
6 11 4 10 7 8 6 168 93 11-neg 11 (6C + 5T) 
6 11 4 10 7 84 6 168 484 11-neg 1T 
6 11 4 234 7 8 6 168 1594 11-31 1C 
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adk fumC gyrB icd mdh purA recA 1CC 2ST 3Clonotype No. isolates and origin (C=chicken; T=turkey) 
6 482 4 10 7 8 6 168 3764 482-41 1T 
10 27 5 8 8 7 2 226 226 27-41 2C 
6 31 5 28 1 1 2 350 57 31-27 2 (1C + 1T) 
6 31 5 28 1 1 2 350 57 31-31 1T 
6 31 83 28 1 1 2 350 350 31-54 2T 
6 31 83 28 1 1 new 350 STnew4 (ST350-like) 31-54 1T 
85 88 78 29 59 58 62 354 354 88-58 3T 
85 88 78 29 59 58 62 354 354 88-neg 1T 
6 19 33 26 11 8 6 446 602 19-86 3T 
9 65 5 1 9 13 6 469 162 65-32 4 (2C + 2T) 
10 23 109 8 8 8 2 522 522 23-neg 1T 
92 4 87 96 70 58 2 648 648 4-58 6 (2C + 4T) 
92 231 87 96 70 58 2 648 1485 231-58 19 (10C + 9T) 
6 new 4 16 7 13 2 None STnew6 new-1319 2C 
13 new 19 13 23 28 109 None STnew9 new-664 1T 
6 7 57 1 new 8 2 None STnew7 7-54 1T 
20 45 41 43 5 32 2 None 117 45-97 8 (5C + 3T) 
20 45 41 43 5 32 2 None 117 45-151 1C 
13 39 50 13 16 37 25 None 135 39-2 2C 
13 52 10 14 17 25 17 None 141 52-14 1T 
6 29 4 18 11 8 6 None 212 29-38 1C 
6 65 32 26 9 8 2 None 297 65-38 1C 
6 65 32 26 5 8 2 None STnew10 (ST297-like) 65-276 1T 
62 100 17 31 5 5 4 None 362 100-96 1T 
6 4 15 1 22 8 7 None 366 4-30 2T 
96 40 13 100 23 28 66 None 428 40-22 2 (1C + 1T) 
96 40 13 100 23 28 66 None 428 40-neg 4C 
96 40 93 13 23 28 66 None 429 40-20 2C 
101 88 97 108 26 79 2 None 457 88-145 1T 
13 38 84 13 17 64 34 None 569 38-5 1T 
122 11 125 12 96 8 2 None 665 11-30 1C 
122 11 125 12 8 8 2 None STnew3 (ST665-like) 11-30 1C 
6 41 33 18 9 8 6 None 707 41-60 1C 
52 116 55 101 113 40 38 None 770 116-552 7 (5C + 2T) 
6 4 3 16 11 8 6 None 906 4-61 1T 
38 24 84 13 17 30 34 None 919 24-187 2T 
83 23 155 170 133 1 2 None 997 23-31 1T 
6 4 159 44 112 1 17 None 1011 4-31 2 (1C + 1T) 
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adk fumC gyrB icd mdh purA recA 1CC 2ST 3Clonotype No. isolates and origin (C=chicken; T=turkey) 
10 252 5 8 7 8 2 None 1564 252-neg 1T 
101 88 97 108 7 13 2 None 1674 88-138 1T 
10 168 4 8 12 35 2 None 1785 168-54 1T 
18 22 67 31 5 5 4 None 1882 22-123 1T 
36 43 19 13 16 10 25 None 2557 43-225 2C 
267 6 5 26 9 13 98 None 2599 6-32 1T 
31 276 83 140 1 187 19 None 2614 276-108 1C 
6 8 32 159 9 23 7 None 3519 8-31 1C 
6 8 32 159 9 23 7 None 3519 8-39 1C 
79 3 206 451 5 16 182 None 4243 3-1002 5 (4C + 1T) 
410 153 118 83 7 8 6 None 4980 153-39 2C 
52 116 55 101 113 31 38 None 4994 116-270 1C 
443 271 24 198 7 214 359 None 5340 271-58 1T 
9 7 1 8 24 8 7 None 6215 7-34 1T 
96 925 13 100 23 28 66 None 6876 925-neg 1T 
136 11 4 1 9 18 7 None 7315 11-398 1T 
88 24 19 36 17 11 91 None 8611 24-26 2T 
76 1544 19 89 17 1 10 None 10740 1544-9 5 (4C + 1T) 
101 88 97 108 26 79 2 None 457 88-145 1C 
10 23 4 8 571 1 2 None STnew11 23-823 1C 
1 Clonal complexes (CC) and 2 Sequence types (ST) according to the Achtman scheme (Wirth et al., 2006): STnew 
was assigned to allelic combinations not found in EnteroBase, or to those including a new allele within the 7 gene; 
ST-like indicates one nucleotide of difference with the original ST. 2 Clonotype (CH) based on the internal 469-
nucleotide (nt) and 489-nt sequence of the fumC (allele obtained from MLST) and fimH genes, respectively 
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7.4. STUDY 3: GENOMIC CHARACTERIZATION OF ESBL-PRODUCING ESCHERICHIA 
COLI ISOLATES BELONGING TO A HYBRID AEPEC/EXPEC PATHOTYPE 
O153:H10-A-ST10 EAE-BETA1 OCCURRED IN HUMAN DIARRHEAGENIC 




Table 36. Assembly data from EnteroBase of the 17 O153:H10-A-ST10 genomes sequenced using Illumina NextSeq technology 
Code Assembly 
barcode 
Coverage N50 Length 
















LREC-110 ESC_KA7423AA_AS 361 147271 5152970 178 10 ST10 Cplx 38372 37600 2021 O153 H10 
LREC-111 ESC_KA7425AA_AS 370 126323 5239837 221 10 ST10 Cplx 38373 37601 2021 O153 H10 
LREC-112 ESC_KA7429AA_AS 124 109355 5084929 342 10 ST10 Cplx 38377 37605 2021 O153 H10 
LREC-113 ESC_KA7430AA_AS 92 93205 5172711 213 10 ST10 Cplx 38378 37606 2021 O153 H10 
LREC-114 ESC_KA7438AA_AS 163 126323 5201046 213 10 ST10 Cplx 38386 37614 2021 O153 H10 
LREC-115 ESC_KA7437AA_AS 141 126291 5232022 228 10 ST10 Cplx 38385 37613 2021 O153 H10 
LREC-116 ESC_KA7436AA_AS 118 124442 5187480 212 10 ST10 Cplx 38384 37612 2021 O153 H10 
LREC-117 ESC_KA7433AA_AS 163 124771 5160744 169 10 ST10 Cplx 38381 37609 2021 O153 H10 
LREC-118 ESC_KA7706AA_AS 39 69529 5166783 292 10 ST10 Cplx 39187 38299 2021 O153 H10 
LREC-119 ESC_KA7435AA_AS 296 125664 4994631 189 10 ST10 Cplx 38383 37611 2021 O153 H10 
LREC-120 ESC_KA7432AA_AS 150 102481 5263192 230 10 ST10 Cplx 38379 37607 2021 - H10 
LREC-121 ESC_KA7434AA_AS 71 73833 5134535 170 10 ST10 Cplx 38382 37610 2021 - H10 
LREC-122 ESC_KA7440AA_AS 168 124771 5209684 223 10 ST10 Cplx 38388 37616 2021 O153 H10 
LREC-123 ESC_KA7439AA_AS 78 123102 5208501 253 10 ST10 Cplx 38387 37615 2021 O153 H10 
LREC-124 ESC_KA7441AA_AS 201 119599 5258246 171 10 ST10 Cplx 38389 37617 2021 O153 H10 
LREC-125 ESC_KA7442AA_AS 166 119599 5274856 272 10 ST10 Cplx 38390 37618 2021 O153 H10 
LREC-127 ESC_KA7426AA_AS 208 126318 5253322 213 10 ST10 Cplx 38374 37602 58738 O153 H10 
Raw reads were uploaded and automatically assembled in EnteroBase (https://enterobase.warwick.ac.uk/) using SPAdes Genome Assembler v3.5. with a threshold on contigs of 
minimum 200 nt. Subsequently, the de novo assembled contigs were MLST (7 gene ST, wgST, cgST and rST) and serotype predicted using EnteroBase typing tools 
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Year a Country 
a O Antigen 
H 
Antigen ST Lineage 
fimH 
allele cgMLST HC0 HC2 HC5 HC10 HC20 HC50 HC100 HC200 HC400 SNPs 
b 




















2019 United Kingdom O153 H10 10 A 54 129194 129194 129194 129194 129194 129194 124093 37600 8224 8224   
AM_LREC-110 Chicken meat 2010 Spain O153 H10 10 A 54 37600 37600 37600 37600 37600 37600 37600 37600 8224 8224 37 










2007 Spain O153 H10 10 A 54 37606 37606 37606 37606 37606 37606 37600 37600 8224 8224 0 
AM_LREC-114 Beef meat 2008 Spain O153 H10 10 A 54 37614 37614 37614 37614 37614 37600 37600 37600 8224 8224 20 





2006 Spain O153 H10 10 A 54 37612 37612 37612 37612 37612 37606 37600 37600 8224 8224 22 
AM_LREC-117 Beef meat 2007 Spain O153 H10 10 A 54 37609 37609 37609 37609 37609 37609 37600 37600 8224 8224 36 
AM_LREC-118 Chicken breast 2009 Spain O153 H10 10 A 54 38299 38299 38299 38299 38299 37615 37600 37600 8224 8224 24 
AM_LREC-119 Beef meat 2007 Spain O153 H10 10 A 54 37611 37611 37611 37611 37611 37606 37600 37600 8224 8224 15 










AM_LREC-122 Pork meat 2011 Spain O153 H10 10 A 54 37616 37616 37616 37616 37616 37615 37600 37600 8224 8224 28 





2007 Spain O153 H10 10 A 54 37617 37617 37617 37617 37617 37606 37600 37600 8224 8224 31 
AM_LREC-125 Beef meat 2008 Spain O153 H10 10 A 54 37618 37618 37618 37618 37618 37606 37600 37600 8224 8224 21 
AM_LREC-127 Poultry farm environment 2010 Spain O153 H10 10 A 54 37602 37602 37602 37602 37602 37602 37600 37600 8224 8224 54 
E89 Broiler; Liver 2015 Denmark uncertain H10 7003 A 54 36964 36964 36964 36964 36964 36964 36964 36964 8224 8224   
Escherichia 
coli DNA DNA DNA O40 H10 10 A 54 8224 8224 8224 8224 8224 8224 8224 8224 8224 8224   
2312 
a Data not available (DNA); b Not analysed (NA); b SNPs of the core genomic regions present in 90% of the 17 compared genomes of our collection and using LREC-113 as reference 
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Table 38. Number of human stool samples analyzed and positive for aEPEC O153 
Year Nº stool samples 
No.  of positive samples (%) 
for aEPEC O153 
No.  of positive samples (%) 
for O153:H10 eae-beta1 fimAVMT78 
2006 1,842 4 (0.22) 1 (0.05) 
2007 2,095 11 (0.52) 8 (0.4) 
2008 1,001 5 (0.50) 3 (0.3) 
2009 550 0 (0) 0 (0) 
2010 514 0 (0) 0 (0) 
2011 1,207 2 (0.50) 1 (0.08) 
2012 2314 1 (0.04) 1 (0.04) 
Total 9,523 23 (0.14) 14 (0.15) 
 
Table 39. Twenty-three aEPEC O153 human isolates recovered in the period 2006-2012 











22250.06 2006 Diarrhea + - + + - 
37979. 06 2006 Diarrhea + + + - - 
41824. 06 2006 Diarrhea + - + - - 
45990. 06 (LREC 116)* 2006 Diarrhea + + + + + 
57646. 06 2007 Diarrhea + - + - + 
18396.07 (LREC 124)* 2007 Diarrhea + + + + + 
19979. 07 (LREC 113)* 2007 Diarrhea + + + + + 
30981. 07 (LREC 121)* 2007 Diarrhea + + + + + 
31952. 07 2007 Diarrhea + + + + + 
32182. 07 2007 Diarrhea + - + - - 
32651. 07 2007 Hemorrhagic 
gastroenteritis 
+ + + + + 
32884. 07 2007 Diarrhea + + + + + 
34535. 07 2007 Acute gastroenteritis + + + + + 
39044. 07 2007 Acute gastroenteritis + + + + + 
65905/07 2007 Hemorrhagic colitis + - + - + 
110431.08 2008 Hemorrhagic colitis + - + + - 
2477.08 2008 Diarrhea + - + - - 
21011. 08 2008 Diarrhea + + + + + 
38506. 08 2008 Diarrhea + + + + + 
40237. 08 2008 Diarrhea + + + + + 
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48633.11 2011 Diarrhea + - + - - 
9727.011 (LREC 112)* 2011 Hemorrhagic colitis + + + + + 
55515.12 2012 Diarrhea + + + + + 
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Table 40. in silico characterization of seven E. coli related genomes from EnteroBase using CGE databases 
Name Serotype Phylo group CHType ST 
Plasmid content 
Inc group (pMLST) Acquired resistances Virulence genes 




aadA1; catA1; mdf(A); tet(A) astA, eae, espA, espB, gad, iss, mchF, nleA, tir 




aadA1; catA1; mdf(A); tet(A) astA, eae, espA, espB, gad, iss, mchF, nleA, tir 





blaTEM-1B; aph(3´´)-Ib, aph(3´)-Ia, aph(6)-Ib; 
catA1; mdf(A); florR; tet(A); sul2; dfrA8 astA, eae, espA, espB, gad, iss, mchF, nleA, nleC, tir 
E. coli  





aac(3)-IV, aph(3´´)-Ib, aph(3´)-Ia, aph(4)-Ia, 
aph(6)-Ib; mdf(A); tet(A); sul2 
astA, eae, espA, espB, gad, ireA, iss, mchF, nleA, nleC, 
tir 
E89 ND:H10 A 11-54 10 IncF (F2:A-:B-) Col156 aadA1; mdf(A); astA, eae, espA, espB, gad, iss, mchF, nleA, tir 
208917 O40:H10 A 11-54 10 IncF (F2:A-:B-) Col156 mdf(A) astA, eae, espA, gad, ireA, mchF, nleA, nleC, tir 












































Table 41: Characterization of the 391 E. coli isolates recovered from 100 meat samples   
 
CFU/g




6 ExPEC7 UPEC8 
eae
9 Virulence profile10 
ESBL 
/other BL mcr Antibiotic profile
11 
10 
Ch1.I.R C O78:H9 23 23 35 4-35 iutA - 0 NR 0 0 DOX, NAL 
Ch1.I.a F O2:H42 648 648 58 4-58 iutA, KpsM II - K5 chuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, iutA, hlyF, ompT, iss 0 0 NAL 
Ch1.I.b B1 O78:H9 162 469 32 65-32 papAH, iutA fyuA 0 
fimH, papC, papAH, papEF, papGII, iucD, iroN, 
cvaC, traT, iutA, tsh, hlyF, ompT, iss TEM 0 
AMP, DOX, CHL, SXT, 
CIP, NAL 
Ch1.V.a G O24:H18 117 None 151 45-151 iutA chuA, vat, fyuA 0 




AMP, CFZ, CAZ, ATM, 
DOX, CHL, NAL 
30 
Ch2.I.R B2 O25:H4 131 131 22 40-22 iutA, KpsM II - K1 
chuA, fyuA, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
traT, ibeA, malX, usp, iutA, tsh, hlyF, ompT, 
iss 
0 0 GEN, DOX, NAL 
Ch2.I.c B2 O25:H4 131 131 neg 40-neg iutA, KpsM II - K1 
chuA, fyuA, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
traT, ibeA, malX, usp, iutA, tsh, hlyF, ompT, 
iss 
0 0 GEN, DOX, NAL 
Ch2.I.e B2 O25:H4 131 131 neg 40-neg iutA, KpsM II - K1 
chuA, fyuA, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
traT, ibeA, malX, usp, iutA, tsh, hlyF, ompT, 
iss 
0 0 GEN, NAL 
Ch2.I.g E O2:HNM 115 38 270 26-270 iutA, KpsM II chuA, fuyA 0 NR TEM 0 
AMP, DOX, SXT, CIP, 
NAL 
Ch2.I.h E O2:HNM 115 38 270 26-270 iutA, KpsM II chuA, fuyA 0 NR TEM 0 
AMP, DOX, SXT, CIP, 
NAL 
Ch2.I.i B2 O25:H4 131 131 neg 40-neg iutA, KpsM II - K1 
chuA, fyuA, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
traT, ibeA, malX, usp, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 NAL 
Ch2.IV.e A ONT:H40 752 * 10 24 11-24 iutA - 1* fimH, iucD, traT, iutA, hlyF, iss TEM 0 AMP, GEN, DOX, NAL 
Ch2.V.a A O2:H40 NR NR NR NR - - 0 NR CTX-M-32 - TEM 0 
AMP, CFZ, CXM, CTX, 
ATM, GEN 
40 
Ch3.I.R A O40:HNM 7199 None neg 7-neg - - 0 NR TEM 0 AMP 
Ch3.II.g A O123:H34 752 * 10 24 11-24 iutA - 1 fimH, iucD, traT, iutA, hlyF TEM 0 AMP, GEN, DOX, SXT, NAL 
Ch3.III.f Clade  I O1:H45 4994 None 270 116-270 iutA, KpsM II - K5 chuA 0 
fimH, iucD, KspM II, KpsM II - K2, KspM II - K5, 
malX, iutA, ompT 0 0 NAL 
Ch3.III.h B2 O2:H5 10740 None 9 1544-9 iutA, KpsM II - K5 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, ibeA, malX, usp, iutA, hlyF, 
ompT, iss 
TEM 0 - 
Ch3.V.a B1 O103:HAA NR NR NR NR - - 0 NR SHV-12 0 AMP, CFZ, CAZ, CTX, ATM, DOX, NAL 
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410 
Ch4.I.R A O8:H10 2705 10 23 11-23 iutA - 0 NR TEM 0 AMP, DOX, CHL 
Ch4.II.h B2 O117:H4 428 None 22 40-22 iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, fimAv, iucD, iroN, KpsM II, KpsM II - K2, 
neuC, cvaC, traT, ibeA, malX, usp, iutA, tsh, 
hlyF, ompT, iss 
TEM 0 AMP, DOX, CHL, SXT, CIP, NAL 
Ch4.II.i A O123:H34 752 * 10 24 11-24 iutA - 1 fimH, iucD, traT, iutA, hlyF TEM 0 AMP, NAL 
Ch4.II.j E O73:H34 1158 31 47 3-47 iutA, KpsM II chuA 0 KpsM II, iuta TEM 0 
AMP, DOX, SXT, CIP, 
NAL 
Ch4.V.a G O111:H4 117 None 97 45-97 iutA chuA, vat 0 fimH, iucD, iroN, cvaC, traT, malX, iutA, hlyF, ompT, iss CTX-M-1 0 
AMP, CFZ, CXM, CTX, 
DOX 
20 
Ch5.I.R C O78:HNM 23 23 35 4-35 iutA - 0 NR 0 0 NAL 
Ch5.II.a E O2:H9 115 38 270 26-270 iutA, KpsM II chuA, fuyA 0 NR CTX-M-NT 0 
AMP, CFZ, CXM, CTX, 
SXT, CIP, NAL 
Ch5.II.c A O11:H40 752 * 10 NR NR iutA - 1* fimH, iucD, traT, iutA, hlyF, iss 0 0 DOX, NAL 
Ch5.II.f A O80:H26 189 165 NR NR - fyuA 1* fimH, fimAv, traT TEM 0 AMP, GEN, NAL 
Ch5.II.g F O21:H42 1485 648 58 231-58 iutA, KpsM II - K5 
chuA, vat, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, GEN, SXT, CIP, NAL 
Ch5.V.a E O2:H9 115 38 270 26-270 iutA, KpsM II - K2 chuA, fuyA 0 
fimH, iucD, KpsM II, KpsM II - K2, traT, iutA, 
hlyF, ompT CTX-M-9 0 
AMP, CFZ, CXM, CTX, 
SXT, CIP, NAL 
Ch5.V.c D ONT:H18 69 69 27 35-27 iutA, KpsM II - K1 chuA, fuyA 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
traT, iutA, hlyF, ompT, iss SHV-12 0 
AMP, CFZ, CAZ, CTX, 
ATM 
10 
Ch6.I.R F O15:H42 1485 648 58 231-58 iutA, KpsM II - K5 
chuA, vat, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, AMC, GEN, TOB, SXT, CIP, NAL 
Ch6.I.a F O15:H42 1485 648 58 231-58 iutA, KpsM II - K5 chuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, GEN, TOB, DOX, SXT, CIP, NAL 
Ch6.I.f A O145:H40 752 10 24 11-24 - - 1* fimH, traT 0 0 NAL 
Ch6.V.a E O140:H34 1158 31 47 3-47 iutA, KpsM II - K5 chuA 0 
fimH, iucD, KpsM II, KpsM II - K2, KpsM II - K5, 
traT, iutA, hlyF, ompT TEM-52 0 
AMP, CFZ, CXM, CAZ, 
CTX, CIP, NAL 
100 
Ch7.I.R C O78:HNM 23 23 35 4-35 iutA yfcV 0 NR 0 0 NAL 
Ch7.II.a D O73:H45 4243 None 1002 3-1002 iutA, KpsM II chuA 0 NR SHV-12 0 
AMP, CFZ, ATM, GEN, 
NAL 
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Ch7.II.g B2 O175:H5 2557 None 225 43-225 KpsM II - K5, sfa/foc 
chuA, vat, 
fyuA, yfcV 0 
fimH, sfa/foc, iroN, KpsM II, KpsM II - K2, 
KpsM II - K5, ibeA, malX, usp, ompT 0 0 - 
Ch7.II.i B2 O175:H6 2557 None 225 43-225 
iutA, KpsM 
II - K5, 
sfa/foc 
chuA, vat, 
fyuA, yfcV 0 
fimH, sfa/foc, iucD, iroN, KpsM II, KpsM II - 
K2, KpsM II - K5, cvaC, ibeA, malX, usp, iutA, 
tsh, hlyF, ompT, iss 
0 0 NAL 
Ch7.II.j C O78:H45 23 23 35 4-35 iutA chuA, fuyA 0 NR 0 0 GEN, NAL 
Ch7.V.a A O2:H40 NR NR NR NR - - 0 NR CTX-M-32 - TEM 0 
AMP, CFZ, CXM, CAZ, 
CTX, ATM, GEN, NAL 
Ch7.V.b A O5:H10 93 168 58 11-58 iutA, KpsM II - K2 - 0 
iucD, iroN, KpsM II, KpsM II- K2, cvaC, traT, 
iuta, tsh, hlyF, iss CTX-M-1 0 
AMP, CFZ, CXM, CTX, 
DOX, NAL 
70 
Ch8.I.R B1 O109:HNT 162 469 32 65-32 iutA fyuA 0 NR   AMP, DOX, SXT, CIP, NAL 
Ch8.II.a A O132:H37 752 10 24 11-24 - - 1* fimH, traT 0 0 NAL 
Ch8.II.c B2 O25:H4 131 131 neg 40-neg iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
cvaC, traT, ibeA, malX, usp, iutA, tsh, hlyF, 
ompT, iss 
TEM 0 - 
Ch8.V.a E O19:HNT NR NR NR NR iutA chuA 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, CTX, 
ATM 
Ch8.V.b E ONT:H10 NR NR NR NR iutA chuA, fuyA 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, CTX, 
ATM 
30 
Ch9.I.R F O83:H42 1485 648 58 231-58 iutA, KpsM II - K5 
chuA, vat, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, GEN, SXT, NAL 
Ch9.I.e F O83:H42 1485 648 58 231-58 iutA, KpsM II - K5 
chuA, vat, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, GEN, DOX, SXT, NAL 
Ch9.II.a F O83:H42 1485 648 58 231-58 iutA, KpsM II - K5 
chuA, vat, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, GEN, SXT, NAL 
Ch9.II.i B1 O18ac:H49 212 None 38 29-38 - - 0 fimH, traT TEM mcr1.1 AMP, GEN, CST, DOX, CHL, SXT, CIP, NAL 
Ch9.IV.a A O20:H11 48 10 41 11-41 - - 0 NR CTX-M-NT - TEM 0 
AMP, CFZ, CXM, CTX, 
DOX, SXT, NAL 
40 
Ch10.I.R C O159:H16 295 23 38 4-38 - yfcV 0 NR TEM 0 AMP, NAL 
Ch10.I.g B2 O18:H12 1618 73 9 24-9 KpsM II - K5, sfa/foc 
chuA, vat, 
fyuA, yfcV 0 
fimH, sfa/foc, cdtB, iroN, KpsM II, KpsM II - 
K2, KpsM II - K5, traT, malX, usp, hlyF, ompT 0 0 NR 
Ch10.IV.c' E O19:HNM 2614 None 108 276-108 - chuA 0 NR TEM 0 AMP, DOX, CIP, NAL 
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Ch10.V.a A O123/186:H34 752 10 24 11-24 iutA - 1 fimH, iucD, traT, iutA, hlyF CTX-M-1 0 
AMP, CFZ, CXM, CTX, 
NAL 
Ch10.V.b G O111:H4 117 None 97 45-97 iutA chuA, vat 0 fimH, iucD, iroN, cvaC, traT, malX, iutA, hlyF, ompT, iss CTX-M-1 0 
AMP, CFZ, CXM, CTX, 
ATM, DOX, SXT, NAL 
50 
Ch13.I.R B2 O25:H4 131 131 22 40-22 iutA, KpsM II - K1 
chuA, fyuA, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
traT, ibeA, malX, usp, iutA, tsh, hlyF, ompT, 
iss 
0 0 GEN, DOX, NAL 
Ch13.II.b B2 O25:H4 131 131 22 40-22 iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
traT, ibeA, malX, usp, iutA, tsh, hlyF, ompT, 
iss 
0 0 DOX, NAL 
Ch13.II.h Clade  I O15:H16 770 None 552 116-552 iutA, KpsM II - K5 chuA, fuyA 0 
fimH, iucD, KspM II, KpsM II - K2, KspM II - K5, 
traT, malX, iutA, hlyF, ompT 0 0 - 
Ch13.IV.a F O83:H42 1485 648 58 231-58 iutA, KpsM II - K5 
chuA, vat, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, GEN, DOX, SXT, CIP, NAL 
Ch13.V.a B1 O8:H19 NR NR NR NR - - 0 NR SHV-12 0 AMP, CFZ, CAZ, CTX, ATM, NAL 
Ch13.V.b A O88:H7 NR NR NR NR - - 0 NR SHV-12 0 AMP, CFZ, CIP, NAL 
10 
Ch14.I.R B1 O88:H10 162 469 32 65-32 iutA - 0 NR 0 0 CIP, NAL 
Ch14.I.g B2 O2:H5 10740 None 9 1544-9 iutA, KpsM II - K5 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, ibeA, malX, usp, iutA, hlyF, 
ompT, iss 
0 0 - 
Ch14.I.j A O153:H10 10 10 54 11-54 - fyuA 1* fimH, fimAv, traT 0 0 - 
<10 
Ch15.I.R A O84:HNM 10 10 54 11-54 - - 0 NR TEM 0 AMP, GEN, DOX, CIP, NAL 
Ch15.I.b A O86:H5 93 168 41 11-41 iutA, KpsM II - 0 NR TEM 0 
AMP, AMC, GEN, 
DOX, CIP, NAL 
20 
Ch16.I.R F O11:H25 457 None 145 88-145 iutA, KpsM II - K2 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, cvaC, 
traT, malX, iutA, tsh, hlyF, ompT, iss 0 0 GEN, DOX 
Ch16.II.a A O68:H51 10 10 24 11-24 - - 1* fimH, traT TEM 0 AMP, GEN, NAL 
Ch16.V.a E O128:H25 NR NR NR NR iutA chuA 0 NR CTX-M-1 - TEM 0 
AMP, CFZ, CXM, CTX, 
GEN 
Ch16.V.c B1 O8:H51 NR NR NR NR - - 0 NR SHV-12 0 
AMP, CFZ, CXM, CAZ, 
CTX, ATM, DOX, CHL, 
NAL 
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Ch17.II.b B2 O120:H4 428 None neg 40-neg iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, fimAv, iucD, iroN, KpsM II, KpsM II - K2, 
neuC, cvaC, traT, ibeA, malX, usp, iutA, hlyF, 
ompT, iss 
TEM 0 AMP, SXT 
Ch17.II.b A O153:HNM 10 10 NR NR - fyuA 1* fimH, fimAv, traT TEM 0 AMP, DOX, CHL 
Ch17.II.j2 B2 O2:H1 135 None 2 39-2 iutA, KpsM II - K5 
chuA, vat, 
fyuA, yfcV 0 
fimH, fimAv, iucD, iroN, KpsM II, KpsM II - K2, 
KpsM II - K5, cvaC, traT, ibeA, malX, usp, iuta, 
tsh, hlyF, ompT, iss 
0 0 DOX, NAL 
Ch17.V.a A O154:H28 NR NR NR NR - - 0 NR SHV-12 0 
AMP, CFZ, CXM, CAZ, 
CTX, ATM, DOX, CHL, 
CIP, NAL 
440 
Ch18.I.R A O132:HNM 10 10 54 11-54 - - 0 NR   - 
Ch18.IV.b B2 O2:H5 10740 None 9 1544-9 iutA, KpsM II - K5 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, ibeA, malX, usp, iutA, hlyF, 
ompT, iss 
0 0 - 
Ch18.IV.d A O153:H10 10 10 54 11-54 - fyuA 1* fimH, fimAv, traT TEM 0 AMP, GEN, DOX, CHL 
Ch18.IV.g B2 O2:HNM 10740 None 9 1544-9 
iutA, KpsM 
II - K5, 
afa/dra 
chuA, vat, 
fyuA, yfcV 0 
fimH, fimAv, afa/dra, iucD, iroN, KpsM II, 
KpsM II - K2, KpsM II - K5, cvaC, traT, ibeA, 
malX, usp, iutA, hlyF, ompT, iss 
0 0 - 
Ch18.V.a E O140:H25 NR NR NR NR - chuA 0 NR CTX-M-1 0 AMP, CFZ, CXM, CTX, NAL 
Ch18.V.b A O154:H28 NR NR NR NR - - 0 NR SHV-12 0 AMP, CFZ, DOX, CHL, CIP, NAL 
510 
Ch19.I.R B2 O120:H4 428 None neg 40-neg iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, fimAv, iucD, iroN, KpsM II, KpsM II - K2, 
neuC, cvaC, traT, ibeA, malX, usp, iutA, hlyF, 
ompT, iss 
TEM 0 AMP, SXT 
Ch19.I.a B2 O120:H4 428 None neg 40-neg 
iutA, KpsM 
II - K1, 
afa/dra 
chuA, vat, 
fyuA, yfcV 0 
fimH, fimAV, afa/dra, iucD, iroN, KpsM II, 
KpsM II - K2, neuC, cvaC, traT, ibeA, malX, 
usp, iutA, hlyF, ompT, iss 
0 0 AMP, SXT 
Ch19.II.c1 B2 O120:H4 428 None neg 40-neg 
iutA, KpsM 
II - K1, 
afa/dra 
chuA, vat, 
fyuA, yfcV 0 
fimH, fimAV, afa/dra, iucD, iroN, KpsM II, 
KpsM II - K2, neuC, cvaC, traT, ibeA, malX, 
usp, iutA, hlyF, ompT, iss 
0 0 AMP, SXT 
Ch19.V.a A O88:H7 NR NR NR NR - - 0 NR TEM-52 0 AMP, CFZ, CXM, CTX, NAL 
Ch19.V.b E O140:H25 NR NR NR NR - chuA 0 NR CTX-M-1 0 AMP, CFZ, CXM, CTX, ATM, NAL 
40 Ch20.I.R C O15:HNT 23 23 32 4-35 iutA fyuA 0 NR TEM 0 AMP, TOB, DOX, SXT, CIP, NAL 
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Ch20.I.j B2 O2:H1 429 None 20 40-20 iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
cvaC, traT, ibeA, malX, usp, iutA, tsh, hlyF, 
ompT, iss 
0 0 NAL 
Ch20.II.a A O11:HNT 752 * 10 NR NR - fyuA 1* fimH, traT TEM 0 AMP, NAL 
Ch20.II.c B2 O2:H1 429 None 20 40-20 iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
cvaC, traT, ibeA, malX, usp, iutA, tsh, hlyF, 
ompT, iss 
0 0 NAL 
Ch20.II.g A O123:H34 10 10 NR NR - - 1* fimH TEM 0 NAL 
Ch20.V.a E O19:H45 NR NR NR NR - chuA 0 NR SHV-12 0 AMP, CFZ, CAZ, ATM, DOX, CHL 
10 
Ch21.I.R B1 O88:H8 101 101 86 41-86 - vat 0 NR 0 0 - 
Ch21.I.d B2 O2:HNM 95 95 27 38-27 
papAH, 
iutA, KpsM 
II - K1 
chuA, fyuA, 
yfcV 0 
fimH, papC, papAH, papEF, papGII, iucD, iroN, 
KpsM II, KpsM II - K2, neuC, cvaC, traT, malX, 
usp, iutA, hlyF, ompT, iss 
TEM 0 NAL 
Ch21.II.a B2 O2:HNM 95 95 27 38-27 
papAH, 
iutA, KpsM 
II - K1 
chuA, fyuA, 
yfcV 0 
fimH, papC, papAH, papEF, papGII, iucD, iroN, 
KpsM II, KpsM II - K2, neuC, cvaC, traT, malX, 
usp, iutA, hlyF, ompT, iss 
0 0 NAL 
Ch21.V.a A O88:H7 NR NR NR NR - - 0 NR TEM-52 0 AMP, CXM, CTX, NAL 
Ch21.V.e C O19:HNM NR NR NR NR - - 0 NR SHV-12 0 AMP, CAZ, ATM, DOX, CHL, CIP, NAL 
40 
Ch22.II.l A ONT:H51 STnew11 None 823 23-823 - - 1 fimH, fimAv, traT, usp TEM 0 AMP, SXT, CIP, NAL 
Ch22.II.o A O7:HNM 93 168 41 11-41 iutA, KpsM II chuA 0 NR 
SHV-12 - 
TEM 0 
AMP, GEN, TOB, CHL, 
NAL 
Ch22.V.b E O154:H38 NR NR NR NR iutA chuA 0 NR SHV-12 0 AMP, CFZ, CAZ, ATM, DOX, CIP, NAL 
310 
Ch23.I.R E O123:H15 38 38 65 26-65 - chuA, fyuA  0 NR 0 0 NAL 
Ch23.V.a B1 O8:H51 NR NR NR NR iutA - 0 NR SHV-12 0 
AMP, CFZ, CXM, CAZ, 
CTX, ATM, DOX, CIP, 
NAL 
200 
Ch24.I.R D O73:HNT 4243 None 1002 3-1002 iutA, KpsM II - K5 chuA 0 
fimH, iucD, KspM II, KpsM II - K2, KspM II - K5, 
traT, iutA, iss 0 0 GEN, NAL 
Ch24.II.d A O88:H28 NR NR 27 152-27 iutA, KpsM II chuA, vat 0 NR 0 0 - 
Ch24.IV.h G O161:H4 117 None 97 45-97 papAH, iutA 
chuA, vat, 
fyuA 0 
fimH, papC, papAH, papEF, papGII, iucD, iroN, 








6 ExPEC7 UPEC8 
eae
9 Virulence profile10 
ESBL 
/other BL mcr Antibiotic profile
11 
Ch24.V.a A O153:H10 10 10 54 11-54 - fyuA 1* fimH, fimAv, traT CTX-M-32 - TEM 0 
AMP, CFZ, CXM, CTX, 
ATM, GEN, DOX, CHL 
50 
Ch25.I.R A O140:HNM 10 10 54 11-54 - - 0 NR 0 0 DOX 
Ch25.V.a A O19:H17 665 None 30 11-30 - - 0 NR CTX-M-32 0 AMP, CFZ, CXM, CAZ, CTX, ATM, CIP, NAL 
Ch25.V.b A O88:H7 4980 None 39 153-39 - - 0 NR TEM-52 0 AMP, CFZ, CXM, CTX, NAL 




None 30 11-30 iutA - 0 NR CTX-M-32 0 AMP, CFZ, CXM, CAZ, CTX, ATM, CIP, NAL 
Ch25.V.e A O23:H32 10 10 54 11-54 iutA - 0 fimH, fimAv, iucD, iroN, traT, iutA, hlyF, iss SHV-12 0 AMP, CFZ, ATM, NAL 
<10 
Ch26.I.R A O101:H9 5507 10 54 11-54 iutA - 0 NR TEM 0 AMP, AMC, DOX, NAL 
Ch26.I.b A O5:H10 93 168 neg 11-neg iutA, KpsM II - 0 NR 0 0 GEN, TOB, CIP, NAL 
Ch26.I.h A O5:H10 93 168 neg 11-neg iutA, KpsM II - 0 NR TEM 0 GEN, CIP, NAL 
10 
Ch27.I.R B1 O19:HNT 212 None 38 29-38 - - 0 NR TEM 0 AMP, AMC, SXT, CIP, NAL 
Ch27.II.b E ONT:H34 1158 31 47 3-47 iutA, KpsM II chuA 0 NR TEM 0 
AMP, GEN, DOX, CIP, 
NAL 
Ch27.II.e D O17:H45 4243 None 1002 3-1002 iutA, KpsM II - 0 NR 0 0 GEN, NAL 
Ch27.III.b E O25:H45 1011 None 31 4-31 - chuA, fuyA 0 fimH, iroN, traT, tsh, hlyF, ompT, iss TEM 0 AMP, SXT 
Ch27.V.a A O132:H28 10 10 54 11-54 - - 0 NR SHV-12 0 AMP, CFZ, ATM, CHL, NAL 
<10 
Ch28.I.R A O88:HNT STnew1 None 39 153-39 - - 0 NR TEM 0 AMP, AMC, DOX, NAL 
Ch28.V.a B1 O86:H51 155 155 32 4-32 iutA, KpsM II - K5 - 0 




AMP, AMC, CFZ, CAZ, 
CTX, ATM, GEN, TOB, 
DOX, SXT, CIP, NAL 
Ch28.V.e B1 O86:H51 1016 155 32 4-32 - - 0 NR SHV-12 - TEM 0 
AMP, AMC, CFZ, CAZ, 
ATM, GEN, TOB, 
DOX, SXT, CIP, NAL 
<10 
Ch29.I.R A O113:H4 10 10 54 11-54 - - 0 NR 0 0 GEN, TOB, CIP, NAL 
Ch29.II.d B2 O25:H4 131 131 22 40-22 iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
traT, ibeA, malX, iutA, tsh,  hlyF, ompT, iss 0 0 NAL 









6 ExPEC7 UPEC8 
eae
9 Virulence profile10 
ESBL 
/other BL mcr Antibiotic profile
11 
10 
Ch31.I.R A ONT:H7 5826 None 60 4-60 - - 0 NR 0 0 AMP 
Ch31.II.a B2 O15:H5 355 73 154 24-154 iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
cvaC, traT, ibeA, malX, usp, iutA, tsh,  hlyF, 
ompT, iss 
0 0 GEN, DOX, NAL 
Ch31.II.j B2 O2:H5 355 73 154 24-154 iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
cvaC, traT, ibeA, malX, usp, iutA, tsh,  hlyF, 
ompT, iss 
TEM 0 DOX, NAL 
Ch31.V.a A O18:H11/H21 93 168 neg 11-neg 
iutA, KpsM 
II - K5 - 0 
iucD, KpsM II, KpsM II- K2, KpsM II- K5, iuta, 
ompT SHV-12 0 
AMP, AMC, CFZ, CXM, 
CAZ, CTX, ATM, CHL, 
NAL 
<10 
Ch32.I.R B1 O8:H19 162 469 27 65-27 iutA vat 0 NR TEM 0 AMP, GEN, TOB, NAL 
Ch32.V.a B1 O45:H8 297 None 38 65-38 iutA - 0 NR SHV-12 0 AMP, CFZ 
20 
Ch33.I.R B1 O8:H19 162 469 38 65-38 iutA - 0 NR 0 0 AMP, NAL 
Ch33.V.a A O8:H8 STnew6 None 1319 new-1319 papAH, iutA fyuA 0 
fimH, papC, papAH, papEF, iucD, iroN, cvaC, 
traT, iutA, hlyF, ompT, iss 
SHV-12 - 
TEM 0 
AMP, CXM, CAZ, ATM, 
CHL, SXT 
Ch33.V.b A O8:H8 STnew6 None 1319 new-1319 papAH, iutA fyuA 0 
fimH, papC, papAH, papEF, iucD, iroN, cvaC, 
traT, iutA, hlyF, ompT, iss 
SHV-12 - 
TEM 0 
AMP, CAZ, ATM, CHL, 
SXT 
Ch33.V.c B1 O8:H19 162 469 32 65-32 iutA - 0 NR SHV-12 0 AMP, CAZ, ATM, CHL, SXT, CIP, NAL 
80 
Ch34.I.R E O45:HNM 371 350 142 31-142 iutA chuA 0 NR 0 0 GEN, NAL 
Ch34.I.a A O5:H10 93 168 neg 11-neg iutA, KpsM II chuA 0 NR 0 0 GEN, CIP, NAL 
Ch34.V.a Clade  I O1:H45 770 None 552 116-552 iutA, KpsM II - K5 - 0 
fimH, iucD, KpsM II, KpsM II - K2, KpsM II - K5, 
traT, malX, iutA, ompT CTX-M-9 0 
AMP, CFZ, CXM, CTX, 
ATM, GEN, CIP, NAL 
50 
Ch35.I.R G O143:H4 117 None 97 45-97 iutA chuA, fyuA 0 fimH, iucD, traT, malX, iutA,tsh, hlyF, ompT, iss 0 0 AMP 
Ch35.I.e A O7:H4 1594 168 31 11-31 iutA, KpsM II chuA 0 NR 0 0 - 
Ch35.V.a G O132:H4 117 None 97 45-97 iutA chuA, vat 0 fimH, iucD, iroN, cvaC, traT, malX, iutA, hlyF, ompT, iss SHV-12 0 
AMP, CFZ, CAZ, ATM, 
CHL, NAL 
Ch35.V.b A O88:H7 4980 None 39 153-39 - - 0 NR TEM-52 0 AMP, CFZ, CXM, CTX, DOX, SXT, NAL 
Ch35.V.c B1 O51:H21 101 101 86 41-86 iutA - 0 NR CTX-M-1 - TEM 0 
AMP, AMC, CFZ, CXM, 
CTX, NAL 
Ch35.V.d A ONT:H23 707 None 60 41-60 iutA - 0 NR CTX-M-1 - TEM 0 
AMP, CFZ, CXM, CTX, 
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20 
Ch36.I.R A O153:H10 10 10 54 11-54 - fyuA 1* fimH, fimAV, papC, papEF, papGII, traT 0 0 AMP, DOX, CHL, CIP, NAL 
Ch36.V.a A O11:NHM 93 168 41 11-41 iutA, KpsM II - K5 chuA 0 
fimH, fimAv, iucD, KpsM II, KpsM II - K2, KpsM 
II - K5, traT, iutA, hlyF SHV-12 0 
AMP, CFZ, CHL, NIT, 
CIP, NAL 
<10 
Ch37.I.R C O78:HNM 23 23 35 4-35 iutA vat, fyuA 0 NR 0 0 AMP, NAL 
Ch37.II.c F O83:H42 1485 648 58 231-58 iutA, KpsM II - K5 
chuA, vat, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, SXT, CIP, NAL 
Ch37.II.i B2 O2:H5 355 73 154 24-154 iutA, KpsM II - K1 
chuA, fyuA, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
traT, ibeA, malX, usp, iutA, hlyF, ompT, iss 0 0 - 
<10 
Ch38.I.R F O83:H42 1485 648 58 231-58 iutA, KpsM II - K5 
chuA, vat, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, SXT, CIP, NAL 
Ch38.II.j F O83:H42 1485 648 58 231-58 iutA, KpsM II - K5 
chuA, vat, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, SXT, CIP, NAL 
<10 
Ch39.I.h' B2 O25:H4 131 131 22 40-22 iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
cvaC, traT, ibeA, malX, usp, iutA, tsh, hlyF, 
ompT, iss 
0 0 NAL 
Ch39.V.a B1 O8:H51 4162 155 38 4-38 iutA vat 0 NR SHV-12 0 AMP, CFZ, ATM 
<10 
Ch40.I.R A O145:H40 752 10 24 11-24 - - 1* fimH, traT TEM 0 AMP, NAL 
Ch40.I.g B2 O19:HNT 1618 73 9 24-9 
iutA, KpsM 
II - K5, 
sfa/foc 
chuA, vat, 
fyuA, yfcV 0 
fimH, sfa/foc, cdtB, iucD, iroN, KpsM II, KpsM 
II - K2, KpsM II - K5, cvaC, traT, malX, usp, 
iutA, hlyF, ompT, iss 
TEM 0 AMP, GEN, TOB 
Ch40.V.a Clade I O153:HNM 770 None 552 116-552 iutA, KpsM II - K5 fyuA 0 
fimH, iucD, KpsM II, KpsM II - K2, KpsM II - K5, 
traT, malX, iutA, hlyF, ompT SHV-12 0 
AMP, CFZ, CAZ, CTX, 
ATM, CHL, NAL 
<10 
Ch41.II.g D O15:H6 69 69 27 35-27 iutA, KpsM II chuA, fuyA 0 NR TEM 0 AMP, NAL 
Ch41.V.a B1 O8:H51 155 155 32 4-32 - chuA 0 NR SHV-12 0 AMP, CFZ, CAZ, CTX, ATM, CHL, CIP, NAL 
Ch41.V.b Clade I O1:H45 770 None 552 116-552 iutA, KpsM II - K5 chuA 0 
fimH, iucD, KpsM II, KpsM II - K2, KpsM II - K5, 
traT, malX, iutA, ompT SHV-12 0 
AMP, CFZ, CXM, CAZ, 
CTX, ATM, CHL, CIP, 
NAL 
Ch41.V.c B1 O8:H51 155 155 32 4-32 - - 0 NR SHV-12 0 AMP, CFZ, CAZ, ATM, CHL, CIP, NAL 
60 Ch42.I.R C O162:H42 295 23 38 4-38 - fyuA 0 NR TEM 0 AMP, NAL 
30 Ch43.I.R B1 O7:HNT 1730 None 32 69-32 - - 0 NR 0 0 AMP, CHL 
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Ch43.II.b B2 O2:HAA 135 None 2 39-2 iutA, KpsM II - K5 
chuA, vat, 
fyuA, yfcV 0 
fimH, fimAv, iucD, iroN, KpsM II, KpsM II - K2, 
KpsM II - K5, traT, ibeA, malX, usp, iuta, tsh, 
hlyF, ompT, iss 
TEM 0 AMP 
Ch43.II.e E O73:H34 1158 31 47 3-47 iutA, KpsM II chuA 0 NR TEM 0 
AMP, GEN, TOB, SXT, 
CIP, NAL 
Ch43.II.f F O83:H42 1485 648 58 231-58 iutA, KpsM II - K5 
chuA, vat, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 




AMP, CFZ, CAZ, CTX, 
ATM, SXT 
Ch43.V.a E ONT:H25 57 350 27 31-27 iutA chuA 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, ATM, 
CHL 
Ch43.V.b G O57:HNM 117 None 97 45-97 iutA chuA, vat, fyuA 0 
fimH, cdtB, iucD, iroN, traT, malX, iutA, tsh, 
hlyF, ompT, iss SHV-12 0 
AMP, CFZ, CAZ, ATM, 
DOX, CHL 
480 
Ch44.I.d B2 O50/O2:H4 95 95 27 38-27 
papAH, 
iutA, KpsM 
II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, papC, papAH, papEF, papGII, iucD, iroN, 
KpsM II, KpsM II - K2, neuC, cvaC, traT, malX, 
usp, iutA, tsh, hlyF, ompT, iss 
0 0 CIP, NAL 
Ch44.II.g E O73:H34 1158 31 47 3-47 iutA, KpsM II chuA 0 NR TEM 0 
AMP, DOX, SXT, CIP, 
NAL 
Ch44.II.h B2 O15:HNM 95 95 27 38-27 
papAH, 
iutA, KpsM 
II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, papC, papAH, papEF, papGII, iucD, iroN, 
KpsM II, KpsM II - K2, neuC, cvaC, traT, malX, 
usp, iutA, tsh, hlyF, ompT, iss 
0 0 CIP, NAL 
Ch44.V.a Clade I O1:HNT 770 None 552 116-552 iutA, KpsM II - K5 chuA 0 
fimH, iucD, KpsM II, KpsM II - K2,  KpsM II - K5, 
traT, malX, iutA CTX-M-9 0 
AMP, CFZ, CXM, CTX, 
GEN, CIP, NAL 
480 
Ch45.I.R C O60:H9 23 23 35 4-35 iutA - 0 NR TEM 0 AMP 
Ch45.I.p F O174:H42 648 648 58 4-58 iutA, KpsM II - K5 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP 




31 47 3-47 iutA, KpsM II chuA 0 NR TEM 0 
AMP, GEN, TOB, CIP, 
NAL 
Ch45.V.a A O18:NHM 226 226 41 27-41 - fyuA 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, ATM, 
DOX 
Ch45.V.c C O20:H9 410 23 24 4-24 iutA fyuA 0 NR CTX-M-14 0 
AMP, CFZ, CXM, CTX, 
GEN, TOB, DOX, CHL, 
SXT, CIP, NAL 
<10 
Ch46.I.R E O7:H15 38 38 65 26-65 - chuA 0 NR 0 0 AMP, GEN, TOB 
Ch46.II.c B1 O159:H11/H21 641 86 25 6-25 - chuA 0 NR SHV-12 0 
AMP, CFZ, CAZ, CTX, 
ATM, SXT, NAL 
Ch46.V.a B1 O159:H11/H21 641 86 25 6-25 - - 0 NR SHV-12 0 
AMP, CFZ, CAZ, CTX, 
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<10 




None 97 New-97 iutA chuA, vat, fyuA 0 
fimH, iucD, iroN, traT, malX, iutA, tsh, hlyF, 
ompT, iss TEM 0 AMP, GEN, DOX, NAL 
Ch47.I.a A O5:H10 93 168 neg 11-neg iutA, KpsM II chuA 0 NR 0 0 GEN, CIP, NAL 
Ch47.I.o A O5:H10 93 168 neg 11-neg iutA, KpsM II - 0 NR 0 0 GEN, CIP, NAL 
Ch47.V.a A O39:H48 3519 None 39 8-39 - - 0 NR CTX-M-32 0 AMP, CFZ, CXM, CTX, DOX, CIP, NAL 
Ch47.V.b A O39:H48 3519 None 31 8-31 - - 0 NR CTX-M-32 0 AMP, CFZ, CXM, CTX, DOX, CIP, NAL 
120 
Ch48.I.R C O8:H9 23 23 35 4-35 iutA - 0 NR TEM 0 AMP, CHL 
Ch48.I.m A O162:H3 744 10 58 11-58 iutA fyuA 0 NR TEM 0 AMP, GEN, TOB, DOX, SXT, CIP, NAL 
Ch48.I.o A O21:H6 48 10 23 11-23 iutA, KpsM II - 0 NR TEM 0 
AMP, CHL, SXT, CIP, 
NAL 
Ch48.V.a A O18:HNM 226 226 41 27-41 - fyuA 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, ATM, 
DOX 
Ch48.V.b A O127:H21 10 10 54 11-54 - fyuA 0 fimH SHV-12 0 
AMP, CFZ, CXM, CAZ, 
CTX, FOX, ATM, DOX, 
CHL, NAL 
30 
Ch49.I.R B1 O103:H21 101 101 86 41-86 iutA - 0 NR 0 0 AMP 
Ch49.I.c D O44:H45 4243 None 1002 3-1002 iutA, KpsM II chuA 0 NR 0 0 NAL 
Ch49.V.a A O162:H9 617 10 neg 11-neg iutA fyuA 0 NR CTX-M-15 0 
AMP, CFZ, CXM, CAZ, 
CTX, ATM, DOX, SXT, 
CIP, NAL 
Ch49.V.b A O88:HNM 1970 10 54 11-54 - - 0 NR SHV-12 0 AMP, CFZ, CAZ, CTX, ATM 
Ch49.V.d B1 O5:H11 155 155 121 4-121 - - 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, CTX, 
ATM, GEN, TOB 
80 
Ch50.I.R E O99:H15 38 38 65 26-65 - fyuA 0 fimH, traT, hlyF TEM 0 AMP, DOX, SXT, NAL 
Ch50.II.a B2 O25:H4 131 131 22 40-22 iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
traT, ibeA, malX, usp, iutA, tsh, hlyF, ompT, 
iss 
0 0 GEN, NAL 
Ch50.II.d E ONT:HNM 1158 31 47 3-47 iutA, KpsM II chuA 0 KpsM II, iuta TEM 0 
AMP, GEN, DOX, CIP, 
NAL 
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T1.II.h B2 O2:H5 355 73 154 24-154 iutA, KpsM II - K5 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, traT, ibeA, malX, usp, iutA, hlyF, ompT, 
iss 
0 0 DOX, CHL, NAL 
T1.IV.d B2 O2:H5 140 95 15 38-15 iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, fimAv, iucD, KpsM II, KpsM II - K2, neuC, 
traT, ibeA, malX, usp, iutA, hlyF, ompT TEM 0 AMP, DOX, SXT 
T1.IV.e B1 O109:H51 155 155 32 4-32 - - 0 fimH, iroN, traT, hlyF, iss TEM mcr1.1 AMP, GEN, DOX, CHL, CIP, NAL 
T1.V.e A O162/O89:H9 744 10 54 11-54 iutA - 0 
fimH, fimAv, iucD, iroN, cvaC, traT, iutA, tsh, 
hlyF, iss SHV-12  mcr1.1 
AMP, CFZ, CAZ, CTX, 
ATM, CST, DOX, CHL, 
SXT, CIP, NAL 
T1.V.d B1 O8:HNT NR NR NR NR - - 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, ATM, 
DOX, CHL, CIP, NAL 
T1.V.a D OAA:H23 NR NR NR NR - chuA 0 NR SHV-12 0 
AMP, CFZ, CAZ, CTX, 
ATM, DOX, CHL, CIP, 
NAL 
90 
T2.I.R A O16:HNM 10 10 54 11-54 - - 0 NR 0 0 AMP, SXT 




None 276 65-276 iutA, KpsM II chuA, fuyA 0 NR TEM 0 
AMP, DOX, SXT, CIP, 
NAL 
T2.II.d B2 O46:H31 569 None 5 38-5 KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
cvaC, traT, ibeA, usp, hlyF, ompT, iss TEM 0 DOX, NAL 
T2.V.a B1 O19:H21 NR NR NR NR - - 0 NR SHV-12 0 AMP, CFZ, CAZ, ATM, DOX, SXT, CIP, NAL 
100 
T3.I.R B1 ONT:H2 2599 None 32 6-32 iutA - 0 NR TEM 0 AMP, SXT, CIP, NAL 
T3.I.a B1 ONT:H2 2599 None 32 6-32 iutA - 0 NR TEM 0 AMP, SXT, CIP, NAL 
T3.V.c A ONT:H9 NR NR NR NR iutA fyuA 0 NR CTX-M-15 0 
AMP, CFZ, CXM, CAZ, 
CTX, ATM, DOX, CHL, 
CIP, NAL 
T3.V.a B1 ONT:HNM NR NR NR NR - - 0 NR CTX-M-1 - TEM 0 
AMP, CFZ, CXM, CTX, 
ATM, DOX, CHL, SXT, 
NAL 
40 
T4.I.R C O8:H4 88 23 39 4-39 iutA - 0 NR TEM 0 AMP, GEN, SXT, CIP, NAL 
T4.I.e B2 O2:HNM 355 73 154 24-154 iutA, KpsM II - K5 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 




AMP, CFZ, ATM, DOX, 
NAL 
T4.V.c B1 O20:HNM NR NR NR NR - - 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, ATM, 
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T4.V.a F O153:HNM 354 354 neg 88-neg KpsM II - K2 chuA, yfcV 0 
fimH, KpsM II, KpsM II - K2, traT, ibeA, malX, 
usp SHV-12 0 
AMP, CFZ, CXM, CAZ, 
CTX, ATM, CHL, CIP, 
NAL 
70 
T5.I.R B1 O9:HNM 162 469 32 65-32 iutA fyuA 0 NR TEM 0 AMP, DOX, CIP, NAL 
T5.II.a A O51:H52 93 168 neg 11-neg iutA, KpsM II - 0 NR TEM 0 AMP, SXT, CIP, NAL 
T5.V.a E O119:HNT NR NR NR NR - chuA 0 NR SHV-12 0 AMP, CFZ, CAZ, CTX, SXT, CIP, NAL 
T5.V.b E O40/O8:H45 1011 None 31 4-31 - chuA 0 fimH, iroN, traT, hlyF, iss 
SHV-2 - 
TEM 0 
AMP, AMC, CFZ, CXM, 
CTX, DOX, SXT, CIP, 
NAL 
180 
T6.I.R B1 ONT:H4 58 155 32 4-32 iutA fyuA 0 NR 0 0 SXT 
T6.II.b F O171:H4 1485 648 58 231-58 iutA, KpsM II - K5 
chuA, vat, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
0 0 AMP, SXT, CIP, NAL 
T6.V.b A ONT:H10 NR NR NR NR - - 0 NR SHV-12 0 
AMP, CFZ, CXM, CAZ, 
CTX, ATM, DOX, CHL, 
NAL 
T6.V.a B1 O19:H21 NR NR NR NR - - 0 NR SHV-12 0 AMP, CFZ, CAZ, ATM, DOX, SXT, CIP, NAL 
<10 
T7.I.R B1 O9:H53 345 None 31 4-31 - - 0 NR 0 0 AMP, CIP, NAL 
T7.I.i A O9:H11 48 10 400 11-400 - fyuA 0 NR 0 0 - 
T7.V.a A ONT:H9 NR NR NR NR iutA fyuA 0 NR CTX-M-15 0 
AMP, CFZ, CXM, CAZ, 
CTX, ATM, DOX, CHL, 
CIP, NAL 
T7.V.b B1 ONT:HNM NR NR NR NR - - 0 NR CTX-M-1 - TEM 0 
AMP, CFZ, CXM, CTX, 
DOX, CHL, SXT, NAL 
20 
T8.I.R B1 ONT:H7 3580 None 32 65-32 iutA - 0 NR TEM 0 AMP, GEN 
T8.I.d B1 O38:HNM 453 86 31 6-31 iutA, KpsM II fyuA 0 NR TEM 0 AMP, CIP, NAL 
T8.V.a A O101:HNM NR NR NR NR iutA fyuA 0 NR CTX-M-15 0 
AMP, CFZ, CXM, CAZ, 
CTX, ATM, DOX, CHL, 
CIP, NAL 
T8.V.b B1 O19:H21 NR NR NR NR iutA - 0 NR SHV-12 0 
AMP, CFZ, CAZ, CTX, 
ATM, DOX, SXT, CIP, 
NAL 
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250 
T9.I.R B1 O29:H10 1720 86 54 270-54 sfa/foc - 0 NR TEM 0 AMP, DOX, SXT 
T9.I.h B1 O9:H25 NR NR NR NR iutA fyuA 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, CTX, 
ATM, DOX, CHL, SXT 
T9.II.a B1 O9:HNT NR NR NR NR iutA chuA 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, ATM, 
GEN, CHL, CIP, NAL 
T9.II.b B2 O101:H4 6876 None neg 925-neg iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, fimAv, iucD, iroN, KpsM II, KpsM II - K2, 
neuC, cvaC, traT, ibeA, malX, usp, iutA, tsh, 
hlyF, ompT, iss 
0 0 CHL 
T9.II.h B2 O2:H5 355 73 154 24-154 iutA, KpsM II - K5 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, traT, ibeA, malX, usp, iutA, hlyF, ompT, 
iss 
TEM 0 AMP, NAL 
T9.V.a B1 O51:HNM NR NR NR NR sfa/foc - 0 NR SHV-12 - TEM 0 
AMP, CFZ, SXT, CIP, 
NAL 
T9.V.b B1 O9:HNM NR NR NR NR iutA fyuA 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, CTX, 
ATM, DOX, CHL, SXT 
T9.V.e G O118:H4 117 None 97 45-97 iutA chuA, vat, fyuA 0 
fimH, cdtB, iucD, iroN, traT, malX, iutA, tsh, 
hlyF, ompT, iss SHV-12 0 
AMP, CFZ, CXM, CAZ, 
CTX, ATM, DOX, CHL 
300 
T10.I.e A O51:H52 93 168 neg 11-neg iutA, KpsM - 0 NR TEM 0 AMP, NAL 
T10.V.a B1 O83:H23 NR NR NR NR - - 0 NR CTX-M-32 - TEM 0 
AMP, CFZ, CXM, CTX, 
DOX, CIP, NAL 
200 
T11.I.R B1 O9:H19 162 469 32 65-32 iutA - 0 NR 0 0 SXT, CIP, NAL 
T11.I.b B1 O9:H19 162 469 32 65-32 iutA, KpsM II fyuA 0 NR TEM 0 AMP, SXT, CIP, NAL 
T11.II.a E O68:HNM 115 38 270 26-270 iutA, KpsM II chuA, fuyA 0 NR TEM 0 AMP, CIP, NAL 
T11.II.c B1 O9:H19 162 469 32 65-32 iutA, KpsM II chuA, fuyA 0 NR TEM 0 
AMP, DOX, SXT, CIP, 
NAL 
T11.V.a C OAA:H28 NR NR NR NR - - 0 NR SHV-12 - TEM 0 
AMP, AMC, CFZ, CAZ, 
CTX, ATM, DOX, CIP, 
NAL 
440 
T12.I.R A ONT:HNM STnew2 10 neg 11-neg - - 0 NR TEM 0 AMP, CHL, SXT, CIP, NAL 
T12.I.j C O8:H4 NR NR NR NR papAH fyuA 0 fimH, papC, papAH, papEF, traT, ompT 0 0 
AMP, AMC, GEN, 
TOB, DOX, CHL, SXT, 
CIP, NAL 
T12.V.a A O16:HNM NR NR NR NR - - 0 NR SHV-12 - TEM 0 AMP, CFZ, DOX, SXT 
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210 
T13.I.R B1 O29:H9 155 155 32 4-32 - - 0 NR TEM 0 AMP, CIP, NAL 
T13.I.e Clade I ONT:H1 770 None 552 116-552 iutA, KpsM II - K5 chuA, fuyA 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, traT, malX, iutA, hlyF, ompT, iss TEM 0 AMP, CHL, NAL 
T13.II.a A O105:H32 10 10 23 11-23 - - 0 fimH, iroN, hlyF, ompT, iss TEM  mcr1.1 AMP, DOX, CHL, NAL 
T13.II.f.1 D O15:HNT 69 69 27 35-27 - chuA, fuyA 0 NR TEM 0 AMP, CHL, NAL 
T13.II.f.2 B2 O15:H5 355 73 154 24-154 iutA, KpsM II - K5 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, traT, ibeA, malX, usp, iutA, hlyF, ompT, 
iss 
TEM 0 AMP, AMC, NAL 
T13.II.h D O15:H6 69 69 27 35-27 - chuA, fuyA 0 fimH, iroN, traT, hlyF, ompT, iss TEM mcr1.1 AMP, DOX, CHL, NAL 
T13.V.a B1 O37:H10 NR NR NR NR - - 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, CTX, 
ATM, DOX, CHL, CIP, 
NAL 
T13.V.b G O143:HNT 117 None 97 45-97 iutA chuA, fuyA 0 fimH, iucD, traT, malX, iutA, tsh, hlyF, ompT, iss CTX-M-1 0 
AMP, CFZ, CXM, CTX, 
ATM, DOX 
150 
T14.I.R B2 O120:H4 428 None 22 40-22 iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, fimAv, iucD, iroN, KpsM II, KpsM II - K2, 
neuC, cvaC, traT, ibeA, malX, usp, iutA, hlyF, 
ompT, iss 
TEM 0 AMP, SXT 
T14.I.b C O8:H4 88 23 39 4-39 papAH, iutA fyuA 0 
fimH, papC, papAH, papEF, iucD, iroN, cvaC, 
traT, iutA, hlyF, ompT, iss 0 0 
AMP, AMC, GEN, 
TOB, DOX, CHL, SXT, 
CIP, NAL 
T14.I.f C O8:H4 88 23 39 4-39 papAH, iutA fyuA 0 
fimH, fimAV, papC, papAH, papEF, cdtB, iucD, 
iroN, cvaC, traT, iutA, hlyF, ompT, iss 0 0 
AMP, AMC, GEN, 
TOB, DOX, CHL, SXT, 
CIP, NAL 
70 
T15.I.R C O86:H9 410 23 24 4-24 iutA - 0 NR TEM 0 AMP, DOX, CIP, NAL 
T15.IV.b G O33:H4 117 None 97 45-97 papAH, iutA 
chuA, vat, 
fyuA 0 
fimH, papC, papAH, papEF, iucD, iroN, traT, 
mlaX, iutA, hlyF, ompT, iss TEM 0 
AMP, DOX, SXT, CIP, 
NAL 
T15.IV.j E O111:H45 NR NR 31 11-31 iutA, KpsM II chuA 0 NR TEM 0 AMP, SXT, CIP, NAL 
T15.V.a B1 O20:HNM NR NR NR NR iutA - 0 NR CTX-M-15 - TEM 0 
AMP, CFZ, CXM, CAZ, 
CTX, ATM, DOX, CIP, 
NAL 
100 
T16.I.R A O18:H25 10 10 54 11-54 iutA - 0 fimH, fimAv, iucD, iutA, iss TEM 0 AMP, CHL, CIP, NAL 
T16.I.a A O11:HNM 93 168 41 11-41 iutA, KpsM II - 0 NR TEM 0 
AMP, DOX, NIT, SXT, 
CIP, NAL 
T16.II.m B1 O21:HAA 101 101 86 41-86 - - 0 fimH, traT, ompT TEM mcr AMP, DOX, CHL, SXT 
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T16.IV.c B1 O21:H21 101 101 86 41-86 - - 0 fimH, traT, ompT TEM mcr1.1 AMP, CST, DOX, CHL, SXT 
T16.IV.f F O83:H42 1485 648 58 231-58 iutA, KpsM II - K5 
chuA, vat, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, DOX, SXT, CIP, NAL 
60 
T17.I.R A O162/O89:H37 853 10 54 11-54 iutA - 0 
fimH, fimAv, iucD, iroN, traT, iutA, hlyF, 
ompT, iss TEM mcr1.1 AMP, CST, SXT 
T17.I.a A O101:HNM 853 10 54 11-54 iutA - 0 fimH, fimAv, iucD, iroN, traT, iutA, hlyF, ompT, iss TEM mcr  AMP, CST, SXT 
T17.I.b A O101:HNM 853 10 54 11-54 iutA - 0 fimH, fimAv, iucD, iroN, traT, iutA, hlyF, ompT, iss TEM   mcr  AMP, CST, SXT 
T17.I.h F O153:H34 354 354 58 88-58 iutA, KpsM II - K1 
chuA, vat, 
yfcV 0 
fimH, papEF, iucD, iroN, KpsM II, KpsM II - K2, 
neuC, traT, ibeA, malX, usp, iuta, hlyF, iss TEM 0 
AMP, DOX, SXT, CIP, 
NAL 
T17.II.a A O7:HNT 484 168 neg 11-neg iutA, KpsM II chuA 0 NR TEM 0 AMP, SXT 
T17.V.a A O8:HAA NR NR NR NR - - 0 NR TEM-52 0 AMP, CFZ, CAZ, CTX, ATM, DOX 
T17.V.b A O8:20 NR NR NR NR - - 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, CTX, 
ATM, DOX 
40 
T18.I.R B1 O9:HNM 58 155 32 4-32 - fyuA 0 NR TEM 0 AMP, GEN 
T18.II.a F O2:H42 648 648 58 4-58 iutA, KpsM II - K5 chuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, hlyF, iss 0 0 - 
T18.II.d A O57:HNT 189 165 NR NR - fyuA 1* fimH, fimAv, iucD, iroN, cvaC, traT, usp, hlyF, iss TEM 0 
AMP, GEN, TOB, DOX, 
SXT, CIP, NAL 
T18.II.j A O21:H16 93 168 47 11-47 iutA, KpsM II - K5 - 0 
fimH, iucD, KspM II, KpsM II - K2, KspM II - K5, 
traT, iutA TEM 0 
AMP, GEN, TOB, CIP, 
NAL 
T18.V.a A ONT:H9 NR NR NR NR iutA vat 0 NR SHV-12 0 AMP, CFZ, CAZ, ATM, DOX, CHL, CIP, NAL 
90 T19.I.R C O86:H9 410 23 24 4-24 iutA - 0 NR TEM 0 AMP, CIP, NAL 
60 
T20.I.R F O83:H42 1485 648 58 231-58 iutA, KpsM II - K5 
chuA, vat, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, SXT, NAL 
T20.I.a F O83:H42 1485 648 58 231-58 iutA, KpsM II - K5 
chuA, vat, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, SXT, NAL 
T20.V.a A O101:H9 NR NR NR NR iutA vat 0 NR CTX-M-14 0 AMP, CFZ, CXM, CTX, DOX, CHL, CIP, NAL 
T20.V.c A O81:23 NR NR NR NR - - 0 NR SHV-12 - TEM 0 
AMP, CFZ, ATM, DOX, 
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T20.V.d A O172:23 NR NR NR NR - - 0 NR SHV-12 0 AMP, CFZ, CAZ, CTX, ATM, CIP, NAL 
130 
T21.I.R B1 O149:H45 297 None 38 65-38 iutA vat 0 NR 0 0 AMP 
T21.II.h F O83:H42 1485 648 58 231-58 iutA, KpsM II - K5 
chuA, vat, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, GEN, TOB, CHL, SXT, CIP, NAL 
T21.V.a E O53:H51 997 None 31 23-31 - chuA 0 NR SHV-12 0 
AMP, CFZ, CAZ, ATM, 
GEN, TOB, CHL, SXT, 
CIP, NAL 
80 
T22.I.R B2 O1:H7 95 95 30 38-30 
papAH, 
iutA, KpsM 
II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, papC, papAH, papEF, papGII, cdtB, iucD, 
iroN, KpsM II, KpsM II - K2, neuC, cvaC, traT, 
malX, usp, iutA, hlyF, ompT, iss 
0 0 AMP, NAL 
T22.III.q C O8:H4 88 23 39 4-39 papAH, iutA fyuA 0 
fimH, papC, papAH, papEF, iucD, iroN, cvaC, 
traT, iutA, hlyF, ompT, iss 0 0 
AMP, AMC, DOX, CHL, 
SXT, CIP, NAL 
150 
T24.I.R A O20:HNM 48 10 neg 11-neg - - 0 NR TEM 0 AMP, SXT 
T24.II.b A ONT:H10 34 10 neg 11-neg iutA - 0 NR SHV-12 0 AMP, CFZ, CAZ, CTX, ATM, CHL, NAL 
T24.II.f B2 O50/O2:H5 140 95 15 38-15 iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, fimAv, iucD, KpsM II, KpsM II - K2, neuC, 
traT, ibeA, malX, usp, iutA, hlyF, ompT TEM  mcr1.1 AMP, GEN, CHL 
T24.II.i B2 O50/O2:H5 140 95 15 38-15 iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, fimAv, iucD, KpsM II, KpsM II - K2, neuC, 
traT, ibeA, malX, usp, iutA, hlyF, ompT TEM mcr1.1 AMP, GEN, TOB, CHL 
T24.V.a E O83:HNM 57 350 31 31-31 iutA chuA, fuyA 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, CTX, 
ATM, DOX, CHL, SXT 
T24.V.b B2 O50/O2:H6 141 None 14 52-14 iutA, KpsM II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
cvaC, traT, ibeA, malX, usp, iutA, tsh, hlyF, 
ompT, iss 
SHV-12 0 AMP, CFZ, CAZ, ATM, DOX, CHL 
T24.V.c F O153:H34 354 354 58 88-58 KpsM II - K5, sfa/foc chuA, yfcV 0 
fimH, sfa/foc, KpsM II, KpsM II - K2, KpsM II - 
K5, traT, ibeA, malX, usp SHV-12 0 
AMP, CFZ, ATM, CHL, 
CIP, NAL 
T24.V.d A ONT:H9 744 10 54 11-54 - - 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, ATM, 
DOX, CHL, CIP, NAL 
420 
T25.I.R B1 O8:HNM 58 155 32 4-32 iutA vat, fyuA 0 NR 0 0 AMP 
T25.V.a E O119:HNT 350 350 54 31-54 iutA chuA, vat 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, CTX, 
ATM, SXT, CIP, NAL 
20 
T26.I.R B1 O9:H12 58 155 27 4-27 iutA vat, fyuA 0 NR 0 0 AMP 
T26.I.a F O1:H42 648 648 58 4-58 iutA, KpsM II - K5 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
0 0 NAL 









6 ExPEC7 UPEC8 
eae
9 Virulence profile10 
ESBL 
/other BL mcr Antibiotic profile
11 
T26.I.g B2 O25:H4 131 131 22 40-22 iutA, KpsM II - K5 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, ibeA, malX, usp, iutA, tsh, 
hlyF, ompT, iss 
0 0 - 
T26.IV.a A O18:H11/21/47 93 168 neg 11-neg 
iutA, KpsM 
II - 0 NR SHV-12 0 AMP, CHL, NAL 
T26.IV.h D ONT:H45 4243 None 1002 3-1002 iutA, KpsM II chuA 0 NR 0 0 GEN, NAL 
T26.V.a A O18:H11/21/47 93 168 neg 11-neg 
iutA, KpsM 
II - K5 - 0 
iucD, KpsM II, KpsM II- K2, KpsM II- K5, iuta, 
ompT SHV-12 0 AMP, CFZ, CHL, NAL 
220 
T27.I.R B1 O48:H30 58 155 neg 4-neg iutA - 0 NR TEM 0 AMP, CHL, SXT 
T27.V.a B1 O86:H51 155 155 32 4-32 - - 0 NR SHV-12 0 AMP, CFZ, CAZ, ATM, CHL 
T27.V.c E O126:HNT 350 350 54 31-54 iutA chuA, fyuA 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, ATM, 
GEN, DOX, CIP, NAL 
70 
T28.II.c F O1:H42 648 648 58 4-58 iutA, KpsM II - K5 
chuA, fyuA, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
0 0 NAL 
T28.II.g F O1:H42 648 648 58 4-58 iutA, KpsM II - K5 
chuA, fyuA, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
0 0 NAL 
T28.V.a A O101:H9 10 10 54 11-54 - fyuA 0 - SHV-12 - TEM 0 
AMP, AMC, CAZ, CTX, 
ATM, CHL, CIP, NAL 
20 T29.I.R A O101:HNM 744 10 54 11-54 iutA - 0 NR TEM 0 AMP, DOX, CHL, CIP, NAL 
<10 
T30.I.R E ONT_H25 57 350 27 31-27 - chuA, fyuA 0 NR 0 0 - 
T30.II.b E O25:HNM 115 38 270 26-270 iutA, KpsM II chuA, fuyA 0 NR TEM 0 AMP, CIP, NAL 
350 
T31.I.R A O101:HNM 744 10 54 11-54 iutA vat 0 NR TEM 0 AMP, DOX, CHL, SXT, CIP, NAL 
T31.I.b A O148:H30 522 522 neg 23-neg - - 0 iroN, traT, hlyF TEM  mcr1.1 AMP, CFZ, DOX, NIT 
T31.V.a A O33:HNM 7315 None 398 11-398 - - 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, ATM, 
CIP, NAL 
100 
T32.I.R A O6:H10 43 10 54 11-54 - fyuA 0 NR 0 0 AMP 
T32.V.a Clade I O1:H45 770 None 552 116-552 iutA, KpsM II - K5 - 0 
fimH, iucD, KpsM II, KpsM II - K2, KpsM II - K5, 
traT, malX, iutA, ompT SHV-12 0 
AMP, CFZ, CAZ, ATM, 
CHL, CIP, NAL 
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T32.V.e A O154:H28 10 10 54 11-54 - - 0 NR SHV-12 0 AMP, CFZ, CHL, CIP, NAL 
30 
T33.I.R E O7:H15 38 38 65 26-65 KpsM II chuA 0 NR TEM 0 AMP, DOX 
T33.I.d F O11:H25 1674 None 138 88-138 iutA, KpsM II - K5 chuA, yfcV 0 
fimH, fimAv, iucD, iroN, KpsM II, KpsM II - K2, 
KpsM II - K5, cvaC, traT, malX, iuta, hlyF, iss TEM 0 AMP 
T33.I.f B2 O1:H17 STnew9 None 664 new-664 iutA, KpsM II - K5 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, traT, malX, iutA, hlyF, ompT, iss TEM 0 AMP 
T33.V.a A ONT:H4 1141 10 32 11-32 - fyuA 0 NR CTX-M-14 0 AMP, CFZ, CXM, CTX 
T33.V.b C O9:H17 88 23 39 4-39 - - 0 fimH, papEF, traT, ompT CTX-M-14/OXA-1 0 
AMP, AMC, CFZ, CXM, 
CTX, GEN, TOB, DOX, 
CHL, SXT, CIP, NAL 
<10 
T34.I.R B1 O8:HNT 58 155 32 4-32 iutA fyuA 0 NR TEM 0 AMP, SXT, CIP, NAL 
T34.II.i B1 O23:H16 453 86 31 6-31 iutA, KpsM II - 0 NR TEM 0 AMP, CIP, NAL 
<10 
T35.I.R A O7:H4 93 168 41 11-41 iutA - 0 NR TEM 0 AMP, DOX, CHL, SXT, CIP, NAL 
T35.V.a B1 ONT:H8 366 None 30 4-30 - - 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, ATM, 
DOX, CHL 
<10 
T36.I.R B1 O8:H25 58 155 32 4-32 - fyuA 0 NR 0 0 AMP, DOX, SXT, CIP, NAL 
T36.I.e E O7:H6 362 None 96 100-96 iutA, KpsM II chuA 0 NR TEM 0 
AMP, CHL, SXT, CIP, 
NAL 
20 
T37.I.c A O11:H52 3764 168 41 482-41 iutA, KpsM II chuA, fuyA 0 NR TEM 0 AMP 
T37.V.a A O15:H11 48 10 41 11-41 - - 0 NR CTX-M-1 0 AMP, CFZ, CXM, CTX, SXT, CIP, NAL 
30 
T38.I.R B1 ONT:H7 3580 None 32 65-32 iutA - 0 NR 0 0 - 
T38.I.g B2 O113:HNT 8611 None 26 24-26 sfa/foc chuA, vat, fyuA, yfcV 0 
fimH, sfa/foc, iroN, malX, usp, hlyF, ompT, 
iss TEM 0 AMP 
T38.V.a A O20:HNM 1564 None neg 252-neg iutA fyuA 0 NR SHV-12 0 AMP, CFZ, CAZ, CTX, ATM 
T38.V.b B1 O64:HNM 155 155 neg 4-neg - - 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, ATM, 
DOX, CHL 
T38.V.c A O9:HNM STnew7 None 54 7-54 - fyuA 0 NR SHV-12 0 AMP, CFZ, CAZ, CTX, ATM, DOX, CHL, NAL 
210 T39.I.R A O101:H9 744 10 54 11-54 iutA vat 0 NR TEM 0 AMP, DOX, CHL, SXT, CIP, NAL 
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T39.II.j A O51:H52 93 168 neg 11-neg iutA, KpsM II vat 0 NR TEM 0 AMP, SXT, CIP, NAL 




None 54 31-54 iutA chuA 0 NR SHV-12 0 AMP, CFZ, CAZ, CTX, ATM, SXT, CIP, NAL 
T39.V.c B1 O37:H21 10328 None 32 4-32 - - 0 fimH, traT SHV-12 - TEM 0 
AMP, AMC, CFZ, CAZ, 
CTX, ATM, CIP, NAL 
2320 
T40.I.R F O8:HNM 5340 None 58 271-58 iutA chuA, vat, yfcV 0 
fimH, iucD, iroN, cvaC, traT, malX, iutA, tsh, 
hlyF, iss TEM 0 AMP, SXT 
T40.I.k F O11:H6 457 None 145 88-145 iutA, KpsM II - K5 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
0 0 - 
T40.V.a E O102:H45 38 38 65 26-65 KpsM II - K5 chuA, vat 0 
fimH, iroN, KpsM II, KpsM II - K2, KpsM II - K5, 
ompT SHV-12 0 
AMP, CFZ, CXM, CTX, 
ATM, DOX, NAL 
T40.V.b B2 O113:H5 8611 None 26 24-26 - chuA, vat, fyuA, yfcV 0 fimH, iroN, traT, malX, usp, ompT SHV-12 0 
AMP, CFZ, CAZ, ATM, 
DOX, CHL, NAL 
T40.V.c A O9:HNM 6215 None 34 7-34 - chuA 0 NR CTX-M-14 0 AMP, CFZ, CXM, CTX, CHL, CIP, NAL 
T40.V.e B1 O8:HNM 58 155 27 4-27 iutA vat, fyuA 0 NR SHV-12 0 AMP, CFZ, CAZ, ATM, DOX, CHL 
<10 
T41.I.R C O20:HNT 410 23 24 4-24 iutA fyuA 0 NR 0 0 AMP, CIP, NAL 
T41.I.h F O102:H42 1485 648 58 231-58 iutA, KpsM II - K5 chuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, SXT, CIP, NAL 
T41.II.a B2 O1:H7 95 95 30 38-30 
papAH, 
iutA, KpsM 
II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, papC, papAH, papGII, iucD, iroN, KpsM 
II, KpsM II - K2, neuC, cvaC, traT, malX, usp, 
iutA, hlyF, ompT, iss 
TEM 0 AMP 
T41.II.e B2 O15:H5 10740 None 9 1544-9 iutA, KpsM II - K5 
chuA, vat, 
fyuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, ibeA, malX, usp, iutA, hlyF, 
ompT, iss 
0 0 - 
T41.V.a B1 ONT:H8 366 None 30 4-30 - - 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, ATM, 
CHL 
680 
T42.I.R C O60:HNT 410 23 53 4-53 - fyuA 0 NR TEM 0 AMP, DOX 
T42.V.a B1 ONT:H21 602 446 86 19-86 iutA - 0 NR SHV-12 - TEM 0 
AMP, CFZ, ATM, GEN, 
TOB, DOX, SXT, CIP, 
NAL 
T42.V.b A O101:H9 10 10 54 11-54 - fyuA 0 NR SHV-12 - TEM 0 
AMP, AMC, CAZ, ATM, 
CIP, NAL 
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T43.I.a A ONT:HNM 34 10 neg 11-neg iutA - 0 NR SHV-12 - TEM 0 
AMP, CFZ, CXM, CAZ, 
CTX, ATM, DOX, NAL 
T43.I.g B2 O15:HNM 95 95 27 38-27 
papAH, 
iutA, KpsM 
II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, fimAV, papC, papAH, papEF, papGII, 
iucD, iroN, KpsM II, KpsM II - K2, neuC, cvaC, 
traT, malX, usp, iutA, tsh, hlyF, ompT, iss 
0 0 - 
T43.V.a B1 O9:HNM 155 155 32 4-32 iutA fyuA 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, ATM, 
CHL, SXT, NAL 
T43.V.b F O153:H36 354 354 58 88-58 KpsM II - K2, sfa/foc chuA, yfcV 0 
fimH, sfa/foc, KpsM II, KpsM II - K2, traT, 
ibeA, malX, usp SHV-12 0 
AMP, CFZ, CAZ, CTX, 
ATM, CHL, CIP, NAL 
T43.V.c A O20:HNM 1785 None 54 168-54 - - 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, ATM, 
NIT 
<10 
T44.I.R A O176:H11 48 10 neg 11-neg - - 0 NR TEM 0 AMP, NAL 
T44.II.a B2 O25:H4 131 131 22 40-22 KpsM II - K5 
chuA, fyuA, 
yfcV 0 
fimH, cdtB, KpsM II, KpsM II- K2, KpsM II - K5, 
traT, ibeA, malX, usp, ompT TEM 0 AMP 
T44.II.d F O83:H42 1485 648 58 231-58 iutA, KpsM II - K5 chuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, CHL, SXT, CIP, NAL 
T44.III.j F O83:H42 1485 648 58 231-58 iutA, KpsM II - K5 chuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, SXT, CIP, NAL 
T44.V.a B1 O100:H25 359 101 35 41-35 iutA - 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, ATM, 
CHL, SXT, CIP, NAL 
10 T45.I.R A O33:HNM 7315 None 398 11-398 - - 0 NR TEM 0 AMP, GEN, TOB, CHL, CIP, NAL 
1130 
T46.I.R C O19:HNT 410 23 45 4-45 iutA - 0 NR TEM 0 AMP, CIP, NAL 
T46.I.g E O37:H25 57 350 27 31-27 iutA chuA, fuyA 0 NR SHV-12 0 
AMP, CFZ, CAZ, CTX, 
ATM, CHL, SXT, CIP, 
NAL 
T46.II.h B2 O25:H4 131 131 22 40-22 iutA, KpsM II - K1 
chuA, fyuA, 
yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, neuC, 
cvaC, traT, ibeA, malX, usp, iutA, tsh, hlyF, 
ompT, iss 
TEM 0 AMP, NAL 
40 
T47.II.a A O2:H40 10 10 24 11-24 - - 1* fimH, traT, hlyF CMY-2 0 
AMP, AMC, CFZ, CXM, 
CAZ, CTX, FOX, SXT, 
NAL 
T47.II.f A O2:H40 10 10 24 11-24 - - 1 fimH, iucD, iroN, cvaC, traT, hlyF, iss CMY-2 0 
AMP, AMC, CFZ, CXM, 
CAZ, CTX, FOX, DOX, 
SXT, CIP, NAL 
T47.V.a A O101:HNM 167 10 neg 11-neg - fyuA 0 NR CTX-M-1 0 AMP, CFZ, CXM, CTX, CHL, CIP, NA L 
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20 
T48.I.d B2 O2:HNM 95 95 27 38-27 
papAH, 
iutA, KpsM 
II - K1 
chuA, vat, 
fyuA, yfcV 0 
fimH, fimAV, papC, papAH, papEF, papGII, 
iucD, iroN, KpsM II, KpsM II - K2, neuC, cvaC, 
traT, malX, usp, iutA, tsh, hlyF, ompT, iss 
0 0 - 
T48.I.e B2 O115:HNM 919 None 187 24-187 iutA chuA, vat, fyuA, yfcV 0 




AMP, CFZ, CAZ, CTX, 
ATM, SXT, NAL 
T48.I.j D O23:H4 1882 None 123 22-123 iutA, KpsM II chuA 0 NR 0 0 - 
T48.V.a B1 O64:HNM 155 155 neg 4-neg - - 0 NR SHV-12 - TEM 0 
AMP, CFZ, CAZ, CTX, 
ATM, DOX, CHL 
T48.V.a B1 ONT:HNM 155 155 32 4-32 - - 0 NR SHV-12 0 AMP, CFZ, CAZ, CTX, ATM, NAL 
T48.V.c B2 O115:HNM 919 None 187 24-187 iutA chuA, vat, fyuA, yfcV 0 




AMP, CFZ, CAZ, CTX, 
ATM, SXT, NAL 
20 T49.II.g F O83:H42 1485 648 58 231-58 iutA, KpsM II - K5 chuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, SXT, NAL 
110 
T50.II.b F O83:H42 1485 648 58 231-58 iutA, KpsM II - K5 chuA, yfcV 0 
fimH, iucD, iroN, KpsM II, KpsM II - K2, KpsM II 
- K5, cvaC, traT, malX, iutA, tsh, hlyF, ompT, 
iss 
TEM 0 AMP, DOX, SXT, NAL 
T50.II.d E O153:HNM 115 38 270 26-270 iutA, KpsM II chuA, fuyA 0 NR TEM 0 AMP, SXT, CIP, NAL 
T50.V.a B1 O83:H23 906 None 61 4-61 - - 0 NR CTX-M-32 - TEM 0 
AMP, CFZ, CXM, CTX, 
DOX, CIP, NAL 
T50.V.b B1 O19:H21 602 446 86 19-86 iutA - 0 NR SHV-12 - TEM 0 
AMP, CFZ, CXM, CAZ, 
CTX, ATM, GEN, TOB, 
DOX, SXT, CIP, NAL 
T50.V.e B1 O19:H21 602 446 86 19-86 iutA - 0 NR SHV-12 0 AMP, CFZ, CAZ, ATM, DOX, SXT, CIP, NAL 
1CFU: colony forming units; 2Isolate: Origin of isolation-sample number-protocol-letter of the isolate, Ch (chicken meat), T (turkey meat);  3Phylogroup (PG) was designated by PCR according to Clermont scheme 
(Clermont et al., 2013);  4Serotype: O antigen: non-typeable isolates were designated as ONT; H antigen: HNM for non-motile isolates, HNT for those which did not react with any antisera and HAA for self-
agglutinating isolates;  5Sequence type (ST) and clonal complex (CC) were assessed following the Achtman scheme (Wirth et al., 2006), NR for isolates where this was not performed; 6 Clonotype based on the 
internal 469-nucleotide (nt) and 489-nt sequence of the fumC (allele obtained from MLST) and fimH genes, respectively (Weissman et al., 2012), isolates what did not amplified by PCR were designated as 
negative (neg.), NR for isolates where this was not perfromed;  7 ExPEC status + (highlighted in black): E. coli  strains considered with higher capacity of developing extraintestinal pathologies when positive for 
two or more of five markers, including papAH and / or papC, sfa/focDE, afa/draBC, kpsM II and iutA; ExPEC -: strains negative for those markers (Johnson et al., 2003b); 8UPEC status + (highlighted in black): 
strains considered with higher capacity of developing UTI pathologies when positive for three or more of four markers, including chuA, fyuA, vat and yfcV; UPEC -: strains negative for those markers (Spurbeck et 
al., 2012); 9eae: 1 for positive isolates and 1* for isolates typed as eae-β1; 10Virulence profile: NR for isolates where this characterization was not performed;  11Antibiotic profile: Phenotypic resistance interpreted 
according to the CLSI standard guidelines (The Clinical and Laboratory Standards Institute, 2020): ampicillin (AMP), amoxicillin-clavulanic acid (AMC), ceftazidime (CAZ), cefotaxime (CTX), cefoxitin (FOX), 
aztreonam (ATM), imipenem (IMP), gentamicin (GEN), tobramycin (TOB), amikacin (AMK), fosfomycin (FOF), doxycycline (DOX), chloramphenicol (CHL), nitrofurantoin (NIT), sulfamethoxazole-trimethoprim (SXT), 
ciprofloxacin (CIP), nalidixic acid (NAL), tigecycline (TGC) and colistin (CST).  
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